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Glossary 
This is taken in part from the NICE (2014) NICE Guideline Development Manual online,  
https://www.nice.org.uk/article/pmg20/chapter/glossary  
Anti-retroviral treatment (ART): a specific type of treatment for HIV. 
Cost-benefit analysis (CBA): The costs and benefits are measured using the same monetary 
units (for example, pounds sterling) to see whether the benefits exceed the costs. A cost-
benefit ratio of greater than 1 suggests that an intervention is worthwhile, while a ratio of 
less than 1 suggests that the costs outweigh the benefits.  
Cost-consequences analysis (CCA): The costs (e.g. treatment and hospital care) and 
consequences (e.g. health outcomes) of an intervention, test or treatment are compared 
with those for a suitable alternative. Unlike cost–benefit analysis or cost‑effectiveness 
analysis, it does not attempt to summarise outcomes in a single measure (such as the 
quality‑adjusted life year) or in financial terms. Instead, outcomes are shown in their 
natural units (some of which may be monetary) and it is left to decision makers to 
determine whether, overall, the intervention is worth carrying out.  
Cost-effectiveness analysis (CEA): The additional costs and benefits of a new intervention 
are compared with those of the current standard intervention over a time period which is 
deemed long enough to capture these differences, in similar units of outcome. These are 
compared in terms of ‘cost per unit of effect’. In a cost‑effectiveness analysis, the benefits 
are expressed in non‑monetary terms related to health, such as symptom‑free days, heart 
attacks avoided, deaths avoided or life years gained (that is, the number of years by which 
the intervention extends life). Cost‑effectiveness analysis assesses the cost of achieving the 
same benefit by different means. Where an intervention is less costly and provides more 
positive units of effect compared to the next best alternative, it is considered more cost-
effective. 
Cost-savings/cost-minimisation analysis (CSA): Alternative interventions are determined to 
be equally effective and a comparison of costs is made to see which is cheaper. 
Cost-utility analysis (CUA): When alternative interventions produce different levels of 
effect in terms of quantity and quality of life (or different effects), the effects may be 
expressed in utilities. Utilities are measures which comprise both length of life and 
subjective levels of well-being. The best known utility measure is the quality-adjusted life 
year, or QALY. Alternative interventions are compared in terms of cost per unit of utility 
gained (e.g. cost per QALY gained), with lower costs per QALY considered more cost-
effective.  
Disability-adjusted life year (DALY): A measurement of the gap between current health 
status and an ideal health situation where one lives to an advanced age, free from disease 
and disability. 
Emergency contraception (EC): Oral ‘morning after’ pill or IUD usually administered 
subject to license up to five days after unprotected sex. 
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Health promotion: The art and science of helping people discover the synergies between 
their core passions and optimal health, enhancing their motivation to strive for optimal 
health, and supporting them in changing their lifestyle to move toward a state of optimal 
health. Optimal health is a dynamic balance of physical, emotional, social, spiritual and 
intellectual health. Lifestyle change can be facilitated through a combination of learning 
experiences that enhance awareness, increase motivation and build skills, together with, 
most importantly, through the creation of opportunities that open access to environments 
that make positive health practices the easiest choice (O’Donnell 2009). 
Incremental cost-effectiveness ratio (ICER): A ratio of the cost of the intervention less the 
cost of the comparison divided by the outcomes of the intervention less the outcomes of 
the comparison. When comparing two interventions, the one with the lowest ICER will be 
most cost-effective.  
Long-acting reversible contraceptive (LARC): Contraceptive methods with a long period of 
action which are not reliant on users, e.g. intrauterine devices and subdermal implants. 
National Institute for Health and Care Excellence (NICE): a government-funded but 
operationally independent standards organisation which provides advice and guidance to 
improve health and social care in the UK. 
Organisation for Economic Co-operation and Development (OECD): An established 
consortium of (currently) 34 democratic countries with market economies which work 
together to ensure economic growth, development and prosperity.  
Quality-adjusted life year (QALY): A measure of burden of disease in which both the 
quantity of life expectancy and quality of life are taken into account. A year of perfect 
health is worth 1 and death is equivalent to 0. 
Sensitivity analysis: In economic evaluations, a sensitivity analysis examines the 
differences that would result from varying any important assumptions in the model that 
would alter the results, both for better and worse. Sensitivity analyses may address 
methodological uncertainty, parameter uncertainty or uncertainty around the structure of 
the model used to combine costs and outcomes. Conducting a sensitivity analysis may 
involve adding or removing parameters (such as including or removing societal costs), 
changing the value of key parameters (such as the discount rate) or allowing parameters to 
vary over a specified distribution rather than utilising a point estimate. Threshold analysis 
may also be conducted whereby a willingness to pay for a unit of outcome is specified and 
the analyst is then able to determine how effective an intervention would have to be, or 
how low the associated cost would need to be, in order for the cost per unit of outcome to 
fall below the threshold.  
Sexually transmitted infection (STI): Can include human immunodeficiency virus, syphilis, 
chlamydia, gonorrhoea, herpes and hepatitis C.  
User-dependent contraceptive (UDC): Contraceptive methods that are self-administered 
by individuals, i.e. their efficacy is dependent on the users. They can include condoms and 
oral hormonal contraceptives. 
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Abstract 
Background  
Since 2013, health commissioners in England’s local authorities have been responsible for 
sexual health services, including contraception, HIV testing, STI testing and treatment, 
health education and specialist sexual health services. Effective commissioning requires 
information to indicate which interventions may, or may not, be cost-effective. However, 
current UK guidance and recent research on the cost-effectiveness of sexual health services 
provides patchy and fragmented evidence. This study aims systematically to review the 
evidence available on the cost-effectiveness of OECD-based interventions relevant to UK 
local authority-commissioned sexual health services. 
Methods 
Key informants, bibliographic database searches and reference lists of guidance documents 
and included studies were searched for potentially relevant research. Guided by key 
stakeholders, we sought economic evaluations of sexual health interventions within the 
responsibility of local authorities, and focused in the UK, on contraception and on health 
promotion, published between 2010 and 2015 in English. Eligible studies were full economic 
evaluations based in an OECD country. Studies were classified using a specifically developed 
tool and assessed for methodological risk of bias using one of three design-specific 
assessment tools. Descriptive frequencies of codes were analysed to provide a ‘map’ of 
research that informed stakeholder discussions to focus the subsequent synthesis. The 
characteristics of studies, quality ratings and cost outcomes from each included study were 
extracted into tables and findings summarised narratively. Studies were assessed for their 
relative cost-saving or cost-effectiveness according to NICE guidance.  
Results 
In total, 17,705 references were screened; of these, 29 met our inclusion criteria and were 
included in the synthesis. Nine studies were undertaken in the UK; the remainder were US-
based. Fifteen studies examined the economics of contraception and 14 evaluated health 
promotion. Overall, studies were of medium methodological quality.  
In general, economic evaluations of contraception reported cost-effectiveness or cost-
savings for ulipristal acetate (UPA) as emergency contraception, long-acting reversible 
contraceptives (LARCs) for regular, post-natal and post-abortion contraception, and 
targeting to high risk groups; none, however, reported costs per quality-adjusted life year 
(QALY) within NICE thresholds.  
Economic evaluations of sexual health promotion interventions indicated more mixed 
results. Only three interventions were found to be cost-effective according to the NICE 
thresholds for HIV or sexually transmitted infection (STI) outcomes: nurse-led rapid testing 
and tailored counselling; condom negotiations skills training for female sex workers; and a 
teacher-led STI prevention and skills training intervention. 
UK studies focused on health promotion and contraception, and supported the above 
findings. In general, there has been a reasonable amount of economic research into sexual 
health interventions since 2010, and these support current NICE sexual health guidance. 
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Conclusions 
The broad nature of the research question posed in this systematic review resulted in the 
inclusion of a dataset very diverse in terms of populations, interventions, outcomes and 
types of economic evaluation designs. In considering the cost-effectiveness of these 
strategies in relation to their own commissioning climate, policy and decision makers should 
consider carefully the fit between their context and that of individual studies. Use of 
longer-term outcomes in trials used in economic evaluations would strengthen estimates of 
effects such as QALYs, as would the routine use of longitudinal cohort data. 
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How to read this report 
This report has been designed so that key messages appear early in the document, 
condensed into an Executive Summary for quick reference. More detailed methodological 
information appears in the Appendices, including methods of searching (Appendix 1), 
discussion of the types of economic evaluation (Appendix 2), the flow of studies through the 
review (Appendix 3), quality assessment and data extraction tools (Appendix 5), and details 
of the studies, including quality assessment ratings (Appendices 6 and 7), characteristics of 
the included studies (Appendices 4, 8, 9 and 10), structured summaries (Appendix 11) and 
the costs and outcomes of each study (Appendices 12 to 14).  
Readers are encouraged to reference the specific appendices while reading the report.  
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Executive summary 
Background 
Since 2013, health commissioners in England’s local authorities have been responsible for 
putting in place a wide range of sexual health services, including contraception, HIV 
testing, sexually transmitted infection (STI) testing and treatment, health education and 
specialist sexual health services. Provision of these services must be negotiated alongside 
the wider commissioning of multiple statutory and non-statutory local authority services, 
including transport, planning, fire and public safety, housing, social services, libraries, 
waste management and trading standards.  
In order to commission sexual health services, local authorities require information 
regarding the interventions that are clinically effective or effective compared to current 
practice. However, the perceived benefits of these interventions may be outweighed by the 
costs; alternatively, other services may achieve the same (or better) outcomes for less 
money. Data in relation to cost-effectiveness is therefore crucial for informing local 
authority commissioning decisions. However, current UK guidance and recent research on 
the cost-effectiveness of sexual health services provides patchy and fragmented evidence. 
A systematic review was undertaken to bring together this research. The aims of the review 
were to answer the following research questions:  
What evidence is available on cost-effectiveness for local authority commissioned 
sexual health services concerning studies of health promotion and in relation to 
studies of contraception, and what is the evidence specific to the UK? 
Methods 
Guidance from key stakeholders was sought in order to focus on relevant topics for 
synthesis. Stakeholders formed an Advisory Group of sexual health policy makers, charity 
representatives, academics and local commissioners.  
Studies published between 2010 and 2015 were sought through key informants, 
bibliographic database searches, and reference lists of guidance documents and included 
studies. Located references were screened on the basis of title and abstract, and the full-
text reports and papers of potentially relevant references were retrieved and assessed. To 
be included in the review, studies had to: be published during or after 2010, in English; 
evaluate sexual health interventions within local authority responsibility; present economic 
or cost data; be a full economic evaluation; and be conducted in an OECD country. At full 
report screening, potentially relevant studies also had to be focused on either 
contraception or health promotion activities. UK studies were also grouped separately for 
analysis. 
Studies were coded for characteristics of interest, using a data extraction tool developed 
and tested by the research team. Codes included: publication year; targeted population, 
health issue, behaviour; type of economic evaluation; intervention characteristics and 
outcomes measured. Included economic evaluations could be derived from trials, 
systematic reviews of effectiveness or mathematical modelling; for this reason, three types 
of risk of bias assessment tools were used. These were the NICE intervention study checklist 
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(NICE 2012), the AMSTAR tool for systematic reviews (Shea et al. 2009), and a combined 
health and economic evaluation checklist developed from three tools currently in common 
use (Evers et al. 2005; NICE 2012; Phillips et al. 2004).  
Descriptive frequencies of codes extracted from studies were calculated and findings 
narratively summarised across all sexual health services offered by local authorities, 
providing a ‘map’ of literature relevant to the review question. The findings from this map 
informed the identification and synthesis of a more focused set of studies, grouped first by 
their specific focus (UK-based, contraception or health promotion). Where possible, studies 
within each of these were grouped according to the type of economic evaluation in order to 
make comparisons of cost outcomes as similar as possible. Cost outcomes for each group of 
studies were then compared and contrasted in terms of their populations, interventions, 
health outcomes, costs and magnitudes. Studies were also assessed for their relative cost-
saving or cost-effectiveness according to NICE guidance (2012): below GBP £20,000; £20,000 
to £30,000; and above £30,000. All costs were converted to GBP using the relevant 
exchange rate for the year in which they were originally reported. The findings are 
presented narratively and in tabular format. 
To assure review quality, several steps were taken, including: developing searches in 
conjunction with an information scientist using free text and thesaurus terms; manual 
screening on title and abstract and then full reports with two reviewers until good 
agreement was reached, then single screening; assessing for risk of bias and conducting 
synthesis with at least two researchers; and use of EPPI-Reviewer© specialist software 
(Thomas et al. 2010) to manage data, allow rating comparisons and structure the synthesis. 
Results and discussion 
A total of 17,705 potentially relevant references were located; of these, 108 titles and 
abstracts met our inclusion criteria and were retrieved and assessed on the basis of their 
full report. Descriptive ‘map’ findings from a subset of 86 available at the time were 
presented to the Advisory Group, where the decision was made to focus on UK studies 
meeting the initial criteria, plus studies of contraception and health promotion (from any 
OECD country). Reports describing 29 studies meeting these additional criteria were 
available for analysis. Twenty of these were US-based and nine were UK-based. A total of 
15 studies focused on contraception and 14 on health promotion interventions, with some 
overlap between all three groups.  
Contraception studies 
Findings from 15 contraception studies indicated a wide range of interventions considered 
to be cost-effective, although few met NICE thresholds. Studies suggested that: 
 oral ulipristal acetate (UPA) is more cost-effective than oral levonorgestrel (LNG) 
as a method of emergency contraception. 
 advance and on-demand emergency contraception offered in clinics or community 
pharmacies are cost-saving compared to no access, for both high- and low-use 
groups. 
 long-acting reversible contraceptives (LARCs) could be more cost-effective to use 
than user-dependent contraceptive methods in terms of the pregnancies they 
would avert and the resultant costs potentially borne by health and social services. 
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 provision of LARC methods post-natally or post-abortion could generate cost 
savings, particularly beyond one year, though it should be noted that this is based 
on US studies undertaken in a different healthcare system and focusing on a 
specific population of Latina immigrant women. It is open to debate whether they 
would be appropriate in a UK context.  
 expanded contraceptive provision targeted to low- and high-risk groups such as 
sexually active teens, adolescent mothers and new immigrants could result in cost 
savings resulting from services not needing to provide health and social care for 
unintended pregnancy, maternal benefits and early childhood care.  
Of the studies that reported cost per QALY gained as an outcome, none showed a cost of 
less than £20,000 per QALY gained, a nationally recognised threshold for cost-effectiveness. 
Health promotion studies 
Health promotion studies which evaluated HIV prevention interventions indicated that many 
different interventions were cost-effective or cost-saving. For example: 
 studies found that condom distribution or condom negotiation skills programmes 
were cost-effective or cost-saving in comparison to standard care or no 
intervention respectively.  
 clinical provider assessment and counselling was more cost-effective than provision 
by peer or mixed peer and clinical providers.  
 nurse-led rapid HIV testing and tailored counselling was more cost-effective than 
routine screening and counselling, and on-site rapid testing and tailored counselling 
dominated (i.e. was less costly and more effective) off-site testing and referral or 
on-site testing and information only.  
 four educational sessions to reduce onward HIV infections was suggested to be cost-
saving in relation to well-woman examinations for intravenous drug users. 
 offering housing rental assistance to unstably housed HIV-infected persons as part 
of locally provided sexual health services was described as cost-effective in 
comparison to no provision. Multiple HIV prevention strategies evaluated in order to 
determine the ‘optimum package’ of interventions reported cost-savings for 10 
different interventions over current HIV testing and counselling provision or no 
service provision.  
However, of these interventions reported to be cost-effective, only two nurse-led rapid HIV 
testing and tailored counselling (£6,876-£23,472 per QALY gained) and condom negotiations 
skills training for female sex workers (£121-£713 per QALY) were shown to be cost-effective 
within NICE thresholds.  
Health promotion studies evaluating the cost-effectiveness of STI prevention presented 
more mixed findings. Some evaluations suggested clear cost-effectiveness:  
 an analysis of school-based condom distribution compared to a standard school 
nurse intervention was suggested to be cost-effective for STI prevention.  
 a cost-benefit analysis of mass media STI prevention messaging targeted to 
unmarried male adults was deemed to be cost-saving.  
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However, other findings were mixed:  
 while a teacher-led STI prevention and skills training for school-age youth was 
found to be cost-effective in comparison to standard sex and relationships 
education (and cost-effective by NICE standards – £18,041 per QALY gained), the 
peer-led STI prevention and skills training in the same study was not found to be 
cost-effective compared to the teacher-led intervention (£72,062 per QALY 
gained).  
 an STI screening uptake campaign led by sexual health advisers targeted to football 
club members was found to have similar costs and outcomes to a poster-only 
campaign; the same campaign led by football captains was found to be more costly 
and less effective in terms of testing uptake.  
Other findings suggested differential cost-effectiveness:  
 for hepatitis C and gonorrhoea outcomes, well-woman examinations provided to 
women using intravenous drugs in addition to standard drug treatment were found 
to be cost-effective compared to a standard intervention; however, a four-
education session added to standard drug treatment was found to be more cost-
effective for chlamydia outcomes than the standard intervention alone.  
Other economic evaluations found that interventions were not cost-effective, including 
brief risk reduction counselling that included sexual risk behaviour amongst adults 
presenting at substance abuse clinics.  
UK-based studies 
The nine UK-based studies of largely high and medium methodological quality contributed 
to the syntheses of contraception and health promotion studies, indicating that there has 
been a reasonable amount of research into the economics of sexual health services in the 
UK since 2010. Findings from these suggested that: 
 interventions to promote STI screening indicated that point-of-care tests, and 
interventions offered to high-risk groups in more accessible locations such as 
clinics, pharmacy, by phone, or at schools, could potentially be more cost-effective 
than their relevant alternatives.  
 interventions that targeted annual HIV testing to high-risk adults were found to be 
cost-effective by NICE standards, with (£17,500 per QALY gained) and without anti-
retroviral treatment (ART) (£26,800 per QALY gained).  
 UPA could be more cost-effective than LARCs for emergency hormonal 
contraception.  
 LARC methods could be more cost-effective to use than user-dependent 
contraceptive methods in terms of the pregnancies they would avert and the 
resultant costs potentially borne by health and social services.  
 school contraceptive services such as condom distribution, hormonal contraceptive 
provision and advance contraceptive provision could be cost-effective. 
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Limitations 
Several limitations to the set of studies included in this review should be considered. Sexual 
health services encompass a broad range of potential interventions, provided to diverse 
populations in mixed settings. The effectiveness of such interventions is often evaluated by 
measuring different outcomes, also often using comparison conditions that differ across 
studies. For these reasons, it proved difficult to synthesise results across studies other than 
by narrative comparison. The methodological quality of included studies was varied, with 
studies evenly split between low, medium and high methodological quality, suggesting that 
some caution is needed in interpreting the findings. In addition, the inclusion of a majority 
of US-based studies raises questions about the applicability of cost-effectiveness 
judgements to the UK context, given the differences in healthcare system funding, access, 
reimbursement and impact on health inequalities. Different categorisations of some LARCs 
were noted, and some studies of cost consequences may have gone beyond their ability to 
claim cost-effectiveness.  
This review sought to answer a broad research question. While it provided a considerable 
range of information on different interventions and different ways in which they were cost-
effective (or not), the small number of studies across contraception, health promotion and 
UK-based areas meant that limited depth of information on cost-effectiveness was 
available. The assessment of multiple types of studies necessitated the use of several 
different types of risk of bias tools, and the wide range of cost-outcome types also 
necessitated the development of a cost-outcome findings table, showing all results within a 
range of cost-effectiveness (please see Appendices 12 to 14 for more detail). 
Conclusions and recommendations 
The findings from this systematic review suggest that a large amount of research on the 
cost-effectiveness of sexual health services has been undertaken in the past five years, and 
that, while the study findings do not always measure costs per QALY or achieve NICE 
thresholds for cost-effectiveness, this evidence base generally suggests the cost-
effectiveness of interventions that meet current NICE guidance, particularly for sexual 
health services aimed towards young people and those at high risk. However, some 
interventions may be equivocal in terms of their cost-effectiveness, and others show cost-
effectiveness for some STIs but not others. The methodological quality of the included 
studies also warrants caution in interpretation of the findings, and the disparity of 
interventions, outcomes and study designs suggests that policy and decision makers should 
consider carefully the fit between their context and the population that they wish to reach, 
and those of individual studies.  
The differences in methods between economic evaluations make drawing comparisons 
across such studies difficult. Future economic evaluations of sexual health interventions 
which are based on internal trials could be strengthened by designing for longer-term 
outcomes that would allow for more robust modelling. In addition, use of large cohort study 
datasets measuring such long-term outcomes should be routinely used to strengthen model 
estimates.  
1. Background 
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1 Background 
1.1 Rationale for the review 
As of April 2013, following the government’s public health reforms, England’s local 
authorities assumed responsibilities for commissioning comprehensive sexual health services 
(Heath 2014; Hind 2013). These include: 
 contraception; 
 chlamydia testing as part of the National Chlamydia Screening Programme;  
 HIV testing;  
 STI testing and treatment;  
 sexual health aspects of psychosexual counselling; 
 sexual health specialist services such as young people’s sexual health and teenage 
pregnancy services, outreach, HIV prevention and sexual health promotion work, 
and services in schools, colleges and pharmacies. 
In order to commission sexual health services, local authorities require information 
regarding the interventions that are effective. The perceived benefits of these 
interventions may be outweighed by their costs; alternatively, other services may achieve 
the same (or better) outcomes for less money. Data in relation to cost-effectiveness are 
therefore critical in informing local authority commissioning decisions, in order to ensure 
value for money and a return on investment for any public health interventions undertaken 
(Local Government Association 2013). Current National Institute of Health and Care 
Excellence (NICE) guidance suggests that cost-effectiveness ratios of less than £20,000 per 
Quality-adjusted Life Year (QALY) may be considered cost-effective and good value (NICE 
2013a,b).  
Cost-utility analysis is of broad applicability in public health decision making because, as in 
cost-effectiveness analysis, it can explore single or multiple outcomes. However, cost-
utility analysis adds in a notion of value (utilities, measured as QALYs or disability-adjusted 
life years – DALYs). These utilities can be assessed for a range of interventions and 
facilitate comparisons between different health interventions using a common metric. 
However, some limitations for these metrics should be considered, such as their lack of 
compensation for socio-economic and demographic differences.  
Current UK guidance and recent research on the cost-effectiveness of sexual health services 
provides somewhat patchy evidence. In terms of recent research activity, a brief review on 
the economics of sexual health produced by the UK Department of Health to aid 
commissioning and planning for sexual health services was originally published in 2005 
(Payne and O’Brien 2005). This provided a useful, succinct summary of the relative cost-
effectiveness of sexual health services in the areas of health promotion, screening, 
treatment, fertility control and service delivery and organisation. While this report was 
compiled using evidence from a relatively limited number of sources and is in need of 
update, it did provide a basis for examining local authority sexual health provision.  
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Currently there are five existing UK guidelines concerning sexual health, focused on specific 
high-risk groups. Most of these guidelines provide very limited data in relation to the cost 
implications of sexual health services (NICE 2007, 2011a,b, 2014a,b). The cost-implications 
of these sexual health services are summarised below. 
NICE public health guidance 3: prevention of sexually transmitted infections (STI) and 
under-18 conceptions 
In 2007, NICE published guidance examining the effectiveness of interventions for the 
prevention of STI and conceptions in those aged less than 18 years. The authors concluded 
that most brief STI counselling interventions were cost-effective when compared with 
‘usual treatment’, but since no costs were attributed to ‘usual treatment’, the incremental 
cost of adding a new programme on to existing programming would be overestimated. This 
would result in a higher estimate of cost per outcome compared to an analysis that did 
consider the cost of usual care or existing programming (NICE 2007). 
NICE public health guidance on increasing the uptake of HIV testing  
Two NICE guidelines examining the uptake of HIV testing were published in 2011. Both 
guidelines concluded that finding, testing and treating people with HIV before they became 
symptomatic was likely to reduce onward transmission and be cost-effective (NICE 2011a, 
NICE 2011b).  
In NICE public health guideline 33 on increasing the uptake of HIV testing among black 
Africans in England, no studies were available to be included in a review of cost-
effectiveness. An economic model was constructed incorporating data from reviews of 
effectiveness and data on infectivity and the impact of treatment on life expectancy and 
disease progression (NICE 2011a).  
In NICE public health guideline 34 on increasing the uptake of HIV testing among men who 
have sex with men, one US study evaluating a peer education and testing recruitment 
programme was included in a review of cost-effectiveness. Again, an economic model was 
constructed incorporating data from reviews of effectiveness and data on infectivity and 
the impact of treatment on life expectancy and disease progression (NICE 2011b). 
NICE guidance costing report: contraceptive services with a focus on young people up to 
the age of 25.  
This costing report, produced in conjunction with key clinicians and commissioners and 
reviewed by clinical, public health and financial professionals, examined the potential 
resource impact of implementing NICE’s guidance, Contraceptive services focusing on young 
people up to the age of 25 in England (NICE 2014a). A local costing template was produced 
alongside the costing report to help users calculate the local cost impact of implementing 
the guidance. The authors anticipated savings due to a reduction in costs associated with 
unintended pregnancy and birth in young people and subsequent socio-economic 
deprivation, mental health difficulties and lower levels of educational attainment. Savings 
were also estimated in relation to reduced costs for abortion and the treatment of STI 
(NICE 2014a). 
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NICE guidance: Long-acting reversible contraception 
NICE guidance on long-acting reversible contraception (LARC) suggests that: all currently 
available LARC methods (intrauterine devices, the intrauterine system, injectable 
contraceptives and implants) are more cost-effective than the combined oral contraceptive 
pill; intrauterine devices, the intrauterine system and implants are more cost-effective 
than injectable contraceptives; and increasing the uptake of LARC methods will reduce 
costs associated with unintended pregnancies (NICE 2014b).  
The findings from current national guidance and recent systematic reviews provide a 
somewhat limited and potentially out-of-date picture of the cost-effectiveness of sexual 
health services in relation to local authority needs, focusing on specific interventions 
and/or particular populations.  
1.2 Aims and research question 
This review was undertaken in order to provide local authorities with current, rigorously 
assessed research evidence on the cost-effectiveness of sexual health interventions. The 
objective of the review was to classify sexual health interventions according to their 
relative cost-saving or cost-effectiveness as defined by current NICE public health 
guidelines (NICE 2013a, NICE 2013b). The following research question was developed 
following consultation with the funders and our Advisory Group:  
What evidence is available from OECD economic evaluations published in the last 
five years in relation to those sexual health services for which local authorities are 
responsible? 
Studies identified through searching constituted a ‘map’ of research, which provided 
information on the breadth of economic evaluations undertaken in local authority sexual 
health service provision. Further consultation with funders and our advisory group while 
presenting these findings resulted in a second question, which drove more in-depth 
analysis:  
From the relevant identified studies, what evidence is available on cost-effectiveness 
for local authority commissioned sexual health services concerning studies of health 
promotion and in relation to studies of contraception, and what is the evidence 
specific to the UK? 
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2 Methods 
2.1 Stakeholder consultation 
It is beneficial to involve those who will ultimately be affected by the findings of a study, 
for several reasons. Stakeholders provide: expertise on an issue; perspectives on relevant 
areas in which to focus the work; suggestions for presenting findings in an accessible way; 
and the potential to communicate research findings to their networks (Rees and Oliver 
2012).  
Consultation with the Department of Health’s Sexual Health Policy team and key 
commissioning stakeholders in November 2014 resulted in a preliminary research synthesis 
comprising a systematic review of systematic reviews. This was presented to an Advisory 
Group comprised of specialist academics, commissioners, sexual health charity members 
and the funder in April 2015. The Advisory Group members’ role in the project was to 
identify potentially relevant research, to provide feedback on the scope of the review, and 
to comment upon the draft report. Members of sexual health charities were sought in order 
to represent, to some extent, the views of service users.  
The findings from the analysis of data extractions were presented and group members were 
asked to provide their thoughts on how to usefully focus the research. They noted that, 
while this informed their thinking on the scope of research available, it did not provide 
clear answers for local commissioning. A request was made subsequently by the Advisory 
Group for the research team to conduct a similar preliminary research synthesis ‘map’ on 
primary economic evaluations in sexual health. The Advisory Group met once again with 
researchers in July 2015, to consider the findings from this preliminary map and to agree 
upon the focus of the review for the in-depth synthesis presented here. 
2.2 Searching for studies  
Potentially relevant citations were located through three sources: key informants, 
bibliographic database searches and reference lists of included studies. Advisory Group 
members were asked for any relevant reviews of cost-effectiveness. Economic evaluations 
from all NICE guidelines relevant to sexual health services were identified for screening 
assessment. Bibliographic database sources of economic and sexual health literature were 
searched, including EconLIT, NHS Economic Evaluations Database (NHS EED), POPLINE 
(reproductive health literature database) and PubMed.  
Database searches were limited to citations published between 2010 and 2015. Search 
strings based on a combination of free-text and database-specific terms were developed in 
collaboration with our information scientist. The concepts to be combined included: (sexual 
health terms) AND (cost terms). An example showing the PubMed search string is provided 
in Appendix 1. The located citations were uploaded into EPPI-Reviewer software, for 
management of retrieval, coding and synthesis (Thomas et al. 2010). Reference lists of all 
included studies were searched for potentially relevant research.  
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2.3 Inclusion/exclusion screening  
All located citations were assessed first for eligibility on the basis of their titles and 
abstracts. After consultation with our Advisory Group to determine the scope of the in-
depth analysis, the full text of those citations meeting the inclusion criteria were retrieved 
and assessed again for inclusion. At the title and abstract stage of screening, in order to be 
included for further analysis, studies had to: 
 be published during or after 2010  
 be published in the English language 
 evaluate sexual health interventions for which local authorities are responsible 
 present economic or cost data 
 be a full economic evaluation (i.e. cost-effectiveness, cost-benefit, cost-utility, 
cost-minimisation or cost-consequence studies).  
 be conducted in an OECD country. 
Studies published since 2010 were sought in order to reflect current local authority sexual 
health service provision. Only English language studies were included because the time and 
resources available did not permit the translation of foreign language material. However, 
relevant international references were grouped for later translation and could be used 
where resources and need permit.  
Studies which examine cost-effectiveness, cost-utility, cost-benefit, cost-saving and cost-
consequence are considered ‘full economic evaluations’ (Shemilt et al. 2008). Each of these 
types is defined in the Glossary. Full economic evaluations compare both the outcomes and 
costs of an intervention against the outcomes and costs of an alternative condition, which 
may be either standard care, the next best alternative, or a ‘do nothing’ scenario. Full 
economic evaluations were selected for inclusion because they are considered more robust 
than burden of cost or cost of illness studies, which do not have a comparator (Drummond 
2015; Shemilt et al. 2008).  
Finally, only primary studies from OECD countries were sought in order to limit the scope of 
the review, promote relevance for policy makers and avoid the difficulties of comparing 
economic data across different health service commissioning contexts.  
Citations were coded on the basis of their titles and abstracts according to the data 
extraction methods described below. These findings were presented to the Advisory Group 
in July 2015, and the group recommended that further synthesis should focus on specific 
areas of sexual health service delivery. For this reason, full-text reports were retrieved and 
screened according to the above criteria and also according to whether they were:  
 UK-based  
 or about contraception 
 or focused on health promotion activities. 
2.4 Data extraction/coding 
Studies were coded according to characteristics of interest, including: 
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 year of publication  
 targeted population  
 targeted health issue or condition 
 targeted behaviour 
 type of economic evaluation  
 intervention characteristics 
 outcomes measured 
To code the studies, data on the above characteristics were extracted from each study, 
using a tool developed and tested by the research team.  
2.5 Risk of bias assessments 
Two types of risk of bias/methodological quality assessment were undertaken in this 
review. Full economic evaluations can be conducted based on a trial of effectiveness 
(internal economic evaluation), or based on findings from a review of effectiveness 
(external economic evaluation). Such economic evaluations will provide an estimate of 
actual costs and outcomes. Full economic evaluations can also be developed as a 
hypothetical model of costs and outcomes within a given context; in this case, the model 
will draw on multiple sources of effectiveness evidence to justify the parameters used. 
These can include prevalence studies or findings from several effectiveness studies. These 
economic evaluations provide an estimate of potential costs and outcomes, given a similar 
context.  
Because these two types of full economic evaluation contain different sources of 
effectiveness evidence, we utilised different risk of bias/methodological quality assessment 
tools to consider the studies. Where internal economic evaluations were undertaken, a 
previously tested risk of bias tool was used (NICE 2012). If effectiveness evidence arose 
from systematic reviews, AMSTAR criteria were used to assess review quality (Shea et al. 
2009). In addition, where an economic evaluation was built on modelled costs and 
outcomes, a tool combining relevant criteria from recognised risk of bias and 
methodological quality assessment tools for economic evaluations was developed by three 
health economists, tested for face validity and applied (Evers et al. 2005, NICE 2012, 
Phillips et al. 2004).  
2.6 Synthesis 
Citations determined to be potentially relevant to the review question were coded based on 
their title, abstract and citation information, using codes developed from the data 
extraction items described above. Descriptive frequencies of these codes were calculated 
and findings narratively summarised, providing a ‘map’ of literature relevant to the review 
question. The findings from this map informed the identification and synthesis of a more 
focused set of studies. These were grouped first by their specific focus (UK-based; 
contraception; health promotion). Within each group, studies were organised first by 
whether they were based on an ‘internal’ or ‘external’ trial or whether they were derived 
from a model. Where the number of studies allowed, each of these were then grouped by 
the type of full economic evaluation (i.e. CBA, CUA, CEA, cost saving) in order to make 
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comparison of cost outcomes as similar as possible. Costs were converted according to the 
following rates listed in Table 2.1. 
Table 2.1: Cost-conversion rates 
Year USD to GBP Euro to GBP 
2002 0.658 - 
2003 0.659 - 
2004 0.655 - 
2005 0.649 - 
2006 0.648 - 
2007 0.645 - 
2008 0.653 - 
2009 0.663 - 
2010 0.675 - 
2011 0.677 - 
2012 0.675 0.74 
2013 0.679 - 
 Source: http://eppi.ioe.ac.uk/costconversion/default.aspx (accessed 8 March 2016). 
Costs and outcomes for each group of studies were then compared and contrasted in terms 
of their populations, interventions, health outcomes, costs and cost-effectiveness. Studies 
were also arranged according to their relative cost-saving or cost-effectiveness (NICE 
2013a,b):  
 Below GBP £20,000 per QALY gained (cost-effective) 
 £20,000 - £30,000 per QALY gained (potentially cost-effective) 
 Above £30,000 per QALY gained (not cost-effective). 
2.7 Quality assurance 
Several steps were taken to assure the review’s quality. Searches were developed in 
consultation with our information scientist, using a combination of free-text and thesaurus 
terms to ensure sensitivity of searching. At each stage of screening (i.e. title/abstract stage 
and full report stage), risk of bias/methodological quality assessment and data extraction 
and synthesis were initially undertaken by at least two researchers with expertise in either 
health research methods or health economics. Once inter-rater reliability for screening was 
established (kappa=0.9), individual screening was subsequently undertaken. All references 
were manually screened. Two researchers independently assessed risk of bias/ 
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methodological quality and extracted data from all studies, meeting to compare and agree 
ratings. For each stage of the review, EPPI-Reviewer specialist systematic review software 
was used to manage data, allow rating comparisons and structure the synthesis (Thomas et 
al. 2010). 
2.8 Presentation of findings 
The findings were synthesised narratively and also presented in tabular format; these are 
presented in the Appendices at the end of this report. In addition, consultations with 
Advisory Group commissioners suggested that the development of structured summaries for 
each included study would help readers to interpret and generalise the study descriptions 
and results to their own context.  
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3 Results 
3.1 Flow of studies through the review 
In total, 17,705 potentially relevant references were identified on the basis of title and 
abstract. Of these, 108 were retrieved and assessed for inclusion again based on the full 
report. A subset of 86 of these available for analysis were included in a descriptive map of 
research, which is described in further detail below. After consultation with our Advisory 
Group, further screening according to revised criteria, and removal of linked and duplicate 
studies, a total of 29 studies were included for further analysis. The reasons for exclusion 
at each stage of the inclusion screening process is documented in Appendix 3. 
3.2 Map of studies 
Findings from 86 available reports meeting our inclusion criteria were descriptively 
analysed by country, topic, setting, population, intervention focus, targeted behaviour and 
type of economic evaluation. The map was intended to serve as a method of illustrating the 
breadth of research available in order to facilitate discussion and decision making by the 
Advisory Group and research team as to which areas would be most appropriate for in-
depth analysis. Tables and charts illustrating these characteristics of included studies are 
provided in Appendix 4.  
The majority of reports included in the map described economic evaluations which took 
place in the US (n=56). A total of nine UK economic evaluations were located, the next 
highest number by country, followed by Australia (n=4), Canada (n=2), and one each for 
France, Italy, the Netherlands, Mexico and Portugal. Ten reports did not specify the country 
of origin.  
Sexual health topics under study varied considerably, and many reports examined multiple 
topics. HIV was studied most often (n=45), followed by contraception (n=23) and STIs 
(n=18). Related to these were the relevant interventions which were evaluated. These 
included: screening (n=39), sexual health promotion (n=16), contraception (n=15), 
treatment (n=14) service delivery and organisation (n=8) and other (n=3). 
The reports did not describe well the settings in which interventions took place: only 33 of 
the 86 reports provided this information. Sexual health or genitourinary medicine (GUM) 
clinics were the setting in the largest group of studies (n=13), followed by clinic settings of 
unspecified type and family planning clinics (n=3 each).  
There was considerable variation in the populations studied by the economic evaluations. 
These included women (n=21) most often, followed by men who have sex with men (n=14), 
and then studies with the general population (n=11). A total of 24 reports did not describe 
the populations under study.  
Targeted behaviour most often focused on service provision (n=63), followed by uptake of 
screening (n=15) and unspecified behaviour (n=10).  
Finally, studies were mapped according to the type of economic evaluation design 
employed. A total of 48 reports described cost-effectiveness design, followed by 31 reports 
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estimating cost-utility. Cost-benefit designs were used in seven reports and two reported 
using cost-minimisation designs.  
3.3 Stakeholder consultation on map and in-depth topics 
The descriptive map findings above were presented to Advisory Group members in July 
2015. Various combinations of topics, setting, populations and designs were discussed, as 
was the overlap of the current review with other work taking place on pre-exposure 
prophylaxis for HIV, and on hepatitis, and wider screening functions shared with national 
screening programmes. Advisory Group members considered that it was important to focus 
the review in three ways, in order to provide the most relevant information for local 
authority decision making. They advised a focus on UK economic evaluations, and economic 
evaluations of contraception and of health promotion.  
The reports included in the map were re-screened according to these topics and, once 
linked studies and duplicates were identified, a final set of 29 studies was included in 
further analysis. Of the modelling studies, the majority utilised decision-analytic or Markov 
modelling (n=7), followed by cost-effectiveness modelling (n=4). Two studies each utilised 
Bernoulli, compartmental or state transition modelling. The remainder described cost-
utility (n=1), cost-benefit (n=1), cost-consequence (n=1), progression (n=1), cost-sequence 
analysis (n=1) and general modelling (n=3). Eight models were based on internal randomised 
controlled trials; five models were based on observational studies. The studies are 
described by topic below: UK-based, contraception and health promotion. 
3.4 UK-based economic evaluations 
A total of nine UK-based economic evaluations published since 2010 were located (Cooper 
et al. 2012; Crawford et al. 2015; Jackson et al. 2015; Long et al. 2014; National 
Collaborating Centre (NCC) 2013; Pilgrim et al. 2010; Roberts et al. 2012; Thomas and 
Cameron 2013; Turner et al. 2014). Of these, four were cost-effectiveness analyses (Cooper 
et al. 2012; NCC 2013; Pilgrim et al. 2010; Thomas and Cameron 2013). Two were cost-
consequence analyses (Jackson et al. 2015; Roberts et al. 2012). Long et al. (2014) and 
Crawford et al. (2015) undertook cost-utility analyses and Turner et al. (2014) conducted 
both cost-effectiveness and cost-utility analyses. These studies focused on STI screening 
and treatment, contraception and health promotion interventions. They are summarised 
below, with their main findings. Full details of these studies are provided in the Evidence 
Tables in Appendix 8, and relative costs and outcomes are shown in the Costs and Outcomes 
Tables in Appendix 12. 
3.4.1 STI screening 
Four of the nine included studies undertaken in the UK examined the costs and outcomes of 
STI screening (Long et al. 2014; Jackson et al. 2015; Roberts et al. 2012; Turner et al. 
2014). Two of these focused on methods of testing and treatment (Long et al. 2014; Turner 
et al. 2014); the other two examined specific health promotion interventions (Jackson et 
al. 2015; Roberts et al. 2012).  
The findings from two studies undertaking cost-utility analyses suggested that, compared to 
standard care, annual HIV testing and treatment targeted to high risk groups and point-of-
care testing for chlamydia and gonorrhoea provided to GUM clinic patients met NICE 
threshold criteria for cost-effectiveness. No cost benefit analyses were conducted. In order 
to test potential expanded HIV testing in the UK, Long et al. (2014) modelled different HIV 
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epidemic scenarios based on different interventions in a hypothetical UK population aged 
15 to 64 years, categorised by country of origin and risk states (men who sleep with men - 
MSM, injecting drug users - IDU, men and women from HIV-endemic countries with high 
disease prevalence) and further subdivided by HIV infection and diagnosis status, ART status 
and male circumcision status. The interventions under study were: universal HIV testing, 
targeted HIV testing and expanded ART, each compared to current HIV testing and 
treatment levels. The findings indicated that annual HIV testing of all adults could avert 5% 
of new infections, even with no behaviour change after diagnosis, due to the earlier 
initiation of ART treatment. However, this could rise to 18% if risky behaviour were reduced 
by half. The authors reported that this strategy cost £67,000-106,000 per QALY gained 
(2012 GBP), not cost-effective according to the NICE threshold for cost-effectiveness (NICE 
2013a,b). However, annual testing targeted to high-risk groups compared to universal one-
time testing resulted in averting 4–5% of new infections, with a cost outcome of £17,500 per 
QALY gained. Targeted annual testing with ART treatment compared to universal one-time 
testing resulted in 145,000 QALYs added to the population over ten years, with a cost 
outcome of £17,500 per QALY gained. This falls below the £20,000 per QALY gained NICE 
threshold for cost-effectiveness.  
The study rated as ‘medium’ in terms of its methodological quality. It was one of the first 
to combine epidemiological, behaviour and CD4 bands into a complex HIV disease progress 
assessment for a cost-effectiveness analysis of HIV screening in the UK, using different 
sources of data. Although some limitations can be identified, the presented results are 
robust and informative for policies on interventions for HIV. The reviewers (i.e. the 
research team undertaking this review) noted that in addition to the limitations identified 
by the authors, HIV treatment was not explicitly modelled; instead, upon diagnosis it was 
assumed that individuals were estimated to have a longer life expectancy that was 
(implicitly) due to ART, and that the assumed reductions in HIV infectiousness were due to 
reductions in viral load due to ART. Additional attempts can be made to better explore the 
implications of early HIV screening and treatment to better understand the impact of the 
costs of ART in the long term for the control of HIV transmission. The reviewers also 
suggested that, rather than the 3% used for both costs and outcomes, a 3% discount rate 
could be applied for costs and 1.5% for health effects in line with NICE recommendations 
for treatment effects that are substantial in restoring health and are sustained over a very 
long period (at least 30 years). Using a lower discount rate to value QALYS gained in the 
future will result in more QALYs gained and is therefore likely to result in a more 
favourable cost-effectiveness ratio.  
Turner et al. (2014) estimated the costs and consequences of providing a point of care 
(POC) chlamydia and gonorrhoea test to a hypothetical sample of 1.2 million GUM clinic 
patients, compared to the standard practice of off-site testing. The model estimated that 
189 cases of pelvic inflammatory disease (PID) would be prevented per year, with 17,561 
onward transmissions prevented per year, saving £11.7 million (2012 GBP) and adding 46 
QALYs compared with the standard off-site testing. The authors suggested that this was a 
cost-saving intervention. This study was determined to be of high methodological quality by 
the reviewers, however limitations were noted associated with the availability of quality 
data to model the implications of POC nucleic acid amplification test (NAAT) testing on 
STIs. 
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Two studies utilised other methods to evaluate costs and outcomes. Roberts et al. (2012) 
aimed to examine the costs and consequences of accelerated partner therapy (APT) offered 
by telephone or in community pharmacies, compared to routine patient referral partner 
notification for sex partners of people with chlamydia, gonorrhoea or non-gonococcal 
urethritis. Accelerated partner therapy is a form of partner notification in which 
identification and treatment of potentially affected partners is expedited more by 
professionals. The authors suggested that both interventions were more cost-effective than 
the control condition, but because this was a cost-comparison analysis, neither intervention 
was better than the other. In comparison to routine patient referral partner notification, 
which cost £46 per partner treated (2008 GBP) and identified 11% of partners, the phone 
APT intervention identified 35% more partners for treatment, and cost £54 per partner 
treated. The community pharmacy APT intervention identified 34% of partners for 
treatment at a cost of £53 per partner treated. This study rated medium on methods for its 
economic evaluation. The main limitations are associated with the fact that, as an 
exploratory analysis, emphasis should have been given to the assessment of key parameters 
used in the model to better understand sources of uncertainties. 
Jackson et al. (2015) aimed to compare the costs and outcomes of two STI screening 
interventions targeting men aged 18 years and older in six England football clubs, by 
undertaking a randomised controlled trial (RCT) in which cost data were also collected. 
Two interventions were evaluated. A STI screening health promotion campaign led by team 
captains and one led by sexual health advisers were each compared with a poster-only 
campaign control condition. The results indicated that all three interventions cost similar 
amounts, but the sexual health-adviser-led intervention was most cost-effective in terms of 
screening uptake, as it led to 67% screening at a cost of £88.33 per person screened (2012-
2013 GBP), compared to the poster-only campaign, which cost £81.87 but resulted in only 
61% screening uptake. The team captain-led intervention was least cost-effective, resulting 
in 50% screening uptake at a cost of £88.89 per person. The economic evaluation conducted 
alongside the trial also aimed to assess the cost per case of gonorrhoea and chlamydia 
detected; however, no cases were identified as part of the trial. The trial was judged to be 
of medium methodological quality, with many uncertainties around the parameters used in 
the analysis. It was unclear whether costs were annuitised, and the time horizon was 
unclear. Seemingly, the analysis was undertaken for a time horizon of one year and the 
costs with posters were considered for three years. If this was the case, the costs may be 
slightly underestimated. 
In summary, UK-based HIV/STI economic evaluations suggested that the following strategies 
could potentially be cost-effective: (1) targeted annual HIV testing and ART to high risk 
groups (compared to universal testing and no treatment); (2) point-of-care chlamydia and 
gonorrhoea testing to people presenting at GUM clinics (compared to off-site testing); and 
(3) accelerated partner therapy either by phone or through community pharmacy 
notification (compared to routine referral); and (4) sexual health adviser-led screening 
promotion (compared to poster-only screening promotion). Two strategies were found to 
not be cost-effective. Universal HIV testing of whole populations was estimated to cost 
more than accepted NICE thresholds for cost-effectiveness; and football team captain-led 
STI screening uptake promotion was found to be more costly and less effective than sexual 
health adviser-led or poster-only alternatives. Only targeted annual testing (Long et al. 
2014) and point of care testing (Turner et al. 2014) were found to fall below NICE 
thresholds for cost-effectiveness. Methodological quality of this set of studies varied from 
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low to high, limiting somewhat the confidence readers can place in the findings. All STI 
screening studies are summarised in Appendix 11.  
3.4.2 Contraception 
Three of the UK economic evaluations that were included examined contraception. One 
focused on methods of emergency contraception, one on long-acting reversible 
contraceptives (LARCs), and one on promoting uptake of contraceptive services among 
disadvantaged youth.  
Thomas and Cameron (2013) modelled the cost-effectiveness of ulipristal acetate (UPA) 
versus levonorgestrel (LNG) as emergency hormonal contraception (EC) among women in 
England presenting for contraception within 24 to 72 hours of unprotected intercourse. The 
authors estimated that ‘almost one-quarter’ of pregnancies in England were unintended, 
and UPA was shown to cost between £194 and £1,453 less per avoided pregnancy than LNG 
(2011 GBP), depending on whether social care costs were included or not. This led the 
authors to conclude that it was a cost-saving intervention. The methodological quality of 
this economic modelling study was rated as low due to limitations in: outcome 
measurement, model cycle, baseline estimates of health effect and resource use, 
sensitivity analyses, model calibration and unclear reporting of the time horizon and 
adverse events. 
The National Collaborating Centre for Women and Children’s Health (NCC-WCH) (2013) 
aimed to evaluate the cost-effectiveness of LARCs (IUD, IUS, injectable or implant) 
compared with user-dependent methods (combined oral contraceptives (COC), the male 
condom), and non-reversible contraceptive methods (i.e. male and female sterilisation). 
The number of unintended pregnancies averted and costs for care and contraception were 
calculated. The economic outcome was the cost per pregnancy averted. Costs and 
effectiveness were modelled from an NHS (i.e. direct costs) in a hypothetical cohort of 
1,000 UK women using contraception. The results suggested that over one year of use, LARC 
methods would be associated with a smaller number of unintended pregnancies due to 
contraceptive failure compared to combined oral contraceptives and male condoms. Over 
15 years of use, all LARCs would dominate user-dependent methods (i.e. would be less 
costly and more effective). Comparing LARCs to each other, the IUD and implant were 
found to dominate the IUS; and all three dominated the injectable method. However, which 
LARC dominates is also dependent on how long each method is used. For example, implants 
had a lower cost per pregnancy than all other LARCs over the first three years of use, 
potentially costing £14,730-17,866 per pregnancy averted (2004-2005 GBP). The 
methodological quality of this economic modelling study was rated as medium because 
many uncertainties were not fully described relating to the parameters and structure of the 
model. Sensitivity analyses were undertaken to examine variation in: the duration of use, 
combined use with condoms, changes in ingredients and costs of health service 
comparisons, ideal use of condom and combined oral contraceptives, and discount rates. 
Key parameters should be assessed in a sensitivity analysis to account for uncertainties 
related to them. In addition, the model was adapted from previous studies, but no 
validation and/or calibration was reported. 
Pilgrim et al. (2010) also focused on health promotion topics, by testing three different 
school-based contraceptive models to determine their cost-effectiveness. In the first, two 
strategies were tested amongst a hypothetical cohort of 100,000 young people aged 14 to 
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16 years: condom provision was compared to a routine school nurse role only; and hormonal 
contraceptive provision was compared to condom provision. Condom provision was 
estimated to cost £38 for each pregnancy averted and to cost £822 for each abortion 
avoided (2007-2008 GBP). In comparison to condom provision only, contraceptive provision 
was estimated to cost £443 for each averted pregnancy and £1,453 for each abortion 
avoided. In the second model, school-based peer education and social work case 
management to prevent repeat pregnancy was examined amongst teen mothers under 19 
years of age who were attending school, compared to no follow-up after the first 
pregnancy. The authors suggested that this resulted in an estimated £4,031-15,155 cost for 
each repeat pregnancy averted. The third model estimated the costs per pregnancy averted 
and abortion avoided when providing advanced hormonal contraception to a hypothetical 
cohort of 100,000 young people aged 15 to 19 years, compared to no advance provision. 
The findings estimated that advanced provision cost £310 for each repeat pregnancy 
averted, and cost £2,795 for each abortion avoided. The methodological quality of this 
economic modelling study was rated as medium due to limitations in outcome measures, 
baseline and treatment effect estimates, missing costs, conflict of interest reporting and 
model validation. 
In summary, the findings from UK-based contraception economic evaluations suggest: (1) 
UPA could be more cost-effective than LNG; (2) LARCs are potentially more cost-effective 
than user-dependent contraceptive methods, and implants more cost-effective than other 
LARCs by three years of use; (3) school-based contraceptive provision could be more cost-
effective than condom provision, which itself is more cost-effective than school nurse 
services; and (4) school-based advance provision of contraception was more cost-effective 
than costs related to pregnancy. The mixed methodological quality of these studies 
suggests some caution in applying the findings. These cost and outcome findings are 
presented in Appendix 12.  
3.4.3 Health promotion 
Four economic evaluations focused on health promotion topics (Cooper et al. 2012; 
Crawford et al. 2015; Jackson et al. 2015; Pilgrim et al. 2010). Using a cost-effectiveness 
analysis design, Cooper et al. (2012) compared teacher- or peer-led sexual health 
education interventions to standard school sexual health education. The authors suggested 
that compared to standard sexual health education, the teacher-led intervention was cost-
effective at £18,041 per QALY gained (2011-2012 GBP); this demonstrates cost-
effectiveness as it is below the £20,000 NICE threshold. However, in comparison to the 
teacher-led intervention, the peer-led intervention exceeded the NICE upper limit for cost-
effectiveness at £72,062 per QALY gained. This economic evaluation was rated as high in 
terms of its methodological quality.  
As noted above, Jackson et al. (2015) focused on a cost comparison of screening and 
health promotion (as described above). A STI screening health promotion campaign led by 
team captains and one led by sexual health advisers were each compared with a poster-
only campaign control condition. The results indicated that all three interventions cost 
similar amounts, but the sexual health-adviser-led intervention was most cost-effective, as 
it led to 67% screening at a cost of £88.33 per person screened (2012-2013 GBP), compared 
to the poster-only campaign which cost £81.87 but resulted in only a 61% screening uptake. 
The team captain-led intervention was the least cost-effective, resulting in 50% screening 
uptake at a cost of £88.89 per person. The trial was judged to be of medium 
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methodological quality, with many uncertainties around the parameters used in the 
analysis. It was unclear whether costs were annuitised, and the time horizon was unclear. 
Seemingly, the analysis was undertaken for a time horizon of one year and the costs with 
posters were considered for three years. If this was the case, the costs may be slightly 
underestimated. 
As described above, Pilgrim et al. (2010) examined contraception and health promotion 
strategies by testing three different school-based contraceptive models for cost per unit of 
health effect, where health effects were expressed as pregnancies averted and abortions 
avoided. Condom provision was estimated to cost £38 for each pregnancy averted and to 
cost £822 for each abortion avoided (2007-2008 GBP), compared to routine school nurse 
utilisation. In comparison to condom provision only, contraceptive provision was estimated 
to cost £443 for each averted pregnancy and £1,453 for each abortion avoided. In the 
second model, school-based peer education and social work case management to prevent 
repeat pregnancy was compared to no follow-up after the first pregnancy. The authors 
suggested that this resulted in an estimated £4,031-15,155 cost for each repeat pregnancy 
averted. The third model estimated the costs per pregnancy averted and abortion avoided 
when providing advanced hormonal contraception compared to no advance provision. The 
findings estimated that advanced provision cost £310 for each repeat pregnancy averted, 
and cost £2,795 for each abortion avoided. The methodological quality of this economic 
modelling study was rated as medium due to the limitations described above. 
One other economic evaluation was identified which took a health promotion focus. 
Crawford et al. (2015) aimed to investigate the clinical and cost-effectiveness of brief 
advice for excessive alcohol consumption, which included sexual health education amongst 
people aged 19 years and older attending one of three sexual health clinics in London, 
England. The researchers used an RCT design in which costs were collected and analysed 
and a cost-utility analysis undertaken. Comparison group participants received a health 
education leaflet only. While costs to provide intervention or control conditions were 
similar in both groups (intervention £311 per person v. control £319 per person) (2010-2011 
GBP) and the average additional cost of the intervention was modest at £12.57 (SD £6.59), 
no significant differences in either 90-day alcohol consumption or reported unprotected sex 
were found. The authors concluded that the intervention was not cost-effective as it was 
more costly than not providing any intervention and did not provide any additional benefit. 
The methodological quality of the integral trial was rated to be high, as study design and 
parameters seemed to be appropriately explored, also in a sensitivity analysis, where the 
authors tested the strength of the findings: ‘bootstrap’ techniques and non-hierarchical 
linear models were undertaken to assess missing data. The quality of the economic 
evaluation was also rated as high.  
In summary, UK-based health promotion studies evaluated a diverse range of interventions, 
most of which were found to be potentially cost-effective. A sexual health adviser-led 
screening promotion campaign amongst football clubs had a lower cost per case detected 
compared to the poster-only comparison. In school settings, hormonal contraceptive 
provision could be more cost-effective than condom provision, which itself was predicted to 
be more cost-effective than school nurse services; and school-based advance provision of 
contraception was estimated to be more cost-effective than no provision. Teacher-led 
sexual health education was found to be cost-effective according to NICE thresholds, but 
peer-led interventions were less cost-effective in comparison to those which were teacher-
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led. In contrast, brief alcohol advice and referral provided in STI clinics was found to be 
less costly but also less effective than health information leaflet provision, and football 
team captain-led STI screening uptake promotion amongst football club members was found 
to be more costly and less effective than a poster-only campaign. Again, it should be noted 
that the findings were derived from economic evaluations of mixed quality, suggesting that 
some caution is needed in the interpretation. The costs and outcome findings are described 
in more detail in Appendix 12.  
3.5 Economic evaluations of contraception  
A total of fifteen studies were economic evaluations of contraception. Three of these 
examined emergency hormonal contraception (Bayer et al. 2013; Foster et al. 2010; 
Thomas and Cameron 2013); nine assessed long-acting versus user-dependent contraception 
methods (Foster et al. 2013; Han et al. 2014; NCC 2013; Rodriguez et al. 2010a,b; Salcedo 
et al. 2013; Trussell et al. 2013, 2014, 2015); and two studies examined different 
contraceptive services provision (NCC 2013; Pilgrim et al. 2010). Full details of these 
studies are provided in the Evidence Tables in Appendix 10; and relative costs and 
outcomes are shown in the Costs and Outcomes Tables in Appendix 13. 
3.5.1 Emergency hormonal contraception 
Three economic evaluations modelled different scenarios of the provision of emergency 
hormonal contraception (EC): one cost-benefit analysis (Foster et al. 2010) and two cost-
effectiveness studies (Bayer et al. 2013; Thomas and Cameron 2013). 
The cost-benefit analysis by Foster et al. (2010) modelled two scenarios: (1) advance 
emergency contraception (EC) provision and (2) on-demand community or pharmacy 
provision of an unspecified contraceptive drug in comparison to no access within three 
hypothetical cohorts of one million sexually active US women using a public payer 
perspective. For both high and low frequency of use, both scenarios were estimated to 
produce a lower pregnancy rate than no access. The authors estimated that the cost savings 
ratio for both types of provision was greater than 1.00, meaning that the money saved by 
averting pregnancies was less than the cost of providing the EC, and the advance provision 
was slightly more cost-saving than on-demand provision. This economic evaluation was 
judged to be of medium methodological quality. Some limitations were noted, for example, 
that the authors only looked at savings from pregnancies averted for one year, potentially 
underestimating cost savings of advance provision if an EC supply was kept for longer. Also, 
the authors assumed that unprotected acts of intercourse occurred randomly throughout 
the menstrual cycle, but costs savings would be higher if women were more likely to use 
emergency contraceptive for acts that occurred in the week before ovulation. The authors 
only modelled intercourse where no contraception was used; in this case cost-effectiveness 
would be lower if EC were used in situations where the likelihood of conception was lower 
than with no contraception (e.g. missed pill). In addition, the authors only considered the 
medical costs of unintended pregnancy for up to two years after a birth, but social, welfare 
and private costs were likely to be much higher. The reviewers suggest that the authors 
model scenarios assessing the identified limitations for a longer period, and that they 
should include complications such as STIs in a long-term assessment of health benefits and 
costs.  
Two cost-effectiveness studies examined the use of oral UPA compared to oral LNG. Bayer 
et al. (2013) modelled the use of UPA 30 mg compared to oral LNG 1.5 mg administered 
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within 120 hours of unprotected sex. This was examined in a hypothetical US national 
cohort of reproductive-aged women. Over an unstated but assumed 10-month time horizon, 
use of UPA was estimated to result in 54,295 unintended pregnancies at a cost of £270.25 
million (2011 GBP) ($399.19 million 2011 USD), compared to 91,884 unintended pregnancies 
with use of LNG at a cost of £348.96 ($515.45) million. Cost-effectiveness was estimated to 
be £78.73 million ($116 million) per 8,053 QALYs, leading the authors to conclude that UPA 
was cost saving. This economic evaluation was rated low in terms of its methodological 
quality. The reviewers noted that the analysis was limited by a number of issues, including 
the fact that the authors did not state the perspective of analysis, so the reviewers were 
unsure whether results could be extrapolated to the entire society or not, or whether they 
should be interpreted only from the perspective of Medicaid users. The reviewers also 
noticed that complications such as STIs were not included.  
Thomas and Cameron (2013) modelled the provision of UPA 30 mg within 120 hours of 
unprotected intercourse versus LNG 1.5 mg taken within 72 hours of unprotected sexual 
intercourse, using a healthcare and societal perspective in a hypothetical cohort of sexually 
active UK women. The authors suggested that the associated costs of unintended pregnancy 
would be £1,663-2,922 (2011 GBP), depending on the perspective used, and the model 
suggested that UPA would cost £194-1,453 less per avoided pregnancy than LNG. The 
methodological quality of this economic modelling study was rated as low due to limitations 
in outcome measurement, model cycle, baseline estimates of health effect and resource 
use, and sensitivity analyses and model calibration, and unclear reporting of the time 
horizon and adverse events.  
Taken together, these three economic evaluations suggest that advance and on-demand EC 
are cost-saving in relation to no access for both high- and low-use groups, and that oral UPA 
is more cost-effective than LNG as a method of emergency contraception. However, these 
findings are based on studies that are rated low and medium in terms of their 
methodological quality.  
3.5.2 Long-acting versus user-dependent methods 
Nine studies assessed the economics of long-acting reversible contraception (LARCs). Five of 
these looked specifically at how different contraceptive methods compared with each other 
or with no contraception.  
Foster et al. (2013) examined all contraceptive methods in comparison to no contraception 
using a cost-benefit model. Data were assessed from over 1 million low-income US women 
using contraceptive services offered through the American Family PACT medical health 
insurance programme over a two-year period. Findings suggest that all forms of 
contraception are effective in reducing unintended pregnancies, and all would potentially 
save more money than they cost to provide. Contraceptive implants and copper and 
hormonal intrauterine systems (IUS) were estimated to provide the largest cost savings, 
ranging from £3.24 to £3.32 (2009 GBP) ($4.89 to $5.00 2009 USD) in costs averted for each 
$1.00 spent. This economic evaluation was judged to be of medium methodological quality. 
The main limitations associated with the study were identified by the authors, but the 
reviewers also suggest that future research incorporates the long-term benefits, in terms of 
costs and health outcomes, of the impact on complications such as HIV and other STIs.  
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Similarly, Trussell et al. (2015) assessed the cost-effectiveness of all contraceptive 
methods versus no method, and LARCs versus UDC, using a hypothetical cohort of US 
women aged 20 to 29 years and a public payer perspective. Modelling predicted that 2.1 
years of any type of LARC use (IUD, IUS or implants) would result in cost savings in 
comparison to user-dependent contraceptive methods (injectables, oral contraceptives - 
OC, ring, patch, condoms). This study was rated medium in terms of methodological 
quality. The reviewers suggested the inclusion of long-term complications into the analysis 
to better understand the benefits of the interventions; they also noticed that costs of 
interventions might be underestimated because only the price of wholesale acquisition 
seemed to be taken into account. 
Three economic evaluations compared the use of LARCs directly against UDC methods. The 
National Collaborating Centre (NCC) study (2013) evaluated the cost-effectiveness of 
LARC methods (IUD, IUS, implant, injectable) in comparison to user-dependent methods 
(combined oral contraceptive - COC, male condom)1. Costs and effectiveness were 
modelled in a hypothetical cohort of UK men and women of reproductive age. The results 
estimated that over 15 years of use, LARCs would dominate user-dependent methods (i.e. 
were less costly and more effective), and implants would dominate all other LARCs over the 
first three years of use, potentially costing £14,730-17,866 (2004-2005 GBP) per pregnancy 
averted. The methodological quality of this economic modelling study was rated as medium 
because many uncertainties were not fully described relating to the parameters and 
structure of the model; in addition, no validation or calibration of the previous model 
adapted for use in this study was reported.  
Trussell et al. (2013) undertook a US-based cost analysis of LARCs (implant, IUD, IUS) 
versus user-dependent reversible contraceptives (UDCs) (COC, condoms, patch, injectables, 
vaginal ring). The authors suggested that higher LARC uptake from OC or from no 
contraception would result in cost savings, and that cost neutrality would be achieved at 
just over two years of use. Trussell et al. (2014) further examined the costs of LNG-IUS 
against all other types of contraception (OC, ring, patch, injectables, implant, condoms). 
Using a hypothetical cohort of US women aged 20 to 29 years requiring contraception and a 
third-party healthcare payer perspective, the authors estimated that LARC use over three 
years would result in 64 unintended pregnancies, compared to 276 potentially occurring 
with use of UDC. The costs for each intervention were estimated at LNG-IUS £866,348 (2012 
GBP) ($1,283,479 2012 USD) v. UDCs £1,257,277 ($1,862,633), suggesting that LNG-IUS 
dominates UDC methods. The reliability/quality rating of these two economic evaluations 
using our assessment tool was low. The reviewers noted that a limited age group was 
explored in the analysis and that future results should assess whether this could influence 
the final outcome. In addition, the reviewers suggested the modelling of complications 
associated with unintended pregnancies (including HIV and STIs) in order to better capture 
the long-term potential benefits of the interventions.  
In sum, these economic evaluations suggest that LARC methods could be more cost-
effective to use than user-dependent contraceptive methods in terms of the pregnancies 
                                               
1Note that in some studies, injectable contraception was classified as a LARC; in other 
studies it was classified as a UDC. 
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they would avert and the resultant costs potentially borne by health and social services. 
This is based on findings from studies of medium and low methodological quality.  
The remaining four studies examined the costs and effects of different configurations of 
contraceptive services. Han et al. (2014) conducted a cost-effectiveness and cost-savings 
analysis to estimate the potential savings from post-natal implant insertion offered to 
adolescent mothers, compared to standard contraceptive initiation over three years. A 
cohort of adolescents aged 13-22 years enrolled in a pre-natal/post-natal programme. This 
provided clinical data and a healthcare payer perspective was taken to estimate costs. The 
authors reported that in the first year of provision, £0.53 (2013 GBP) ($0.79 2013 USD) 
would be saved for each $1.00 spent; however, the estimated cost savings rose in each 
subsequent year to £2.40 ($3.54) at two years and £4.41 ($6.50) saved for each $1.00 spent 
in comparison to standard contraceptive provision. This economic evaluation was judged to 
be of low methodological quality, because the reviewers considered that the robustness of 
the results might be compromised because only one parameter was assessed in the 
sensitivity analysis (rather than all). The reviewers also reported that the benefits - in 
terms of repeat pregnancy rates by type of complications - were not reported, so the full 
benefits generated by each outcome were not captured.  
Rodriguez et al. (2010a) undertook a cost-benefit analysis to assess potential cost savings 
over five years if post-natal IUD insertion was offered to recently immigrated low-income 
women compared to no IUD insertion, using a hospital and societal perspective. The authors 
estimated that over five years, £1.93 (2002 GBP) ($2.94 2002 USD) would be saved for every 
$1.00 spent on post-natal IUD provision. This study was rated low in terms of its 
methodological quality. The reviewers suggested that further research was necessary into 
interstate migratory patterns and their probabilities in order to better interpret the results. 
In a related publication (Rodriguez et al. 2010b), the authors evaluated the cost-
effectiveness of this expansion of Medicaid provision of post-natal IUD insertion for the 
same population, concluding that, from a hospital perspective, expanded provision would 
result in hospitals losing £0.46 per £0.66 GBP ($1 2002 USD) spent on expanded provision. 
However, from a state perspective, £1.92 ($2.92 2002 USD) would be saved for every £0.66 
($1) spent. The study was rated low in terms of its methodological quality and the 
reviewers suggested that further research into interstate migratory patterns and 
probabilities should be conducted to assess the economic value of a federal mandate for 
preventive coverage of new immigrants.  
Finally, Salcedo et al. (2013) used cost-benefit analysis to assess whether post-abortion 
IUD insertion for low-income women was more cost-effective compared to IUD insertion at 
a first post-abortion follow-up visit. The authors reported that post-abortion IUD insertion 
would potentially save $111 in direct hospital costs per woman at one year, rising to a 
potential £548 (2011 GBP) ($810 2011 USD) in savings over five years. With societal costs 
included, this increases to savings of £1,324-2,908 ($1,956-4,296) per woman compared to 
insertion at follow-up visit. The methodological quality of this study was determined to be 
medium. The reviewers noted that the model was heavily based on administrative data and 
the authors should have discussed the applicability of the parameters and the implications 
of extension of the conclusions to the general population; the implications were only partly 
included in the model (no STIs for example). 
3. Results 
 
Sexual health promotion and contraceptive services in local authorities: a systematic 
review of economic evaluations 2010-2015  25 
 
These economic evaluations of earlier provision of LARC methods post-natally or post-
abortion suggest that long-acting contraception could generate cost savings, particularly 
beyond one year. However, these findings should be tempered by the low to medium 
methodological quality of the studies and further by the challenges of interpreting their 
results for use outside the specific health system context within which they were situated. 
3.5.3 Contraceptive services 
Two studies assessed the costs and effects of different contraceptive services provision. A 
cost-effectiveness study by Pilgrim et al. (2010) modelled two different scenarios: (1) 
school-based condom provision compared to school nurse services only; and (2) hormonal 
contraception provision versus condom distribution in secondary schools. This was modelled 
in three hypothetical cohorts of: young people aged 14 to 16 years in school; young mothers 
in school; and sexually active young people aged 15 to 19 years, taking a societal 
perspective. The authors asserted that both scenarios were cost-effective: school-based 
condom provision cost £38 (2007-2008 GBP) for each pregnancy avoided and £822 for each 
abortion avoided compared to school nurse only; and contraceptive provision cost £443 for 
each avoided pregnancy and £1,453 for each abortion avoided compared to condom 
distribution. The methodological quality of this economic modelling study was rated as 
medium because the parameters used in the model were not validated and calibrated using 
empirical data.  
Thomas (2012) conducted a cost-benefit analysis to model three scenarios of service 
provision, compared to no such programme: (1) a mass media campaign targeted to 
unmarried men aged 15 to 44 years; (2) a teenage pregnancy prevention programme 
targeted to unmarried low socio-economic status (SES) youth; and (3) expanded Medicaid 
coverage for contraception provision to low-income unmarried youth. A hypothetical cohort 
of 10,000 nationally representative individuals aged 15 to 44 years was assembled, and a 
social and public sector (government) perspective was taken. The mass media campaign 
would potentially save £2.81 (2008 GBP) ($4.31 2008 USD) for each $1 spent, with the 
teenage pregnancy prevention programme estimated to save £1.61 ($2.46) for each $1 
spent. The expanded contraception coverage was predicted to save £3.67 ($5.62) for each 
$1 spent. The study was rated as medium by the reviewers. The main limitations were 
discussed by the authors; however, the reviewers suggest that short- and long-term 
complications associated with unintended pregnancies (and unprotected sex) be taken into 
account to further understand the benefits, in terms of health outcomes and costs, of the 
interventions. For example, not all studies explored the role of STIs, such as congenital 
syphilis, associated with unintended pregnancies in the short- and long-term. Adverse 
outcomes associated with STIs and unintended pregnancies are still a challenge in high-
income settings.  
In summary, these economic studies of medium methodological quality suggest that 
expanded contraceptive provision targeted to high-risk groups could result in cost savings 
resulting from health and social care services not needing to be provided for unintended 
pregnancy, maternal benefits and early childhood care.  
3.6 Economic evaluations of health promotion interventions 
Overall, fourteen studies were identified which conducted economic evaluations of sexual 
health promotion or HIV/STI prevention. Of these, nine evaluated the costs and outcomes 
of HIV health promotion/prevention and six evaluated STI health promotion/prevention 
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interventions (one study examined both HIV and STIs). These are summarised below; full 
details of these studies are provided in the Evidence Tables in Appendix 9 and relative cost 
outcomes are shown in the Costs and Outcomes Tables in Appendix 14. 
3.6.1 HIV health promotion/prevention interventions 
Cost-effectiveness was evaluated for HIV prevention interventions in nine included studies 
(Burgos et al. 2010; Holtgrave et al. 2012, 2013; Kessler et al. 2013; Lasry et al. 2012; 
Marseille et al. 2011; Ruger et al. 2014; Sanders et al. 2010; Schackman et al. 2013). Seven 
of these addressed particular HIV/STI prevention programmes, while two sought to identify 
the ‘optimised’ group of interventions to deliver from a range of those currently delivered.  
Burgos et al. (2010) reported a cost-effectiveness analysis of a brief condom negotiation 
skills intervention designed to improve HIV and STI incidence amongst female sex workers, 
compared to an information-only session on HIV and STI prevention. Using an NHS 
perspective, the authors reported HIV cost outcomes only, suggesting that without universal 
Highly Active Anti-Retroviral Treatment (HAART) access, providing a once-only session could 
result in 33 HIV-averted infections for 151 days of quality-adjusted life expectancy (QALE), 
costing £121 (2009 GBP) ($183 2009 USD) per QALY and £1,571 ($2,370) to prevent each HIV 
case. The authors suggested that this intervention was cost-effective; and it is cost-
effective according to the NICE threshold for cost-effectiveness. An annually provided 
session could result in an additional 29 new HIV cases prevented, at a cost per QALY gained 
of between £713 and £8,893 ($1,075 and $13,413) per HIV case averted. These would also 
be cost-effective according to the NICE threshold criteria (i.e., less than £20,000 per 
QALY). This economic evaluation rated medium in terms of its methodological quality. The 
reviewers suggested that that HIV complications be explicitly modelled into the analysis, in 
addition to implicitly through the use or non-use HAART by CD4 levels, in order to better 
understand the implications on costs and health outcomes in the long term.  
Holtgrave et al. (2012) examined the cost-effectiveness and cost-utility of a female 
condom distribution and HIV prevention education programme targeted universally to men 
and women. At a cost of £2.15 (2012 GBP) ($3.19 2012 USD) per product used (including the 
education component), the intervention was estimated to be cost saving from a societal 
perspective when 1.13 new infections were averted, and from a payer perspective when 
1.50 new infections were averted. The methodological quality of this study was determined 
to be high. When the model allows use of male condoms by women, at a specific level, the 
cost-utility analysis is still costing-saving, as well as when female use of male and female 
condoms were dropped as low as 7.04%; these results were demonstrated in a sensitivity 
analysis. 
Marseille et al. (2011) conducted a cost-effectiveness modelling of three interventions to 
reduce onward HIV transmissions amongst HIV-infected individuals in a clinic setting. 
Primary care clinical provider-led brief computer-based risk assessment and individual 
counselling, peer educator-based individual or group counselling and mixed primary care 
provider and peer-educator based counselling were compared with a standard care 
condition of provider-based risk assessment without specific counselling. Primary provider 
assessment and counselling was found to dominate the other two conditions; in comparison 
to no intervention, its cost-effectiveness was estimated at £72,668 (2010 GBP) ($107,656 
2010 USD) per HIV case averted. The study was rated as high for its methodological quality. 
The reviewers suggested that future research explore complications associated with HIV 
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infections in the long term to better capture the potential health and costs benefits of the 
intervention. 
Ruger et al. (2014) undertook at cost-effectiveness and cost-utility analysis of two health 
promotion interventions compared to standard assessment and treatment of women who 
inject drugs. Findings from a trial and a modelling study were reported. One condition 
tested well-woman examination with standard care; the second condition evaluated four 
HIV prevention education sessions in addition to the well-woman examination and standard 
care. A healthcare and societal perspective was taken. Findings from the trial suggested 
that the well-woman examinations were more costly and less effective than the standard 
intervention for HIV, and that for the modelled outcomes (relative to the standard 
intervention), the well-woman examination cost £137,280 (2003 GBP) ($208,316 2003 USD) 
per primary HIV infection averted. This economic evaluation rated high in terms of its 
methodological quality. The reviewers suggested that complications regarding HIV 
complications by CD4 level be assessed for a full understanding of the long-term benefits of 
the intervention.  
Sanders et al. (2010) conducted a cost-effectiveness and cost-benefit analysis of primary 
care patients who received either nurse-initiated routine screening with traditional HIV 
testing and counselling or nurse-initiated rapid HIV testing and streamlined counselling in 
comparison to traditional HIV testing and counselling, taking a healthcare payer and patient 
perspective. Uptake of screening and receipt of results were the health outcomes. The 
results estimated that traditional HIV testing and counselling offered a per-patient lifetime 
discounted cost of £31,379 (2007 GBP) ($48,650 2007 USD) and benefits of 16.271 QALYs, 
which could be potentially cost-effective according to the NICE cost-effectiveness threshold 
criteria (i.e. £20,000-30,000 per QALY). Likewise, both nurse-initiated routine screening 
and traditional HIV testing and counselling and nurse-initiated routine screening with rapid 
testing and streamlined counselling conditions were found to be cost-effective according to 
the NICE threshold (respectively adding £34 ($53) and 0.0013 more QALYs and £42 ($66) and 
0.66 more QALYs above those estimated by the traditional condition). The nurse-initiated 
routine screening with rapid testing and streamlined counselling remained cost-effective 
whether benefit of reduced HIV transmission was incorporated into the model or not. This 
economic evaluation was rated medium in terms of its methodological quality. The 
reviewers noted that costs were modelled based on reimbursement costs not economic 
costs, which may have an influence on the final results (costs maybe either be under- or 
over-estimated). They suggested that a cost estimation based on the use of resources be 
conducted and taken into account in the model, and that complications associated with HIV 
by CD4 levels be assessed to capture the long-term benefits of the intervention. 
Schackman et al. (2013) undertook a cost-effectiveness and cost-utility analysis by 
modelling the findings from an intervention study targeting high-risk groups presenting at a 
substance use treatment clinic using a societal perspective. Here, on-site rapid HIV testing 
with information only or on-site rapid HIV testing with risk reduction counselling were 
compared with off-site HIV testing and referral in terms of costs and sexual risk behaviour. 
On-site rapid testing and information only was found to dominate the other conditions, 
resulting in a cost-effectiveness ratio of £39,979 (2009 GBP) ($60,300 2009 USD) per QALY. 
This is not cost-effective according to the NICE cost-effectiveness threshold criteria (i.e. it 
exceeds £30,000 per QALY). The on-site rapid testing with counselling cost £7 ($11) more 
per person but did not provide additional benefit. This economic evaluation was rated high 
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in terms of its methodological quality. The authors acknowledged the main limitations of 
their model and analysis and the reviewers did not have further suggestions.  
A later study by Holtgrave et al. (2013) assessed the cost-utility of a rental assistance 
programme for homeless and unstably-housed persons living with HIV, using an unstated 
perspective. The authors suggested that the cost per QALY saved by the intervention was 
£40,558 (2005 GBP) ($62,493 2005 USD). This also exceeds the NICE criteria for determining 
cost-effectiveness. This economic evaluation was rated low in terms of its methodological 
quality. The trial on which the economic evaluation was based was considered to have 
significant potential for bias, because the findings were based on as-treated analyses rather 
than intention to treat. Further, the model did not capture any complications associated 
with HIV, thus none of the long-term benefits in terms of costs and health outcomes could 
be captured. In addition, the reviewers were unable to judge if the time horizon for the 
analysis was satisfactory to capture changes in HIV transmission or behaviour, as this 
information was not presented. 
Taken together, each of these seven studies evaluated one intervention (or combination of 
interventions) delivered in one setting. All reported cost-effectiveness or cost-savings, and 
the majority of studies were of medium to high methodological quality. Two studies were 
targeted to universal populations, i.e. a mix of low- and high-risk individuals (Holtgrave et 
al. 2012; Sanders et al. 2010). The remaining studies focused on different risk groups, such 
as HIV-infected individuals (Marseille et al. 2011; Holtgrave et al. 2013) and individuals 
either at risk of HIV or of abusing substances (Burgos et al. 2010; Ruger et al. 2014; 
Schackman et al. 2013). Likewise, these studies addressed disparate interventions, 
including condom distribution, condom negotiation skills and rental assistance to influence 
HIV outcomes. Four studies did focus on various forms of risk assessment, testing and 
counselling (Marseille et al. 2011; Ruger et al. 2014; Sanders et al. 2010; Schackman et al. 
2013). Only two of these were found to be cost-effective or potentially cost-effective 
according to NICE threshold criteria, or were cost saving (Ruger et al. 2014; Sanders et al. 
2010). However, even the Ruger et al. study was cost-effective for hepatitis C outcomes 
rather than HIV. Only the condom distribution intervention reported by Holtgrave et al. 
(2012) was deemed to be cost saving. Thus limited cost-effectiveness relative to the UK 
standards is found within these studies.  
Two further included studies examined multiple widely-delivered HIV prevention 
programmes. Kessler et al. (2013) conducted a cost-saving analysis to model the cost-
effectiveness of all programmes, and then to model the optimum configuration of cost-
effective interventions within an annual budget for each intervention of £242,999 (2010 
GBP) ($360,000 2010 USD). A total of 16 single interventions were estimated to be cost-
effective in preventing HIV infection or transmission over 20 years. The ten most cost-
effective were: condom distribution (£126,368 ($187,212) per infection averted), social 
marketing (£55,709 ($82,532)) or community-based prevention (£4,482 ($7,173)) to all risk 
groups; prioritised use of surveillance data in HIV infected individuals (£18,673 ($27,663)); 
co-factor risk reduction in HIV-infected, high risk individuals (£21,130 ($31,304)); a brief 
intervention and referral for alcohol use in HIV-infected, high risk individuals (£24,821 
($36,772)); linkage to care for HIV-infected individuals (£257,112 ($380,906)); HIV-infected 
individuals’ linkage to support services (£83,896 ($124,291)); partner services for HIV-
infected individuals (£133,821 ($198,253)); and STI screening of HIV-infected, high-risk 
individuals (£228,843 ($339,026)). Interventions estimated not to be cost-effective included 
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STD screening (£322,639 ($477,984)) or risk reduction (£518,016 ($767,431)) of HIV-infected 
individuals; social services for HIV-uninfected, high-risk groups (£706,311 ($1,046,387)); 
care coordination for HIV-infected individuals on ART (£781,784 ($1,158,199)); clinical 
(£1,190,066 ($1,763,061)) or non-clinical (£2,099,507 ($3,110,381)) testing in people 
uninfected with HIV; and co-factor screening (£2,451,098 ($3,631,257)), brief alcohol 
interventions (£2,629,434 ($3,895,458)), pre-exposure prophylaxis (£6.075 million 
($9,803,449)) or STD screening (£7,698,044 ($11,404,509)) in any HIV-uninfected, high-risk 
individuals. The most optimum hypothetical package (of seven modelled in total) was a 
combination of community-level interventions, linkage to support HIV positive individuals 
and STD screening of high-risk individuals (estimating 20,211 HIV infections averted at a 
cost of £71,805 ($106,378) per infection averted). This economic evaluation rated high in 
terms of its methodological quality. The authors had calibrated their model by using 
empirical figures, and had identified the main limitations of the study. The reviewers also 
suggested that in future analysis, the costs of ART and the treatment of complications 
associated with HIV be included in accordance with patient health status (defined by the 
patient’s level of CD4 cell counts). In addition, the time horizon should be extended to a 
lifetime analysis. This approach would better capture the full long-term costs and benefits 
of intervention strategies. 
Finally, Lasry et al. (2012) used cost-utility analysis methods to model the cost-
effectiveness of currently funded HIV testing and education interventions and an optimised 
model of the same interventions targeted to high risk groups (i.e. MSM, IVDU, HIV-infected 
and high risk individuals) delivered for the same cost (£216.8 million 2009 GBP ($327 million 
2009 USD)). Over five years, the model predicted that, in comparison to no funding, 
currently funded interventions would avert 13% of the 252,000 new infections predicted 
with no funding, at a cost of £37,332 ($56,311 2012 USD) per infection averted. The 
optimised model would avert 31% of new infections predicted with no funding, and at a cost 
of £17,985 ($27,128) per infection averted. The study was rated low in its methodological 
quality. Reviewers noted that the time horizon for the analysis was too short to account for 
all the benefits generated by reductions in infection and recommended that a lifetime or 
other longer period for analysis be considered to capture the long-term benefits of the 
intervention, including an assessment of complications due to HIV. 
In summary, both economic evaluations focused on nationally delivered interventions and 
examined a comprehensive range of services and strategies; however, they were mixed in 
terms of methodological quality. They modelled different interventions in low-risk as well 
as various high-risk groups (HIV-infected, high-risk behaviour, MSM, intravenous drug users 
etc.), which provide a wide-ranging look at cost-effective services and relevant 
populations. These two studies together suggested that optimised use of specific 
interventions targeting high-risk or HIV-infected individuals can make better use of existing 
budgets. However, it is not clear whether these combinations of intervention provision 
would work in different UK local authorities with such different populations and HIV 
incidence. Thus the information on single intervention cost-effectiveness is perhaps more 
generalisable to specific UK local authorities.  
3.6.2 Sexually transmitted infection interventions 
A total of six studies examined cost-effectiveness related to various STI prevention 
programmes (Cooper et al. 2012; Crawford et al. 2015; Jackson et al. 2015; Pilgrim et al. 
2010; Ruger et al. 2014; Thomas 2012). Full details of these studies are provided in the 
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Evidence Tables in Appendix 9, and relative cost outcomes are shown in the Costs and 
Outcomes Tables in Appendix 14. 
Cooper et al. (2012) conducted a cost-effectiveness analysis of teacher- or peer-led STI 
prevention and skills training compared to standard sex education (which may or may not 
have had a skills training component). The authors suggested that compared to standard 
sexual health education, the teacher-led intervention was cost-effective at £18,041 per 
QALY gained (2011-2012 GBP): this is cost-effective as it is below the £20,000 per QALY 
NICE threshold for cost-effectiveness. However, in comparison to the teacher-led 
intervention, the peer-led intervention was not cost-effective as, at £72,062 per QALY 
gained, it exceeded the NICE threshold. This economic evaluation was rated as high in 
terms of its methodological quality. The reviewers suggested that the model be repeated 
using empirical data to better define interventions that are cost-effective. 
Crawford et al. (2015) aimed to investigate the clinical and cost-effectiveness of brief 
advice for excessive alcohol consumption which included sexual health education amongst 
people aged 19 years and older attending one of three sexual health clinics in London, 
England. The researchers used an RCT design in which the costs were collected and 
analysed and a cost-utility analysis undertaken. Comparison group participants received a 
health education leaflet only. While costs to provide intervention or control conditions 
were similar in both groups (intervention £311 per person v. control £319 per person) (2010-
2011 GBP) and the average additional cost of the intervention was modest at £12.57 (SD 
£6.59), no significant differences in either 90-day alcohol consumption or reported 
unprotected sex were found. Further, the ICER was calculated at −£1,200 per QALY, leading 
authors to conclude that the intervention was not cost-effective since it was more costly 
than not providing any intervention and did not provide any additional benefit. The 
methodological quality of the integral trial was rated to be high, as the study design and 
parameters seemed to be appropriately explored; also in a sensitivity analysis, where 
authors tested the strength of the findings; ‘bootstrap’ techniques and non-hierarchical 
linear models were undertaken to assess missing data. 
Jackson et al. (2015) focused on a cost comparison of screening and health promotion (as 
described earlier). A STI screening health promotion campaign led by team captains and 
one led by sexual health advisers were each compared with a poster-only campaign control 
condition. The results indicated that all three interventions cost similar amounts, but the 
sexual health-adviser-led intervention was most cost-effective, as it led to 67% screening at 
a cost of £88.33 per person screened (2012-2013 GBP), compared to the poster-only 
campaign which cost £81.87 but resulted in only 61% screening uptake. The team captain-
led intervention was least cost-effective, resulting in 50% screening uptake at a cost of 
£88.89 per person. The trial was judged to be of medium methodological quality, with 
many uncertainties around the parameters used in the analysis. Clarifications are necessary 
regarding the annuitisation of costs with posters and the time horizon for the analysis. It 
seems that the analysis was undertaken for a time horizon of one year and the costs with 
posters were considered for three years. If this was the case, the costs may be 
overestimated. 
Also described earlier, Pilgrim et al. (2010) examined contraception and health promotion 
strategies by testing three different school-based contraceptive models to determine their 
cost-effectiveness. Condom provision was estimated to cost £38 for each pregnancy averted 
3. Results 
 
Sexual health promotion and contraceptive services in local authorities: a systematic 
review of economic evaluations 2010-2015  31 
 
and to cost £822 for each abortion avoided (2007-2008 GBP), compared to routine school 
nurse utilisation. In comparison to condom provision only, contraceptive provision was 
estimated to cost £443 for each averted pregnancy and £1,453 for each abortion avoided. In 
the second model, school-based peer education and social work case management to 
prevent repeat pregnancy was compared to no follow-up after the first pregnancy. The 
authors suggested that this resulted in an estimated £4,031-15,155 cost for each repeat 
pregnancy averted. The third model estimated the costs per pregnancy averted and 
abortion avoided when providing advanced hormonal contraception compared to no 
advance provision. The findings estimated that advanced provision cost £310 for each 
repeat pregnancy averted, and cost £2,795 for each abortion avoided. The methodological 
quality of this economic modelling study was rated as medium because the parameters used 
in the model were not validated and calibrated using empirical data. 
Ruger et al. (2014) undertook a cost-effectiveness and cost-utility analysis of two health 
promotion interventions compared to standard assessment and treatment of women who 
inject drugs. The findings from a trial and a modelling study were reported. One condition 
tested well-woman examination with standard care; the second condition evaluated four 
HIV prevention education sessions in addition to the well-woman examination and standard 
care. A healthcare provider and societal perspective was taken. Results from modelling 
suggested that in terms of impact on hepatitis C infection rates, the well-woman 
examination, at £72,034 (2007-2008 GBP) ($109,308 2007-2008 USD) per additional infection 
averted, was less costly and more effective compared to the four education sessions. 
Similarly, the well-woman examination was less costly and more effective than the four 
education sessions intervention in reducing gonorrhoea rates (£706,949 ($1,072,760) per 
additional QALY). However, for chlamydia rates, the four education sessions intervention 
was less costly and more effective than the well-woman examination at £2,273,217 
($3,449,495) per additional QALY. This economic evaluation was rated high in terms of its 
methodological quality. Reviewers suggested assessing HIV complications by differences in 
CD4 level  for a full understanding of the long-term benefits of the intervention.  
Thomas (2012) conducted a cost-benefit analysis to model three scenarios of service 
provision, compared to no such programme: (1) a mass media campaign targeted at 
unmarried men aged 15 to 44 years; (2) a teenage pregnancy prevention programme 
targeted at unmarried low SES young people; and (3) expanded Medicaid coverage for 
contraception provision to low-income unmarried young people. A hypothetical cohort of 
10,000 nationally representative individuals aged 15 to 44 years was assembled, and a 
social and public sector (government) perspective was taken. The mass media campaign 
would potentially save £2.81 ($4.31 (2008 USD)) for each $1 spent, with the teenage 
pregnancy prevention programme estimated to save £1.61 ($2.46) for each $1 spent. The 
expanded contraception coverage was predicted to save £3.67 ($5.62) for each $1 spent. 
The study was rated as of medium methodological quality by the reviewers. The main 
limitations were discussed by the authors. The reviewers suggested that short- and long-
term complications associated with unintended pregnancies (and unprotected sex) be taken 
into account to further understand the benefits, in terms of health outcomes and costs, of 
the interventions. 
In summary, this set of studies of mixed but mostly medium methodological quality 
examining the costs and outcomes of STI health promotion interventions provided equivocal 
results. All authors but one (Crawford et al. 2015) reported cost-effectiveness, cost savings 
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or positive costs and benefits for all interventions. After any relevant cost outcomes were 
compared to NICE thresholds for cost-effectiveness, three of these would still be deemed 
cost-effective or potentially cost-effective (Burgos et al. 2010; Pilgrim et al. 2010; Thomas 
2012). Three studies were above the NICE criteria and thus not cost-effective (Cooper et al. 
2012; Crawford et al. 2015; Ruger et al. 2014); and one study provided costs and outcomes 
similar to comparison conditions (Jackson et al. 2015). Three of the four studies examining 
the cost-effectiveness of interventions targeted to universal populations were not deemed 
cost-effective in a UK context or were equivocal (Cooper et al. 2012; Crawford et al. 2015; 
Jackson et al. 2015). Conversely, three of the four studies focusing on higher-risk groups 
were cost-effective relative to the UK context (Burgos et al. 2010; Pilgrim et al. 2010; 
Thomas 2012). Skills negotiation interventions provided equivocal results (Burgos et al. 
2010; Cooper et al. 2012); however, this may have been because they targeted different 
(universal and high-risk) groups. Similarly, wide-ranging prevention campaigns provided 
mixed results and also targeted very different populations, which could explain the findings 
(Jackson et al. 2015; Thomas 2012).  
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4 Discussion  
4.1  Main findings  
This systematic review represents a comprehensive update examining the cost-
effectiveness of economic evaluations of sexual health interventions undertaken since 
2010, of specific interest to local authorities. In order to avoid duplicating review efforts 
being undertaken by Public Health England, and on the advice of our Advisory Group, we 
prioritised economic evaluations related to contraception and health promotion, and also 
assessed any UK-based economic studies of sexual health interventions. This resulted in the 
identification of 29 relevant economic evaluations. 
4.1.1 Economic evaluations of contraception  
Looking across the 15 identified economic evaluations focused on contraception, the 
findings from two cost-effectiveness studies suggested that oral UPA is more cost-effective 
than oral LNG as a method of emergency contraception (EC), based on one cost-benefit 
analysis and one cost-effectiveness analysis undertaken in the US and the UK respectively. 
One US cost-benefit analysis also reported that advance and on-demand EC offered in 
clinics or community pharmacies are cost-saving compared to no access, for both high- and 
low-use groups. This supports current NICE guidance (NICE 2014a).  
In terms of longer-term contraceptive methods, the findings from one cost-benefit study, 
two cost-effectiveness studies, one cost-savings analysis and one costing study suggested 
that LARCs could be more cost-effective to use than user-dependent contraceptive methods 
in terms of the pregnancies they would avert and the resultant costs potentially borne by 
health and social services. Both US and UK studies reported findings with the same direction 
of effect. These findings support the most recent NICE recommendations (NICE 2014b). 
Modelled findings from two cost-benefit studies and two cost-savings analyses suggested 
that earlier provision of LARC methods post-natally or post-abortion could generate cost 
savings, particularly beyond one year. While these findings were based on studies 
conducted in the US, with a different healthcare system funding structure, it could be 
argued that this is a potential strategy which could be cost-effective in the UK. Of course, 
its relative merit would require discussion by stakeholders. 
Lastly, findings from one US cost-benefit study and one UK cost-effectiveness study 
suggested that expanded contraceptive provision targeted to low- and high-risk groups such 
as sexually active teens, adolescent mothers and new immigrants could result in cost 
savings resulting from services not needing to provide health and social care for unintended 
pregnancy, maternal benefits and early childhood care. These findings support the most 
recent NICE recommendations on contraceptive use in those under 25 (NICE 2014a).  
4.1.2 Economic evaluations of HIV/STI health promotion/prevention 
Fourteen health promotion studies focused on HIV or STI health promotion or prevention 
strategies. Of these, nine examined a range of HIV health promotion/prevention 
interventions and reported overall cost-savings or cost-effectiveness. The findings from one 
cost-effectiveness/cost-utility analysis and one cost-effectiveness analysis suggested that 
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condom distribution or condom negotiation skills programmes were cost-effective or cost-
saving. Within interventions to assess risks and provide tailored testing or counselling to 
patients at risk of HIV, the findings from three cost-effectiveness analyses suggested that 
clinical provider assessment and counselling was more cost-effective than peer- or peer-
provider counselling; that nurse-led rapid testing and tailored counselling was more cost-
effective than routine screening and counselling; that on-site rapid testing and tailored 
counselling was better than either off-site testing and referral or than on-site testing and 
information only. A series of four educational sessions on HIV infections was suggested to be 
cost-saving in relation to well-woman examinations for intravenous drug users in one cost-
effectiveness/cost-utility analysis; and one study of rental assistance to HIV-infected 
persons was described as cost-effective by the authors. In addition, two studies examining 
the cost-effectiveness of multiple HIV prevention strategies in order to determine the 
‘optimum package’ of interventions reported cost-savings over current HIV testing and 
counselling provision or no service provision. While all of these studies reported cost-
effectiveness or cost-savings for some or all evaluated interventions, only four studies 
reported costs per QALY; of these, only nurse-led rapid testing and tailored counselling and 
condom negotiations skills training for female sex workers were shown to be cost-effective 
or potentially cost-effective within NICE thresholds.  
Six studies evaluated the costs and outcomes related to STI health promotion or prevention. 
These reported somewhat more mixed findings with respect to cost-effectiveness. Some 
findings were clear, for example, a cost-effectiveness analysis of school condom 
distribution was suggested to be cost-effective for STIs and a cost-benefit analysis of mass 
media STI prevention targeted to unmarried male adults was deemed to be cost-saving. 
Others provided more equivocal findings: teacher-led STI prevention and skills training for 
school-age youth was found to be cost-effective in comparison to standard sex and 
relationships education; however, peer-led STI prevention and skills training was not found 
to be cost-effective. An STI screening uptake campaign led by sexual health advisers 
targeted to football club members was found to have similar costs and outcomes to a 
poster-only campaign; the same campaign led by football captains was found to be more 
costly and less effective. For hepatitis C and gonorrhoea outcomes, well-woman 
examinations provided to women using intravenous drugs in addition to standard drug 
treatment was found to be cost-effective, but a four-education session added to standard 
drug treatment was found to be more cost-effective for chlamydia outcomes. And one 
evaluation of brief risk-reduction counselling that included sexual risk behaviour amongst 
adults presenting at substance abuse clinics was not found to be cost-effective. Of these six 
economic evaluations, only the teacher-led STI prevention and skills training intervention 
was found to be cost-effective by NICE standards.  
Only four health promotion studies were UK-based (Cooper et al. 2012; Crawford et al. 
2015; Jackson et al. 2015; Pilgrim et al. 2010). All were focused on STI prevention, and only 
Cooper et al. (2012) reported cost per QALY, allowing comparison against NICE thresholds. 
The remaining STI cost evaluation studies were all US-based, as were the entire subset of 
studies examining HIV health promotion/prevention. Thus there is limited information on 
cost-effectiveness relative to the UK. 
4.1.3 UK economic evaluations 
The findings from this systematic review of economic evaluations suggest that there has 
been a reasonable amount of research into the economics of sexual health services in the 
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UK since 2010: in total, nine full economic evaluations met the inclusion criteria for this 
review. UK-based cost-effectiveness and cost-consequence analyses focusing on 
interventions to promote STI screening indicated that those offered to high-risk groups, in 
more accessible locations such as clinics, pharmacy, by phone, or at community football 
clubs, could potentially be more cost-effective than their relevant alternatives. Cost-utility 
analyses of point-of-care testing for STIs was found to be cost-effective according to NICE 
thresholds, as were interventions that targeted annual HIV testing to high-risk adults, with 
or without ART. These findings support those of current Department of Health and NICE 
guidance, which recommend rapid access to testing in a variety of settings and for high-risk 
groups (Hind 2013; NICE 2011a,b, 2014a).  
UK studies also indicated that UPA could be more cost-effective than LARCs for emergency 
hormonal contraception. Studies examining LARCs versus user-dependent methods 
suggested that LARC methods could be more cost-effective to use than user-dependent 
contraceptive methods in terms of the pregnancies they would avert and the resultant costs 
potentially borne by health and social services. These findings are consistent with current 
NICE guidance on long-acting contraceptives (NICE 2014b). In addition, it was suggested 
that school contraceptive services, such as condom distribution, hormonal contraceptive 
provision and advance contraceptive provision could be cost-effective compared to the 
alternatives; all of these are supported by current NICE guidance (NICE 2014a). Teacher-led 
sexual health education was also found to be cost-effective according to NICE thresholds; 
however, in comparison to teachers, peer-led education was not cost-effective. 
4.2 Strength of evidence  
There were more cost-benefit analyses undertaken on contraceptive topics (n=5) than on 
health promotion topics (n=1). It could be argued that cost and health outcome data for 
contraception studies (e.g. pregnancy/abortion rates, dispensing costs) are discrete, simple 
to access and have a more direct causal effect on outcomes than those of health promotion 
interventions. In addition, long-term outcomes of unintended pregnancy (e.g. future loss of 
earnings due to lower employability, need for childcare) may be easier to monetise than 
those outcomes resulting from health promotion (or a lack of it), including behaviour 
change, future ill health or infertility due to chronic STIs.  
Only five of the included studies undertook cost-utility analyses, limiting our ability to 
judge intervention cost-effectiveness against NICE recommended thresholds. This further 
limited the comparability of interventions across the review.  
The economic evaluations were evenly varied in their methodological and/or reporting 
quality: ten each were of low and medium methodological quality and nine were of high 
quality, according to the combined health economic evaluations checklist. While it is 
encouraging to see that over half of the included studies rated medium quality or higher, 
some caution in the interpretation of pooled findings is needed, particularly where there 
are few studies informing readers on the cost-effectiveness of an intervention and some of 
these are of low quality.  
4.3 Evidence gaps 
The majority of included economic evaluations were US-based and focused on interventions 
modelled in general populations or with those at low risk. Despite a call for locally-provided 
sexual health interventions to be provided to higher-risk groups such as those with learning 
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disabilities (Hind 2013), no relevant economic evaluations of such interventions were 
identified. In relation to other vulnerable groups relevant to the UK, only one US economic 
evaluation targeting sex workers was identified. In addition, no full economic evaluations of 
other popular sexual health interventions currently discussed in the literature were 
identified. For example, there are indications that internet-based STI screening and results 
provision are of increasing interest and may be acceptable to higher-risk groups (Gilbert et 
al. 2013; Greacen et al. 2013). While evaluations of such interventions have been published 
or are in process (Bailey et al. 2015b, Bracebridge et al. 2012; Wilson et al. 2015), no full 
economic evaluations were located. Systematic reviews of sexual health interventions 
offered population-wide and to vulnerable groups report limited or no data available on 
cost-effectiveness (Bailey et al. 2015a; Bonell et al. 2013; Gomez et al. 2013; O’Mara-Eves 
et al. 2013; Whitaker et al. 2014). This suggests a need for UK-based economic evaluations 
of sexual health interventions, as well as economic evaluations specific to vulnerable 
groups in the UK. It should also be noted that while economic evaluations of HIV pre-
exposure prophylaxis were identified, they were not included in this review because of 
work currently being undertaken by Public Health England (McCormack et al. 2016).  
4.4 Limitations of the dataset 
In addition to issues previously identified in assessing the methodological rigour of the 
included studies, several other potential limitations of the dataset should be considered.  
The research question posed by this systematic review asked a broad question of all sexual 
health services provided by local authorities. This resulted in the inclusion, assessment and 
synthesis of multiple intervention strategies, which (in concert with the review timelines) 
made synthesis of the findings amenable to only narrative discussion of the results. 
Similarly, challenges were identified in drawing comparisons across studies due to the use 
of different comparators (e.g. one economic evaluation comparing skills training to 
‘standard intervention’ but another comparing skills training to ‘no intervention’). Each 
economic comparison also differed (e.g. cost-effectiveness ICERs versus cost utility; cost 
per QALY versus costs per person intervened upon or per outcome for each group), which 
made further comparisons of effectiveness across common interventions difficult.  
This review sought economic evaluations of sexual health promotion interventions provided 
in local authorities. It should be considered that while costs for these services are borne by 
local authorities, the benefits may be accrued elsewhere, as health promotion 
interventions often show results over a longer term and in different sectors than local 
authorities. An example is services relating to unintended teenage pregnancy. These are 
paid for by the local authority; however, most benefits, such as reduced unemployment/ 
better job prospects of mothers who delay childbearing until they have completed their 
education, and better health of infants in terms of reduced hospital or GP visits, are seen in 
cost savings experienced by other public sectors, and over a longer term. Research studies 
tend to report cost outcomes relevant to hospital services or welfare and education sectors 
rather than to local authorities per se. This requires stakeholders to take a much broader 
interdisciplinary approach when considering the costs and benefits of local authority sexual 
health service provision. Related to this, it should be noted that only some of the economic 
evaluations used a societal perspective, which is helpful in considering the wider social 
benefits. Decision making by local authorities requires a similarly broad consideration of 
these wider benefits to society.  
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The majority of economic evaluations included in this review were from the US (n=20), 
which has a different healthcare system from the UK. In particular, the US has a third-party 
payer (i.e. health insurance) system for reimbursing healthcare costs, and about 17% of the 
population is without any kind of protection in case of need. In contrast, the UK has 
universal healthcare free at the point of access (Berry 2015; Brown 2003; Centers for 
Disease Control and Prevention 2015). The context in which economic evaluations are 
undertaken is of critical importance when determining the cost-effectiveness of 
interventions (Anderson and Shemilt 2010). While differences in funding structures could 
raise some questions of applicability of economic evaluations between countries, we 
included US-based studies at the request of our Advisory Group in order to provide as much 
information as possible about the cost-effectiveness of relevant sexual health 
interventions. Several key differences between the US and UK healthcare systems exist that 
could impact on the findings and should thus be considered. These include: the use of 
insurer or reimbursement data whose costs do not cover the full range of benefits available 
in the NHS; the lack of US funding for abortion services; consideration that the drug costs in 
US studies would be limited to those provided in hospital whereas in the UK they are more 
likely to be covered; the potential for greater uptake of services in the UK due to the 
tendency of US analyses to look only at specific insured populations. 
Related to the issue of context, the perspectives varied widely according to which 
economic evaluations were analysed in included studies. A total of five studies examined 
costs from a healthcare (i.e. hospital or clinic) perspective alone; at least 12 studies 
examined cost-effectiveness from a societal perspective and six used a third-party payer 
perspective only. Two studies did not report their perspective, and the remaining four 
utilised more than one perspective. This variation in perspectives alters the breadth of 
costs included in the analysis, potentially over- or underestimating cost-effectiveness 
where relevant costs are, and are not, taken into account. It has been suggested that 
employing a wider societal perspective provides a more realistic representation in terms of 
highlighting the costs and outcomes experienced beyond healthcare and over longer periods 
(Drummond et al. 2015); it is also argued that whichever perspective is selected, care 
should be taken to establish all reasonable costs and outcomes (Drummond and Sculpher 
2005). However, within perspectives, it was not always clear if the same aspect was being 
examined. For example, US economic evaluations described their perspective as ‘third-
party payer’, ‘health insurance company’, ‘state’, ‘government’. Without clear explanation 
from individual authors, it was not always possible to determine the extent to which these 
perspectives overlapped; presumably different costs could be derived from each.  
Across the set of included studies, the costs and outcomes of interventions were assessed 
against different comparators in each case. For example, some studies compared 
interventions against ‘standard care’, others against ‘no intervention’, and others against a 
second intervention. The lack of standardised comparators across studies makes 
comparisons of cost-effectiveness difficult. For example, in some cases, it may be 
appropriate to compare an intervention to ‘no care’; however, in another context it may be 
more suitable to compare that same intervention to ‘standard care’. This is an issue also 
described in other systematic reviews of economic evaluations (Mangham-Jeffries et al. 
2014).  
It was also noted that some contraceptive methods (e.g. injectables) were labelled as 
LARCs in one study (NCC 2013) but as UDCs in another (Trussell et al. 2014). However, these 
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findings were not likely to have affected the overall conclusions, as analyses were 
undertaken separately for each method of contraception in each study, allowing readers to 
see direct costs and outcomes. 
Finally, it should be noted that two cost-consequence analyses were included (Jackson et 
al. 2015; Roberts et al. 2012). While recognised by NICE as providing valid information on 
costs and outcomes (NICE 2012), cost-consequence studies can be challenging to interpret 
because often multiple outcomes are reported and it is difficult to know what proportion of 
costs should be attributed to which outcomes. Attributing the full cost to a single outcome 
may overestimate the cost of producing that outcome and does not take into account the 
synergies or externalities associated with additional benefits.  
4.5 Limitations of review methods 
Due to the broad nature of sexual health services commissioning in local authorities, the 
research question resulted in a wide range of relevant economic evaluations, but little 
depth due to the small number of studies evaluating each intervention. This limited our 
ability to build up a consistent picture of cost-effectiveness across a range of interventions; 
however, it did allow the illustration of the breadth of interventions that have been 
evaluated for cost-effectiveness as well as where gaps still remain. Such mapping of the 
range of economic evaluations available to inform a policy decision is considered useful 
(Anderson 2010; Anderson and Shemilt 2010; Gomersall et al. 2015). The findings from this 
review thus highlight priority areas for economic evaluation for researchers and policy 
makers to consider in the future.  
Public engagement in reviews is important, to ensure that reviews are focused on questions 
and findings that are of use to those who are affected by the policies under study (Rees and 
Oliver 2012). To gain these perspectives, we consulted with sexual health charity members 
who provided input during Advisory Group meetings. Further discussions between local 
commissioners and patient groups would be recommended when the findings of this review 
are utilised to inform service commissioning.  
For the purposes of this systematic review, economic evaluations of trials were presented 
alongside those based on modelling estimates. While it has been recommended that 
economic evaluations of RCTs and models be assessed separately (Anderson and Shemilt 
2010), we opted to present both together in order to highlight the range of available 
research, clearly indicating where the findings arose from trials and from models. The 
incorporation of multiple economic evaluation designs also necessitated a much wider 
assessment of quality than any one quality assessment tool could provide, and our appraisal 
of relevant economic evaluations quality assessment tools indicated a large amount of 
overlap. This meant that quality assessment of the individual studies took considerably 
longer than anticipated, and necessitated the development and testing of an amalgamated 
tool to address all the study designs.  
All cost outcomes were converted to current GBP according to good practice; however, no 
adjustments for inflation were made due to the potential for missing key costs due to 
limited reporting in studies. The potential impact of not adjusting for inflation means that 
costs are not directly comparable across studies. For example, those reported in 2002 GBP 
are not directly comparable to those reported in 2013 GBP. 
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In general, the findings supported recommendations made by the most current NICE 
guidance available related to contraceptive service provision and health promotion 
interventions. This may be the result of searching the current NICE guidelines for relevant 
economic evaluations. It should however be noted that local authorities may have a 
different willingness to pay than the NHS, and local judgements about whether an 
intervention is ‘cost-effective’ for that context may differ between local authorities.  
Finally, we had intended to use the system of grading economic evaluations presented by 
Payne and O’Brien (2005) in this review, as a method of facilitating comparisons across 
different interventions. However, the complex nature of these studies and the need for 
transparent reporting of costs and outcomes required modification of the Payne and 
O’Brien framework, which resulted in the Cost Outcomes tables presented in Appendices 12 
to 14.  
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5 Conclusions  
This review sought to answer the research question:  
From the relevant identified studies, what evidence is available on the cost-
effectiveness of local authority commissioned sexual health services from UK-based 
studies, concerning studies of health promotion and in relation to studies of 
contraception?  
The findings from this systematic review suggest that a large amount of evidence on the 
cost-effectiveness of sexual health services has been undertaken in the past five years, and 
that, while the study findings do not always measure costs per QALY or report cost-
effectiveness or potential cost-effectiveness according to NICE thresholds, this evidence 
base generally suggests the cost-effectiveness of interventions that support current NICE 
guidance, particularly for sexual health services aimed towards young people and those at 
high risk. However, some interventions may be equivocal in terms of the cost-effectiveness, 
and others show cost-effectiveness for some STIs but not others. 
Asking broad questions about wide-ranging services amongst multiple populations inevitably 
created challenges. In order to present the findings from such diverse studies, we employed 
the use of structured summaries, evidence tables and cost-outcomes tables. These were 
designed with input from local commissioners, to assist readers in making comparisons 
between different interventions using standard formats. It is hoped that this will allow 
assessment of whether clear cost-effectiveness has been established and indicate to 
readers whether further consideration of costs and outcomes is required for their particular 
context.  
5.1 Implications for future economic evaluations of sexual health research  
As noted above, the methodological differences between economic evaluations make 
drawing comparisons across such studies difficult. While good practice for modelling studies 
has long been in place (Phillips et al. 2004), just under one-third of all included economic 
evaluations were rated highly in terms of their methodological quality. This suggests a need 
for economic evaluations to be designed and conducted according to recommended 
guidance (Anderson and Shemilt 2010; Drummond et al. 2015).  
Future economic evaluations of sexual health interventions which are based on internal 
trials could be strengthened by designing for longer-term outcomes that would allow for 
more robust modelling. Similarly, modelling studies could be designed with longer-term 
costs and outcomes in mind. Such studies could also have more impact if they were 
designed and executed in a manner to show clearly the cross-sectoral benefits of investing 
in health services. In addition, the feasibility of complementary use of large cohort study 
datasets measuring such long-term outcomes could be investigated, in order to strengthen 
future model estimates.  
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Appendices 
Appendix 1: Search strategy: PubMed 
((Contraception[MH] OR Contraception, Postcoital[MH] OR Contraception, Immunologic[MH] 
OR Contraception, Barrier[MH] OR Contraception Behavior[MH] OR Contraceptive 
Agents[MH] OR Contraceptive Devices[MH] OR Contraceptive Agents, Male[MH] OR 
Contraceptive Agents, Female[MH] OR Contraceptive Devices, Male[MH] OR Contraceptive 
Devices, Female[MH] OR Vaccines, Contraceptive[MH] OR Spermatocidal Agents[MH] OR 
Contraceptives, Oral, Hormonal[MH] OR Contraceptives, Oral, Sequential[MH] OR 
Contraception, Immunologic[MH] OR Intrauterine Devices[MH] OR Condoms[MH] OR 
Condoms, Female[MH] OR Population Control[MH] OR Natural Family Planning Methods[MH] 
OR Family Planning Services[MH] OR Family Planning Policy[MH] OR Reproductive Health 
Services[MH] OR Sex Education[MH])  
OR  
(contraception[TIAB] OR contraceptive[TIAB] OR contraceptives[TIAB] OR family 
planning[TIAB] OR reproductive health service*[TIAB] OR sexual health service*[TIAB] OR 
fertility control[TIAB] OR condom[TIAB] OR condoms[TIAB]) OR sex education[TIAB] OR 
unplanned pregnancy[TIAB] OR unplanned pregnancies[TIAB] OR unwanted pregnancy[TIAB] 
OR unwanted pregnancies[TIAB]) OR ((HIV Infections[MH] OR HIV[TIAB] OR Human 
immunodeficiency virus[TIAB] OR Herpes Simplex[MH] OR Herpes Genitalis[MH] OR herpes 
simplex[TIAB] OR herpes genitalis[TIAB] OR genital herpes[TIAB] OR herpes virus[TIAB] OR 
Gonorrhea[MH] OR gonorrhea[TIAB] OR Syphilis[MH] OR syphilis[TIAB] OR Candida 
albicans[MH] OR candidiasis[TIAB] OR candida[TIAB] OR candidal[TIAB] OR candidosis[TIAB] 
OR vulvovaginitis[TIAB] OR vulvitis[TIAB] OR vulvodynia[TIAB] OR balanitis[TIAB] OR 
Chlamydia trachomatis[MH] OR chlamydia[TIAB] OR LGV[TIAB] OR Papillomavirus 
Infections[MH] OR human papillomavirus[TIAB] OR HPV[TIAB] OR genital wart*[TIAB] OR 
anogenital wart*[TIAB] OR anorectal wart*[TIAB] OR penile wart*[TIAB] OR Vaginosis, 
Bacterial[MH] OR Gardnerella[MH] OR Gardnerella vaginalis[MH] OR bacterial 
vaginosis[TIAB] OR gardnerella vaginalis[TIAB] OR vaginitis[TIAB] OR vaginosis[TIAB]) OR 
sexual health[TIAB]))  
AND  
((Economics[MH] OR Health care costs[MH] OR (costs and cost analysis[MH]) OR Cost 
allocation[MH] OR Cost-benefit analysis[MH] OR Cost control[MH] OR Cost savings[MH] OR 
Direct service costs[MH] OR Health expenditures[MH] OR economics, medical[MH] OR 
budgets[MH] OR Health Care Economics and Organizations[MH] OR cost-effective[TIAB] OR 
cost-effectiveness[TIAB]) OR economic analysis[TIAB] OR economic evaluation[TIAB]) OR 
((effectiveness[TIAB] OR analysis[TIAB] OR savings[TIAB] OR minimisation[TIAB] OR 
minimization[TIAB] OR utility[TIAB] OR benefit[TIAB]) AND (cost))) 
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Appendix 2: Types of economic evaluation 
Cost analysis and cost minimisation analysis 
A key component of economic evaluation is understanding the costs associated with the 
delivery of an intervention. This can be done by performing a cost analysis; the aim is 
generally to identify, measure and value resources used to deliver an intervention. The 
results of a cost analysis may include an estimate of the total cost of an intervention and a 
breakdown of total costs by input or cost category. These data can be used to quantify and 
describe how resources are being used to deliver an intervention, identify who is using 
resources and understand how they are being used. A cost-minimisation analysis can be 
performed when the effectiveness of two or more alternatives is exactly equal and only 
costs vary (Drummond et al. 2005). 
Cost-consequence analysis 
A cost-consequence analysis goes one step beyond cost analysis by adding a description of 
the consequences associated with the intervention or programme being costed. This 
approach typically incorporates a range of consequences, which may vary across 
comparator interventions. This approach is considered a partial economic evaluation since 
the costs and consequences are reported separately and costs are not attached to a specific 
consequence in order to generate a cost per unit of consequence. 
Cost-effectiveness analysis 
Cost-effectiveness analysis is one of three approaches to conducting a full economic 
analysis. The defining feature is that health effects or outcomes are measured in natural 
units relative to programme objectives. In order to facilitate comparison between 
interventions, the consequences of the alternatives considered must be reported in the 
same units. Analyses focusing on interventions aimed at reducing mortality may use cost 
per life year gained or death averted as the main outcome, whereas interventions aiming to 
reduce unintended pregnancies may report the cost per unintended pregnancy averted.  
Comparing the costs and effectiveness of two interventions, the ratio reflects the 
incremental cost and effect of one over the other and so is referred to as an Incremental 
Cost Effectiveness Ratio (ICER). An ICER is constructed as follows:  
𝐼𝐶𝐸𝑅 =  
𝐶𝑜𝑠𝑡 𝐼𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛 𝐴− 𝐶𝑜𝑠𝑡𝐼𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛 𝐵
𝐸𝑓𝑓𝑒𝑐𝑡𝐼𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛 𝐴 −  𝐸𝑓𝑓𝑒𝑐𝑡𝐼𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛 𝐵
 
Using this approach, a lower cost-effectiveness ratio, or lower cost per unit of health 
effect, is considered desirable and an indication that the intervention being evaluated is 
more cost-effective than the comparator. Standard practice is to compare a new 
intervention with the standard of care, or next best alternative. Where no comparable 
intervention or service is currently available, one may compare an intervention to a ‘do 
nothing’ alternative, in which case the resulting ratio would simply be a CER (Morris et al. 
2007).  
While this approach is very useful for making comparisons between interventions with 
health effects that can be measured in the same units, this requirement can make it 
difficult to use cost-effectiveness analysis to conduct comparisons across different types of 
interventions. In this case, it is not possible to compare the relative cost-effectiveness of 
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the two different types of interventions because the measures of effect are reported in 
different units. In order to meaningfully compare interventions with different objectives 
and health effects, a composite measure of benefit is required.  
Cost-utility analysis 
A second approach to full economic evaluation is cost-utility analysis. Strictly speaking, this 
is a sub-type of cost-effectiveness analysis, since health effects are also measured in 
natural units. However, this approach is distinct in that it uses composite measures of 
benefit based on utility, which is a broad term used in economics to refer to the 
satisfaction that individuals gain from consumption. In terms of valuing health outcomes, 
utility-based measures refer to individual or societal preferences for different health 
outcomes or health states. These types of measures consider values placed on both quantity 
and quality of life and use weighting formulae to combine values into a single measure. A 
variety of direct and indirect methods for measuring utility are available. A commonly used 
indirect measure is the EQ-5D, a multi-attribute health status classification system which 
can be used along with weights derived from population surveys to value individual health 
states in terms of how they compare to either death or perfect health. The resulting score 
can be used to calculate the commonly used outcome measure, the Quality-adjusted Life 
Years (QALY) (Drummond et al. 2005).  
For a given intervention, the number of QALYs gained is calculated by multiplying the 
utility score associated with a given condition or health state by the number of years of life 
gained as a result of the intervention. For example, consider a condition with a health 
utility score of 0.5 and an intervention which prolongs life for people with this condition by 
2 years in this health state. The number of QALYs gained then would be 1 (0.5 utility score 
× 2 years). Other approaches to measurement that can be used to generate QALYs include 
the Health Utilities Index and the SF-36D (Drummond et al. 2005).  
Cost-utility ratios are calculated in the same fashion as cost-effectiveness ratios, dividing 
differences in the cost of two or more interventions by the differences in outcomes. The 
incremental cost-utility ratio calculation is provided below. (Note that this is commonly 
referred to as an incremental cost-effectiveness ratio even when a utility-based outcome 
measure is used). 
𝐼𝐶𝐸𝑅 =  
𝐶𝑜𝑠𝑡 𝐼𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛 𝐴− 𝐶𝑜𝑠𝑡𝐼𝑛𝑡𝑒𝑟𝑣𝑛𝑒𝑡𝑖𝑜𝑛 𝐵
𝑄𝐴𝐿𝑌𝑠 𝐺𝑎𝑖𝑛𝑒𝑑𝐼𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛 𝐴 −  𝑄𝐴𝐿𝑌𝑠 𝐺𝑎𝑖𝑛𝑒𝑑𝐼𝑛𝑡𝑒𝑟𝑣𝑒𝑛𝑡𝑖𝑜𝑛 𝐵
 
Cost-utility analysis is of broad applicability in public health decision making because, as in 
a cost-effectiveness analysis, it can explore single or multiple outcomes. However, cost-
utility analysis adds in a notion of value (utilities, measured as QALYs or DALYs). These 
utilities can be assessed for a range of interventions and facilitate comparisons between 
different health interventions using a common metric. However, some limitations for these 
metrics should be considered, such as their lack of compensation for socio-economic and 
demographic differences.  
Cost-benefit analysis 
The final type of full economic analysis is a cost-benefit analysis. Its defining feature is that 
both the costs and health effects associated with an intervention are translated into 
monetary terms. This approach also typically seeks to include a broader range of social 
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benefits and costs beyond those that may accrue only to the health sector or patients 
themselves. The results are commonly expressed as a ratio of benefits to costs (where 
benefits are expressed as the monetary value of benefits), or in terms of money saved per 
unit of currency spent. Using this paradigm, interventions where social benefits outweigh 
the social costs associated with an intervention or programme are considered desirable.  
An attractive feature of this approach to economic evaluation is that it is possible to 
incorporate costs and benefits occurring beyond the health sector. However, in practice, 
the process of converting benefits into monetary terms can be challenging. Beyond 
methodological challenges, the moral implications of placing a monetary value on life have 
led many researchers to steer away from this approach, particularly because there is 
potential for undervaluing health gains accrued to individuals with lower socio-economic 
status.  
A key feature of the cost-benefit approach is that the analysis can be completed for a 
single intervention since the comparison is between costs and outcomes, not the difference 
between costs and outcomes as with cost-effectiveness and cost-utility analysis. 
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Appendix 3: Flow of studies through review 
 
Total references N = 17,705 
Excluded duplicates N = 192 + 11 = 203 
Deleted item = 1 
Screened on title and abstract 
N = 17,501 
Excluded on title and abstract: 
N = 17,393 
Ex 1 non-English     n = 926 
Ex 2 Not OECD    n = 2,318 
Ex 3 Review/commentary/animal study n = 2,689 
Ex 4 Not sexual health   n = 9,081 
Ex 5 Not full economic evaluation  n = 1,558 
Ex 6 Not local authority responsibility n = 464 
Ex 7 Chlamydia economic evaluation n = 61 
Ex 8 Cancer screening econ. evaluation  n = 85 
Ex 9 Pre 2010    n = 176 
Ex 10 Systematic review   n = 27 
Ex 11 Pre-exposure prophylaxis  n = 0 
Ex 12 Abstract only/ not available  n = 0 
Ex 13 Not UK/contraception/HP  n = 8 
Screened on full text 
N = 108 
Excluded on full text N = 79 
Ex 1 non-English    n = 0 
Ex 2 Not OECD    n = 1 
Ex 3 Review/commentary/animal study n = 1 
Ex 4 Not sexual health   n = 0 
Ex 5 Not full economic evaluation n = 11 
Ex 6 Not local authority responsibility n = 6 
Ex 7 Chlamydia economic evaluation n = 1 
Ex 8 Cancer screening econ. eval.  n = 0 
Ex 9 Pre 2010    n = 4 
Ex 10 Systematic review  n = 0 
Ex 11 Pre-exposure prophylaxis  n = 5 
Ex 12 Abstract only/not available n = 2 
Ex 13 Not UK/contraception/HP n = 42 
Linked study    n = 6 
Included on full text 
N = 29 
UK studies 
N = 9 
Contraception studies 
N = 15 
Health promotion studies 
N = 14 
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Appendix 4: Characteristics of included studies: Descriptive map 
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Appendix 5: Risk of bias/methodological quality assessment tools 
NICE Intervention Study Checklist  
1. Source population/source area well described? 
Was the country (e.g. developed or non-developed, type of healthcare system), setting 
(primary schools, community centres etc.), location (urban, rural), population 
demographics etc. adequately described? 
++ 
Indicates that for that particular aspect of study design, the study has been designed or 
conducted in such a way as to minimise the risk of bias. 
+ 
Indicates that either the answer to the checklist question is not clear from the way the 
study is reported, or that the study may not have addressed all potential sources of 
bias for that particular aspect of study design. 
- 
Should be reserved for those aspects of the study design in which significant sources of 
bias may persist. 
Not reported 
Should be reserved for those aspects in which the study under review fails to report 
how they have (or might have) been considered.  
Not applicable 
Should be reserved for those study design aspects that are not applicable given the 
study design under review. 
2. Eligible population/area representative of source population/area? 
Was the recruitment of individuals, clusters or areas well defined (e.g. advertisement, 
birth register)? Was the eligible population representative of the source? Were important 
groups under-represented? 
++ 
Indicates that for that particular aspect of study design, the study has been designed or 
conducted in such a way as to minimise the risk of bias. 
+ 
Indicates that either the answer to the checklist question is not clear from the way the 
study is reported, or that the study may not have addressed all potential sources of 
bias for that particular aspect of study design. 
- 
Should be reserved for those aspects of the study design in which significant sources of 
bias may persist. 
Appendix 5 
 
Sexual health promotion and contraceptive services in local authorities: a systematic 
review of economic evaluations 2010-2015  57 
 
Not reported 
Should be reserved for those aspects in which the study under review fails to report 
how they have (or might have) been considered.  
Not applicable 
Should be reserved for those study design aspects that are not applicable given the 
study design under review. 
3. Do selected participants/areas represent the eligible population/ area? 
++ 
Indicates that for that particular aspect of study design, the study has been designed or 
conducted in such a way as to minimise the risk of bias. 
+ 
Indicates that either the answer to the checklist question is not clear from the way the 
study is reported, or that the study may not have addressed all potential sources of 
bias for that particular aspect of study design. 
- 
Should be reserved for those aspects of the study design in which significant sources of 
bias may persist. 
Not reported 
Should be reserved for those aspects in which the study under review fails to report 
how they have (or might have) been considered.  
Not applicable 
Should be reserved for those study design aspects that are not applicable given the 
study design under review. 
4. Allocation to exposure and comparison randomised? 
Was allocation to exposure and comparison randomised? Was it truly random ++ or pseudo-
randomised + (e.g. consecutive admissions)? If not randomised, was significant confounding 
likely (−) or not (+)? If a cross-over, was order of intervention randomised? 
++ 
Indicates that for that particular aspect of study design, the study has been designed or 
conducted in such a way as to minimise the risk of bias. 
+ 
Indicates that either the answer to the checklist question is not clear from the way the 
study is reported, or that the study may not have addressed all potential sources of 
bias for that particular aspect of study design. 
- 
Should be reserved for those aspects of the study design in which significant sources of 
bias may persist. 
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Not reported 
Should be reserved for those aspects in which the study under review fails to report 
how they have (or might have) been considered.  
Not applicable 
Should be reserved for those study design aspects that are not applicable given the 
study design under review. 
5. Interventions (and comparisons) well described and appropriate? 
Were interventions and comparisons described in sufficient detail (i.e. enough for study to 
be replicated)? Were comparisons appropriate (e.g. usual practice rather than no 
intervention)? 
++ 
Indicates that for that particular aspect of study design, the study has been designed or 
conducted in such a way as to minimise the risk of bias. 
+ 
Indicates that either the answer to the checklist question is not clear from the way the 
study is reported, or that the study may not have addressed all potential sources of 
bias for that particular aspect of study design. 
- 
Should be reserved for those aspects of the study design in which significant sources of 
bias may persist. 
Not reported 
Should be reserved for those aspects in which the study under review fails to report 
how they have (or might have) been considered.  
Not applicable 
Should be reserved for those study design aspects that are not applicable given the 
study design under review. 
6. Was allocation concealed? 
Could the person(s) determining allocation of participants or clusters to intervention or 
comparison groups have influenced the allocation? Adequate allocation concealment (++) 
would include centralised allocation or computerised allocation systems. 
++ 
Indicates that for that particular aspect of study design, the study has been designed or 
conducted in such a way as to minimise the risk of bias. 
+ 
Indicates that either the answer to the checklist question is not clear from the way the 
study is reported, or that the study may not have addressed all potential sources of 
bias for that particular aspect of study design. 
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- 
Should be reserved for those aspects of the study design in which significant sources of 
bias may persist. 
Not reported 
Should be reserved for those aspects in which the study under review fails to report 
how they have (or might have) been considered.  
Not applicable 
Should be reserved for those study design aspects that are not applicable given the 
study design under review. 
7. Participants and/or investigators blind to exposure and comparison? 
Were participants and investigators – those delivering or assessing the intervention – kept 
blind to intervention allocation? (Triple or double blinding score ++) If lack of blinding is 
likely to cause important bias, score − 
++ 
Indicates that for that particular aspect of study design, the study has been designed or 
conducted in such a way as to minimise the risk of bias. 
+ 
Indicates that either the answer to the checklist question is not clear from the way the 
study is reported, or that the study may not have addressed all potential sources of 
bias for that particular aspect of study design. 
- 
Should be reserved for those aspects of the study design in which significant sources of 
bias may persist. 
Not reported 
Should be reserved for those aspects in which the study under review fails to report 
how they have (or might have) been considered.  
Not applicable 
Should be reserved for those study design aspects that are not applicable given the 
study design under review. 
8. Exposure to the intervention and comparison adequate? 
Is reduced exposure to intervention or control related to the intervention (e.g. adverse 
effects leading to reduced compliance) or fidelity of implementation (e.g. reduced 
adherence to protocol)? Was lack of exposure sufficient to cause important bias? 
++ 
Indicates that for that particular aspect of study design, the study has been designed or 
conducted in such a way as to minimise the risk of bias. 
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+ 
Indicates that either the answer to the checklist question is not clear from the way the 
study is reported, or that the study may not have addressed all potential sources of 
bias for that particular aspect of study design. 
- 
Should be reserved for those aspects of the study design in which significant sources of 
bias may persist. 
Not reported 
Should be reserved for those aspects in which the study under review fails to report 
how they have (or might have) been considered.  
Not applicable 
Should be reserved for those study design aspects that are not applicable given the 
study design under review. 
9. Contamination acceptably low? 
Did any in the comparison group receive the intervention or vice versa? If so, was it 
sufficient to cause important bias? If a cross-over trial, was there a sufficient wash-out 
period between interventions? 
++ 
Indicates that for that particular aspect of study design, the study has been designed or 
conducted in such a way as to minimise the risk of bias. 
+ 
Indicates that either the answer to the checklist question is not clear from the way the 
study is reported, or that the study may not have addressed all potential sources of 
bias for that particular aspect of study design. 
- 
Should be reserved for those aspects of the study design in which significant sources of 
bias may persist. 
Not reported 
Should be reserved for those aspects in which the study under review fails to report 
how they have (or might have) been considered.  
Not applicable 
Should be reserved for those study design aspects that are not applicable given the 
study design under review. 
10. Other interventions similar in both groups? 
Did either group receive additional interventions or have services provided in a different 
manner? Were the groups treated equally by researchers or other professionals? Was this 
sufficient to cause important bias? 
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++ 
Indicates that for that particular aspect of study design, the study has been designed or 
conducted in such a way as to minimise the risk of bias. 
+ 
Indicates that either the answer to the checklist question is not clear from the way the 
study is reported, or that the study may not have addressed all potential sources of 
bias for that particular aspect of study design. 
- 
Should be reserved for those aspects of the study design in which significant sources of 
bias may persist. 
Not reported 
Should be reserved for those aspects in which the study under review fails to report 
how they have (or might have) been considered.  
Not applicable 
Should be reserved for those study design aspects that are not applicable given the 
study design under review. 
11. All participants accounted for at study conclusion? 
Were those lost-to-follow-up (i.e. dropped or lost pre-, during or post-intervention) 
acceptably low (i.e. typically <20%)? Did the proportion dropped differ by group? For 
example, were drop-outs related to the adverse effects of the intervention? 
++ 
Indicates that for that particular aspect of study design, the study has been designed or 
conducted in such a way as to minimise the risk of bias. 
+ 
Indicates that either the answer to the checklist question is not clear from the way the 
study is reported, or that the study may not have addressed all potential sources of 
bias for that particular aspect of study design. 
- 
Should be reserved for those aspects of the study design in which significant sources of 
bias may persist. 
Not reported 
Should be reserved for those aspects in which the study under review fails to report 
how they have (or might have) been considered.  
Not applicable 
Should be reserved for those study design aspects that are not applicable given the 
study design under review. 
Appendix 5 
 
Sexual health promotion and contraceptive services in local authorities: a systematic 
review of economic evaluations 2010-2015  62 
 
12. Does setting reflect usual UK practice? 
Did the setting in which the intervention or comparison was delivered differ significantly 
from usual practice in the UK? For example, did participants receive intervention (or 
comparison) condition in a hospital rather than a community-based setting? 
++ 
Indicates that for that particular aspect of study design, the study has been designed or 
conducted in such a way as to minimise the risk of bias. 
+ 
Indicates that either the answer to the checklist question is not clear from the way the 
study is reported, or that the study may not have addressed all potential sources of 
bias for that particular aspect of study design. 
- 
Should be reserved for those aspects of the study design in which significant sources of 
bias may persist. 
Not reported 
Should be reserved for those aspects in which the study under review fails to report 
how they have (or might have) been considered.  
Not applicable 
Should be reserved for those study design aspects that are not applicable given the 
study design under review. 
13. Does intervention/comparison reflect usual UK practice? 
++ 
Indicates that for that particular aspect of study design, the study has been designed or 
conducted in such a way as to minimise the risk of bias. 
+ 
Indicates that either the answer to the checklist question is not clear from the way the 
study is reported, or that the study may not have addressed all potential sources of 
bias for that particular aspect of study design. 
- 
Should be reserved for those aspects of the study design in which significant sources of 
bias may persist. 
Not reported 
Should be reserved for those aspects in which the study under review fails to report 
how they have (or might have) been considered.  
Not applicable 
Should be reserved for those study design aspects that are not applicable given the 
study design under review. 
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14. Outcome measures reliable? 
Were outcome measures subjective or objective (e.g. biochemically validated nicotine 
levels ++ vs self-reported smoking −)? How reliable were outcome measures (e.g. inter- or 
intra-rater reliability scores)? Was there any indication that measures had been validated 
(e.g. validated against a gold standard measure or assessed for content validity)? 
++ 
Indicates that for that particular aspect of study design, the study has been designed or 
conducted in such a way as to minimise the risk of bias. 
+ 
Indicates that either the answer to the checklist question is not clear from the way the 
study is reported, or that the study may not have addressed all potential sources of 
bias for that particular aspect of study design. 
- 
Should be reserved for those aspects of the study design in which significant sources of 
bias may persist. 
Not reported 
Should be reserved for those aspects in which the study under review fails to report 
how they have (or might have) been considered.  
Not applicable 
Should be reserved for those study design aspects that are not applicable given the 
study design under review 
15. All outcome measurements complete? 
Were all or most study participants who met the defined study outcome definitions likely 
to have been identified? 
++ 
Indicates that for that particular aspect of study design, the study has been designed or 
conducted in such a way as to minimise the risk of bias. 
+ 
Indicates that either the answer to the checklist question is not clear from the way the 
study is reported, or that the study may not have addressed all potential sources of 
bias for that particular aspect of study design. 
- 
Should be reserved for those aspects of the study design in which significant sources of 
bias may persist. 
Not reported 
Should be reserved for those aspects in which the study under review fails to report 
how they have (or might have) been considered.  
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Not applicable 
Should be reserved for those study design aspects that are not applicable given the 
study design under review 
16. All important outcomes assessed? 
Were all important benefits and harms assessed? Was it possible to determine the overall 
balance of benefits and harms of the intervention versus comparison? 
++ 
Indicates that for that particular aspect of study design, the study has been designed or 
conducted in such a way as to minimise the risk of bias. 
+ 
Indicates that either the answer to the checklist question is not clear from the way the 
study is reported, or that the study may not have addressed all potential sources of 
bias for that particular aspect of study design. 
- 
Should be reserved for those aspects of the study design in which significant sources of 
bias may persist. 
Not reported 
Should be reserved for those aspects in which the study under review fails to report 
how they have (or might have) been considered.  
Not applicable 
Should be reserved for those study design aspects that are not applicable given the 
study design under review. 
17. Outcomes relevant? 
Where surrogate outcome measures were used, did they measure what they set out to 
measure? (e.g. a study to assess impact on physical activity assesses gym membership – a 
potentially objective outcome measure – but is it a reliable predictor of physical activity? 
++ 
Indicates that for that particular aspect of study design, the study has been designed or 
conducted in such a way as to minimise the risk of bias. 
+ 
Indicates that either the answer to the checklist question is not clear from the way the 
study is reported, or that the study may not have addressed all potential sources of 
bias for that particular aspect of study design. 
- 
Should be reserved for those aspects of the study design in which significant sources of 
bias may persist. 
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Not reported 
Should be reserved for those aspects in which the study under review fails to report 
how they have (or might have) been considered.  
Not applicable 
Should be reserved for those study design aspects that are not applicable given the 
study design under review. 
18. Similar follow-up times in exposure and comparison groups? 
If groups are followed for different lengths of time, then more events are likely to occur 
in the group followed-up for longer distorting the comparison. Analyses can be adjusted to 
allow for differences in length of follow-up (e.g. using person-years). 
++ 
Indicates that for that particular aspect of study design, the study has been designed or 
conducted in such a way as to minimise the risk of bias. 
+ 
Indicates that either the answer to the checklist question is not clear from the way the 
study is reported, or that the study may not have addressed all potential sources of 
bias for that particular aspect of study design. 
- 
Should be reserved for those aspects of the study design in which significant sources of 
bias may persist. 
Not reported 
Should be reserved for those aspects in which the study under review fails to report 
how they have (or might have) been considered.  
Not applicable 
Should be reserved for those study design aspects that are not applicable given the 
study design under review. 
19. Follow-up time meaningful? 
Was follow-up long enough to assess long-term benefits or harms? Was it too long, e.g. 
participants lost to follow-up? 
++ 
Indicates that for that particular aspect of study design, the study has been designed or 
conducted in such a way as to minimise the risk of bias. 
+ 
Indicates that either the answer to the checklist question is not clear from the way the 
study is reported, or that the study may not have addressed all potential sources of 
bias for that particular aspect of study design. 
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- 
Should be reserved for those aspects of the study design in which significant sources of 
bias may persist. 
Not reported 
Should be reserved for those aspects in which the study under review fails to report 
how they have (or might have) been considered.  
Not applicable 
Should be reserved for those study design aspects that are not applicable given the 
study design under review. 
20. Exposure and comparison groups similar at baseline? 
Were there any differences between groups in important confounders at baseline? If so, 
were these adjusted for in the analyses (e.g. multivariate analyses or stratification). Were 
there likely to be any residual differences of relevance? 
++ 
Indicates that for that particular aspect of study design, the study has been designed or 
conducted in such a way as to minimise the risk of bias. 
+ 
Indicates that either the answer to the checklist question is not clear from the way the 
study is reported, or that the study may not have addressed all potential sources of 
bias for that particular aspect of study design. 
- 
Should be reserved for those aspects of the study design in which significant sources of 
bias may persist. 
Not reported 
Should be reserved for those aspects in which the study under review fails to report 
how they have (or might have) been considered.  
Not applicable 
Should be reserved for those study design aspects that are not applicable given the 
study design under review. 
21. Intention to treat (ITT) analysis conducted? 
Were all participants (including those that dropped out or did not fully complete the 
intervention course) analysed in the groups (i.e. intervention or comparison) to which they 
were originally allocated? 
++ 
Indicates that for that particular aspect of study design, the study has been designed or 
conducted in such a way as to minimise the risk of bias. 
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+ 
Indicates that either the answer to the checklist question is not clear from the way the 
study is reported, or that the study may not have addressed all potential sources of 
bias for that particular aspect of study design. 
- 
Should be reserved for those aspects of the study design in which significant sources of 
bias may persist. 
Not reported 
Should be reserved for those aspects in which the study under review fails to report 
how they have (or might have) been considered.  
Not applicable 
Should be reserved for those study design aspects that are not applicable given the 
study design under review. 
22. Study sufficiently powered? 
Was the study sufficiently powered to detect an intervention effect (if one exists)? A 
power of 0.8 (that is, it is likely to see an effect of a given size if one exists, 80% of the 
time) is the conventionally accepted standard. Is a power calculation presented? If not, 
what is the expected effect size? Is the sample size adequate? 
++ 
Indicates that for that particular aspect of study design, the study has been designed or 
conducted in such a way as to minimise the risk of bias. 
+ 
Indicates that either the answer to the checklist question is not clear from the way the 
study is reported, or that the study may not have addressed all potential sources of 
bias for that particular aspect of study design. 
- 
Should be reserved for those aspects of the study design in which significant sources of 
bias may persist. 
Not reported 
Should be reserved for those aspects in which the study under review fails to report 
how they have (or might have) been considered.  
Not applicable 
Should be reserved for those study design aspects that are not applicable given the 
study design under review. 
23. Effect size given or calculable? 
Were effect estimates (e.g. relative risks, absolute risks) given or possible to calculate? 
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++ 
Indicates that for that particular aspect of study design, the study has been designed or 
conducted in such a way as to minimise the risk of bias. 
+ 
Indicates that either the answer to the checklist question is not clear from the way the 
study is reported, or that the study may not have addressed all potential sources of 
bias for that particular aspect of study design. 
- 
Should be reserved for those aspects of the study design in which significant sources of 
bias may persist. 
Not reported 
Should be reserved for those aspects in which the study under review fails to report 
how they have (or might have) been considered.  
Not applicable 
Should be reserved for those study design aspects that are not applicable given the 
study design under review. 
24. Analytical methods appropriate? 
Were important differences in follow-up time and likely confounders adjusted for? If a 
cluster design, were analyses of sample size (and power), and effect size performed on 
clusters (and not individuals)? Were subgroup analyses pre-specified? 
++ 
Indicates that for that particular aspect of study design, the study has been designed or 
conducted in such a way as to minimise the risk of bias. 
+ 
Indicates that either the answer to the checklist question is not clear from the way the 
study is reported, or that the study may not have addressed all potential sources of 
bias for that particular aspect of study design. 
- 
Should be reserved for those aspects of the study design in which significant sources of 
bias may persist. 
Not reported 
Should be reserved for those aspects in which the study under review fails to report 
how they have (or might have) been considered.  
Not applicable 
Should be reserved for those study design aspects that are not applicable given the 
study design under review. 
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25. Precision of intervention effects given or calculable? 
Was the precision of intervention effects given or calculable? Were they meaningful? Were 
confidence intervals or p values for effect estimates given or possible to calculate? Were 
CIs wide or were they sufficiently precise to aid decision-making? If precision is lacking, is 
this because the study is under-powered? 
++ 
Indicates that for that particular aspect of study design, the study has been designed or 
conducted in such a way as to minimise the risk of bias. 
+ 
Indicates that either the answer to the checklist question is not clear from the way the 
study is reported, or that the study may not have addressed all potential sources of 
bias for that particular aspect of study design. 
- 
Should be reserved for those aspects of the study design in which significant sources of 
bias may persist. 
Not reported 
Should be reserved for those aspects in which the study under review fails to report 
how they have (or might have) been considered.  
Not applicable 
Should be reserved for those study design aspects that are not applicable given the 
study design under review. 
26. Study results internally valid (i.e. unbiased)? 
How well did the study minimise sources of bias (i.e. adjusting for potential confounders)? 
Were there significant flaws in the study design?  
++ All or most of the checklist criteria have been fulfilled, where they have not been 
fulfilled the conclusions are very unlikely to alter. 
+ Some of the checklist criteria have been fulfilled, where they have not been fulfilled, or 
not adequately described, the conclusions are unlikely to alter. 
− Few or no checklist criteria have been fulfilled and the conclusions are likely or very 
likely to alter. 
++ 
Indicates that for that particular aspect of study design, the study has been designed or 
conducted in such a way as to minimise the risk of bias. 
+ 
Indicates that either the answer to the checklist question is not clear from the way the 
study is reported, or that the study may not have addressed all potential sources of 
bias for that particular aspect of study design. 
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- 
Should be reserved for those aspects of the study design in which significant sources of 
bias may persist. 
27. Study results externally valid (i.e. generalisable to source population)? 
Are the findings generalisable to the source population (i.e. externally valid)? Are there 
sufficient details given about the study to determine if the findings are generalisable to 
the source population? Consider: participants, interventions and comparisons, outcomes, 
resource and policy implications. 
 
++ All or most of the checklist criteria have been fulfilled, where they have not been 
fulfilled the conclusions are very unlikely to alter. 
+ Some of the checklist criteria have been fulfilled, where they have not been fulfilled, or 
not adequately described, the conclusions are unlikely to alter. 
− Few or no checklist criteria have been fulfilled and the conclusions are likely or very 
likely to alter. 
++ 
Indicates that for that particular aspect of study design, the study has been designed or 
conducted in such a way as to minimise the risk of bias. 
+ 
Indicates that either the answer to the checklist question is not clear from the way the 
study is reported, or that the study may not have addressed all potential sources of 
bias for that particular aspect of study design. 
- 
Should be reserved for those aspects of the study design in which significant sources of 
bias may persist. 
AMSTAR Systematic Reviews Checklist 
1 Was an ‘a priori’ design provided? 
The research question and inclusion criteria should be established before the conduct of 
the review.  
Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published 
research objectives to score a “yes.”  
 Yes 
 No 
 Not reported 
 Not applicable 
2 Was there duplicate study selection and data extraction? 
There should be at least two independent data extractors and a consensus procedure for 
disagreements should be in place. 
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Note: 2 people do study selection, 2 people do data extraction, consensus process or one 
person checks the other’s work. 
 Yes 
 No 
 Not reported 
 Not applicable 
3 Was a comprehensive literature search performed? 
At least two electronic sources should be searched. The report must include years and 
databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must 
be stated and where feasible the search strategy should be provided. All searches should 
be supplemented by consulting current contents, reviews, textbooks, specialized registers, 
or experts in the particular field of study, and by reviewing the references in the studies 
found. Note: If at least 2 sources + one supplementary strategy used, select “yes” 
(Cochrane register/Central counts as 2 sources; a grey literature search counts as 
supplementary) 
 Yes 
 No 
 Not reported 
 Not applicable 
4 Was the status of publication (i.e. grey literature) used as an inclusion criterion? 
The authors should state that they searched for reports regardless of their publication 
type. The authors should state whether or not they excluded any reports (from the 
systematic review), based on their publication status, language etc. Note: If review 
indicates that there was a search for “grey literature” or “unpublished literature,” 
indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial registries 
are all considered grey for this purpose. If searching a source that contains both grey and 
non-grey, must specify that they were searching for grey/unpublished lit. 
 Yes 
 No 
 Not reported 
 Not applicable 
5 Was a list of studies (included and excluded) provided? 
A list of included and excluded studies should be provided. Note: Acceptable if the 
excluded studies are referenced. If there is an electronic link to the list but the link is 
dead, select “no.” 
 Yes 
 No 
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 Not reported 
 Not applicable 
6 Were the characteristics of the included studies provided? 
In an aggregated form such as a table, data from the original studies should be provided on 
the participants, interventions and outcomes. The ranges of characteristics in all the 
studies analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, 
duration, severity, or other diseases should be reported. Note: Acceptable if not in table 
format as long as they are described as above. 
 Yes 
 No 
 Not reported 
 Not applicable 
7 Was the scientific quality of the included studies assessed and documented? 
‘A priori’ methods of assessment should be provided (e.g., for effectiveness studies if the 
author(s) chose to include only randomized, double-blind, placebo controlled studies, or 
allocation concealment as inclusion criteria); for other types of studies alternative items 
will be relevant. Note: Can include use of a quality scoring tool or checklist, e.g., Jadad 
scale, risk of bias, sensitivity analysis, etc., or a description of quality items, with some 
kind of result for EACH study (“low” or “high” is fine, as long as it is clear which studies 
scored “low” and which scored “high”; a summary score/range for all studies is not 
acceptable) 
 Yes 
 No 
 Not reported 
 Not applicable 
8 Was the scientific quality of the included studies used appropriately in formulating 
conclusions? 
The results of the methodological rigor and scientific quality should be considered in the 
analysis and the conclusions of the review, and explicitly stated in formulating 
recommendations. Note: Might say something such as “the results should be interpreted 
with caution due to poor quality of included studies.” Cannot score “yes” for this question 
if scored “no” for question 7.  
 Yes 
 No 
 Not reported 
 Not applicable 
9 Were the methods used to combine the findings of studies appropriate? 
For the pooled results, a test should be done to ensure the studies were combinable, to 
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assess their homogeneity (i.e., Chi-squared test for homogeneity, I2). If heterogeneity 
exists a random effects model should be used and/or the clinical appropriateness of 
combining should be taken into consideration (i.e., is it sensible to combine?). Note: 
Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they 
cannot pool because of heterogeneity/variability between interventions. 
 Yes 
 No 
 Not reported 
 Not applicable 
10 Was the likelihood of publication bias assessed? 
An assessment of publication bias should include a combination of graphical aids (e.g., 
funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, 
Hedges-Olken). Note: If no test values or funnel plot included, score “no”. Score “yes” if 
mentions that publication bias could not be assessed because there were fewer than 10 
included studies. 
 Yes 
 No 
 Not reported 
 Not applicable 
11 Was conflict of interest included? 
Potential sources of support should be clearly acknowledged in both the systematic review 
and the included studies.  
Note: To get a “yes,” must indicate source of funding or support for the systematic review 
AND for each of the included studies.  
 Yes 
 No 
 Not reported 
 Not applicable 
Overall quality 
Score 1 for not applicable. Score 0 for not reported. 
 Sound 
Must score ‘yes’ for question 1, 3, 7 and 9 and ‘yes’ for more than 5 questions 
overall. 
 Unsound 
Does NOT score ‘yes’ for questions 1, 3, 7 and 9, and/or scores 5 or less overall 
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Combined Health Economic Evaluation Checklist  
Section 1. Applicability 
For all questions: 
-answer ‘yes’ if the study fully meets the criterion 
-answer ‘partly’ if the study largely meets the criterion but differs in some important 
respect 
-answer ‘no’ if the study deviates substantively from the criterion 
-answer ‘unclear’ if the report provides insufficient information to judge whether the 
study complies with the criterion 
-answer ‘NA (not applicable)’ if the criterion is not relevant in a particular instance. 
For ‘partly’ or ‘no’ responses, use the comments column to explain how the study deviates 
from the criterion. 
1.1 Is the study population appropriate? 
The study population should be defined as precisely as possible and should be in line with 
that specified in the guideline scope and any related review protocols. 
This includes consideration of appropriate subgroups that require special attention. For 
many interventions, the capacity to benefit will differ for participants with differing 
characteristics. This should be explored separately for each relevant subgroup as part of 
the base-case analysis by the provision of estimates of clinical and cost-effectiveness. The 
characteristics of participants in each subgroup should be clearly defined and, ideally, 
should be identified on the basis of an a priori expectation of differential clinical or cost-
effectiveness as a result of biologically plausible known mechanisms, social characteristics 
or other clearly justified factors. 
Answer ‘yes’ if the study population is fully in line with that in the guideline question(s) 
and if the study differentiates appropriately between important subgroups. Answer 
‘partly’ if the study population is similar to that in the guideline question(s) but: (i) it 
differs in some important respects; or (ii) the study fails to differentiate between 
important subgroups. Answer ‘no’ if the study population is substantively different from 
that in the guideline question(s). 
 Yes 
 Partly 
 No/Unclear 
 Not applicable 
This should rate as 1 so as not to disadvantage a study which rightly does not 
assess this. 
1.2 Are the interventions and services appropriate? 
All relevant alternatives should be included, as specified in the guideline scope and any 
related review protocols. These should include routine and best practice in the NHS, 
existing NICE guidance and other feasible options. 
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Answer ‘yes’ if the analysis includes all options considered relevant for the guideline, even 
if it also includes other options that are not relevant. Answer ‘partly’ if the analysis omits 
one or more relevant options but still contains comparisons likely to be useful for the 
guideline. Answer ‘no’ if the analysis does not contain any relevant comparisons. 
 Yes 
 No/Unclear 
 Partly 
 Not applicable 
This should rate as 1 so as not to disadvantage a study which rightly does not 
assess this. 
1.3 Is the healthcare system in which the study was conducted sufficiently similar to 
the current UK NHS context? 
This relates to the overall structure of the healthcare system within which the 
interventions were delivered. For example, an intervention might be delivered on an 
inpatient basis in one country whereas in the UK it would be provided in the community. 
This might significantly influence the use of healthcare resources and costs, thus limiting 
the applicability of the results to a UK setting. In addition, old UK studies may be severely 
limited in terms of their relevance to current NHS practice. 
Answer ‘yes’ if the study was conducted within the UK and is sufficiently recent to reflect 
current NHS practice. For non-UK or older UK studies, answer ‘partly’ if differences in the 
healthcare setting are unlikely to substantively change the cost-effectiveness estimates. 
Answer ‘no’ if the healthcare setting is so different that the results are unlikely to be 
applicable in the current NHS. 
 Yes 
 Partly 
 No/Unclear 
 Not applicable 
This should rate as 1 so as not to disadvantage a study which rightly does not 
assess this. 
1.4 Are costs measured from the societal, health care and personal social services (PSS) 
perspective? 
The decision-making perspective of an economic evaluation determines the range of costs 
that should be included in the analysis. NICE works in a specific context; in particular, it 
does not set the budget for the NHS. The objective of NICE is to offer guidance that 
represents an efficient use of available NHS and PSS resources. For these reasons, the 
perspective on costs used in the NICE reference case is that of the NHS and PSS. 
Productivity costs and costs borne by patients and carers that are not reimbursed by the 
NHS or PSS are not included in the reference case. The reference case also excludes costs 
to other government bodies, although these may sometimes be presented in additional 
analyses alongside the reference case. 
Answer ‘yes’ if the study only includes costs for resource items that would be paid for by 
the NHS and PSS. Also answer ‘yes’ if other costs have been included in the study, but the 
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results are presented in such a way that the cost-effectiveness can be calculated from an 
NHS and PSS perspective. Answer ‘partly’ if the study has taken a wider perspective but 
the other non-NHS/PSS costs are small in relation to the total expected costs and are 
unlikely to change the cost-effectiveness results. Answer ‘no’ if non-NHS/PSS costs are 
significant and are likely to change the cost-effectiveness results. 
Some interventions may have a substantial impact on non-health outcomes or costs to 
other government bodies (for example, treatments to reduce illicit drug misuse may have 
the effect of reducing drug-related crime). In such situations, if the economic study 
includes non-health costs in such a way that they cannot be separated out from NHS/PSS 
costs, answer ‘no’ but consider retaining the study for critical appraisal. If studies 
containing non-reference-case costs are retained, use the comments column to note why. 
 Yes 
 Partly 
 No/Unclear 
 Not applicable 
This should rate as 1 so as not to disadvantage a study which rightly does not 
assess this. 
1.5 Are non-direct health effects on individuals excluded? 
In the NICE reference case, the perspective on outcomes should be all direct health 
effects, whether for patients or, when relevant, other people (principally carers). This is 
consistent with an objective of maximising health gain from available healthcare 
resources. Some features of healthcare delivery that are often referred to as ‘process 
characteristics’ may ultimately have health consequences; for example, the mode of 
treatment delivery may have health consequences through its impact on concordance with 
treatment. Any significant characteristics of healthcare technologies that have a value to 
people that is independent of any direct effect on health should be noted. These 
characteristics include the convenience with which healthcare is provided and the level of 
information available for patients. 
This question should be viewed in terms of what is excluded in relation to the NICE 
reference case; that is, non-health effects. 
Answer ‘yes’ if the measure of health outcome used in the analysis excludes non-health 
effects (or if such effects can be excluded from the results). Answer ‘partly’ if the analysis 
includes some non-health effects but these are small and unlikely to change the cost-
effectiveness results. Answer ‘no’ if the analysis includes significant non-health effects 
that are likely to change the cost-effectiveness results. 
 Yes 
 Partly 
 No/Unclear 
 Not applicable 
This should rate as 1 so as not to disadvantage a study which rightly does not 
assess this. 
1.6 Are both costs and health effects discounted at an annual rate of 3.5%? 
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NOTE: 3.0% is also considered an acceptable rate. The need to discount to a present value 
is widely accepted in economic evaluation, although the specific rate varies across 
jurisdictions and over time. NICE considers it appropriate to discount costs and health 
effects at the same rate. The annual rate of 3.5%, based on the recommendations of the 
UK Treasury for the discounting of costs, applies to both costs and health effects. 
Answer ‘yes’ if both costs and health effects (for example, quality-adjusted life years 
[QALYs]) are discounted at 3.5% per year. Answer ‘partly’ if costs and health effects are 
discounted at a rate similar to 3.5% (for example, costs and effects are both discounted at 
3% per year). Answer ‘no’ if costs and/or health effects are not discounted, or if they are 
discounted at a rate (or rates) different from 3.5% (for example, 5% for both costs and 
effects, or 6% for costs and 1.5% for effects). Note in the comments column what discount 
rates have been used. If all costs and health effects accrue within a short time (roughly a 
year), answer ‘NA’. 
 Yes 
 Partly 
 No/Unclear 
 Not applicable 
This should rate as 1 so as not to disadvantage a study which rightly does not 
assess this. 
1.7 Is the value of health effects expressed in terms of quality-adjusted life years 
(QALYs)? 
The QALY is a measure of a person’s length of life weighted by a valuation of their health-
related quality of life (HRQoL) over that period. Given its widespread use, the QALY is 
considered by NICE to be the most appropriate generic measure of health benefit that 
reflects both mortality and effects on HRQoL. It is recognised that alternative measures 
exist (such as the healthy-year equivalent), but few economic evaluations have used these 
methods and their strengths and weaknesses are not fully established. 
NICE’s position is that an additional QALY should be given the same weight regardless of 
the other characteristics of the patients receiving the health benefit. 
Answer ‘yes’ if the effectiveness of the intervention is measured using QALYs; answer ‘no’ 
if not. There may be circumstances when a QALY cannot be obtained or where the 
assumptions underlying QALYs are considered inappropriate. In such situations answer ‘no’, 
but consider retaining the study for appraisal. Similarly, answer ‘no’ but retain the study 
for appraisal if it does not include QALYs but it is still thought to be useful for Guideline 
Development Group decision-making: for example, if the clinical evidence indicates that 
an intervention might be dominant, and estimates of the relative costs of the 
interventions from a cost-minimisation study are likely to be useful. When economic 
evaluations not using QALYs are retained for full critical appraisal, use the comments 
column to note why. 
 Yes 
 Partly 
 No/Unclear 
Appendix 5 
 
Sexual health promotion and contraceptive services in local authorities: a systematic 
review of economic evaluations 2010-2015  78 
 
 Not applicable 
This should rate as 1 so as not to disadvantage a study which rightly does not 
assess this. 
1.8 Are changes in health-related quality of life (HRQoL) reported directly from patients 
and/or carers? 
In the NICE reference case, information on changes in HRQoL as a result of treatment 
should be reported directly by patients (and directly by carers when the impact of 
treatment on the carer’s health is also important). When it is not possible to obtain 
information on changes in patients’ HRQoL directly from them, data should be obtained 
from carers (not from healthcare professionals). 
For consistency, the EQ-5D is NICE’s preferred measure of HRQoL in adults. However, when 
EQ-5D data are not available or are inappropriate for the condition or the effects of 
treatment, other multi-attribute utility questionnaires (for example, SF6D, QWB or HUI) or 
mapping methods from disease-specific questionnaires may be used to estimate QALYs. For 
studies not reporting QALYs, a variety of generic or disease-specific methods may be used 
to measure HRQoL. 
Answer ‘yes’ if changes in patients’ HRQoL are estimated by the patients themselves. 
Answer ‘partly’ if estimates of patients’ HRQoL are provided by carers. Answer ‘no’ if 
estimates come from healthcare professionals or researchers. Note in the comments 
column how HRQoL was measured (EQ-5D, QWB, HUI and so on). Answer ‘NA’ if the cost-
effectiveness study does not include estimates of HRQoL (for example, studies reporting 
‘cost per life year gained’ or cost-minimisation studies). 
 Yes 
 Partly 
 No/Unclear 
 Not applicable 
This should rate as 1 so as not to disadvantage a study which rightly does not 
assess this. 
1.9 Is the valuation of changes in HRQoL (utilities) obtained from a representative 
sample of the general public? 
The NICE reference case specifies that the valuation of changes in HRQoL (utilities) 
reported by patients should be based on public preferences elicited using a choice-based 
method (such as the time trade-off or standard gamble) in a representative sample of the 
UK population. 
Answer ‘yes’ if HRQoL valuations were obtained using the EQ-5D UK tariff. Answer ‘partly’ 
if the valuation methods were comparable to those used for the EQ-5D. Answer ‘no’ if 
other valuation methods were used. Answer ‘NA’ if the study does not apply valuations to 
HRQoL (for studies not reporting QALYs). In the comments column note the valuation 
method used (such as time trade-off or standard gamble) and the source of the 
preferences (such as patients or healthcare professionals). 
 Yes 
 Partly 
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 No/Unclear 
 Not applicable 
This should rate as 1 so as not to disadvantage a study which rightly does not 
assess this. 
1.10 Section 1 judgement 
Classify the applicability of the economic evaluation to the clinical guideline, the current 
NHS situation and the context for NICE guidance as one of the following: 
Directly applicable – the study meets all applicability criteria, or fails to meet one or more 
applicability criteria but this is unlikely to change the conclusions about cost-
effectiveness. 
Partially applicable – the study fails to meet one or more applicability criteria, and this 
could change the conclusions about cost-effectiveness. 
Not applicable – the study fails to meet one or more applicability criteria, and this is likely 
to change the conclusions about cost-effectiveness. Such studies would usually be excluded 
from further consideration and there is no need to continue with the rest of the checklist. 
 Directly applicable=1 
 Partially applicable=0.5 
 No applicability=0 
Section 2. Study limitations 
For all questions: 
-answer ‘yes’ if the study fully meets the criterion 
-answer ‘partly’ if the study largely meets the criterion but differs in some important 
respect 
-answer ‘no’ if the study deviates substantively from the criterion 
-answer ‘unclear’ if the report provides insufficient information to judge whether the 
study complies with the criterion 
-answer ‘NA (not applicable)’ if the criterion is not relevant in a particular instance. 
For ‘partly’ or ‘no’ responses, use the comments column to explain how the study deviates 
from the criterion. 
2.1 Does the model structure adequately reflect the nature of the health condition 
under evaluation? 
This relates to the choice of model and its structural elements (including cycle length in 
discrete time models, if appropriate). Model type and its structural aspects should be 
consistent with a coherent theory of the health condition under evaluation. The selection 
of treatment pathways, whether health states or branches in a decision tree, should be 
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based on the underlying biological processes of the health issue under study and the 
potential impact (benefits and adverse consequences) of the intervention(s) of interest. 
Answer ‘yes’ if the model design and assumptions appropriately reflect the health 
condition and intervention(s) of interest. Answer ‘partly’ if there are aspects of the model 
design or assumptions that do not fully reflect the health condition or intervention(s) but 
these are unlikely to change the cost-effectiveness results. Answer ‘no’ if the model omits 
some important aspect of the health condition or intervention(s) and this is likely to 
change the cost-effectiveness results. Answer ‘NA’ for economic evaluations based on data 
from a clinical study which do not extrapolate treatment outcomes or costs beyond the 
study context or follow-up period. 
 Yes 
 Partly 
 No/Unclear 
 Not applicable 
This should rate as 1 so as not to disadvantage a study which rightly does not 
assess this. 
2.2 Is the time horizon sufficiently long to reflect all important differences in costs and 
outcomes? 
The time horizon is the period of analysis of the study: the length of follow-up for 
participants in a trial-based evaluation, or the period of time over which the costs and 
outcomes for a cohort are tracked in a modelling study. This time horizon should always be 
the same for costs and outcomes, and should be long enough to include all relevant costs 
and outcomes relating to the intervention. A time horizon shorter than lifetime could be 
justified if there is no differential mortality effect between options, and the differences 
in costs and HRQoL relate to a relatively short period (for example, in the case of an acute 
infection). 
Answer ‘yes’ if the time horizon is sufficient to include all relevant costs and outcomes. 
Answer ‘partly’ if the time horizon may omit some relevant costs and outcomes but these 
are unlikely to change the cost-effectiveness results. Answer ‘no’ if the time horizon omits 
important costs and outcomes and this is likely to change the cost-effectiveness results. 
 Yes 
 Partly 
 No/Unclear 
 Not applicable 
This should rate as 1 so as not to disadvantage a study which rightly does not 
assess this. 
2.3 Are all important and relevant health outcomes included? 
All relevant health outcomes should include direct health effects relating to harms from 
the intervention (adverse effects) as well as any potential benefits. 
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Answer ‘yes’ if the analysis includes all relevant and important harms and benefits. 
Answer ‘partly’ if the analysis omits some harms or benefits but these would be unlikely to 
change the cost-effectiveness results. Answer ‘no’ if the analysis omits important harms 
and/or benefits that would be likely to change the cost-effectiveness results. 
 Yes 
 Partly 
 No/Unclear 
 Not applicable 
This should rate as 1 so as not to disadvantage a study which rightly does not 
assess this. 
2.4 Are the estimates of baseline health outcomes from the best available source? 
The estimate of the overall net treatment effect of an intervention is determined by the 
baseline risk of a particular condition or event and/or the relative effects of the 
intervention compared with the relevant comparator treatment. The overall net 
treatment effect may also be determined by other features of the people comprising the 
population of interest. 
The process of assembling evidence for economic evaluations should be systematic – 
evidence must be identified, quality assessed and, when appropriate, pooled, using 
explicit criteria and justifiable and reproducible methods. These principles apply to all 
categories of evidence that are used to estimate clinical and cost-effectiveness, evidence 
for which will typically be drawn from a number of different sources. 
The sources and methods for eliciting baseline probabilities should be described clearly. 
These data can be based on ‘natural history’ (patient outcomes in the absence of 
treatment or with routine care), sourced from cohort studies. Baseline probabilities may 
also be derived from the control arms of experimental studies. Sometimes it may be 
necessary to rely on expert opinion for particular parameters. 
Answer ‘yes’ if the estimates of baseline health outcomes reflect the best available 
evidence as identified from a recent well-conducted systematic review of the literature. 
Answer ‘partly’ if the estimates are not derived from a systematic review but are likely to 
reflect outcomes for the relevant group of patients in routine NHS practice (for example, 
if they are derived from a large UK-relevant cohort study). Answer ‘no’ if the estimates 
are unlikely to reflect outcomes for the relevant group in routine NHS practice. 
 Yes 
 Partly 
 No/Unclear 
 Not applicable 
This should rate as 1 so as not to disadvantage a study which rightly does not 
assess this. 
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2.5 Are the estimates of relative treatment effects from the best available source? 
The objective of the analysis of clinical effectiveness is to produce an unbiased estimate of 
the mean clinical effectiveness of the interventions being compared. 
The NICE reference case indicates that evidence on outcomes should be obtained from a 
systematic review, defined as the systematic location, inclusion, appraisal and synthesis of 
evidence to obtain a reliable and valid overview of the data relating to a clearly 
formulated question. 
Synthesis of outcome data through meta-analysis is appropriate provided that there are 
sufficient relevant and valid data obtained using comparable measures of outcome. 
Head-to-head randomised controlled trials (RCTs) provide the most valid evidence of 
relative treatment effect. However, such evidence may not always be available. 
Therefore, data from non-randomised studies may be required to supplement RCT data. 
Any potential bias arising from the design of the studies used in the assessment should be 
explored and documented. 
Data from head-to-head RCTs should be presented in the base-case analysis, if available. 
When head-to-head RCTs exist, evidence from indirect or mixed treatment comparison 
analyses may be presented if it is considered to add information that is not available from 
the head-to-head comparison. This indirect or mixed treatment comparison must be fully 
described and presented as additional to the base-case analysis. (A ‘mixed treatment 
comparison’ estimates effect sizes using both head-to-head and indirect comparisons.) 
If data from head-to-head RCTs are not available, indirect treatment comparison methods 
should be used. (An ‘indirect treatment comparison’ is a synthesis of data from a network 
of trials that compare the interventions of interest with other comparators.) 
When multiple interventions are being assessed that have not been compared within a 
single RCT, data from a series of pairwise head-to-head RCTs should be presented. 
Consideration should also be given to presenting a combined analysis using a mixed 
treatment comparison framework if it is considered to add information that is not 
available from the head-to-head comparison. 
Only indirect or mixed treatment comparison methods that preserve randomisation should 
be used. The principles of good practice for standard meta-analyses should also be 
followed in mixed and indirect treatment comparisons. 
The methods and assumptions that are used to extrapolate short-term results to final 
outcomes should be clearly presented and there should be documentation of the reasoning 
underpinning the choice of survival function. 
Evidence for the evaluation of diagnostic technologies should normally incorporate 
evidence on diagnostic accuracy. It is also important to incorporate the predicted changes 
in health outcomes and costs resulting from treatment decisions based on the test result. 
The general principles guiding the assessment of the clinical and cost-effectiveness of 
diagnostic interventions should be the same as for other technologies. However, particular 
consideration of the methods of analysis may be required, particularly in relation to 
evidence synthesis. Evidence for the effectiveness of diagnostic technologies should 
include the costs and outcomes for people whose test results lead to an incorrect 
diagnosis, as well as for those who are diagnosed correctly. 
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As for other technologies, RCTs have the potential to capture the pathway of care 
involving diagnostic technologies, but their feasibility and availability may be limited. 
Other study designs should be assessed on the basis of their fitness for purpose, taking into 
consideration the aim of the study (for example, to evaluate outcomes, or to evaluate 
sensitivity and specificity) and the purpose of the diagnostic technology. 
Answer ‘yes’ if the estimates of treatment effect appropriately reflect all relevant studies 
of the best available quality, as identified through a recent well-conducted systematic 
review of the literature. Answer ‘partly’ if the estimates of treatment effect are not 
derived from a systematic review but are similar in magnitude to the best available 
estimates (for example, if the economic evaluation is based on a single large study with 
treatment effects similar to pooled estimates from all relevant studies). Answer ‘no’ if 
the estimates of treatment effect are likely to differ substantively from the best available 
estimates. 
 Yes 
 Partly 
 No/Unclear 
 Not applicable 
This should rate as 1 so as not to disadvantage a study which rightly does not 
assess this. 
2.6 Are all important and relevant costs included? 
Costs related to the condition of interest and incurred in additional years of life gained as 
a result of treatment should be included in the base-case analysis. This should include the 
costs of handling non-adherence to treatment and treating side effects. Costs that are 
considered to be unrelated to the condition or intervention of interest should be excluded. 
If introduction of the intervention requires additional infrastructure to be put in place, 
consideration should be given to including such costs in the analysis. 
Answer ‘yes’ if all important and relevant resource use and costs are included given the 
perspective and the research question in the economic study under consideration. Answer 
‘partly’ if some relevant resource items are omitted but these are unlikely to affect the 
cost-effectiveness results. Answer ‘no’ if important resource items are omitted and these 
are likely to affect the cost-effectiveness results. 
 Yes 
 Partly 
 No/Unclear 
 Not applicable 
This should rate as 1 so as not to disadvantage a study which rightly does not 
assess this. 
2.7 Are the estimates of resource use from the best available source? 
It is important to quantify the effect of the interventions on resource use in terms of 
physical units (for example, days in hospital or visits to a GP) and valuing those effects in 
monetary terms using appropriate prices and unit costs. Evidence on resource use should 
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be identified systematically. When expert opinion is used as a source of information, any 
formal methods used to elicit these data should be clearly reported. 
Answer ‘yes’ if the estimates of resource use appropriately reflect all relevant evidence 
sources of the best available quality, as identified through a recent well-conducted 
systematic review of the literature. Answer ‘partly’ if the estimates of resource use are 
not derived from a systematic review but are similar in magnitude to the best available 
estimates. Answer ‘no’ if the estimates of resource use are likely to differ substantively 
from the best available estimates. 
 Yes 
 Partly 
 No/Unclear 
 Not applicable 
This should rate as 1 so as not to disadvantage a study which rightly does not 
assess this. 
2.8 Are the unit costs of resources from the best available source? 
Resources should be valued using the prices relevant to the NHS and PSS. Given the 
perspective of the NICE reference case, it is appropriate for the financial costs relevant to 
the NHS/PSS to be used as the basis of costing, although these may not always reflect the 
full social opportunity cost of a given resource. A first point of reference in identifying 
costs and prices should be any current official listing published by the Department of 
Health and/or the Welsh Government. 
When the acquisition price paid for a resource differs from the public list price (for 
example, pharmaceuticals and medical devices sold at reduced prices to NHS institutions), 
the public list price should be used in the base-case analysis. Sensitivity analysis should 
assess the implications of variations from this price. Analyses based on price reductions for 
the NHS will only be considered when the reduced prices are transparent and can be 
consistently available across the NHS, and if the period for which the specified price is 
available is guaranteed. 
National data based on healthcare resource groups (HRGs) such as the Payment by Results 
tariff can be used when they are appropriate and available. However, data based on HRGs 
may not be appropriate in all circumstances (for example, when the definition of the HRG 
is broad, or the mean cost probably does not reflect resource use in relation to the 
intervention(s) under consideration). In such cases, other sources of evidence, such as 
micro-costing studies, may be more appropriate. When cost data are taken from the 
literature, the methods used to identify the sources should be defined. When several 
alternative sources are available, a justification for the costs chosen should be provided 
and discrepancies between the sources explained. When appropriate, sensitivity analysis 
should have been undertaken to assess the implications for results of using alternative 
data sources. 
Answer ‘yes’ if resources are valued using up-to-date prices relevant to the NHS and PSS. 
Answer ‘partly’ if the valuations of some resource items differ from current NHS/PSS unit 
costs but this is unlikely to change the cost-effectiveness results. Answer ‘no’ if the 
valuations of some resource items differ substantively from current NHS/PSS unit costs and 
this is likely to change the cost-effectiveness results. 
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 Yes 
 Partly 
 No/Unclear 
 Not applicable 
This should rate as 1 so as not to disadvantage a study which rightly does not 
assess this. 
2.9 Is an appropriate incremental analysis presented or can it be calculated from the 
data? 
An appropriate incremental analysis is one that compares the expected costs and health 
outcomes of one intervention with the expected costs and health outcomes of the next-
best non-dominated alternative. 
Standard decision rules should be followed when combining costs and effects, and should 
reflect any situation where there is dominance or extended dominance. When there is a 
trade-off between costs and effects, the results should be presented as an incremental 
cost-effectiveness ratio (ICER): the ratio of the difference in mean costs to the difference 
in mean outcomes of a technology compared with the next best alternative. In addition to 
ICERs, expected net monetary or health benefits can be presented using values placed on a 
QALY gained of £20,000 and £30,000. 
For cost-consequence analyses, appropriate incremental analysis can only be done by 
selecting one of the consequences as the primary measure of effectiveness. 
Answer ‘yes’ if appropriate incremental results are presented, or if data are presented 
that allow the reader to calculate the incremental results. Answer ‘no’ if: (i) simple ratios 
of costs to effects are presented for each alternative compared with a standard 
intervention; or (ii) if options subject to simple or extended dominance are not excluded 
from the incremental analyses. 
 Yes 
 Partly 
 No/Unclear 
 Not applicable 
This should rate as 1 so as not to disadvantage a study which rightly does not 
assess this. 
2.10 Are all important parameters whose values are uncertain subjected to appropriate 
sensitivity analysis? 
There are a number of potential selection biases and uncertainties in any evaluation (trial- 
or model-based) and these should be identified and quantified where possible. There are 
three types of bias or uncertainty to consider: 
Structural uncertainty – for example in relation to the categorisation of different states of 
health and the representation of different pathways of care. These structural assumptions 
should be clearly documented and the evidence and rationale to support them provided. 
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The impact of structural uncertainty on estimates of cost-effectiveness should be explored 
by separate analyses of a representative range of plausible scenarios. 
Source of values to inform parameter estimates – the implications of different estimates 
of key parameters (such as estimates of relative effectiveness) must be reflected in 
sensitivity analyses (for example, through the inclusion of alternative scenarios). Inputs 
must be fully justified, and uncertainty explored by sensitivity analysis using alternative 
input values. 
Parameter precision – uncertainty around the mean health and cost inputs in the model. 
Distributions should be assigned to characterise the uncertainty associated with the 
(precision of) mean parameter values. Probabilistic sensitivity analysis is preferred, as this 
enables the uncertainty associated with parameters to be simultaneously reflected in the 
results of the model. In non-linear decision models – when there is not a straight-line 
relationship between inputs and outputs of a model (such as Markov models) – probabilistic 
methods provide the best estimates of mean costs and outcomes. Simple decision trees are 
usually linear. The mean value, distribution around the mean, and the source and 
rationale for the supporting evidence should be clearly described for each parameter 
included in the model. Evidence about the extent of correlation between individual 
parameters should be considered carefully and reflected in the probabilistic analysis. 
Assumptions made about the correlations should be clearly presented. 
Answer ‘yes’ if an extensive sensitivity analysis was undertaken that explored all key 
uncertainties in the economic evaluation. Answer ‘partly’ if the sensitivity analysis failed 
to explore some important uncertainties in the economic evaluation. Answer ‘no’ if the 
sensitivity analysis was very limited and omitted consideration of a number of important 
uncertainties, or if the range of values or distributions around parameters considered in 
the sensitivity analysis were not reported. 
 Yes 
 Partly 
 No/Unclear 
 Not applicable 
This should rate as 1 so as not to disadvantage a study which rightly does not 
assess this. 
2.11 Is there no potential conflict of interest? 
The British Medical Journal (BMJ) defines competing interests for its authors as follows: "A 
competing interest exists when professional judgment concerning a primary interest (such 
as patients’ welfare or the validity of research) may be influenced by a secondary interest 
(such as financial gain or personal rivalry). It may arise for the authors of a BMJ article 
when they have a financial interest that may influence, probably without their knowing, 
their interpretation of their results or those of others." 
Whenever a potential financial conflict of interest is possible, this should be declared. 
Answer ‘yes’ if the authors declare that they have no financial conflicts of interest. 
Answer ‘no’ if clear financial conflicts of interest are declared or apparent (for example, 
from the stated affiliation of the authors). Answer ‘unclear’ if the article does not 
indicate whether or not there are financial conflicts of interest. 
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 Yes 
 Partly 
 No/Unclear 
 Not applicable 
This should rate as 1 so as not to disadvantage a study which rightly does not 
assess this. 
2.12 Section judgement 
The overall methodological study quality of the economic evaluation should be classified 
as one of the following: 
Minor limitations – the study meets all quality criteria, or fails to meet one or more 
quality criteria but this is unlikely to change the conclusions about cost-effectiveness. 
Potentially serious limitations – the study fails to meet one or more quality criteria, and 
this could change the conclusions about cost-effectiveness. 
Very serious limitations – the study fails to meet one or more quality criteria, and this is 
highly likely to change the conclusions about cost-effectiveness. Such studies should 
usually be excluded from further consideration. 
 Minor limitations=1 
 Potentially serious limitations=0.5 
 Very serious limitations=0 
Section 3. Modelling appraisal 
3.1 Have methodological uncertainties been addressed? 
Methodological uncertainty relates to whether particular analytical steps taken in the 
analysis are the most appropriate. Have methodological uncertainties been addressed by 
running alternative versions of the model with different methodological assumptions? 
 Yes 
 Partly 
 No 
 Not applicable 
3.2 Have structural uncertainties been addressed? 
Is there evidence that structural uncertainties have been addressed via sensitivity analysis? 
 Yes 
 Partly 
 No 
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 Not applicable 
3.3 Have heterogeneity uncertainties been addressed? 
It is important to distinguish between uncertainty resulting from the process of sampling 
from a population and variability due to heterogeneity (i.e. systematic differences 
between patient subgroups). Has heterogeneity been dealt with by running the model 
separately for different subgroups? 
 Yes 
 Partly 
 No 
 Not applicable 
3.4 Have internal and external consistency issues been considered? 
There should be evidence that the internal consistency of the model has been evaluated in 
terms of its mathematical logic. In addition, the results of a model should be explicable. 
Either results should make intuitive sense or counterintuitive results should be fully 
explained. 
All relevant available data should be incorporated into a model. Data should not be 
withheld for purposes of assessing external consistency.  
The results of a model should be compared with those of previous models and any 
differences should be explained.  
Consider: 
-Is there evidence that the mathematical logic of the model has been tested thoroughly 
before use? 
-Are any counterintuitive results from the model explained and justified? 
-If the model has been calibrated against independent data, have any differences been 
explained and justified? 
-Have the results of the model been compared with those of previous models and any 
differences in results explained? 
 Yes 
 Partly 
 No 
 Not applicable 
3.5 Section judgement 
The overall methodological study quality of the economic evaluation should be classified 
as one of the following: 
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Minor limitations – the study meets all quality criteria, or fails to meet one or more 
quality criteria but this is unlikely to change the conclusions about cost-effectiveness. 
Potentially serious limitations – the study fails to meet one or more quality criteria, and 
this could change the conclusions about cost-effectiveness. 
Very serious limitations – the study fails to meet one or more quality criteria, and this is 
highly likely to change the conclusions about cost-effectiveness. Such studies should 
usually be excluded from further consideration. 
 Minor limitations=1 
 Potentially serious limitations=0.5 
 Very serious limitations=0 
Section 4. Overall quality rating 
FOR AN INTRINSIC OR EXTRINSIC TRIAL 
Section 1 + Section 2  
 High 
Rating Sections 1+2=2 
 Medium 
Rating Sections 1+2=1 or 1.5 
 Low 
Rating Sections 1+2=0 or 0.5 
 
FOR MODELLING STUDIES 
Section 1 + Section 2 + Section 3 
HIGH=2.5-3 / MEDIUM=1.5-2 / LOW=0-0.5 
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Appendix 6: Risk of bias ratings: Trials and systematic reviews 
Trials 
Study (year) Internal 
validity rating 
External 
validity rating 
Overall 
validity 
Burgos (2010) + + + 
Crawford (2015) ++ + ++ 
Han (2014) - - - 
Holtgrave (2013) - - - 
Jackson (2015) + + + 
Marseille (2011) - - - 
Roberts (2012) - + - 
Rodriguez (2010b) - - - 
Ruger (2014) - - - 
Sanders (2010) - - - 
Schackman (2013) + + + 
Thomas & Cameron (2013) ++ ++ ++ 
++ All or most of the checklist criteria have been fulfilled; where they have not been 
fulfilled the conclusions are very unlikely to alter. 
+ Some of the checklist criteria have been fulfilled; where they have not been fulfilled, or 
not adequately described, the conclusions are unlikely to alter. 
− Few or no checklist criteria have been fulfilled and the conclusions are likely or very 
likely to alter. 
Systematic reviews 
Study (year) 1. A 
priori 
question 
3. 
Literature 
search 
7. QA 
included 
studies 
9. 
Appropriate 
synthesis 
Two other 
criteria 
score ‘yes’ 
Overall 
Validity 
NCC (2013) NR Y Y Y N Unsound 
Pilgrim (2010) Y Y Y Y N Unsound 
Sound Review must score ‘yes’ for question 1, 3, 7 and 9 and ‘yes’ for more than 5 
questions overall. 
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Unsound Review does NOT score ‘yes’ for questions 1, 3, 7 and 9, and/or scores 5 or less 
overall.
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Appendix 7: Quality assessment ratings: Combined Health Economic Evaluation 
Checklist  
Study (year) Applicability Study 
limitations 
Modelling 
appraisal 
Overall 
score 
Rating 
Bayer (2013) 0.5 0.5 0 1 Low 
Burgos (2010) 0.5 0.5 1 2 Medium 
Cooper (2012) 1 1 1 3 High 
Crawford (2015) 1 1 1 3 High 
Foster (2010) 0.5 0.5 0.5 1.5 Medium 
Foster (2013) 0.5 0.5 0.5 1.5 Medium 
Han (2014) 0.5 0 0 0.5 Low 
Holtgrave (2012) 1 1 0.5 2.5 High 
Holtgrave (2013)  0  0  0 0 Low  
Jackson (2015) 0.5 0.5 0.5 1.5 Medium 
Kessler (2013) 1 1 1 3 High 
Lasry (2012) 0.5 0.5 0 1 Low 
Long (2014) 1 1 0.5 2.5 High 
Marseille (2011) 1 1 1 3 High 
NCC (2013) 1 0.5 0.5 2 Medium 
Pilgrim (2010) 0.5 0.5 0.5 1.5 Medium 
Roberts (2012) 1 0.5 0 1.5 Medium 
Rodriguez (2010a) 0.5 0 0 0.5 Low 
Rodriguez (2010b) 0.5 0 0.5 1 Low 
Ruger (2014) 1 1 1 3 High 
Salcedo (2013) 0.5 0.5 0.5 1.5 Medium 
Sanders (2010) 0.5 0.5 1 2 Medium 
Schackman (2013) 1 1 1 3 High 
Thomas (2012) 0.5 0.5 0.5 1.5 Medium 
Appendix 7 
 
Sexual health promotion and contraceptive services in local authorities: a systematic 
review of economic evaluations 2010-2015  93 
 
Study (year) Applicability Study 
limitations 
Modelling 
appraisal 
Overall 
score 
Rating 
Thomas and Cameron (2013) 0.5 0.5 0 1 Low 
Trussell (2013) 0.5 0.5 0.5 1.5 Medium 
Trussell (2014) 0.5 0 0.5 1 Low 
Trussell (2015) 0.5 0.5 0.5 1.5 Medium 
Turner (2014) 1 1 1 3 High 
1: All or most of the checklist criteria have been fulfilled; where they have not been 
fulfilled the conclusions are very unlikely to alter. 
0.5: Some of the checklist criteria have been fulfilled; where they have not been fulfilled, 
or not adequately described, the conclusions are unlikely to alter. 
0: Few or no checklist criteria have been fulfilled and the conclusions are likely or very 
likely to alter.
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Appendix 8: Included studies: UK-based interventions  
Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and methods of 
analysis 
Results Notes 
Cooper et al. 
(2012) 
Aim of study: To 
assess the cost-
effectiveness of 
school-based 
behavioural 
interventions for 
the prevention of 
STIs in young 
people through 
the development 
of an economic 
model 
Type of 
economic 
analysis: Cost-
effectiveness 
Economic 
perspective: 
National Health 
Service (NHS) and 
Personal Social 
Services (PSS) 
Source 
populations: Boys 
and girls aged 15 
years old 
Setting: UK 
Data sources: 
HRQoL: Previous 
utility studies using 
validated tools for 
groups of patients 
who developed STI 
complications 
Costs: published 
studies 
Prevalence and 
transmission 
probabilities of 
STIs: National 
Chlamydia 
Screening 
programme and 
Health Protection 
Agency, case series 
study, literature 
Intervention 
description:  
Teacher-led: Twenty 
sessions taking place over 
a 2-year period (10 
sessions at age 13–14 
years, and 10 sessions at 
age 14–15 years). It 
involved active learning 
(small group work and 
games), information 
leaflets on sexual health, 
and development of 
skills, primarily through 
the use of interactive 
video and role playing 
Peer-led: Three sessions 
led by peer educators 
lasting 1 hour each, over 
one school term. The 
sessions covered 
relationships, sexually 
transmitted infections, 
and use of condoms and 
contraception. They were 
Outcomes: Total number 
of STI cases averted, 
QALY, savings in medical 
costs 
Time horizon: 1 year 
Costing year(s) and 
currency: 2011-2012 Euro  
Discount rates: Not 
applicable as the time 
horizon is for one year 
Perspective: National 
Health Service (NHS) and 
Personal Social Services 
(PSS) 
Measures of uncertainty: 
Deterministic and 
probabilistic sensitivity 
and scenario analysis 
Modelling method: 
Bernoulli statistical model 
Primary analysis: 
Teacher-led intervention: 
- Total cost: £7,672 
(€10,320)  
- Total medical costs 
averted: £1,297 (€1,745)  
- Net additional cost: 
£6,375 (€8,575) 
- Cost per case averted 
(all STIs): £3,017 (€4,058) 
- Incremental cost per 
QALY gained: £18,041 
(€24,268) 
*the intervention averted 
an extra two STI cases 
with a corresponding 
quality of life gain of 
0.35 QALY compared with 
standard sex education 
Peer-led intervention:  
- Total cost: £26,762 
(€36,000) 
Limitations identified 
by author:  
- Effectiveness data 
drawn from a meta-
analysis did not show a 
statistically significant 
effect on behavioural 
outcomes 
- The model compares 
teacher-led to standard 
sexual health education 
and peer-led 
interventions to 
standard sexual health 
education, but no direct 
evidence is available 
directly comparing 
peer-led and teacher-
led interventions  
- The intervention 
effect was assumed to 
be the same for both 
interventions so 
differences in outcomes 
are due primarily to 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and methods of 
analysis 
Results Notes 
Quality score: 
High 
Applicability: 
Directly 
applicable 
review, 
assumptions 
Effectiveness: 
Systematic review 
and meta-analysis 
Proportion of 
sexually active 
young people in 
England and their 
condom use at last 
intercourse: Cross-
national Health 
Behaviour in 
School-aged 
Children (HBSC) 
survey 
Number of sexual 
partners that 
young people have 
has been: Multi-
purpose survey in 
Great Britain 
Number of 
occasions of 
heterosexual sex in 
the past 4 weeks: 
designed to be informal 
using small group work, 
role plays, and condom 
use skills demonstrations 
Comparator/control 
description:  
Standard sexual health 
education, which is 
generally provided by 
teachers in British schools 
as part of the SRE 
curriculum. Standard 
sexual health education 
generally provides basic 
information on STIs and 
sexual health, but does 
not necessarily teach 
safer sex negotiation 
skills. It is, therefore, the 
teaching of safer sex 
skills and other broader 
activities that 
distinguishes the 
behavioural intervention 
from standard education 
- Total medical costs 
averted: £1,297 (€1745) 
- Net additional cost: 
£25,465 (€34,255) 
- Cost per case averted 
(all STI): £12,050 
(€16,210)  
- Incremental cost per 
QALY gained: £72,062 
(€96,938) 
* the intervention had 
the same health gains, in 
terms of cases averted 
and QALYs gained when 
compared with the base 
case. In conclusion, the 
peer-led behavioural 
intervention is less cost-
effective than the 
teacher-led intervention 
compared with standard 
sex education 
Secondary analysis: 
None 
Sensitivity analysis:  
differences in costs. 
The differences costs 
were because there was 
less need for training in 
the teacher-led 
intervention  
- Due to a lack of data 
for the <16-year-old age 
group, the parameters 
for this age group are 
based on assumptions 
and extrapolations from 
other age groups 
Limitations identified 
by review team: 
Sensitivity analyses 
showing large 
uncertainty around the 
results 
Evidence gaps and/or 
recommendations for 
future research: Given 
the uncertainties 
surrounding the results, 
further studies are 
necessary to define 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and methods of 
analysis 
Results Notes 
The UK National 
Survey of Sexual 
Attitudes and 
Lifestyles (NATSAL) 
Interventions: 
Scottish study (the 
SHARE trial- 
teacher-led) and 
English trial (the 
RIPPLE trial- peer-
led) 
Others: Systematic 
searches, 
administrative 
databases for the 
United Kingdom, 
and prospective 
studies, 
assumptions 
 
Sample sizes: Simulated 
cohort of 1,000 boys and 
1,000 girls 
Deterministic sensitivity 
analysis: The results 
were most sensitive to 
the intervention effect, 
the transmission 
probability, and the 
number of sexual 
partners 
Scenario analysis for 
older teenagers: In this 
age group, there are 
more STI cases averted, 
QALYs gained, and 
medical costs averted 
that in the younger age 
group 
Probabilistic sensitive 
analysis:  
- The teacher-led 
intervention had an ICER 
between £0 and £26,762 
(€36,000) per QALY for 
48% of iterations, more 
than £26,762 (€36,000) 
per QALY for 28% of 
iterations and was 
cost-effective 
interventions 
Source of funding: KC, 
JS, JP, JJ, AH, EB-P, 
AC, DH and AP received 
an NIHR Health 
Technology Assessment 
Programme grant 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and methods of 
analysis 
Results Notes 
associated with a QALY 
loss for 24% of iterations 
- The peer-led 
intervention had an ICER 
between £0 and £26,762 
(€36,000) per QALY for 16 
percent of iterations 
Crawford et al.  
(2015) 
Aim of study: To 
examine the 
clinical and cost-
effectiveness of 
brief advice for 
excessive alcohol 
consumption 
among people 
who attend 
sexual health 
clinics 
Type of 
economic 
analysis: Cost-
utility analysis 
Economic 
perspective: 
Source 
populations: 802 
people aged 19 
years or over 
attending one of 
three sexual health 
clinics and drinking 
excessively 
Setting: Sexual 
health clinics in 
London, UK 
Data sources: 
Computer-assisted 
self-completion 
questionnaire; 
EuroQol-5D scale; 
Adult Service Use 
Schedule; national 
UK unit costs 
Intervention 
description: Brief advice: 
feedback on alcohol and 
health, written 
information, offer of an 
appointment with an 
alcohol health worker 
Comparator/control 
description: Leaflet on 
health and lifestyle 
Sample sizes:  
Total N = 802 
Intervention N = 402 
Control N = 400 
Outcomes: Outcomes 
measured 6 months after 
randomisation and 
assessed behaviour in the 
3 months prior to the date 
of the assessment 
(objective measures) 
Primary: Mean weekly 
alcohol consumption 
Secondary: Proportion of 
participants who reported 
any unprotected sex; 
mean units of alcohol 
consumed per drinking 
day; percentage days 
abstinent; whether the 
participant was drinking 
excessively  
Primary outcomes:  
benefits:  
-QALY for control = 0.475 
-QALY for intervention = 
0.450  
-Incremental QALY (QALY 
intervention minus QALY 
control = -0.007) 
Costs: 
-Average costs for control 
group: £310.87; average 
cost for intervention 
group: £319.28 
-Incremental cost (cost 
intervention minus cost 
control = £8.41)  
Limitations identified 
by author:  
- Participants were 
recruited at sexual 
health clinics. In order 
to limit exposure of 
control participants to 
questions about alcohol 
consumption, very little 
baseline data on 
alcohol-related 
behaviour was 
collected. Analysis of 
available data suggests 
groups were 
comparable. 
- No follow-up was 
collected for 
approximately 25% of 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and methods of 
analysis 
Results Notes 
NHS/Personal 
Social Service 
perspective 
Quality score: 
High 
Applicability: 
Directly 
applicable 
 
Sexual behaviour 
outcomes: Number of 
sexual partners; number of 
unprotected sexual 
partners; any incidence of 
regretted sex; any 
incidence of unprotected 
sex after drinking alcohol 
or while drunk; how long 
they knew their last sexual 
partner before they had 
sex with them; unplanned 
pregnancy; any new 
diagnosis of a sexually 
transmitted infection  
Cost and cost-
effectiveness outcomes: 
Cost of the brief advice; 
QALY  
Time horizon: 6 months 
Costing year(s) and 
currency: 2010-2011 GBP 
Discount rates: Not 
applicable as time horizon 
was less than one year 
-No significant difference 
in costs or QALY 
Secondary analysis: Not 
presented as cost/QALY 
Because the difference in 
costs and QALY were not 
significant, acceptability 
curves were used to 
estimate the probability 
that the intervention 
would be cost-effective 
for given thresholds of 
willingness to pay (WTP) 
per QALY gained; the 
results showed no 
evidence of this at any 
WTP values  
Sensitivity analysis: 
Statistical model used 
and inclusion of missing 
data gave similar findings 
of a small difference 
around statistical 
significance for the 
primary outcome 
intervention 
participants. These 
participants were 
excluded from the final 
analysis, which may 
have biased estimates 
of intervention 
effectiveness 
Limitations identified 
by review team: Short 
time horizon to capture 
behaviour change  
Evidence gaps and/or 
recommendations for 
future research: 
Authors could have 
modelled potential 
scenarios for behaviour 
change based on 
available data in the 
literature 
Source of funding: 
NIHR Health Technology 
Assessment programme 
and the Department of 
Health, Chelsea and 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and methods of 
analysis 
Results Notes 
Perspective: 
NHS/Personal Social 
Service 
Measures of uncertainty: 
Sensitivity analysis: non-
parametric bootstrapping 
and non-hierarchical linear 
models 
Modelling method: 
Random-effects linear 
regression, ordinary 
parametric models 
Westminster NHS 
Foundation Trust, 
Central and North West 
London NHS Foundation 
Trust, Turning Point, 
and Imperial College 
Academic Health 
Sciences Centre 
 
Jackson et al.  
(2015) 
Aim of study: To 
compare the 
costs and 
outcomes of two 
sexually 
transmitted 
infection 
screening 
interventions 
targeted at men 
in football club 
settings in 
Source 
populations: Men 
≥18 years in six 
London amateur 
football clubs  
Setting: UK 
Data sources:  
Costs: Unit Costs of 
Health and Social 
Care 2013; other 
primary costing 
data collection 
Consequences: 
Intervention 
description: 
1. Captain-led and poster 
STI screening promotion. 
2. Sexual health adviser-
led and poster STI 
screening promotion 
Comparator/control 
description: Poster-only 
STI screening promotion. 
Sample sizes:  
Total N = 153 
Intervention N = 56+46 
Primary outcome 
(objective): proportion of 
eligible men accepting 
screening  
Time horizon: Not clearly 
stated, but probably equal 
to the intervention (one 
year) 
Costing year(s) and 
currency: 2012-2013 GBP 
Discount rates: Discount 
rates were not applied. 
Only start-up costs (costs 
Primary analysis:  
benefits: Number and 
proportion of men 
accepting screening: 
- Captain-led and poster 
STI screening promotion: 
28 (50%) 
- Sexual health adviser-
led and poster STI 
screening promotion: 31 
(67%) 
Limitations identified 
by author:  
- Uptake of screening 
could not be accurately 
estimated for 
intervention arms 
- Variability in the 
acceptability of 
screening intervention 
between clubs limited 
ability to estimate 
acceptability 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and methods of 
analysis 
Results Notes 
England, 
including 
screening 
promoted by 
team captains 
Type of 
economic 
analysis: Cost-
consequence 
analysis 
Economic 
perspective: 
Health service 
perspective 
Quality score: 
Medium 
Applicability: 
Partially 
applicable 
Three-arm trial and 
results from blood 
sample 
 
Control N = 51 with the posters) were 
annuitised at 3% (for 3 
years)  
Perspective: NHS 
Measures of uncertainty: 
One-way deterministic 
sensitivity analysis for 
costs and outcomes 
Modelling method: Not 
applicable 
- Poster-only STI 
screening promotion: 31 
(61%) 
Costs: (average cost per 
player tested): 
-Captain-led and poster 
STI screening promotion: 
£88.99 
-Sexual health adviser-
led and poster STI 
screening promotion: 
£88.33 
-Poster-only STI screening 
promotion: £81.87 
Secondary analysis: 
None  
Sensitivity analyses:  
Variables affecting the 
overall cost: Time 
needed for club 
recruitment; incentive of 
£1,000 for each club to 
help maximise 
participation; costs for 
team captains to deliver 
- Difficulty in 
recruitment meant that 
target sample size was 
not reached  
- Subsequent testing 
that may have occurred 
outside of the 
intervention but been 
motivated by 
intervention materials 
was not captured, 
meaning that the 
uptake of STI testing 
linked to the 
intervention may be an 
underestimate  
- No cases of chlamydia 
or gonorrhoea were 
identified as part of the 
intervention making it 
impossible to estimate 
a cost per case 
diagnosed 
- The influence of 
captains on uptake of 
testing was not 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and methods of 
analysis 
Results Notes 
the promotion; 
intervention costs; cost 
of the test kit boxes; 
sample processing costs 
anticipated. However, 
this appears to have 
played a substantial 
role with some captains 
encouraging players to 
participate in screening 
in team-wide 
communications 
Limitations identified 
by review team: None  
Evidence gaps and/or 
recommendations for 
future research: 
Authors clearly stated 
this analysis was 
conducted for the pilot 
phase, and that was the 
reason for a cost-
consequence analysis. A 
full cost-effectiveness 
analysis with a 
probabilistic analysis 
might help with 
uncertainties around 
the costs and 
consequences, 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and methods of 
analysis 
Results Notes 
especially between the 
captain-led and the 
health adviser–led 
interventions  
Source of funding: 
SPORTSMART study, 
part of NIHR-funded 
BALLSEYE Programme 
‘Targeting Men for 
Better Sexual Health’; 
no competing interests 
declared 
Long et al.  
(2014) 
Aim of study: To 
estimate the 
effectiveness and 
cost-
effectiveness of 
HIV testing in the 
UK 
Type of 
economic 
analysis: Cost-
utility analysis 
Source 
populations: UK 
adult population 15 
to 64 years 
Categorised by risk 
behaviours or 
country of origin: 
MSM; PWID; men 
from HIV-endemic 
countries with high 
HIV prevalence; 
women from HIV-
endemic countries; 
Intervention 
description: 
-Universal testing every 3 
years 
-Universal testing every 2 
years 
-Universal testing every 
year 
-Universal testing every 
year + ART 
-High-risk testing every 
year, low-risk testing 
every 2 years 
Outcomes: HIV prevalence 
and incidence; QALYs 
gained; lifetime 
healthcare costs; costs of 
voluntary counselling and 
testing (VCT) and 
antiretroviral therapy 
(ART)/person; HIV 
infections averted and 
incremental cost-
effectiveness ratios (cost 
per QALY gained for 
various scenarios) 
Primary analysis:  
benefits (incremental 
QALY): 
-Universal testing every 3 
years: £13,000 
-Universal testing every 2 
years: £32,900 
-Universal testing every 
year: £57,400 
-Universal testing every 
year + ART: £161,700 
Limitations identified 
by author:  
-Simplification of 
complex dynamics of 
HIV disease progression, 
development of 
resistance, and changes 
in viral suppression  
-Assumption of a 
standard proportional 
mixing model of 
partnership selection 
does not include 
preferential mixing by 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and methods of 
analysis 
Results Notes 
Economic 
perspective: 
Societal, 
healthcare and 
personal social 
services 
perspective 
Quality score: 
High 
Applicability: 
Directly 
applicable 
other men; and 
other women  
Population groups 
subdivided by HIV 
infection status: 
uninfected, acute 
HIV infection, 
asymptomatic HIV 
with CD4 count 350 
cells/mm3, 
symptomatic HIV 
with CD4 count 
200–350 
cells/mm3, or AIDS 
with CD4 count 200 
cells/mm3; HIV 
diagnosis status; 
ART status if 
infected; and male 
circumcision status 
Setting: UK 
Data sources:  
Previously 
published studies, 
assumptions and 
calculations 
-High-risk testing every 
year, low-risk testing 
once  
-High-risk testing every 
year, low-risk testing 
once + ART 
Comparator/control 
description:  
Current scenario 
(assumption): 25% of 
MSM, 25% of people from 
HIV-endemic countries, 
77% of PWID and 10% of 
other adults in the 
population receiving an 
HIV test in the last 12 
months. Simulated 
various scaling-up 
scenarios under different 
HIV testing and 
treatment and accounted 
for various risk behaviour  
Sample sizes: Simulated 
cohort of individuals of 
unknown size 
Time horizon: Projected 
HIV prevalence and 
incidence over a 10-year 
time horizon, and lifetime 
QALYs gained in the 
population 
Costing year(s) and 
currency: 2012 GBP 
Discount rates: Costs and 
benefits discounted at 3% 
Perspective: Societal 
Measures of uncertainty: 
Model calibration through 
comparison of the model 
projected outcomes with 
available data on 
prevalence, incidence, and 
diagnosis trends. All model 
parameters were varied in 
a sensitivity analysis 
Modelling method: 
Dynamic compartmental 
model based on a 
previously published 
-High-risk testing every 
year, low-risk testing 
every 2 years: £53,100 
-High-risk testing every 
year, low-risk testing 
once: £42,900 
-High-risk testing every 
year, low-risk testing 
once + ART: £145,300 
Costs (incremental costs 
in billions): 
-Universal testing every 3 
years: £1.25 
-Universal testing every 2 
years: £2.18 
-Universal testing every 
year: £4.61 
-Universal testing every 
year + ART: £7.41 
-High-risk testing every 
year, low-risk testing 
every 2 years: £2.37 
-High-risk testing every 
year, low-risk testing 
once: £0.75 
HIV status, race or 
immigration status 
-Differential condom 
use by HIV status not 
considered  
-Due to a lack of data 
on HIV prevalence 
among newly arrived 
immigrants, similar HIV 
prevalence levels for 
newly arriving 
immigrants and those 
already living in the UK 
were assumed 
-Cost of HIV testing, 
counselling and 
treatment inputs based 
on current estimates 
which are linked to the 
current model and 
volume of delivery. 
Changes in service 
delivery patterns may 
have an impact on costs 
and this has not been 
accounted for.  
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and methods of 
analysis 
Results Notes 
(particularly a 
measure for initial 
distribution for 
acute HIV stage; 
calculation based 
on assumptions and 
published studies) 
dynamic HIV epidemic 
model 
-High-risk testing every 
year, low-risk testing 
once + ART: £3.49 
ICERS (for CEA, CUA) 
(cost/QALY gained) 
-Universal testing every 3 
years: £96,200 
-Universal testing every 2 
years: £66,300 
-Universal testing every 
year: £80,300 
-Universal testing every 
year + ART: £240,000 
-High-risk testing every 
year, low-risk testing 
every 2 years: £44,700 
-High-risk testing every 
year, low-risk testing 
once: £17,500 
-High-risk testing every 
year, low-risk testing 
once + ART: £26,800 
Secondary analysis: 
None 
Limitations identified 
by review team: 
Limitations were 
comprehensively 
discussed, especially for 
the model simplification 
for HIV transmission 
rates, development of 
resistance and changes 
in viral suppression  
Evidence gaps and/or 
recommendations for 
future research: 
Additional attempts can 
be made to better 
explore implications of 
early HIV screening and 
treatment to better 
understand the impact 
of costs of ART in the 
long term for the 
control of HIV 
transmission 
Source of funding: EL, 
SA, and MB obtained 
grant funding from the 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and methods of 
analysis 
Results Notes 
Sensitivity analyses: All 
parameters were varied 
in a one-way sensitivity 
analysis and in a 
probabilistic analysis. 
The extent to which VCT 
reduces risky sexual 
partnerships among 
newly diagnosed people 
living with HIV was the 
primary driver of health 
outcomes and cost-
effectiveness. 
Cost-effectiveness 
estimates were affected 
by reduction in sexual 
partnership across all 
risk-groups; epidemic’s 
baseline trajectory; 
testing, counselling and 
ART costs; adherence 
level and ART 
effectiveness 
US National Institute on 
Drug Abuse. The 
authors declare that the 
funder had no role in 
study design, data 
collection and analysis, 
decision to publish, or 
preparation of the 
manuscript 
 
National 
Collaborating 
Centre (NCC) for 
Source 
populations: Male 
Intervention 
description: LARC 
methods: IDU, IUS: LNG-
Outcomes: Number of 
pregnancies averted by the 
use of one contraceptive 
Primary analysis: 
(Comparison across 
reversible contraceptive 
Limitations identified 
by author:  
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and methods of 
analysis 
Results Notes 
Women’s and 
Children’s 
Health (2013) 
Aim of study: 
Overall aim was 
to provide 
(clinical and 
educational) 
guidance on 
LARC. The cost-
effectiveness 
analysis aimed at 
assessing LARC 
methods 
compared to 
combined oral 
contraceptive pill 
(COC) 
Type of 
economic 
analysis: Cost-
effectiveness  
Economic 
perspective: 
Public health 
(NHS) 
and females in 
reproductive ages 
Setting: UK 
Data sources:  
Costs: COC use in 
England in 2002, 
2004 NHS reference 
costs, British 
National Formulary 
(49, March 2005), 
GP fee schedule, 
opinion of the 
Guideline 
Development 
Group (GDG), 
published 
literature 
Effectiveness: 
systematic 
literature review, 
agreements 
between GDG 
members, national 
statistics, 
published 
literature 
IUS (Mirena), injectable 
hormones, implant 
Comparator/control 
description: Combined 
oral contraceptive pill 
(COC), male condom and 
non-reversible 
contraceptive methods 
(female and male 
sterilisation) 
Sample sizes: Simulated 
cohort of 1,000 sexually 
active women choosing 
one method of 
contraception 
method in comparison with 
another  
Time horizon: 1 to 15 
years 
Costing year(s) and 
currency: 2004-2005 GBP 
Discount rates: 3.5% 
Perspective: NHS 
Measures of uncertainty: 
Sensitivity analysis, 
scenario analysis 
Modelling method: 
Decision-analytic model – 
Markov model 
methods: LARC methods, 
COC, male condom)  
1 year of use: 
Total pregnancy: 
Implant: 14 
IUS: 17 
IUD: 18 
Injectable: 33 
COC: 91 
Condom: 150 
Total costs:  
Implant: £262,117 
IUS: £270,749 
IUD: £195,442 
Injectable: £190,534 
COC: £232,932 
Condom: £212,658 
Incremental cost-
effectiveness ratio: 
- Implant vs IUD: 
£17,367/pregnancy 
averted 
- The relative cost-
effectiveness of LARC 
methods highly 
sensitive to changes in 
discontinuation rates in 
several cases 
- Adverse events, side 
effects associated with 
contraceptive use and 
non-contraceptive 
benefits are not 
considered in the model  
Limitations identified 
by review team:  
- Key parameters were 
not assessed 
individually in the 
sensitivity analysis, 
making it difficult to 
identify which 
parameter contributes 
more uncertainty in the 
model 
- Authors noted that 
LARC and COC or non-
reversible methods may 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and methods of 
analysis 
Results Notes 
Quality score: 
Medium 
Applicability: 
Highly applicable 
 
- IUS: dominated by 
implant 
- IUD vs injectable: 
£339/pregnancy averted 
- COC: dominated by IUD 
and injectable 
- Condom: dominated by 
IUD and injectable 
2 years of use: 
Total pregnancy: 
Implant: 51 
IUD: 55 
IUS: 57 
Injectable: 99 
COC: 190 
Condom: 295 
Total costs:  
Implant: £ 322,939 
IUD: £256,572 
IUS: £337,093 
Injectable: £338,376 
COC: £406,366 
Condom: £418,125 
not always be 
substitutes since not 
every woman will be 
eligible for all methods. 
This was acknowledged 
in discussion model 
structure and 
limitations, but this 
scenario was not 
incorporated in the 
sensitivity analysis  
- The model was 
adapted from a 
previous model but no 
discussion was carried 
out about validity and 
calibration 
Evidence gaps and/or 
recommendations for 
future research:  
Model can be validated 
and calibrated and 
variables should be 
assessed individually to 
check for uncertainty 
among parameters 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and methods of 
analysis 
Results Notes 
Incremental cost-
effectiveness ratio: 
- Implant vs IDU: 
£17,866/pregnancy 
averted  
- IUS: Dominated by 
implant, IUD  
- Injectable: Dominated 
by implant, IUD, IUS 
- COC: Dominated by all 
LARC methods 
Condom: Dominated by 
all LARC methods 
3 years of use: 
Total pregnancy: 
Implant: 101 
IUD:105 
IUS: 109 
Injectable: 167 
COC: 289 
Condom: 435 
Total costs:  
Implant: £400,947 
Source of funding: Not 
declared 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and methods of 
analysis 
Results Notes 
IUD: £337,207 
IUS: £418,616 
Injectable: £482,178 
COC: £575,320 
Condom: £616,644 
Incremental cost-
effectiveness ratio: 
- Implant vs IUD: 
£14,730/pregnancy 
averted 
- IUS: Dominated by 
implant, IUD  
- Injectable: Dominated 
by implant, IUD, IUS 
- COC: Dominated by all 
LARC methods 
- Condom: Dominated by 
all LARC methods 
5 years of use: 
Total pregnancy: 
Implant: 215 
IUS: 228 
IUD: 232 
Appendix 8 
 
Sexual health promotion and contraceptive services in local authorities: a systematic review of economic evaluations 2010-2015  110 
 
Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and methods of 
analysis 
Results Notes 
Injectable: 302 
COC: 482 
Condom: 707 
Total costs:  
Implant: £667,275 
IUS: £603,534 
IUD: £534,555 
Injectable: £760,600 
COC: £899,697 
Condom: £993,769 
Incremental cost-
effectiveness ratio: 
- Implant vs IUD: 
£7,574/pregnancy 
averted, extended 
dominance 
- Implants vs IUS: 
£4,598/pregnancy 
averted 
- IUS vs IUD: 
£18,845/pregnancy 
averted 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and methods of 
analysis 
Results Notes 
- Injectable: Dominated 
by implant, IUD, IUS 
- COC: Dominated by all 
LARC methods 
- Condom: Dominated by 
all LARC methods 
10 years of use: 
Total pregnancy: 
Implant: 483 
IUS:522 
IUD: 551 
Injectable: 635 
COC: 932 
Condom: 1291 
Total costs:  
Implant: £1,210,419 
IUS: £1,119,079 
IUD: £1,050,425 
Injectable: £1,401,818 
COC: £1,632,762 
Condom: 1,830,496 
Incremental cost-
effectiveness ratio: 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and methods of 
analysis 
Results Notes 
- Implant vs IUD: 
£2,342/pregnancy 
averted/ extended 
dominance 
- Implant vs IUS: 
£2,339/pregnancy 
averted 
- IUS vs IUD: 
£2,346/pregnancy 
averted  
- Injectable: Dominated 
by implant, IUD, IUS  
- COC: Dominated by all 
LARC methods 
- Condom: Dominated by 
all LARC methods 
15 years of use: 
Total pregnancy: 
Implant: 719 
IUS: 778 
IUD: 828 
Injectable: 948 
COC: 1330 
Condom: 1788 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and methods of 
analysis 
Results Notes 
Total costs:  
Implant: £1,622,769 
IUS: £1,563,548 
IUD: £1,469,754 
Injectable: £1,965,220 
COC: £2,260,880 
Condom: £2,534,998 
Incremental cost-
effectiveness ratio: 
- Implant vs IUD: 
£1,403/pregnancy 
averted/ extended 
dominance 
- Implant vs IUS: 
£999/pregnancy averted 
- IUS vs IUD: 
£1,884/pregnancy 
averted  
- Injectable: Dominated 
by implant, IUD, IUS  
- COC: Dominated by all 
LARC methods 
- Condom: Dominated by 
all LARC methods 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and methods of 
analysis 
Results Notes 
Secondary analysis: 
(Comparison of LARC 
methods with non-
reversible contraceptive 
methods) 
1 year of use: 
Total pregnancies: 
Male sterilisation: 7 
Female sterilisation: 19 
Implant: 719 
IUS: 778 
IUD: 828 
Injectable: 948 
Total costs: 
Male sterilisation: 
£466,776 
Female sterilisation: 
£750,191 
Implant: £1,622,769 
IUS: £1,563,548 
IUD: £1,469,754 
Injectable: £1,965,220 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and methods of 
analysis 
Results Notes 
Incremental cost-
effectiveness ratio: 
Implant: Dominated by 
male and female 
sterilisation 
IUS: Dominated by male 
and female sterilisation 
IUD: Dominated by male 
and female sterilisation 
Injectable: Dominated by 
male and female 
sterilisation 
Sensitivity analysis: 
Comparison across 
reversible contraceptive 
methods: LARC methods, 
COC, male condom: 
- Varying the failure rates 
of COC and male condom 
by ±10%: no impact in the 
base-case results 
- Varying the failure rates 
of LARC methods by 
±10%: no impact in the 
cost-effectiveness of the 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and methods of 
analysis 
Results Notes 
base-case results relative 
to the COC and male 
condom. No impact in the 
ranking of LARC methods 
in terms of effectiveness 
or the case dominance 
across LARC methods 
- Varying the failure rate 
of IUD: moderate impact 
on the ICERs of the 
implant versus IUD only 
for short periods of 
contraceptive use (3-4 
years) 
Comparison of LARC 
methods with non-
reversible contraceptive 
methods: 
- Varying the failure rates 
of female and male 
sterilisation by ±10%: no 
impact in the base-case 
results  
- Varying the failure rates 
of LARC methods by 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and methods of 
analysis 
Results Notes 
±10%: no impact in the 
cost-effectiveness results 
Pilgrim et al. 
(2010) 
Aim of study: To 
assess the cost-
effectiveness of a 
range of 
interventions to 
encourage young 
people, 
especially socially 
disadvantaged 
young people, to 
use 
contraceptives or 
contraceptive 
services 
Type of 
economic 
analysis: Cost-
effectiveness 
Economic 
perspective: 
Public sector 
Source 
populations:  
1. Young people 
aged 14-16 who 
have not previously 
been a parent (but 
who may or may 
not have been 
pregnant without 
carrying to term) 
within secondary 
school 
2. Young mothers 
within a secondary 
school 
3. Young people 
aged 15–19 who are 
sexually active 
Setting: UK 
Data sources:  
Probability of 
abortion and birth: 
national 
Intervention 
description: 
1. School-based 
dispensing of hormonal 
contraceptives within the 
school (DH); school-based 
dispensing of condoms 
(DC)  
2. Intensive case 
management to prevent 
repeat pregnancy 
(includes a culturally 
matched school-based 
social worker [including 
home visits], weekly 
school-based peer 
education support and 
comprehensive medical 
care including 
contraception) (ICM) 
3. Advance provision of 
emergency hormonal 
contraception (AP) 
Primary outcomes: Cost 
per pregnancy averted, 
cost per abortion averted 
Secondary outcomes: Cost 
of the intervention and 
additional contraception 
required as a result of the 
intervention; cost of 
maternity care; cost of 
abortion; cost of 
miscarriage/ ectopic 
pregnancy/ stillbirth; cost 
of treatment for low birth 
weight babies; cost of 
treatment of STIs; cost of 
government-funded 
benefits  
Time horizon: Lifetime 
Costing year(s) and 
currency: 2007-2008 GBP 
Discount rates: 3.5% 
Perspective: Public sector 
Primary analysis:  
Model 1: Deterministic 
results (discounted) 
Total cost (billions): 
- ND: £1,527 
- DC: £1,519 
- DH: £1,417 
Cost per abortion 
averted: 
- DC: £815 
- DH: £1,514 (compared 
with DC) 
Cost per pregnancy 
averted (excluding 
benefits): 
- DC: £32 
- DH: £441 (compared 
with DC) 
Cost per pregnancy 
averted (including 
benefits): 
Limitations identified 
by author:  
- A lack of data on the 
long-term employment 
and education impacts 
of teenage pregnancy 
meant that this could 
not be included in the 
analysis. If negative 
impacts on future 
productivity were 
included, the 
intervention may 
appear more cost-
effective. 
- Only primary 
transmission of STIs is 
considered in the 
model. Consideration of 
additional infections 
averted could improve 
the cost-effectiveness 
ratio.  
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and methods of 
analysis 
Results Notes 
Quality score: 
Medium 
Applicability: 
Partly applicable 
 
government 
statistics for 
England and Wales 
Probability of 
miscarriage and 
ectopic pregnancy: 
Hospital Episode 
Statistics (HES); a 
Denmark study was 
used to 
parameterise the 
miscarriage rates  
Long term 
outcomes of a 
teenage birth: 
Literature review 
including only UK 
papers, and 
elicitation 
technique with 
programme 
development group 
(PDG) at NICE 
Sexually 
transmitted 
infection (STI) 
Comparator/control 
description:  
1. School nurse only (ND) 
2. No follow-up following 
first pregnancy 
3. No advance provision 
of EHC (No AP) 
Sample sizes: Simulated 
cohort of 100,000 young 
individuals 
Measures of uncertainty: 
One-way and probabilistic 
sensitivity analysis 
Modelling method: Cost-
effectiveness modelling 
study with a hypothetical 
cohort over a lifetime 
from the age at which the 
intervention is provided; 
the following scenarios 
were modelled:  
1. School-based 
interventions for 
nulliparous young people 
2. School-based 
interventions to prevent 
repeat pregnancy 
3. Interventions to 
encourage the use of 
emergency hormonal 
contraception following 
unprotected sex 
- DN: dominated by DC 
- DC: dominated by DH 
- DH: dominates DC and 
ND 
Model 2: Deterministic 
results (discounted) 
Total costs (millions): 
- no follow-up: £655,572 
- ICM: £705,730 
Cost per repeat teenage 
pregnancy averted 
(excluding benefits): ICM: 
£15,155 
Cost per repeat teenage 
pregnancy averted 
(including benefits): ICM: 
£4,031 
Model 3: Deterministic 
results (discounted) 
Total cost (billions): 
- No AP: £1,524 
- AP: £1,447 
Cost per abortion 
averted: AP: £2,795 
- The long term 
implications of the 
interventions are not 
well known. For 
example, it is not clear 
if teenage pregnancies 
are averted or delayed. 
- Available evidence on 
contraceptive 
effectiveness in 
teenagers has been 
generated based on 6-
12 months of follow-up  
- Outcomes are not 
reported in terms of 
QALYs gained, limiting 
the extent to which 
they can be compared 
with other interventions 
using this outcome 
- Variability in baseline 
health and risk factors 
is not captured in the 
model  
- The comparison within 
Model 1 is highly 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and methods of 
analysis 
Results Notes 
outcomes: NICE Sex 
and Relationship 
Education (SRE) 
public health 
guidance  
Effectiveness: 
National statistics 
assumptions 
Benefits: Office for 
National Statistics 
(ONS, 2009), 
previous published 
studies, 
assumptions 
Costs: British 
National Formulary 
(BNF 58, 2009), 
NICE assessment of 
LARCs, health 
economic model 
developed for the 
NICE SRE public 
health guidance, 
NHS reference 
costs 
Cost per age pregnancy 
averted: 
AP (excluding benefits): 
£310 
Cost per age pregnancy 
averted: AP (including 
benefits) dominates 
Secondary analysis:  
Model 1: Expected 
results (discounted) 
Total cost (billions): 
- DN: £1,524 
- DC: £1,517 
- DH: £1,515 
Cost per abortion 
averted: 
- DC: £822 
- DH: £1,495 (compared 
with DC) 
Cost per pregnancy 
averted (excluding 
benefits): 
- DC: £38 
dependent upon the 
true effectiveness of 
each of the methods of 
contraception 
- Research comparing 
the cost-effectiveness 
of different methods of 
contraception in terms 
of both STIs and 
contraception is sparse 
due to the limitations 
around which outcome 
measure can reasonably 
capture both effects 
- the cost of maternity 
services may differ for 
teenage mothers 
compared with older 
mothers 
Limitations identified 
by review team: 
Authors stated that no 
preterm births were 
assessed which may be 
more common amongst 
young people; however, 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and methods of 
analysis 
Results Notes 
- DH: £443 (compared 
with DC) 
Cost per pregnancy 
averted (including 
benefits): 
- DN: dominated by DC 
- DC: dominated by DH 
- DH: dominates DC and 
ND 
Model 1: Expected 
results (undiscounted): 
Total cost (billions): 
- DN: £2,307 
- DC: £2,297 
- DH: £2,295 
Cost per abortion 
averted: 
- DC: £848 
- DH: £1,535 (compared 
with DC) 
Cost per pregnancy 
averted (excluding 
benefits): 
this statement seems 
odd since multiples and 
low birth weight are 
included - unless low-
birth weight is the same 
as preterm. Other 
adverse events 
associated with teen 
pregnancy such as 
fistula were not 
mentioned. 
Evidence gaps and/or 
recommendations for 
future research: 
Modelling was based on 
previous model (NICE), 
but no discussion of 
model calibration has 
been provided  
Source of funding: Not 
declared 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and methods of 
analysis 
Results Notes 
- DC: £92 
- DH: £488 (compared 
with DC) 
Cost per pregnancy 
averted (including 
benefits): 
- DN: dominated by DC 
- DC: dominated by DH 
- DH: dominates DC and 
ND 
Model 2: Expected 
results (discounted) 
Total cost (millions): 
- no follow-up: £654,756 
- ICM: £705,164 
Cost per repeat teenage 
pregnancy averted 
(excluding benefits):  
ICM: £15,175 
Cost per repeat teenage 
pregnancy averted 
(including benefits):  
ICM: £4,052 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and methods of 
analysis 
Results Notes 
Model 2: Expected 
results (undiscounted) 
Total cost (millions): 
- no follow-up: £825,978 
- ICM: £866,883 
Cost per repeat teenage 
pregnancy averted 
(excluding benefits):  
ICM: £15,186 
Cost per repeat teenage 
pregnancy averted 
(including benefits): ICM: 
£2,935 
Model 3: Expected 
results (discounted)  
Total cost (billions): 
- no AP: £1,522 
- AP: £1,445 
Cost per abortion 
averted: AP: £2,803 
Cost per age pregnancy 
averted: AP (excluding 
benefits): £314 
Appendix 8 
 
Sexual health promotion and contraceptive services in local authorities: a systematic review of economic evaluations 2010-2015  123 
 
Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and methods of 
analysis 
Results Notes 
Cost per age pregnancy 
averted: AP (including 
benefits) dominates 
Model 3: Expected 
results (undiscounted)  
Total cost (billions): 
- no AP: £2,303 
- AP: £2,198 
Cost per abortion 
averted: AP: £2,948 
Cost per age pregnancy 
averted: AP (excluding 
benefits): £395 
Cost per age pregnancy 
averted: AP (including 
benefits) dominates 
Sensitivity analysis: 
Model 1: 
PSA: The analysis shows 
very little difference in 
both costs and 
effectiveness between 
dispensing condoms 
within schools and 
dispensing hormonal 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and methods of 
analysis 
Results Notes 
contraceptives within 
schools. There is the 
possibility that either one 
could be more effective 
and/or more costly than 
the other  
One-way: 
-Delay in births averted 
(14-16 years to 17-19 
years): (1) DC would 
remain cost saving 
compared with ND for the 
cost per age 14–16 
pregnancy averted 
including government-
funded benefits; (2) DH 
would remain cost saving 
compared with DC within 
schools for this outcome  
- Pregnancies averted at 
ages 14–16 years would 
have been additional: 
cost-effectiveness ratio 
for the cost per abortion 
averted decreases 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and methods of 
analysis 
Results Notes 
- Probability of condom 
failure is doubled: DC 
results in greater net 
costs than DH 
- Doubled risk of 
miscarriage: DC is 
estimated to result in net 
cost savings compared 
with ND 
- Increase in medical 
abortions: net cost 
savings of DC compared 
with ND 
- Increase in relative risk 
of both interventions: 
higher cost-effectiveness 
ratios than the base case 
analysis 
Model 2 
PSA: 
- ICM is unlikely to result 
in net cost savings when 
excluding benefit 
payments 
Appendix 8 
 
Sexual health promotion and contraceptive services in local authorities: a systematic review of economic evaluations 2010-2015  126 
 
Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and methods of 
analysis 
Results Notes 
- 20% probability that ICM 
will result in net cost 
savings (with 
government-funded 
benefits) compared with 
no follow-up after first 
teenage pregnancy 
One way: 
- Reducing cost of 
intervention: cost per 
repeat teenage 
pregnancy averted 
(excluding benefits) of 
£6,844 
- Including benefits: ICM 
will dominate no follow-
up after a teenage birth 
- Other variations do not 
have substantial impact 
upon the model results 
Model 3 
PSA: 
- AP is unlikely to result 
in net cost savings using 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and methods of 
analysis 
Results Notes 
the cost per abortion 
averted outcome 
- 24% probability AP will 
result in net cost savings 
when using the cost per 
age 15–19 pregnancy 
averted outcome 
(excluding benefit 
payments) 
- AP is likely to be cost 
saving using a cost per 
age 15–19 pregnancy 
averted outcome 
(including benefit 
payments) 
One way: 
- Increasing the baseline 
usage of EHC following 
unprotected sex: AP 
dominates including and 
excluding government-
funded benefit payments; 
estimated cost per 
abortion averted 
associated with AP 
decreases to £688 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and methods of 
analysis 
Results Notes 
- Other variations do not 
have substantial impact 
upon the model results 
Roberts et al.  
(2012) 
Aim of study: To 
assess two new 
models of partner 
notification (PN), 
known as 
Accelerated 
Partner Therapy 
(APT Hotline and 
APT Pharmacy), 
as compared with 
routine patient 
referral PN, for 
sex partners of 
people with 
chlamydia, 
gonorrhoea and 
non-gonococcal 
urethritis 
Type of 
economic 
analysis: Cost-
Source 
populations: 
Clients in 2 GUM 
clinics and 6 
community 
pharmacies 
participating in a 
clinical trial in the 
UK 
Setting: UK 
Data sources:  
-Effectiveness 
measures data 
come from a trial 
-Data on resources 
use comes from 
Chlamydia 
Screening Studies 
(ClaSS) project and 
Unit Costs of 
Health and Social 
Care 2008 
Intervention 
description:  
-APT Hotline: Telephone 
assessment of sex partner 
by a clinic-based nurse-
qualified health adviser. 
In Clinic B, majority of 
advisers were not nurse-
qualified and a clinic 
doctor needed to conduct 
a short additional 
telephone consultation 
with the patient to 
ensure safe prescribing 
-APT Pharmacy 
assessment of sex partner 
by a trained community 
pharmacist 
Comparator/control 
description: Routine PN 
(patient referral, which 
included infection-
specific information, 
Primary outcome: 
Average cost/partner 
treated 
Secondary outcomes: 
Number of partners 
treated by allocated 
method; median time from 
diagnosis to treatment 
Time horizon: Unclear, 
but it seems to be one 
year 
Costing year(s) and 
currency: 2008 GBP 
Discount rates: No 
discount rate applied to 
costs and outcomes as the 
analysis seems to be for 
one year; cost of 
telephone device was 
annuitised for 3 years at 
3% interest rate 
Perspective: NHS  
Primary analysis:  
Benefits: 
Number partners treated 
by allocated method: 
APT hotline: 47 
APT pharmacy: 15 
Routine PN: 13 
Median time from 
diagnosis to treatment 
(days): 
APT hotline: 1 
APT pharmacy: 1 
Routine PN: 4 
Average costs:  
APT Hotline: £2558 
APT pharmacy: £799  
Routine PN: £597 
ICERS (for CEA, CUA): 
Cost-consequence 
analysis: APT strategies 
Limitations identified 
by author:  
-Analysis is carried out 
on data collected in an 
exploratory trial where 
there was no 
randomisation of index 
cases or partners to the 
alternative strategies, 
which provides 
considerable potential 
for bias in the results 
-In some cases the 
outcome data relied on 
reported results from 
the index patient 
Limitations identified 
by review team: The 
authors stated that, 
because it was an 
exploratory analysis, a 
sensitivity analysis was 
not carried out. The 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and methods of 
analysis 
Results Notes 
consequence 
analysis 
Economic 
perspective: NHS 
perspective 
Quality score: 
Medium 
Applicability: 
Directly 
applicable 
advice that sex partner 
should attend clinic for 
testing and treatment 
and, in one clinic, a 
standard letter detailing 
antibiotic treatment 
options for the sex 
partner to give to his/her 
general practitioner if 
appropriate) 
Sample sizes:  
Total N (APT+PN): 296 
Intervention N:  
APT hotline: 135 
APT pharmacy: 44 
Total: 179 
Control N: Routine PN: 
117 
 
Measures of uncertainty: 
No sensitivity analysis was 
carried out 
Modelling method: Not 
applicable; cost-
consequence analysis 
were more costly and 
more effective in terms 
of treating partners 
compared to routine PN; 
PN was the least cost 
strategy, but had the 
fewest partners treated; 
there was no strategy 
that was either clearly 
dominant or dominated: 
APT Hotline: £54.42 per 
partner treated 
APT pharmacy: £53.29 
per partner treated 
Routine PN: £45.89 per 
partner treated 
Secondary analysis: 
None 
Sensitivity analysis: No 
sensitivity analysis was 
carried out 
review team disagrees 
and see a sensitivity 
analysis as a way to 
better identify 
parameters that 
generate more 
uncertainty for further 
exploration in a future 
economic evaluation for 
these strategies 
Evidence gaps and/or 
recommendations for 
future research: We 
would suggest that 
effectiveness and costs 
parameters are further 
explored in a sensitivity 
analysis  
Source of funding: 
Department of Health, 
through the Sexual 
Health and HIV 
Research Strategy 
Committee of the 
Medical Research 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and methods of 
analysis 
Results Notes 
Council; no competing 
interests declared 
Thomas and 
Cameron (2013) 
Aim of study: To 
calculate the cost 
of an unintended 
pregnancy in 
2011 and use this 
cost in a cost-
effectiveness 
model comparing 
ulipristal acetate 
(UPA) with 
levonorgestrel 
(LNG) for 
emergency 
hormonal 
contraception 
(EHC) 
Type of 
economic 
analysis: Cost-
effectiveness 
analysis 
Source 
populations: 
Women in England 
presenting in 
primary care for 
EHC within 24 to 72 
hours of 
unprotected sexual 
intercourse 
Setting: English 
primary care 
Data sources:  
Health outcome: 
Probabilities of 
unintended 
pregnancies from 
clinical trials of 
EHC and published 
data sources and 
studies conducted 
on pregnancy 
intention in women 
in UK. 
Intervention 
description: Ulipristal 
acetate (UPA) 30 mg 
indicated for EC within 
120 hrs of unprotected 
sexual intercourse (UPSI) 
Comparator/control 
description: 
Levonorgestrel (LNG) 1.5 
mg, which is indicated 
for EC if taken within 72 
hrs of UPSI 
Sample sizes: Not 
described clearly  
Primary outcome: Number 
of unintended pregnancies 
and direct and indirect 
costs of unintended 
pregnancy 
Secondary outcome: 
Consequence of 
unintended pregnancy 
(miscarriage, abortion, 
ectopic pregnancy, 
stillbirth or live birth) 
Time horizon: One year 
Costing year(s) and 
currency: 2011 GBP 
Discount rates: Not 
applicable as time horizon 
was one year 
Perspective: Healthcare 
and societal 
Measures of uncertainty: 
Sensitivity analysis: failure 
rates of EHC and costs of 
unintended pregnancies  
Primary analysis:  
Direct health costs of a 
pregnancy: £3.9 billion 
(average cost: £3,903) 
-Cost per event: 
Miscarriage: £554; 
abortion: £714; ectopic 
pregnancy: £1,228; 
stillbirth: £3,765; live 
birth: £5,337 
Indirect health costs: 
Government expenditure 
on maternal health 
benefits: £2.3 billion plus 
£34 billion in tax credits 
and child benefits 
Overall analysis:  
-Cost of treating woman 
with UPA instead of LGN: 
Healthcare cost: £1,469; 
health and societal costs: 
£1,469 (same) 
Limitations identified 
by author:  
-Post-natal care costs 
for the mother were not 
included in the analysis 
-Cost estimates are 
based on average 
pregnancy costs, which 
may be different from 
the costs associated 
with an unintended 
pregnancy  
Limitations identified 
by review team: No 
additional limitations 
identified for this type 
of analysis 
Evidence gaps and/or 
recommendations for 
future research: Long-
term implications for 
the interventions could 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and methods of 
analysis 
Results Notes 
Economic 
perspective: 
Healthcare only 
or health plus 
social care 
Quality score: 
Low 
Applicability: 
Partially 
applicable 
Measure of 
effectiveness was 
number needed to 
treat 
Costs: Records 
from the NHS 
hospitals; NHS 
national Schedule 
of Reference Costs  
Modelling method: N/A - 
not a modelling study 
-Avoided costs 
(pregnancy averted): 
Healthcare costs: £1,663, 
health and societal costs: 
£2,992 
-ICER (net benefit) costs 
of treating minus avoided 
costs: 
Healthcare costs: −£194; 
Health and societal costs: 
−£1,453 
Secondary analysis: 
None 
Sensitivity analysis: All 
main parameters were 
varied. The sensitivity 
analysis did not change 
the results and has 
produced negative ICERs 
for the main outcomes of 
analysis, indicating 
robustness of the cost-
saving analysis 
be explored in a 
modelling study 
Source of funding: 
Funded by HRA Pharma 
UK & Ireland Ltd, 
manufacturers of 
ellaOne (UPA) 
CT has worked as a 
consultant for HRA 
Pharma Ltd, the 
manufacturer of UPA. 
SC has received lecture 
fees from HRA Pharma 
Ltd and was the 
principal investigator 
for the clinical studies 
of UPA, which were also 
sponsored by HRA 
Pharma Ltd 
 
Turner et al. 
(2014) 
Source 
populations: 
Simulated cohort 
Intervention 
description:  
POC NAAT for chlamydia 
Primary outcome: Total 
cost per QALY gained 
Primary analysis:  
QALY: 
Limitations identified 
by author:  
-Difficulty in obtaining 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and methods of 
analysis 
Results Notes 
Aim of study: To 
estimate the 
costs and 
benefits of 
clinical pathways 
incorporating a 
point of care 
(POC) nucleic 
acid amplification 
test (NAAT) for 
chlamydia and 
gonorrhoea in 
genitourinary 
medicine (GUM) 
clinics compared 
with standard 
off-site 
laboratory testing 
Type of 
economic 
analysis: Cost-
utility analysis 
and cost-
effectiveness 
analysis  
of 1.2 million index 
patients at GUM 
clinics 
Setting: England 
national health 
service GUM clinic 
Data sources:  
Epidemiological 
data: based on the 
Genitourinary 
Medicine Clinic 
Activity Dataset 
2011 
Utilities: 
Assumptions and 
published data 
Costing data: 
Published data 
and gonorrhoea in GUM 
clinics 
Comparator/control 
description:  
Standard off-site 
laboratory testing 
Sample sizes: Simulated 
cohort of 1.2 million 
hypothetical index 
patients  
(incremental cost-
effectiveness ratio) 
Secondary outcome: 
Number of inappropriate 
treatments, complications 
and transmissions averted 
Time horizon: The model 
cycle length was 1 day 
with an overall length of 
28 days 
Costing year(s) and 
currency: 2013 GBP 
Discount rates: Not 
applicable as time horizon 
was less than one year 
Perspective: NHS GUM 
clinic 
Measures of uncertainty:  
-Scenario analysis 
-Univariate sensitivity 
analysis (disease 
progression and 
transmission) 
Modelling method: 
Decision analytic model 
-POC NAAT: 184.059 
-Standard care: 184,012 
Costs: 
-POC NAAT: £103.9 
million 
-Standard care: £115.6 
million 
ICERS (for CEA, CUA): 
POC NAAT dominates 
(negative ICER, which 
means the intervention is 
cost saving) 
Inappropriate treatments 
avoided: POC NAAT: 
95,382 
Complications averted 
(Cases of pelvic 
inflammatory disease 
prevented): POC NAAT: 
189  
Transmission averted 
(onward transmissions 
averted annually): POC 
NAAT: 17 561  
accurate patient 
management parameter 
estimates from the 
literature due to 
reliance on presumptive 
treatment data 
- The only complication 
considered was pelvic 
inflammatory disease in 
women 
-Both tests were 
assumed to have 
equivalent sensitivity 
and specificity 
-Changes in uptake of 
testing due to POC 
testing were not 
considered  
-Patient costs 
associated with repeat 
visits or returning to 
collect treatment were 
not considered 
-The cost of changing 
testing protocol was not 
considered 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and methods of 
analysis 
Results Notes 
Economic 
perspective: 
National Health 
Service  
Quality score: 
High 
Applicability: 
Directly 
applicable 
 Secondary analysis: 
None 
Sensitivity analysis: 
Depending on the 
assumptions on 
prevalence rates and 
level of infectivity, the 
ICERs vary, but POC NAAT 
is still cost-effective 
Limitations identified 
by review team: None 
Evidence gaps and/or 
recommendations for 
future research:  
-Combination of 
qualitative and 
quantitative research to 
better capture changes 
in uptake over time  
- Impact of POC NAAT 
tests on patient 
experience 
- New generation POC 
NAAT tests need to be 
evaluated 
independently 
-Impact of POC NAAT on 
prevalence of 
complications by type 
of complication 
Source of funding: 
Cepheid, the 
manufacturer of the 
POC NAAT testing 
equipment  
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Appendix 9: Included studies table: Health promotion interventions 
Study details Population and 
setting 
Intervention/comparator Outcomes and methods 
of analysis 
Results Notes 
Burgos et al. 
(2010) 
Aim of study: To 
investigate the 
cost-effectiveness 
of Mujer Segura 
(Healthy Woman) 
intervention to 
reduce incidence 
of HIV and STIs in 
the border region 
of northern Mexico  
Type of economic 
analysis: Cost-
effectiveness 
Economic 
perspective: 
Government 
healthcare payer 
Quality score: 
Medium 
Applicability: 
Partly applicable 
Source 
populations: 
Female sex workers 
(FSWs) 
Setting: Tijuana 
and Cuidad Juarez, 
Mexico 
Data sources:  
Individual 
characteristics: 
Randomly assigned 
using distributions 
derived from the 
Mujer Segura 
cohort and other 
studies  
Costs: Observed 
costs per screening 
during the Mujer 
Segura study, 
National Center for 
AIDS Prevention in 
Mexico (CENSIDA) 
and published 
Intervention description: 
Mujer Segura (Healthy Woman) 
intervention (once only or 
annually): brief (35-minute) 
behavioural intervention 
focused on increasing condom 
negotiation skills and reducing 
incidence of HIV and STIs 
among FSWs 
Comparator/control 
description: No intervention 
Sample sizes:  
Intervention: 409 
Control: 460 
Total: 869 
Outcomes: Incidence HIV 
infection and QALY; HIV 
cases prevented, changes 
in quality-adjusted life 
expectancy (QALE), and 
costs per additional QALY 
gained  
Time horizon: Lifetime 
Costing year(s) and 
currency: 2009 USD 
Discount rates: 3% 
Perspective: Government 
healthcare payer 
Measures of uncertainty: 
One-, two- and multi-way 
sensitivity analyses; 
second-order Monte Carlo 
simulation for a 
multivariate probabilistic 
sensitivity analysis; 
probabilistic sensitivity 
analysis using Monte Carlo 
simulation methods and 
Primary analysis: 
No intervention 
- Cost: £12,730 ($19,200) 
- QALYs gained: 21,863 
Mujer Segura intervention 
offered once only 
- Cost: £64,576 ($97,400) 
- Incremental cost: £51,847 
($78,200) 
- HIV infections prevented: 33  
- Increase in the QALE per 
FSW: 151 days  
- Incremental cost per HIV 
case prevented: £1,571 
($2,370) 
- QALY: 22,290 
- incremental QALY: 427 
- incremental cost per QALY: 
£121 ($183) 
Mujer Segura intervention 
offered annually 
- Cost: £322,483 ($486,400) 
Limitations identified 
by author:  
- The assessment of 
intervention 
effectiveness relies on 
only 6 months of follow-
up and modelling 
assumes sustained 
effect, which may not 
be realistic 
- Mujer Segura 
participants are at high 
risk for HIV and STI 
infection meaning that 
the results may not be 
generalisable to other 
lower risk populations 
or to other settings 
- Multivariate sensitivity 
analyses generate 
present confidence 
intervals; however, 
published data from the 
US and Africa were used 
to parameterise HIV 
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Study details Population and 
setting 
Intervention/comparator Outcomes and methods 
of analysis 
Results Notes 
reports from 
Mexico 
Other parameters: 
Published 
literature 
multi-way sensitivity 
analyses 
Modelling method: 
Markov Model and Monte 
Carlo simulation  
- Incremental cost: £257,907 
($389,000) 
- HIV infections prevented: 62  
- Increase in the QALE per 
FSW: 283 days  
- Incremental cost per HIV 
case prevented: £8,893 
($13,413) 
- QALY: 22,652 
- Incremental QALY: 362 
- Incremental cost per QALY: 
£713 ($1,075)  
Secondary analysis: Base-
case results considering 
universal access to HAART 
Incremental cost per HIV case 
averted: 
- Mujer Segura annual: cost-
saving 
- Mujer Segura once: 
dominated 
- no-intervention: dominated 
Incremental cost per QALY: 
progression in the 
model  
Limitations identified 
by review team: 
Authors have covered 
major issues; model was 
calibrated, as it was 
adapted from previous 
model 
Evidence gaps and/or 
recommendations for 
future research: To 
better capture 
complications of HIV, 
analysis could also 
consider assessments by 
CD4 levels 
Source of funding: 
Funding for the Mujer 
Segura study provided 
by the National 
Institute of Mental 
Health. JB funded by 
the National Institute of 
Drug Abuse 
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Study details Population and 
setting 
Intervention/comparator Outcomes and methods 
of analysis 
Results Notes 
- Mujer Segura annual: net-
saving 
- Mujer Segura once: 
dominated 
- No intervention: dominated 
Sensitivity analysis:  
1. Two-way sensitivity 
analysis - base case results 
considering universal access 
to HAART, ignoring added 
costs for antiretroviral 
medications: 
Incremental cost per HIV case 
averted: 
- Mujer Segura once: $2,370 
- No intervention: $13,258 
Incremental cost per QALY: 
- Mujer Segura once: $2,435 
- No-intervention: $14,136 
2. One-way sensitivity 
analyses: Results were 
sensitive to changes in HIV 
incidence 
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Study details Population and 
setting 
Intervention/comparator Outcomes and methods 
of analysis 
Results Notes 
3. Probabilistic sensitivity 
analysis: The cost-
effectiveness acceptability 
curve indicated that there 
was a greater than 95% 
probability of a cost per QALY 
gained less than £16,906 
($25,499) for the intervention 
offered once and £10,078 
($15,200) for the intervention 
offered annually 
4. Mujer Segura intervention 
is no longer cost-effective 
with changes in incidence of 
HIV, STI, syphilis, gonorrhoea 
and chlamydia 
Cooper et al. 
(2012) 
Aim of study: To 
assess the cost-
effectiveness of 
school-based 
behavioural 
interventions for 
the prevention of 
STIs in young 
Source 
populations: Boys 
and girls aged 13 to 
15 years old 
Setting: UK 
Data sources:  
HRQoL: Previous 
utility studies using 
validated tools for 
Intervention description:  
Teacher-led: Twenty sessions 
delivered over two years: 10 
sessions at age 13–14 years, 
and 10 sessions at age 14–15 
years. 
Active learning (small group 
work and games), information 
leaflets on sexual health, and 
development of skills, using 
Outcomes: Total number 
of STI cases averted, 
QALY, savings in medical 
costs 
Time horizon: 1-year 
Costing year(s) and 
currency: 2011-2012 Euro 
Primary analysis: 
Teacher-led intervention: 
- Total cost: £7,672 (€10,320)  
- Total medical costs averted: 
£1,297 (€1,745)  
- Net additional cost: £6,375 
(€8,575) 
- Cost per case averted (all 
STIs): £3,017 (€4,058) 
Limitations identified 
by author:  
-Effectiveness data 
drawn from a meta-
analysis did not show a 
statistically significant 
effect on behavioural 
outcomes 
-The model compares 
teacher-led to standard 
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Study details Population and 
setting 
Intervention/comparator Outcomes and methods 
of analysis 
Results Notes 
people through the 
development of an 
economic model 
Type of economic 
analysis: Cost-
effectiveness 
Economic 
perspective: 
National Health 
Service (NHS) and 
Personal Social 
Services (PSS) 
Quality score: 
High 
Applicability: 
Directly applicable 
groups of patients 
who developed STI 
complications 
Costs: Published 
studies 
Prevalence and 
transmission 
probabilities of 
STIs: National 
Chlamydia 
Screening 
programme and 
Health Protection 
Agency, case series 
study, literature 
review, 
assumptions 
Effectiveness: 
Systematic review 
and meta-analysis 
Proportion of 
sexually active 
young people in 
England and their 
condom use at last 
intercourse: Cross-
interactive video and role 
playing 
Peer-led: Three one-hour 
peer-educator-led sessions 
delivered over one school 
term. 
 Topics: relationships, sexually 
transmitted infections and use 
of condoms and 
contraception. Informal 
format using small group 
work, role plays and condom 
use skills demonstrations 
Comparator/control 
description: Standard sexual 
health education provided by 
teachers in British schools as 
part of the SRE curriculum. 
Topics: basic information on 
STIs and sexual health, which 
may or may not teach safer 
sex negotiation skills.  
Sample sizes: Simulated 
cohort of individuals of 
unclear size 
Discount rates: Not 
applicable as the time 
horizon is for one year 
Perspective: National 
Health Service (NHS) and 
Personal Social Services 
(PSS) 
Measures of uncertainty: 
Deterministic and 
probabilistic sensitivity 
and scenario analysis 
Modelling method: 
Bernoulli statistical model 
- Incremental cost per QALY 
gained: £18,041 (€24,268) 
*the intervention averted an 
extra two STI cases with a 
corresponding gain of 0.35 
QALY compared with standard 
sex education 
Peer-led intervention:  
- Total cost: £26,762 
(€36,000) 
- Total medical costs averted: 
£1,297 (€1,745) 
- Net additional cost: £25,465 
(€34,255) 
- Cost per case averted (all 
STIs): £12,050 (€16,210)  
- Incremental cost per QALY 
gained: £72,062 (€96,938) 
* the intervention had the 
same health gains, in terms of 
cases averted and QALYs 
gained when compared with 
the base case 
Secondary analysis: None 
sexual health education 
and peer-led 
interventions to 
standard sexual health 
education, but no direct 
evidence is available 
directly comparing 
peer-led and teacher-
led interventions  
- The intervention 
effect was assumed to 
be the same for both 
interventions so 
differences in outcomes 
are due primarily to 
differences in costs. 
The differences in costs 
were primarily because 
a lower frequency of 
training was needed in 
the teacher-led 
intervention  
- Due to a lack of data 
for the <16-year-old age 
group, the parameters 
for this age group are 
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Study details Population and 
setting 
Intervention/comparator Outcomes and methods 
of analysis 
Results Notes 
national Health 
Behaviour in 
School-aged 
Children (HBSC) 
survey 
Number of sexual 
partners that 
young people have 
had: Multi-purpose 
survey in Great 
Britain 
Number of 
occasions of 
heterosexual sex in 
the past 4 weeks: 
The UK National 
Survey of Sexual 
Attitudes and 
Lifestyles (NATSAL) 
Interventions: 
Scottish study (the 
SHARE trial- 
teacher-led) and 
English trial (the 
RIPPLE trial- peer-
led) 
Sensitivity analysis:  
Deterministic sensitivity 
analysis: Results most 
sensitive to intervention 
effect, transmission 
probability, and number of 
sexual partners 
Scenario analysis for older 
teenagers: In this age group, 
there are more STI cases 
averted, QALYs gained and 
medical costs averted than in 
the younger age group 
Probabilistic sensitive 
analysis:  
- The teacher-led 
intervention ICER was 
between £0 and £26,762 
(€36,000) per QALY for 48% of 
iterations, more than £26,762 
(€36,000) per QALY for 28% of 
iterations and was associated 
with a QALY loss for 24% of 
iterations 
based on assumptions 
and extrapolations from 
other age groups 
Limitations identified 
by review team: 
Sensitivity analyses 
showing large 
uncertainty around the 
results 
Evidence gaps and/or 
recommendations for 
future research: Given 
the uncertainties 
surrounding the results, 
further studies are 
necessary to define 
cost-effective 
interventions 
Source of funding: KC, 
JS, JP, JJ, AH, EB-P, 
AC, DH and AP received 
an NIHR Health 
Technology Assessment 
Programme grant 
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Study details Population and 
setting 
Intervention/comparator Outcomes and methods 
of analysis 
Results Notes 
Others: Systematic 
searches, 
administrative 
databases for the 
United Kingdom 
and prospective 
studies, 
assumptions 
- The peer-led intervention 
ICER between £0 and £26,762 
(€36,000) per QALY for 16% of 
iterations 
Crawford et al.  
(2015)  
Aim of study: To 
examine the 
clinical and cost-
effectiveness of 
brief advice for 
excessive alcohol 
consumption 
among people who 
attend sexual 
health clinics 
Type of economic 
analysis: Cost-
utility analysis 
Economic 
perspective: 
NHS/Personal 
Source 
populations: 802 
people aged 19+ 
years attending 
one of three sexual 
health clinics and 
drinking 
excessively 
Setting: Sexual 
health clinics in 
London, UK 
Data sources: 
Computer-assisted 
self-completion 
questionnaire; 
EuroQol-5D scale; 
Adult Service Use 
Intervention description: 
Brief advice: feedback on 
alcohol and health, written 
information, offer of an 
appointment with an alcohol 
health worker 
Comparator/control 
description: Leaflet on health 
and lifestyle 
Sample sizes:  
Total N = 802 
Intervention N = 402 
Control N = 400 
Outcomes: Outcomes 
measured 6 months after 
randomisation and 
assessed behaviour in the 
3 months prior to the 
date of the assessment 
(objective measures) 
Primary outcome: Mean 
weekly alcohol 
consumption 
Secondary outcomes: 
Proportion of participants 
who reported any 
unprotected sex; mean 
units of alcohol consumed 
per drinking day; 
percentage days 
abstinent; whether the 
Primary outcomes:  
Benefits:  
-QALY for control = 0.475 
-QALY for intervention = 
0.450  
-Incremental QALY (QALY 
intervention minus QALY 
control): −0.007 
Costs: 
-Average costs for control 
group: £310.87 
-Average cost for intervention 
group: £319.28  
-Incremental cost (cost of 
intervention minus cost of 
control): £8.41  
Limitations identified 
by author:  
-Participants were 
recruited at sexual 
health clinics. In order 
to limit exposure of 
control participants to 
questions about alcohol 
consumption, very little 
baseline data on 
alcohol-related 
behaviour was 
collected. Analysis of 
available data suggests 
groups were 
comparable. 
-No follow-up was 
collected for 
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Study details Population and 
setting 
Intervention/comparator Outcomes and methods 
of analysis 
Results Notes 
Social Service 
perspective 
Quality score: 
High 
Applicability: 
Directly applicable 
 
Schedule; national 
UK unit costs 
participant was drinking 
excessively  
Sexual behaviour 
outcomes: Number of 
sexual partners; number 
of unprotected sexual 
partners; any incidence of 
regretted sex; any 
incidence of unprotected 
sex after drinking alcohol 
or while drunk; how long 
they knew their last 
sexual partner before 
they had sex with them; 
unplanned pregnancy; any 
new diagnosis of a 
sexually transmitted 
infection  
Cost and cost-
effectiveness outcomes: 
Cost of the brief advice; 
QALY  
Time horizon: 6 months 
Costing year(s) and 
currency: 2010-2011 GBP 
-No significant difference in 
costs or QALY 
Secondary analysis: Not 
presented as cost/QALY. 
Because the difference in 
costs and QALY were not 
significant, acceptability 
curves were used to estimate 
the probability that the 
intervention would be cost-
effective for given thresholds 
of willingness to pay (WTP) 
per QALY gained; the results 
showed no evidence of this at 
any WTP values  
Sensitivity analysis:  
Statistical model used and 
inclusion of missing data gave 
similar findings of a small 
difference around statistical 
significance for the primary 
outcome 
approximately 25% of 
intervention 
participants. These 
participants were 
excluded from the final 
analysis, which may 
have biased estimates 
of intervention 
effectiveness 
Limitations identified 
by review team: Short 
time horizon to capture 
behaviour change  
Evidence gaps and/or 
recommendations for 
future research: 
Authors could have 
modelled potential 
scenarios for behaviour 
change based on 
available data in the 
literature 
Source of funding: 
NIHR Health Technology 
Assessment programme 
and the Department of 
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Study details Population and 
setting 
Intervention/comparator Outcomes and methods 
of analysis 
Results Notes 
Discount rates: Not 
applicable as time horizon 
was less than one year 
Perspective: 
NHS/Personal Social 
Service 
Measures of uncertainty: 
Sensitivity analysis: non-
parametric bootstrapping 
and non-hierarchical 
linear models 
Modelling method: 
Random-effects linear 
regression, ordinary 
parametric models 
Health, Chelsea and 
Westminster NHS 
Foundation Trust, 
Central and North West 
London NHS Foundation 
Trust, Turning Point, 
and Imperial College 
Academic Health 
Sciences Centre 
 
Holtgrave et al.  
(2012) 
Aim of study: To 
examine the 
affordability, 
performance 
standards and 
cost-effectiveness 
of female condom 
Source 
population: 
Women 
Setting: 
Washington, DC, 
USA 
Data sources: 
Female Health 
Company and MAC 
Intervention description: 
Female condom distribution 
and education programme 
Comparator/control 
description: No intervention 
Sample sizes: Not clearly 
stated but understood as a 
simulation using eligible 
Primary outcome: Costs 
saved 
Secondary outcomes: 
Total costs, HIV infections 
averted, net cost-savings 
per QALY averted 
Time horizon: 1 year and 
lifetime 
Costing year(s) and 
currency: 2012 USD 
Primary analysis:  
Benefits (HIV infections 
averted): 
-Female to female 
transmission: 5.08 
-No STI, male to male: 6.61 
-Non ulcerative STI, male to 
female: 6.54 
Limitations identified 
by author:  
-Retrospective analysis 
meant that uncertainty 
was explored using 
mathematical modelling 
techniques  
-Simplified assumption 
of random distribution 
of sexual acts 
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Study details Population and 
setting 
Intervention/comparator Outcomes and methods 
of analysis 
Results Notes 
(FC2) provision and 
education  
Type of economic 
analysis: Cost 
analysis, cost-
effectiveness and 
cost-utility 
analysis 
Economic 
perspective: 
Societal and public 
sector payer 
perspectives, USA  
Quality score: 
High 
Applicability: 
Directly applicable 
 
AIDS Fund for all 
cost elements 
population (men and women 
of reproductive age) 
 
Discount rates: 3% 
Perspective: Societal and 
public sector payer 
perspectives, USA 
Measures of uncertainty: 
Sensitivity analysis (type 
not mentioned, but 
understood as one-way 
sensitivity analysis) 
Modelling method: Cost 
analysis; threshold 
analysis 
-Ulcerative STI, male to 
female: 5.13 
-Total HIV infections averted: 
23.35 
Total cost: 
-Total overall programme 
cost: £279,575 ($414,186) 
-Cost per female condom 
using during sex: £2.15 
($3.19) 
Threshold analysis (cost 
saving per HIV infection 
averted) – cost-utility: 
-Societal perspective: net 
savings of £5.51 million 
($8.16 million) 
-Payer perspective: net 
savings of £4.06 million 
($6.017 million)  
Allowance for male condom 
crowd-out: 
-Total HIV infection averted: 
20.32 
-Prevention of 
secondary transmission 
of HIV not considered. 
This is likely to lead to 
conservative estimates 
of effectiveness 
Limitations identified 
by review team:  
- Authors have only 
stated that the results 
were robust in terms of 
benefits gained and 
costs averted  
-We suggest that the 
sensitivity analysis be 
more detailed and 
informative in terms of 
showing which 
parameter(s) bring 
more uncertainty to the 
model/estimates 
Evidence gaps and/or 
recommendations for 
future research: When 
alternatives are 
dominant, present this 
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Study details Population and 
setting 
Intervention/comparator Outcomes and methods 
of analysis 
Results Notes 
-Societal perspective (cost-
utility analysis): net savings 
of £4.76 million ($7.046 
million) 
-Payer perspective: net 
savings of £3.5 million 
($5.181 million) 
Sensitivity analysis: 
Threshold analysis: From the 
societal perspective, 1.13 
infections would need to be 
averted for the intervention 
to be cost saving and 0.46 
infections averted for the 
intervention to fall below a 
threshold of £67,500 
($100,000) per QALY gained. 
From the payer perspective, 
1.5 infections would need to 
be averted for the 
intervention to be cost saving 
Crowding out: If increased 
uptake of FC2 leads to a 13% 
decrease in male condom use 
(known as crowding out), the 
intervention would still be 
and subsequent 
alternatives that were 
not dominant 
Source of funding: 
Female Health 
Company, the producer 
of the female condom 
product, FC2, provided 
support for the 
economic evaluation, 
education and 
dissemination. The MAC 
AIDS fund provided 
funding for the 
educational project 
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Study details Population and 
setting 
Intervention/comparator Outcomes and methods 
of analysis 
Results Notes 
associated with 20.32 
infections averted which 
means it would still be cost 
saving 
Reduced FC2 effectiveness: If 
the effectiveness of FC2 
dropped as low as 7.04%, the 
intervention would still be 
cost-effective.  
Holtgrave et al. 
(2013) 
Aim of study: To 
present a cost-
utility analysis of 
supportive housing 
for homeless and 
unstably housed 
persons living with 
HIV, through the 
combination of 
three favourable 
outcomes 
(undetectable HIV 
viral load, less use 
of emergency 
rooms as a source 
Source 
populations: 
Homeless and 
unstably housed 
persons living with 
HIV in Baltimore, 
Chicago and Los 
Angeles 
Setting: Baltimore, 
Chicago and Los 
Angeles/ USA 
Data sources: 
Previously 
published cost and 
effectiveness data 
Intervention description: 
Supportive housing for 
homeless and unstably housed 
persons living with HIV: people 
who did not spend any night 
homeless during the past 6 
months 
Comparator/control 
description: Persons living 
with HIV who spent at least 
one night homeless during the 
past 6 months 
Sample sizes: Simulated 
cohort of individuals of 
unspecified size 
Primary outcome: Cost 
per QALY saved by the 
Housing and Health 
intervention 
Secondary outcomes:  
- Average cost per client 
per year to receive the 
Housing and Health 
services (C) 
- Average medical cost 
savings per client accrued 
because of lowered 
emergency department 
use (E)  
- Number of HIV 
transmissions averted to 
Primary analysis: 
-Average per-client cost 
across Baltimore, Chicago and 
Los Angeles: 
C = £7,975 ($12,288) 
E = £63 ($97) 
A = 0.01567 
T = £205,022 ($315,904) 
QPSS = 0.0324 
QTA = 5.33 (discounted) 
- Cost per QALY saved by the 
HIV-related housing services: 
£40,558 ($62,493) 
Secondary analysis: None 
Limitations identified 
by author:  
- Estimates of the 
number of infections 
averted is based on 
estimates obtained 
from the literature as 
this could not be 
observed directly  
- The study used results 
from the as-treated 
analysis, rather than 
the intent-to-treat 
analysis, so is not 
possible to establish a 
causal relationship 
between housing status 
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Study details Population and 
setting 
Intervention/comparator Outcomes and methods 
of analysis 
Results Notes 
of medical care, 
and lower 
perceived stress) 
with information 
on the costs of 
service delivery 
and mathematical 
model estimates of 
the cost per QALY 
saved by the 
intervention 
Type of economic 
analysis: Cost-
utility 
Economic 
perspective: Not 
clear 
Quality score: Low 
Applicability: 
Partly applicable 
from the Housing 
and Health Study 
HIV seronegative partners 
of HIV seropositive clients 
(A)  
- Net present value of 
downstream medical care 
costs saved when an HIV 
infection is averted (T)  
- Average number of 
QALYs saved for each 
client living with HIV due 
to improvements in 
perceived stress (QPSS) 
- Net present value of the 
downstream QALYs saved 
each time an HIV 
transmission is averted 
from one HIV seropositive 
client in the study to an 
HIV seronegative partner 
(QTA) 
Time horizon: Not clear 
Costing year(s) and 
currency: 2005 USD 
Discount rates: 3% 
Perspective: Not clear 
Sensitivity analysis: The 
threshold analysis for the 
parameter A indicated that 
even if A sank as low as 
0.01054, the cost-utility ratio 
would be £64,900 ($100,000) 
or less. This is also true if the 
value for QTA decreased to as 
low as 2.56. 
and the outcomes of 
interest 
- Estimates of the net 
present value of QALYs 
saved due to averted 
transmissions (QTA) were 
based on available 
literature at the time of 
analysis; however, more 
recent CDC estimates 
suggest that a higher 
value could be used, 
meaning that the 
estimates in the present 
study are conservative  
-Secondary HIV 
transmissions averted 
are not included in the 
model, meaning that 
estimates of the 
number of transmissions 
averted are 
conservative 
-It is assumed that no 
HIV transmissions occur 
from a seropositive 
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Study details Population and 
setting 
Intervention/comparator Outcomes and methods 
of analysis 
Results Notes 
Measures of uncertainty: 
Sensitivity analysis: 
threshold analysis 
Modelling method: 
Mathematical modelling 
individual with an 
undetectable viral load 
to a seronegative 
partner, though it is 
theoretically possible 
that this could occur, 
but the risk of 
transmission per sex act 
is expected to be very 
low. The threshold 
analysis for number of 
HIV transmissions 
averted to HIV 
seronegative partners 
of HIV seropositive 
clients (A) suggests that 
the results are robust to 
this assumption 
- Study participants 
were recruited through 
HIV service 
organisations which may 
have resulted in a 
sample that is more 
able to negotiate access 
to services compared to 
Appendix 9 
 
Sexual health promotion and contraceptive services in local authorities: a systematic review of economic evaluations 2010-2015  148 
 
Study details Population and 
setting 
Intervention/comparator Outcomes and methods 
of analysis 
Results Notes 
the general population 
of homeless and 
unstably housed 
individuals  
Limitations identified 
by review team: Main 
limitations already 
identified by authors 
Evidence gaps and/or 
recommendations for 
future research: To 
assess complications of 
HIV and long-terms 
costs and benefits of 
interventions, we 
suggest adding an 
analysis by CD4 levels 
Source of funding: 
Funding received from 
the US Centers for 
Disease Control and 
Prevention and the 
Department of Housing 
and Urban Development 
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Study details Population and 
setting 
Intervention/comparator Outcomes and methods 
of analysis 
Results Notes 
Jackson et al.  
(2015) 
Aim of study: To 
compare the costs 
and outcomes of 
two sexually 
transmitted 
infection screening 
interventions 
targeted at men in 
football club 
settings in 
England, including 
screening 
promoted by team 
captains 
Type of economic 
analysis: Cost-
consequence 
analysis 
Economic 
perspective: 
Health service 
perspective 
Source 
populations: Men 
≥18 years in six 
London amateur 
football clubs  
Setting: UK 
Data sources:  
Costs: Unit Costs of 
Health and Social 
Care 2013; other 
primary costing 
data collection 
Consequences: 
Three-arm trial and 
results from blood 
sample 
 
Intervention description: 
1. Captain-led and poster STI 
screening promotion 
2. Sexual health adviser-led 
and poster STI screening 
promotion 
Comparator/control 
description: Poster-only STI 
screening promotion 
Sample sizes:  
Total N = 153 
Intervention N = 56+46 
Control N = 51 
Primary outcome 
(objective): Proportion of 
eligible men accepting 
screening  
Time horizon: Not clearly 
stated, but probably 
equal to the intervention 
(one year) 
Costing year(s) and 
currency: 2012-2013 GBP 
Discount rates: Only 
start-up costs (costs with 
the posters) were 
discounted at 3% (for 3 
years)  
Perspective: NHS 
Measures of uncertainty: 
One-way deterministic 
sensitivity analysis for 
costs and outcomes 
Modelling method: Not 
applicable 
Primary analysis:  
Benefits: Number and 
proportion of men accepting 
screening: 
-Captain-led and poster STI 
screening promotion: 28 (50%) 
-Sexual health adviser-led and 
poster STI screening 
promotion: 31 (67%) 
-Poster-only STI screening 
promotion: 31 (61%) 
Costs (average cost per 
player tested): 
-Captain-led and poster STI 
screening promotion: £88.99 
-Sexual health adviser-led and 
poster STI screening 
promotion: £88.33 
-Poster-only STI screening 
promotion: £81.87 
Secondary analysis: None  
Sensitivity analyses: 
Variables affecting the overall 
cost: Time needed for club 
Limitations identified 
by author:  
-Uptake of screening 
could not be accurately 
estimated for 
intervention arms 
-Variability in the 
acceptability of 
screening intervention 
between clubs limited 
ability to estimate 
acceptability 
-Difficulty in 
recruitment meant that 
target sample size was 
not reached  
-Subsequent testing 
that may have occurred 
outside of the 
intervention but been 
motivated by 
intervention materials 
was not captured, 
meaning that the 
uptake of STI testing 
linked to the 
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Study details Population and 
setting 
Intervention/comparator Outcomes and methods 
of analysis 
Results Notes 
Quality score: 
Medium 
Applicability: 
Partially 
applicable 
recruitment; incentive of 
£1000 for each club to help 
maximise participation; costs 
for team captains to deliver 
the promotion; intervention 
costs; cost of the test kit 
boxes; sample processing 
costs 
intervention may be an 
underestimate  
-No cases of chlamydia 
or gonorrhoea were 
identified as part of the 
intervention, making it 
impossible to estimate 
a cost per case 
diagnosed 
-The influence of 
captains on uptake of 
testing was not 
anticipated. However, 
this appears to have 
played a substantial 
role, with some 
captains encouraging 
players to participate in 
screening in team-wide 
communications 
Limitations identified 
by review team:  
- Only one outcome was 
explored: the 
proportion of eligible 
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Study details Population and 
setting 
Intervention/comparator Outcomes and methods 
of analysis 
Results Notes 
men accepting 
screening 
- Time horizon was 
unclear, although the 
analysis seems to be for 
one year. If analysis was 
conducted for one year, 
costs might be 
overestimated, as costs 
for posters were 
discounted for three 
years; authors had not 
stated if only a 
proportion or the full 
costs were allocated 
into the analysis  
Evidence gaps and/or 
recommendations for 
future research: 
Authors clearly stated 
that this analysis was 
conducted for the pilot 
phase, and that was the 
reason for a cost-
consequence analysis. A 
full cost-effectiveness 
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Study details Population and 
setting 
Intervention/comparator Outcomes and methods 
of analysis 
Results Notes 
analysis with a 
probabilistic analysis 
might help with 
uncertainties around 
the costs and 
consequences, 
especially between the 
captain-led and the 
health adviser–led 
interventions  
Source of funding: 
SPORTSMART study, 
part of NIHR-funded 
BALLSEYE Programme 
‘Targeting Men for 
Better Sexual Health’; 
no competing interests 
declared 
Kessler et al. 
(2013) 
Aim of study: To 
inform HIV 
prevention 
planning in the 
jurisdiction by 
comparing cost-per 
Source 
populations: HIV 
infected; HIV 
infected, high risk; 
HIV infected, 
hazardous alcohol 
users; HIV infected 
and partners; HIV 
Intervention description:  
Increases in investment in HIV 
prevention programmes  
- CD - Condom distribution 
- SM - Social marketing  
- CI - community intervention  
Outcomes:  
-Number and percentage 
of infections averted 
-Cost per infection 
averted 
* threshold of £243,000 
($360,000) per infection 
Primary analysis: 
Base case: 
- 58,632 new cases of HIV 
infection over a 20-year time 
period 
- Average incidence of 2,932 
new infections per year 
Limitations identified 
by author:  
- Not all inputs are 
known with certainty, 
and results are partially 
dependent on the 
assumptions embedded 
in the model 
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Study details Population and 
setting 
Intervention/comparator Outcomes and methods 
of analysis 
Results Notes 
infection averted 
between the 
various Enhanced 
Comprehensive HIV 
Prevention 
Planning (ECHPP) 
strategies and by 
identifying the 
optimal package of 
prevention 
services in NYC 
Type of economic 
analysis: Cost-
effectiveness 
analysis 
Economic 
perspective: NYC 
Department of 
Health and Mental 
Hygiene (NYC 
DOHMH) 
Quality score: 
High 
infected on ART; 
HIV uninfected; HIV 
uninfected, high 
risk; providers; all 
population 
Setting: New York 
City, USA 
Data sources:  
Population of NYC 
in 2009: NYC HIV 
surveillance data 
Costs: Estimates of 
programmatic 
expenditures 
within the DOHMH 
Other inputs: 
Literature; 
discussion and 
consensus amongst 
the study team 
 
- SD - Prioritised use of 
surveillance data  
- CF - Cofactors (brief 
screening and treatment for 
co-morbid STDs) 
- SBIRT - Screening, brief 
intervention and referral for 
treatment for unhealthy 
alcohol use  
- LC - Linkage to care  
- LS - Linkage to support  
- PS - Partner services  
- RR - risk reduction  
- STD screening 
- TC - Testing – clinical 
- TNC - Testing – non-clinical  
- CC - Care coordination 
- SS - Social services  
- PEP - Post-exposure 
prophylaxis (provision of post-
exposure prophylaxis to 
populations) 
Comparator/control 
description: Current scenario: 
averted was selected as 
cost-saving 
Time horizon: 20 years 
Costing year(s) and 
currency: 2010 USD 
Discount rates: 
Apparently no discount 
rate was applied 
Perspective: NYC 
Department of Health and 
Mental Hygiene (NYC 
DOHMH) 
Measures of uncertainty: 
Sensitivity analyses with 
alternative time horizons 
of potential interest for 
policy decisions (5 years 
and 10 years); costs 
(±50%) 
Modelling method: 
Deterministic 
compartmental model of 
HIV transmission/micro-
simulation HIV disease 
progression model 
- 16,159 persons were 
predicted to have died of 
AIDS-related conditions over 
20-year simulation  
- Average 808 deaths per year 
Increases in investment in HIV 
prevention programmes:  
Cost per infection 
averted/cost-saving? 
CD1: £2,004 ($2,969) / YES 
CD2: £2,345 ($3,474) / YES 
CD3: £86,883 ($128,715) / 
YES 
CD4: £126,368 ($187,212) / 
YES 
SM1: £2,345 ($3,474) / YES 
SM2: £54,888 ($81,315) / YES 
SM3: £55,709 ($82,532) / YES 
SM4: £228,843 ($339,026) / 
YES 
CI1: £4,482 ($7,173) / YES 
SD1: £18,673 ($27,663) / YES 
CF1: £21,130 ($31,304) / YES 
- Costs were not 
addressed from the 
comprehensive societal 
perspective and 
therefore may not be 
inclusive or reflective 
of all costs incurred by 
society or payers 
outside the NYC DOHMH 
- Recently approved 
biomedical 
interventions and 
modalities still under 
investigation were not 
considered in the model 
(for example, rapid HIV 
self-testing and pre-
exposure prophylaxis, 
microbicides and HIV 
vaccine) 
- Modelled interventions 
are not mutually 
exclusive as the 
implementation of one 
intervention may 
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Study details Population and 
setting 
Intervention/comparator Outcomes and methods 
of analysis 
Results Notes 
Applicability: 
Directly 
applicable. 
 
without incremental 
investment in HIV prevention 
programmes or strategies 
Sample sizes: Simulated 
cohort of individuals. Number 
of individuals in cohort not 
reported.  
 
 CF2: £2,451,098 ($3,631,257) 
/ NO 
SBIRT1: £24,821 ($36,772) / 
YES 
SBIRT2: £2,629,434 
($3,895,458) / NO 
LC1: £257,112 ($380,906) / 
YES 
LS1: £83,896 ($124,291) / YES 
PS1: £133,821 ($198,253) / 
YES 
RR1: £518,016 ($767,431) / 
NO 
STD1: £228,843 ($339,026) / 
YES 
STD2: £322,639 ($477,984) / 
NO 
STD3: £7,698,044 
($11,404,509) / NO 
STD4: £11,907,321 
($17,640,475) / NO 
TC1: £1,190,066 ($1,763,061) 
/ NO 
impact on pathways or 
outcomes of another  
- Per-person costs in the 
model were derived 
from programmatic 
estimates from the 
DOHMH and were 
applied in a ‘pre 
purchased’ approach. 
This neither accounts 
for the potential 
economies of scale that 
may be operational nor 
the actual utilisation of 
an intervention. 
Therefore, potential 
bias towards 
overestimation of costs 
of interventions may 
occur, leading to a 
more conservative 
estimate of portfolios of 
interventions that may 
be ‘cost-saving’ 
- The model does not 
explicitly consider costs 
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Study details Population and 
setting 
Intervention/comparator Outcomes and methods 
of analysis 
Results Notes 
TNC1: £2,099,507 
($3,110,381) / NO 
CC1: £781,784 ($1,158,199) / 
NO 
SS1: £706,311 ($1,046,387) / 
NO 
PEP1: £7,698,044 
($11,404,509) / NO 
PEP2: £9,812,825 
($14,537,519) / NO 
Secondary analysis:  
Analysis with cost-saving 
intervention:  
- CD (high-risk HIV infected 
persons), SM (HIV-infected 
persons), CI, CF (HIV-infected 
persons), and LS (HIV-infected 
persons, partner) are 
interventions included in 
different packages located on 
the efficiency frontier 
- CI+LS (HIV+)+STD (HIV 
infected, high risk)+PS is the 
package to prevent the most 
infections (20,211 and cost 
of the antiretroviral 
medications or the 
routine care needed by 
a person living with 
HIV/AIDS, although 
these costs informed 
the estimation of the 
£243,000 ($360,000) 
threshold 
- Assumptions that the 
authors have made may 
have also contributed to 
the model’s limitations 
- There are little to no 
reliable data to inform 
how different 
interventions would 
impact on each other if 
implemented in 
tandem.  
- A conservative 
approach was chosen by 
research team  
Limitations identified 
by review team: Main 
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Study details Population and 
setting 
Intervention/comparator Outcomes and methods 
of analysis 
Results Notes 
per infection averted £71,805 
($106,378) 
Analysis including all 
interventions 
PEP (HIV-), LS, SM (HIV+), CI 
and TC is the package to 
prevent the greatest number 
of infections (33,004 
infections averted) and cost 
per infection averted £6.075 
million ($9 million) 
Sensitivity analysis:  
- Several of the interventions 
had >10% absolute change in 
their projected effectiveness 
in one-way sensitivity analysis  
- Varying all parameters and 
evaluating the effects of all 
interventions under these 
conditions demonstrated that 
the prevention interventions 
considered to be of 
favourable value were robust  
- No intervention with a cost 
per infection averted greater 
limitations covered by 
authors 
Evidence gaps and/or 
recommendations for 
future research: Future 
research could include 
an assessment of 
reduction in number of 
complications of HIV 
taking into account 
levels of CD4 and 
effects on lifetime costs 
and health outcomes 
Source of funding: The 
study was sub-
contracted by the 
Department of Health 
and Mental Hygiene, 
Bureau of HIV/AIDS 
Prevention and Control 
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Study details Population and 
setting 
Intervention/comparator Outcomes and methods 
of analysis 
Results Notes 
than the £243,000 ($360,000) 
threshold under base case 
assumptions crossed this 
threshold under any other 
conditions.  
- Several of the interventions 
(CD, LS, PS and STD) that 
were considered cost-saving 
under base case assumptions 
had cost-per-infection ratios 
which increased above the 
threshold considered as cost-
saving under other, specific 
conditions  
- Under conditions where ART 
initiation was not restricted 
by CD4 count there were no 
differences in the list of 
interventions that were 
considered to be cost-saving 
or in the relative rankings of 
interventions by cost per 
infections averted  
- Variation in the time 
horizon did not change the 
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Study details Population and 
setting 
Intervention/comparator Outcomes and methods 
of analysis 
Results Notes 
group of interventions 
considered cost-saving  
Lasry et al. (2012) 
Aim of study: To 
support the 
planning efforts of 
the Division of 
HIV/AIDS 
Prevention (DHAP) 
and inform the 
decision-making 
process for HIV 
resource allocation 
Type of economic 
analysis: Cost-
saving 
Economic 
perspective: 
Government 
Quality score: Low 
Applicability: 
Partly applicable 
 
Source 
populations: HIV 
transmission risk 
group and gender: 
male high risk 
heterosexuals 
(HRH), female 
HRH, men who 
have sex with men 
(MSM), male 
injection drug 
users (IDUs) and 
female IDUs (black, 
Hispanic and all 
others – whites, 
Asians, Pacific 
Islanders, Alaska 
natives and 
American Indians) 
and general U.S. 
population 
Setting: USA-wide 
Data sources:  
Intervention description:  
Allocation for: 
- HIV testing 
- Individual and group-level 
counselling and education 
Comparator/control 
description: No allocation 
Sample sizes: Simulated 
cohort of individuals of 
unspecified size 
 
Outcomes:  
- Projection of HIV 
infections over time given 
a specific funding 
allocation scenario 
- Amounts to allocate 
each year toward 
interventions and 
population subgroups to 
minimise new infections  
- General population: Per-
person cost of testing 
based on the cost of opt-
out testing in emergency 
department settings and 
the cost of a CDC-led 
expanded testing 
programme 
targeted to high risk 
populations 
-Cost of testing in STD 
clinic settings and the 
Primary analysis: New 
infections averted, £216.8 
($327 million) budget 
- Baseline allocation: 13% 
- Optimised allocation: 31%  
HIV resource allocation 
model: Allocated proportion 
of budget ($327 million)  
Allocation by intervention 
(counselling+testing) and risk 
group 
- Baseline: 29% to the general 
US adult population; 23% to 
MSM; 11% to IDUs and 36% to 
HRH  
- Optimised: entire budget 
allocated to the MSM, IDU and 
HHR (51%, 11% and 38% 
respectively) 
Allocation by intervention 
(counselling+testing) and race 
ethnicity: 
Limitations identified 
by author:  
-An underlying 
assumption of the 
model is that 
interventions can be 
scaled up to effectively 
reach 100% of the 
target population. 
However, some 
individuals in high-risk 
populations may be 
more difficult and 
therefore more costly 
to reach  
- The cost of 
antiretroviral treatment 
and variation in the risk 
of transmission per sex 
act according to viral 
load are not considered 
in the model. Since 
early diagnosis and 
treatment reduces HIV 
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Study details Population and 
setting 
Intervention/comparator Outcomes and methods 
of analysis 
Results Notes 
-Cycle 6 (2002) of 
the National Survey 
of Family Growth 
(NSFG), Division of 
HIV/AIDS 
-Prevention (DHAP) 
data, other 
previously 
published studies 
and assumptions 
 
cost of testing in outreach 
settings 
Time horizon: Five years 
Costing year(s) and 
currency: 2009 USD 
Discount rates: 
Apparently not used; 
results were presented as 
undiscounted values 
Perspective: CDC 
Measures of uncertainty: 
Univariate sensitivity 
analysis function  
Modelling method:  
- HIV resource allocation 
model  
- Dynamic compartmental 
model: epidemic model  
- Optimisation model 
- Baseline: 32% for blacks, 
17% Hispanics and 22% others 
- Optimised: 36% for blacks; 
29% for Hispanics and 35% 
others 
Allocation to counselling and 
education by serostatus:  
- Baseline: 11% of the budget 
targeted for diagnosed 
positives and 89% for those 
susceptible 
- Optimised: 100% of the 
budget targeted for diagnosed 
positives 
* current baseline and the 
optimal allocation of funds 
can be considered cost-saving 
when compared to the HIV 
lifetime treatment costs 
Secondary analysis: 
Incremental Budget 
Constraint Scenario (from 
£66.3 million ($100 million) to 
£331.5 million ($500 million) 
By intervention: 
transmission, the 
benefits of HIV 
diagnoses may be 
underestimated. This 
may mean that a 
greater focus on testing 
may be warranted  
- For most interventions 
considered, the cost per 
person was derived 
using a microcosting 
approach which does 
not take into account 
the higher level 
management and 
administrative costs 
associated with 
allocating and 
channelling funds  
Limitations identified 
by review team: Time 
horizon too short to 
account for all benefits 
generated by reduction 
in infection 
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Study details Population and 
setting 
Intervention/comparator Outcomes and methods 
of analysis 
Results Notes 
- At £66.3 million ($100 
million), the budget is 
allocated to testing only but 
as the budget increases, more 
funds are allocated to 
counselling and education 
interventions  
- At a budget of £331.5 
million ($500 million) more 
funds are allocated to 
counselling and education 
interventions than to testing 
By risk group: 
- At £66.3 million ($100 
million), 84% of the budget is 
allocated to MSM and the 
remainder to IDUs; as the 
budget increases, more funds 
are allocated to all three risk 
groups 
- At a budget of £331.5 
million ($500 million) the 
proportion of funds allocated 
to MSM, IDUs and HRH is 55%, 
16% and 29% respectively 
Evidence gaps and/or 
recommendations for 
future research: Future 
research could include 
an assessment of 
reduction in number of 
complications of HIV, 
taking into account 
levels of CD4 and 
effects on lifetime costs 
and health outcomes 
Source of funding: No 
support or funding 
reported 
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Study details Population and 
setting 
Intervention/comparator Outcomes and methods 
of analysis 
Results Notes 
New infections: The marginal 
infections averted decrease 
from 38,506 to 5,906 and 
represent the reduction in 
HIV incidence for each 
additional £66.3 million ($100 
million) made available in the 
annual budget 
Sensitivity analysis: Of over 
100 sensitivity analysis 
scenarios conducted, only 9 
scenarios altered the key 
results 
Marseille et al. 
(2011) 
Aim of study: To 
reports the cost-
effectiveness of 
the demonstration 
sites. It addresses 
the following 
questions:  
1. What were the 
total and unit 
costs over the 3 
years of the 
Source 
populations: HIV-
infected patients 
seen in clinical 
settings: All 
patients (including 
new and returning 
patients); Male 
patients reporting 
sexual activity with 
other males in the 
last 6 months; All 
returning patients; 
Intervention description: 
Counselling based 
interventions: 
- Primary care provider-based 
(clinical provider): brief risk 
assessments administered by 
computer to patients in 
private while they waited for 
their medical appointments. It 
was based on proven effective 
health behaviour change 
theories that helped clinicians 
to identify the best points of 
Outcomes: Unit costs for 
each of the intervention 
types; average cost per 
dose-minute of service; 
HIV infections averted 
Time horizon: 3 years 
Costing year(s) and 
currency: 2010 USD 
Discount rates: not clear 
Perspective: Healthcare 
system 
Primary analysis: 
Total average costs: 
- Clinical provider: £98,601 
($146,075) 
- Specialist: £228,070 
($337,881) 
- Mixed: £181,515 ($268,911) 
- Total costs for all 13 sites: 
£2,473,197 ($3,663,995) 
Average cost/dose-minute of 
service: 
Limitations identified 
by author:  
- Because the site was 
the unit of analysis, our 
sample was too small to 
yield definitive results 
- assessing the cost of 
prevention with positive 
(PWP) activities 
required the allocation 
of expenditures across 
the categories, direct 
services, training, 
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Study details Population and 
setting 
Intervention/comparator Outcomes and methods 
of analysis 
Results Notes 
demonstration 
project and how 
did costs vary 
across the three 
intervention types?  
2. What was the 
cost-effectiveness 
of the Services 
Administration’s 
Special Projects of 
National 
Significance (SPNS) 
demonstration 
project considered 
as a whole?  
3. What was the 
incremental cost-
effectiveness 
among the three 
intervention types?  
Secondarily, to 
understand the 
specific cost 
elements that 
accounted for 
variations in unit 
All men who have 
sex with men 
(MSM) patients; 
Patients diagnosed 
with HIV for at 
least 3 months; 
Patients older than 
age 45 years 
reporting 
unprotected sex in 
the last 12 months; 
Patients reporting 
sexual activity or 
drug use in the last 
3 months; Female 
patients; Patients 
reporting risk in 
the last 6 months; 
Patients with sex 
or drug risk in the 
last 6 months; 
Patients reporting 
sexual activity or 
IDU in last 6 
months 
Setting: USA:  
intervention with brief 
counselling sessions for a 
particular patient  
- social worker or peer 
educator-based (specialist): 
one-on-one client-oriented 
sessions, group session or a 
combination. Individual 
sessions were led by either 
social workers or trained HIV-
infected peer interventionists. 
Group sessions were usually 
co-led by a social worker and 
peers  
- mix of primary care and 
specialist-based (mixed): 
Interventions using both 
strategies, provider-delivered 
and specialist-delivered 
interventions 
Comparator/control 
description: Standard care  
Sample sizes: 
Clinical provider: 768  
Specialist: 975 
Measures of uncertainty: 
Multivariate sensitivity 
analyses, Monte Carlo 
simulation, threshold 
analysis, scenario analysis 
Modelling method: 
Computer-based epidemic 
model of HIV transmission  
- Clinical provider: £11.79 
($17.46) 
- Specialist: £4.97 ($7.37) 
- Mixed: £9.30 ($13.78) 
HIV cases averted: 
- Clinical provider: 2.71 
- Specialist: 1.11 
- Mixed: 3.02 
Cost-effectiveness ($ per HIV 
case averted): 
- Clinical provider x standard 
of care: £72,668 ($107,656) 
- Clinical provider x mixed: 
Clinical provider sites 
dominate 
- Clinical provider x 
specialist: Clinical provider 
sites dominate 
- All sites combined x 
standard of care: 361,653 
($535,782) 
Secondary analysis: None 
Sensitivity analysis:  
research and 
administration/ 
overhead. These 
allocations were not 
based on standard or 
pre-existing accounting 
templates and 
therefore required 
personal judgement by 
staff members. 
Although we reviewed 
and discussed the 
allocations and their 
rationales carefully, 
this method is 
imperfect. However, 
most of the potential 
misallocations do not 
affect our primary 
results 
- Misallocations 
between PWP and non-
PWP activities at the 
same sites would affect 
the accuracy of our 
results, but these are 
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Study details Population and 
setting 
Intervention/comparator Outcomes and methods 
of analysis 
Results Notes 
cost and the 
relationship 
between 
programme scale 
and unit costs 
Type of economic 
analysis: Cost-
effectiveness 
Economic 
perspective: 
Healthcare system 
Quality score: 
High 
Applicability: 
Directly applicable 
-Medical care 
provider only: 
Johns Hopkins 
University, 
Baltimore, 
University of 
Alabama 
Birmingham 
-HIV specialist 
only: El Rio/Special 
Immunology Health 
Center, Tucson; St. 
Luke’s Roosevelt 
Hospital, New 
York; University of 
Washington, 
Seattle; Fenway 
Community Health 
Center, Boston; Mt. 
Sinai Hospital, 
Chicago, University 
of Miami 
-Medical care 
provider and HIV 
specialist: DeKalb 
County Board of 
Mixed: 758  
Standard care: 1,055 
 
Monte Carlo simulation:  
- With 50,000 trials, the cost-
effectiveness of the clinical 
provider sites at the 80% 
confidence level varied from 
£53,900 ($79,852) to £99,500 
($147,482) using beta 
distributions for the three 
variables and from £39,492 
($58,507) to £139,596 
($206,809) using uniform 
distributions (both under the 
threshold of £204,593 
($303,100)) 
- Considering the average 
cost-effectiveness of all sites, 
cost-effectiveness ranges 
from £268,890 ($398,355) to 
£503,675 ($746,185) (beta) 
and from £197,049 ($291,925) 
to £710,947 ($1,053,255) 
(uniform). The low end of the 
range using uniform 
distributions is thus just on 
the favourable side of the 
threshold 
unlikely to have 
occurred to a significant 
degree because 
accounting reports were 
required by Health 
Resources and Services 
Administration to track 
PWP expenditures and 
because intervention 
staff can readily 
distinguish between 
these two types of 
activities 
- Estimates of 
intervention effect are 
based on self-reported 
changes in behaviour. 
Although these methods 
are standard in low-
prevalence settings, 
they contain potential 
for social desirability 
bias, which may inflate 
the estimates of 
intervention benefit 
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Study details Population and 
setting 
Intervention/comparator Outcomes and methods 
of analysis 
Results Notes 
Health, Decatur; 
Drexel University, 
Philadelphia; 
University of 
California San 
Diego, Owen Clinic; 
University of 
California, Davis; 
University of North 
Carolina, Chapel 
Hill 
Data sources:  
Annual costs: 
Intervention 
expenditure 
records 
Number of clients 
served in each 
programme year: 
Standardised 
reporting 
documents 
required by the 
Health Resources 
and Services 
Administration 
Multivariable threshold 
analysis: 
- even if programme 
effectiveness was only 50% of 
that found, costs could also 
rise by almost 50% before the 
clinical provider interventions 
stopped being cost-effective 
compared with no 
intervention 
Scenario analysis using only 
sites showing benefit: 
- Four sites exhibited 
increased risky behaviour and 
thus had ‘negative benefits’. 
Two of these were specialist 
and two were mixed sites. If 
these sites are disregarded, 
the incremental cost-
effectiveness ratio of mixed 
versus provider is £661,457 
$979,936 per case averted. In 
this scenario, both provider 
and mixed dominate 
specialist 
- It was assumed that 
all averted infections 
are truly averted, not 
merely postponed. 
Estimating the portion 
of cases that are 
postponed is rarely 
done in the assessment 
of HIV interventions. 
Obtaining a precise 
estimate requires a 
number of assumptions 
about the evolution of 
partners’ risk profiles 
- Estimates of risk 
reduction are limited to 
patients who 
participated in the 
interventions and do 
not estimate the effects 
on the community 
Limitations identified 
by review team: Time 
horizon too short to 
account for all benefits 
associated with the 
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Study details Population and 
setting 
Intervention/comparator Outcomes and methods 
of analysis 
Results Notes 
Costs: Standard 
cost data 
collection protocol 
and accompanying 
manual 
reduction in risk 
transmission 
Evidence gaps and/or 
recommendations for 
future research: Future 
research could include 
an assessment of 
reduction in number of 
complications of HIV 
taking into account 
levels of CD4 and 
effects on lifetime costs 
and health outcomes 
Source of funding: This 
publication is supported 
by grant number 5 H97 
HA00261 from the 
Health Resources and 
Services Administration 
(HRSA) Special Projects 
of National Significance 
(SPNS) Program 
Pilgrim et al. 
(2010) 
Aim of study: To 
assess the cost-
Source 
populations:  
1. Young people 
aged 14-16 years 
Intervention description: 
1. School-based dispensing of 
hormonal contraceptives 
within the school (DH); school-
Primary outcome: Cost 
per age pregnancies 
averted, cost per 
abortions averted 
Primary analysis:  
Model 1: Deterministic 
results (discounted): 
Limitations identified 
by author:  
- There are several key 
structural uncertainties 
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Study details Population and 
setting 
Intervention/comparator Outcomes and methods 
of analysis 
Results Notes 
effectiveness of a 
range of 
interventions to 
encourage young 
people, especially 
socially 
disadvantaged 
young people, to 
use contraceptives 
or contraceptive 
services 
Type of economic 
analysis: Cost-
effectiveness 
Economic 
perspective: 
Public sector 
Quality score: 
Medium 
Applicability: 
Partly applicable 
 
who have not 
previously been a 
parent (but who 
may or may not 
have been 
pregnant without 
carrying to term) 
within secondary 
school 
2. Young mothers 
within a secondary 
school 
3. Young people 
aged 15–19 years 
who are sexually 
active 
Setting: UK 
Data sources:  
Probability of 
abortion and birth: 
National 
government 
statistics for 
England and Wales 
based dispensing of condoms 
(DC)  
2. Intensive case management 
to prevent repeat pregnancy 
(this involves a culturally 
matched school-based social 
worker, including home visits, 
weekly school-based peer 
education support and 
comprehensive medical care 
including contraception) (ICM) 
3. Advance provision of 
emergency hormonal 
contraception (AP) 
Comparator/control 
description:  
1. School nurse only (ND) 
2. No follow-up following first 
pregnancy 
3. No advance provision of 
EHC (No AP) 
Sample sizes: Simulated 
cohort of 100,000 young 
individuals 
Secondary outcomes: Cost 
of the intervention and 
additional contraception 
required as a result of the 
intervention; cost of 
maternity care; cost of 
abortion; cost of 
miscarriage/ ectopic 
pregnancy/ stillbirth; cost 
of treatment for low birth 
weight babies; cost of 
treatment of STIs; cost of 
government-funded 
benefits  
Time horizon: Lifetime 
Costing year(s) and 
currency: 2007-2008 GBP 
Discount rates: 3.5% 
Perspective: Public 
sector 
Measures of uncertainty: 
One-way and probabilistic 
sensitivity analysis 
Modelling method: Cost-
effectiveness modelling 
Total cost (billions): 
- ND: £1,527 
- DC: £1,519 
- DH: £1,417 
Cost per abortion averted: 
- DC: £815 
- DH: £1,514 (compared with 
DC) 
Cost per pregnancy averted 
(excluding benefits): 
- DC: £32 
- DH: £441 (compared with 
DC) 
Cost per pregnancy averted 
(including benefits): 
- DN: dominated by DC 
- DC: dominated by DH 
- DH: dominates DC and ND 
Model 2: Deterministic 
results (discounted) 
Total costs (millions): 
- no follow-up: £655,572 
- ICM: £705,730 
within the model which 
it was not feasible to 
assess within the PSA 
and these key 
uncertainties are likely 
to underestimate rather 
than overestimate the 
effectiveness of the 
interventions; this 
suggests that cost-
effectiveness ratios are 
more likely to be 
overestimated than 
underestimated 
- There are a large 
number of uncertainties 
within the model due to 
a paucity of evidence 
- The effectiveness 
evidence generally 
reports the percentage 
of young people either 
using contraceptives or 
becoming pregnant over 
a relatively short period 
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Study details Population and 
setting 
Intervention/comparator Outcomes and methods 
of analysis 
Results Notes 
Probability of 
miscarriage and 
ectopic pregnancy: 
Hospital Episode 
Statistics (HES); a 
Denmark study was 
used to 
parameterise the 
miscarriage rates  
Long term 
outcomes of a 
teenage birth: 
Literature review 
including only UK 
papers and 
elicitation 
technique with 
programme 
development group 
(PDG) at NICE 
Sexually 
transmitted 
infection (STI) 
outcomes: NICE Sex 
and Relationship 
Education (SRE) 
study with a hypothetical 
cohort of 100,000 young 
people over a lifetime 
from the age at which the 
intervention is provided; 
the following scenarios 
were modelled:  
1. School-based 
interventions for 
nulliparous young people 
2. School-based 
interventions to prevent 
repeat pregnancy 
3. Interventions to 
encourage the use of 
emergency hormonal 
contraception following 
unprotected sex 
Cost per repeat teenage 
pregnancy averted (excluding 
benefits): ICM: £15,155 
Cost per repeat teenage 
pregnancy averted (including 
benefits): ICM: £4.031 
Model 3: Deterministic 
results (Discounted) 
Total cost (billions): 
- no AP: £1,524 
- AP: £1,447 
Cost per abortion averted: 
AP: £2,795 
Cost per age pregnancy 
averted: AP (excluding 
benefits): £310 
Cost per age pregnancy 
averted: AP (including 
benefits) dominates 
Secondary analysis:  
Model 1: Expected results 
(discounted) 
Total cost (billions): 
- DN: £1,524 
- The evidence around 
the long-term outcomes 
of a teenage birth is 
varied in terms of 
quality and results, 
leading to considerable 
uncertainty around the 
negative consequences 
of teenage births 
- Limited evidence 
exists around the 
outcomes of the child 
of a teenage birth, 
adjusting for the 
characteristics which 
might predispose a 
woman to teenage birth 
- It was not feasible to 
express model 
outcomes in terms of a 
measure which would 
enable comparisons of 
the cost-effectiveness 
of interventions across 
different health topics/ 
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Study details Population and 
setting 
Intervention/comparator Outcomes and methods 
of analysis 
Results Notes 
public health 
guidance  
Effectiveness: 
National statistics 
and assumptions 
Benefits: Office for 
National Statistics 
(ONS, 2009), 
previous published 
studies, 
assumptions 
Costs: British 
National Formulary 
(BNF 58, 2009), 
NICE assessment of 
LARCs, health 
economic model 
developed for the 
NICE Sex and 
Relationship 
Education (SRE) 
public health 
guidance, NHS 
reference costs 
- DC: £1,517 
- DH: £1,515 
Cost per abortion averted: 
- DC: £822 
- DH: £1,495 (compared with 
DC) 
Cost per pregnancy averted 
(excluding benefits): 
- DC: £38 
- DH: £443 (compared with 
DC) 
Cost per pregnancy averted 
(including benefits): 
- DN: dominated by DC 
- DC: dominated by DH 
- DH: dominates DC and ND 
Model 1: Expected results 
(undiscounted): 
Total cost (billions): 
- DN: £2,307 
- DC: £2,297 
- DH: £2,295 
Cost per abortion averted: 
diseases such as the 
QALY 
- the health economic 
model does not capture 
the variability between 
young people 
- The comparison within 
Model 1 is highly 
dependent upon the 
true effectiveness of 
each method of 
contraception 
- Research comparing 
the cost-effectiveness 
of different methods of 
contraception in terms 
of both STIs and 
contraception is sparse 
due to the limitations 
around which outcome 
measure can reasonably 
capture both effects. 
- the cost of maternity 
services may differ for 
teenage mothers 
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Study details Population and 
setting 
Intervention/comparator Outcomes and methods 
of analysis 
Results Notes 
- DC: £848 
- DH: £1,535 (compared with 
DC) 
Cost per pregnancy averted 
(excluding benefits): 
- DC: £92 
- DH: £488 (compared with 
DC) 
Cost per pregnancy averted 
(including benefits): 
- DN: dominated by DC 
- DC: dominated by DH 
- DH: dominates DC and ND 
Model 2: Expected results 
(discounted) 
Total cost (millions): 
- No follow-up: £654,756 
- ICM: £705,164 
Cost per repeat teenage 
pregnancy averted (excluding 
benefits): ICM: £15,175 
compared with older 
mothers 
Limitations identified 
by review team:  
- Authors stated that no 
preterm births were 
assessed, which may be 
more common amongst 
young people 
- Other adverse events 
associated with teen 
pregnancy, such as 
fistula, were not 
mentioned 
Evidence gaps and/or 
recommendations for 
future research: 
Modelling was based on 
previous model (NICE), 
but no mention about 
calibration of the 
model, e.g., tuning of 
probabilities or 
parameters that have 
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Study details Population and 
setting 
Intervention/comparator Outcomes and methods 
of analysis 
Results Notes 
Cost per repeat teenage 
pregnancy averted (including 
benefits): ICM: £4,052 
Model 2: Expected results 
(undiscounted): 
Total cost (millions): 
- No follow-up: £825,978 
- ICM: £866,883 
Cost per repeat teenage 
pregnancy averted (excluding 
benefits): ICM: £15,186 
Cost per repeat teenage 
pregnancy averted (including 
benefits): ICM: £2,935 
Model 3: Expected results 
(discounted):  
Total cost (billions): 
- No AP: £1,522 
- AP: £1,445 
Cost per abortion averted: 
AP: £2,803 
Cost per age pregnancy 
averted: AP (excluding 
benefits): £314 
caused uncertainties in 
previous models 
Source of funding: Not 
declared 
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Study details Population and 
setting 
Intervention/comparator Outcomes and methods 
of analysis 
Results Notes 
Cost per age pregnancy 
averted: AP (including 
benefits) dominates 
Model 3: Expected results 
(undiscounted)  
Total cost (billions): 
- No AP: £2,303 
- AP: £2,198 
Cost per abortion averted: 
AP: £2,948 
Cost per age pregnancy 
averted: AP (excluding 
benefits): £395 
Cost per age pregnancy 
averted: AP (including 
benefits) dominates 
Sensitivity analysis:  
Model 1 
PSA: 
The analysis shows very little 
difference in both costs and 
effectiveness between 
dispensing condoms within 
schools and dispensing 
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Study details Population and 
setting 
Intervention/comparator Outcomes and methods 
of analysis 
Results Notes 
hormonal contraceptives 
within schools. There is the 
possibility that either one 
could be more effective 
and/or more costly than the 
other  
One-way: 
-Delay in births averted (14-
16 years to 17-19 years): (1) 
DC would remain cost saving 
compared with ND for the 
cost per age 14–16 pregnancy 
averted including 
government-funded benefits; 
(2) DH would remain cost 
saving compared with DC 
within schools for this 
outcome  
- Pregnancies averted at ages 
14 – 16 years would have been 
additional: cost-effectiveness 
ratio for the cost per abortion 
averted decreases 
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Study details Population and 
setting 
Intervention/comparator Outcomes and methods 
of analysis 
Results Notes 
- Probability of condom 
failure is doubled: DC results 
in greater net costs than DH 
- Doubled risk of miscarriage: 
DC is estimated to result in 
net cost savings compared 
with ND 
- Increase in medical 
abortions: net cost savings of 
DC compared with ND 
- Increase in relative risk of 
both interventions: higher 
cost-effectiveness ratios than 
predicted within the base 
case analysis 
Model 2 
PSA: 
- ICM is unlikely to result in 
net cost savings when 
excluding benefit payments 
- There is around a 20% 
probability that ICM will 
result in net cost savings 
when including government-
funded benefits compared 
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Study details Population and 
setting 
Intervention/comparator Outcomes and methods 
of analysis 
Results Notes 
with no follow-up after first 
teenage pregnancy 
One way: 
- Reducing cost of 
intervention: results in a cost 
per repeat teenage pregnancy 
averted excluding benefits of 
£6,844 
- Including benefits: ICM will 
dominate no follow-up after a 
teenage birth 
- Other variations do not have 
substantial impact upon the 
model results 
Model 3 
PSA: 
- AP is unlikely to result in 
net cost savings using the cost 
per abortion averted outcome 
- There is around a 24% 
probability AP will result in 
net cost savings when using 
the cost per age 15–19 
pregnancy averted outcome 
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Study details Population and 
setting 
Intervention/comparator Outcomes and methods 
of analysis 
Results Notes 
and benefit payments are 
excluded from the analysis 
- AP is likely to be cost saving 
using a cost per age 15–19 
pregnancy averted outcome 
when benefit payments are 
included 
One way: 
- Increasing the baseline 
usage of EHC following 
unprotected sex: AP 
dominates including and 
excluding government-funded 
benefit payments; estimated 
cost per abortion averted 
associated with AP decreases 
to £688 
- Other variations do not have 
substantial impact upon the 
model results 
Ruger et al. 
(2014) 
Aim of study: To 
assesses cost-
effectiveness of 
Source 
populations: Drug-
using women 
(cocaine, heroin, 
amphetamines or 
Intervention description:  
- WWE – standard intervention 
(SI) and a field-based well 
woman examination (WWE): SI 
+ breast and routine pelvic 
Outcomes: Total number 
of primary and secondary 
infections prevented by 
the intervention; cost of 
achieving an additional 
Primary analysis: 
Randomised controlled trial 
results: 
Baseline for HIV: 
-SI x WWE: WWE dominated 
Limitations identified 
by author:  
Statistical analysis: 
- Bernoullian model 
predicting infection 
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Study details Population and 
setting 
Intervention/comparator Outcomes and methods 
of analysis 
Results Notes 
behavioural 
interventions for 
reducing HIV and 
STDs infections 
among injection 
drug-using women 
Type of economic 
analysis: Cost-
effectiveness and 
cost-utility 
Economic 
perspective: 
Societal and 
provider 
Quality score: 
High 
Applicability:  
Directly applicable 
other injection 
drug use), age 18 
or older and sexual 
activity in the prior 
4 months 
Setting: St. Louis 
area residency, 
USA 
Data sources:  
Cost: Previous 
study developing a 
microcosting 
methodology and 
conducting cost 
analyses  
Effectiveness: 
randomised trial 
and literature 
 
examination with cervical 
cytological testing (Pap smear) 
provided by a nurse 
practitioner, who also 
obtained a short medical 
history  
- 4ES - SI, WWE, plus four 
educational sessions (4ES): SI + 
WWE + 4ES delivered by a peer 
facilitator paired with a health 
professional, based on the 
Health Belief Model. The 
facilitator used a holistic 
approach emphasising 
substance abuse, HIV/AIDS, 
health and nutrition, and 
stress and coping 
Comparator/control 
description: SI - modified 
National Institute on Drug 
Abuse (NIDA) cooperative 
agreement standard 
intervention: 20 minutes of 
HIV pre-test counselling, blood 
collection and the NIDA SI; and 
unit of outcome 
compared to the next 
least costly intervention; 
the cost per additional 
QALY saved 
Time horizon: Trial - 12 
months; model – lifetime  
Costing year(s) and 
currency: 2003 USD 
Discount rates: Only 
QALYs were discounted at 
3% 
Perspective: Societal and 
provider 
Measures of uncertainty: 
One-way, bivariate and 
multivariate sensitivity 
analyses, acceptability 
curves 
Modelling method: 
Bernoullian mathematical 
model estimates of 
infections averted 
-WWE x 4ES: 4ES cost-
effective and cost-saving: 
£62,098 ($94,230) per 
additional infection averted 
STDs total: 
-SI x WWE: WWE dominated 
-WWE x 4ES: 4ES cost-
effective: £5,509 ($8,359) per 
additional infection averted 
Hepatitis C: 
-SI x WWE: WWE cost-
effective and cost-saving: 
£72,034 ($109,308) per 
additional infection averted 
and £27,996 ($42,482) per 
additional QALY saved 
-WWE x 4ES: 4ES dominated 
Syphilis: 
-SI x WWE: WWE dominated 
-WWE x 4ES: 4ES cost-
effective: £28,838 ($43,760) 
per additional infected 
averted 
Chlamydia:  
rates based on sexual 
conduct assumes 
independence 
- Nesting of overlapping 
partners was not 
considered 
- The number of 
partners used in 
predicting secondary 
infections is based on 
participants’ number of 
partners 
Study: 
- Its location in a single 
urban centre limits its 
generalisability 
- data constraints 
prevented incorporating 
future costs, except for 
those from the 
literature included in 
the Bernoullian model 
(e.g. lifetime HIV and 
STD treatment costs), 
suggesting an 
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Study details Population and 
setting 
Intervention/comparator Outcomes and methods 
of analysis 
Results Notes 
2 weeks later, test results and 
HIV post-test counselling 
Sample sizes:  
SI = 144 
WWE = 153 
4ES = 157 
Total = 454 
-SI x WWE: WWE dominated 
-WWE x 4ES: 4ES cost-
effective and cost saving: 
£19,530 ($29,636) per 
additional infection averted 
and £ 2,273,217 ($3,449,495) 
per additional QALY saved 
Gonorrhoea:  
-SI x WWE: WWE cost-
effective and cost saving: 
£6,235 ($9,461) per additional 
infection averted and 
£706,949 ($1,072,760) per 
additional QALY 
-WWE x 4ES: 4ES dominated 
Secondary analysis: 
Bernoullian model results 
HIV primary: 
-SI x WWE: WWE cost-
effective and cost-saving: 
£137,280 ($208,316) per 
additional infection averted 
-WWE x 4ES: 4ES dominated 
HIV total: 
underestimation of the 
intervention’s results 
- by focusing on HIV and 
STD prevention and 
substance abuse, the 
intervention 
incorporated significant 
interactions, but might 
have sacrificed the 
clarity possible in 
studying HIV and/or 
STDs exclusively 
- the model results 
were highly sensitive to 
input parameters, 
especially prevalence 
and transmission 
probability 
- baseline assessment 
determined STD 
prevalence, which may 
underestimate the 
prevalence among 
partners because the 
participants were all 
HIV-negative, 
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Study details Population and 
setting 
Intervention/comparator Outcomes and methods 
of analysis 
Results Notes 
-SI x WWE: WWE cost-
effective and cost-saving: 
£33,460 ($50,774) per 
additional infection averted 
-WWE x 4ES: 4ES dominated 
Hepatitis C: 
-SI x WWE: WWE cost-
effective and cost-saving: 
£3,965 ($6,016) per additional 
infection averted 
-WWE x 4ES: 4ES dominated 
Syphilis: 
-SI x WWE: WWE cost-
effective: £11,257 ($17,082) 
per additional infection 
averted 
-WWE x 4ES: 4ES dominated 
Chlamydia: 
-SI x WWE: WWE cost-
effective and cost-saving: 
£113,548 ($172,303) per 
additional infection averted 
and £13,334,149 
suggesting they have 
fewer STDs than their 
peers 
- QALY measures and 
their estimation have 
many disadvantages 
when used for health 
policy evaluation 
Limitations identified 
by review team: Main 
limitations identified by 
the authors 
Evidence gaps and/or 
recommendations for 
future research: 
Complications of STIs 
could be explored in to 
the model 
Source of funding: -
National Institutes of 
Health (NIH) (National 
Institute on Drug Abuse 
(NIDA) Grant 
R01DA11622, and 
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Study details Population and 
setting 
Intervention/comparator Outcomes and methods 
of analysis 
Results Notes 
($20,233,913) per additional 
QALY saved 
-WWE x 4ES: 4ES dominated 
Gonorrhoea: 
-SI x WWE: WWE cost-
effective and cost-saving: 
£9,255 ($14,044) per 
additional infection averted 
and £1,062,241 ($1,611,898) 
per additional QALY saved 
-WWE x 4ES: 4ES dominated 
Sensitivity analysis:  
One-way  
Trial results:  
- WWE and 4ES sensitive to 
small effectiveness changes in 
preventing hepatitis C  
- WWE is sensitive for HIV and 
syphilis and very robust for 
chlamydia and gonorrhoea 
- 4ES is robust for other 
diseases (except hepatitis C) 
Bernoullian model: 
K01DA01635810 to 
J.P.R.) 
- the Patrick and 
Catherine Weldon 
Donaghue Medical 
Research Foundation 
(Grant DF06-112 to 
J.P.R.) 
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Study details Population and 
setting 
Intervention/comparator Outcomes and methods 
of analysis 
Results Notes 
- Model HIV results require 
large changes in effectiveness 
to show domination for WWE 
and to relieve domination for 
4ES 
Bi- and multivariate: 
WWE is cost-effective or cost-
saving relative to SI in all 
model scenarios 
Acceptability curves: 
-Preventing total STD:  
-WWE x 4ES: WWE has a 0.80 
probability at £19,770 
($30,000) 
 -WWE x SI: WWE less than 
0.20 probability  
Preventing hepatitis C: The 
probabilities of being cost-
effective are considerably 
higher for WWE than 4ES, but 
at £13,180 ($20,000), the two 
curves begin to report 
increasingly similar 
probabilities 
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Study details Population and 
setting 
Intervention/comparator Outcomes and methods 
of analysis 
Results Notes 
Sanders et al. 
(2010) 
Aim of study: To 
examine the costs 
and benefits of 
strategies to 
improve HIV 
testing and receipt 
of results 
Type of economic 
analysis: Cost-
effectiveness 
Economic 
perspective: 
Insurer and patient 
Quality score: 
Medium 
Applicability: 
Partly applicable 
Source 
populations: 
Patients from two 
Departments of 
Veterans Affairs in 
California, aged 
18–65 years, with 
unknown HIV status 
Setting: USA/ 
Southern California 
Data sources:  
Costs: Centres for 
Medicare and 
Medicaid (CMS) 
reimbursement 
rates for the VA, 
Abbott 
Laboratories, 
earlier analysis, 
Bureau of Labour 
Statistics 
Others: 
Randomised 
clinical trial, ‘high-
quality published 
literature’ (quality 
Intervention description:  
-Model B = nurse-initiated 
routine screening with 
traditional HIV testing and 
counselling  
-Model C = nurse-initiated 
routine screening with rapid 
HIV testing and streamlined 
counselling 
Comparator/control 
description: Model A = 
traditional HIV counselling and 
testing 
Sample sizes: Total: 251 
Outcomes: Life-years, 
QALYs, costs and 
incremental cost-
effectiveness (cost/QALY) 
Time horizon: Lifetime 
Costing year(s) and 
currency: 2007 USD 
Discount rates: 3% 
Perspective: Insurer and 
patient (although authors 
assumed the perspective 
as societal) 
Measures of uncertainty: 
One-way, multi-way and 
probabilistic sensitivity 
analyses 
Modelling method: 
Adapted Markov model 
Primary analysis: 
Benefits to partners 
excluded: 
Model B (compared to Model 
A): Incremental cost-
effectiveness (cost/QALY): 
extended dominance 
Model C (compared to Model 
A): Incremental cost-
effectiveness (cost/QALY): 
£23,472 ($36,390) 
Benefits to partners 
included: 
Model B (compared to Model 
A): 
- Incremental cost-
effectiveness (cost/QALY): 
extended dominance 
Model C (compared to Model 
A): 
- Incremental cost-
effectiveness (cost/QALY): 
£6,876 ($10,660) 
Secondary analysis:  
Limitations identified 
by author:  
- The trial was 
performed in Veterans 
Affairs (VA) primary and 
urgent care settings, 
which have different 
patient populations 
than many primary or 
urgent care practices 
- The requirements for 
follow-up may have 
discouraged some 
patients from 
participating. Thus, the 
implications for 
implementation of 
screening outside a trial 
are not known 
- The VA populations 
studied do not reflect 
the distributions or the 
risk groups in some 
other populations or 
settings 
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Study details Population and 
setting 
Intervention/comparator Outcomes and methods 
of analysis 
Results Notes 
criteria not 
reported) and 
expert clinical 
judgement 
Benefits to partners 
excluded: 
Model A: 
- Lifetime costs: £31,379 
($48,650)  
- Life years (LY): 18.8330 
- QALY: 16.2714 
Model B: 
- Lifetime costs: £31,418 
($48,710) 
- Incremental costs: £34 ($53) 
- Life years (LY): 18.8348 
- Incremental life years: 
0.0018 
- Incremental cost-
effectiveness (LY): Extended 
dominance 
- QALY: 16.2727 
- Incremental QALY: 0.0013 
- Increase in life expectancy: 
0.64 years  
- Quality-adjusted life 
expectancy (QALE): 0.47 
Limitations identified 
by review team:  
- Complications 
associated with HIV 
were not included  
- Costs were modelled 
based on 
reimbursement costs 
not real costs, which 
may have an influence 
on the final results 
(costs maybe either 
under- or over-
estimated) 
Evidence gaps and/or 
recommendations for 
future research: It was 
not clear if 
interventions would 
have lifetime effects on 
complications 
depending on levels of 
CD4 
Source of funding: 
Department of Veterans 
Affairs Health Services 
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Study details Population and 
setting 
Intervention/comparator Outcomes and methods 
of analysis 
Results Notes 
Model C: 
- Lifetime costs: £31,424 
($48,720) 
- Incremental costs: £8 ($13) 
- Life years (LY): 18.8355 
- Incremental life years: 
0.0007 
- Incremental cost-
effectiveness (LY): £17,228 
($26,710) 
- QALY: 16.2732 
- Incremental QALY: 0.0005 
- Increase in life expectancy: 
0.87 years  
- QALE: 0.63 
Benefits to partners 
included: 
Model A: 
- Lifetime costs: £31,631 
($49,040) 
- Life years (LY): 18.8153 
- QALY: 16.2530 
Model B: 
Research and 
Development Service 
and the National 
Institute on Drug Abuse 
(R01 DA15612-01). Dr 
Bayoumi was supported 
by a career scientist 
award from the Ontario 
HIV Treatment Network 
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Study details Population and 
setting 
Intervention/comparator Outcomes and methods 
of analysis 
Results Notes 
- Lifetime costs: £31,644 
($49,060)  
- Incremental costs: £27 $27 
- Life years (LY): 18.8178  
- Incremental life years: 
0.0025 
- Incremental cost-
effectiveness (LY): Extended 
dominance  
- QALY: 16.2551  
- Incremental QALY: 0.0021  
Model C: 
- Lifetime costs: £31,650 
($49,070) 
- Incremental costs: £3 ($4) 
- Life years (LY): 18.8187 
- Incremental life years: 
0.0009 
- Incremental cost-
effectiveness (LY): £5,960 
($9,240) 
- QALY: 16.2559 
- Incremental QALY: 0.0008 
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Study details Population and 
setting 
Intervention/comparator Outcomes and methods 
of analysis 
Results Notes 
Sensitivity analysis:  
- Varying prevalence of 
unidentified HIV: cost-
effectiveness of Model C less 
favourable 
- Varying probability of a 
patient receiving an HIV test 
and HIV test acceptance rate: 
cost-effectiveness ratio of 
Model C increases from 
£6,876 ($10,660)/QALY to 
£8,540 ($13,240)/QALY 
- Varying other variables: no 
substantial change in the 
model results 
Schackman et al. 
(2013) 
Aim of study: To 
project the life 
expectancy gains, 
costs, and cost-
effectiveness of 
HIV testing 
strategies 
(evaluated in a 
Source 
populations: 
Substance abuse 
treatment 
programme users 
(12 community-
based substance 
abuse treatment 
programmes) 
Setting: USA 
Intervention description:  
1. Referral for off-site HIV 
testing 
2. Offer of an on-site rapid HIV 
test with information that 
describes the testing 
procedure but no counselling 
about risk behaviours 
3. Brief participant-tailored 
risk-reduction counselling that 
Outcomes: Life 
expectancy, lifetime 
costs and QALYs 
Time horizon: Lifetime 
Costing year(s) and 
currency: 2009 USD 
Discount rates: 3% 
Perspective: Societal  
Measures of uncertainty: 
One-way sensitivity 
Primary analysis: (reference: 
no intervention) 
Offer of off-site test: 
- Cost-effectiveness ratio 
(cost/QALY): dominated 
On-site test + information: 
- Cost-effectiveness ratio 
(cost/QALY): £39,979 
($60,300) 
Limitations identified 
by author:  
- Data were collected in 
a clinical trial 
conducted in 
community-based 
substance abuse 
treatment programmes 
that were diverse, but 
were not representative 
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Study details Population and 
setting 
Intervention/comparator Outcomes and methods 
of analysis 
Results Notes 
trial) to provide 
guidance to policy 
makers and 
substance abuse 
treatment 
programmes 
Type of economic 
analysis: Cost-
effectiveness 
modelling 
Economic 
perspective: 
Societal  
Quality score: 
High  
Applicability: 
Directly applicable 
Data sources: 
QALY: SF-6D data 
derived from a 
national survey of 
HIV infected 
individuals 
Costs: medical 
service utilisation 
data from a 
national cohort and 
national costs  
Population in 
substance abuse 
treatment being 
tested and other 
inputs: The 
National Drug 
Abuse Treatment 
Clinical Trials 
Network (CTN) HIV 
Rapid Testing and 
Counselling Study 
(CTN 0032), 
Multicenter AIDS 
Cohort Study 
(MACS) and 
includes a personalised 
examination of risk focused on 
whatever is salient to the risk 
behaviour of the participant 
and creation of an 
individualised risk-reduction 
plan followed by the offer of 
an on-site rapid HIV test 
Comparator/control 
description: No intervention 
Sample sizes: Total: trial 
population of 1,281 individuals 
analysis (prevalence of 
undiagnosed HIV, CD4 
counts, probability of 
acceptance, costs, HIV 
test frequency, test 
sensitivity and specificity, 
HIV RNA diagnosis for HIV-
infected individuals, ART 
efficacy and costs); 
scenarios analysis 
Modelling method: First-
order state-transition 
Monte Carlo simulation: 
cost-effectiveness of 
Preventing AIDS 
Complications (CEPAC) 
computer simulation 
model 
On-site test + counsel: 
- Cost-effectiveness ratio 
(cost/QALY): dominated 
Secondary analysis:  
Background screen: 
- Undiscounted life 
expectancy per HIV-infected 
person (years): 17.05 
- Cost per HIV infected 
person: £181,671 ($274,013) 
Offer of off-site test: 
- Undiscounted life 
expectancy per HIV-infected 
person (years): 17.85 
- Cost per HIV infected 
person: £196,664 ($296,627) 
- Cost per HIV uninfected 
person: £7 ($11) 
- Incremental cost per 
person: £68 ($102) 
- Incremental QALY per 
person: 0.0016 
On-site test + information: 
of all programmes in 
the US 
- The trial was not 
powered to detect 
prevalence of 
undiagnosed HIV 
- Prevalence of 
undiagnosed HIV may be 
higher in settings where 
there is higher overall 
HIV prevalence and 
fewer substance users 
have been tested 
previously 
- Both the CD4 count at 
diagnosis and the 
frequency of testing 
elsewhere were 
unobserved 
- The model did not 
incorporate future HIV 
transmission behaviour 
- The authors did not 
project future advances 
in HIV care that 
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Study details Population and 
setting 
Intervention/comparator Outcomes and methods 
of analysis 
Results Notes 
published 
literature 
- Undiscounted life 
expectancy per HIV-infected 
person (years): 20.75 
- Cost per HIV infected 
person: £251,361 ($379,126) 
- Cost per HIV uninfected 
person: £27 ($41) 
- Incremental cost per 
person: £239 ($360) 
- Incremental QALY per 
person: 0.0060 
On-site test + counsel: 
- Undiscounted life 
expectancy per HIV-infected 
person (years): 20.52 
- Cost per HIV infected 
person: £247,168 ($372,802) 
- Cost per HIV uninfected 
person: £51 ($77) 
- Incremental cost per 
person: £7 ($11) 
- Incremental QALY per 
person: -0.0005 
improve life expectancy 
nor future gaps in 
treatment that reduce 
life expectancy 
Limitations identified 
by review team: No 
additional comments. 
Authors clearly 
acknowledge main 
limitations 
Evidence gaps and/or 
recommendations for 
future research: 
Authors could explore 
some of their 
limitations in future 
research 
Source of funding: This 
research was supported 
by the National 
Institute on Drug Abuse 
(R01 DA027379, 
K23DA019809); the 
National Drug Abuse 
Treatment Clinical 
Trials Network (CTN) 
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Study details Population and 
setting 
Intervention/comparator Outcomes and methods 
of analysis 
Results Notes 
Sensitivity analysis: One-way 
sensitivity analysis 
- Varying prevalence of 
undiagnosed HIV: on-site 
testing + information vs no 
intervention: cost-
effectiveness ratios are 
higher 
- Varying probability of 
testing: cost-effectiveness 
ratio for on-site testing + 
information= £54,896/QALY 
($82,800/QALY) 
- Other variations have little 
impact on cost-effectiveness 
ratios 
(U10 DA013720, 
U10DA13720-09S, U10 
DA020036, U10DA15815, 
U10DA13034, 
U10DA013038, U10 
DA013732, U10 
DA13036, U10 DA13727, 
U10DA015833, 
HHSN271200522081C, 
HHSN271200522071C); 
the National Institute of 
Mental Health (R01 
MH063869); and the 
National Institute of 
Allergy and Infectious 
Diseases (R37 
A1042006).  
Thomas (2012) 
Aim of study: 
Stated as ‘to 
assess the fiscal 
impact of three 
national-level 
policies designed 
to prevent 
unintended 
Source 
populations: 
10,000 individuals 
aged 15-44 whose 
demographic 
characteristics 
were nationally 
representative (of 
USA)  
Intervention description:  
1. Mass media campaign  
2. Evidence-based teen 
pregnancy prevention 
programme  
3/ Expanded access to 
Medicaid Family Planning 
Outcomes (linked to 
unattained pregnancies):  
Main: benefit-cost ratio 
Others: % reduction in 
abortion; % reduction in 
births; % reduction in 
number of children born 
into poverty; programme 
Primary analysis:  
Benefits: 
-% reduction in abortion: Mass 
media (3.9%); evidence-based 
teen pregnancy prevention 
programme (1.4%); expanded 
access to Medicaid Family 
Planning (3.5%) 
Limitations identified 
by author:  
Does not account for: 
- Spending on children 
over the age of 5 
- Private costs of 
unintended pregnancy 
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Study details Population and 
setting 
Intervention/comparator Outcomes and methods 
of analysis 
Results Notes 
pregnancy’. In 
practice, the 
author assessed 
the financial 
benefit of 
implementing 
interventions to 
prevent 
unintended 
pregnancies 
Type of economic 
analysis: Cost-
benefit analysis 
Economic 
perspective: 
Government and 
social 
Quality score: 
Medium 
Applicability: 
Partially 
applicable 
Setting: United 
States 
Data sources: The 
General Social 
Survey and the 
National Survey of 
Family Growth; 
the Guttmacher 
Institute; the 
National Vital 
Statistics System; 
data from the 
Current 
Population Survey 
were used to 
parameterise the 
model that assigns 
a poverty status 
to each newborn 
child; meta-
analysis for 
behaviour effects; 
Truth, VERB, and 
National Youth 
Anti-Drug Media 
(NYADMC) 
Comparator/control 
description: N/A 
Sample sizes: Total N = 
10,000 simulation cohort 
costs, public savings, 
fiscal savings  
Time horizon: 5 years 
Costing year(s) and 
currency: 2008 USD 
Discount rates: 3% 
Perspective: Social and 
public sector government) 
Measures of uncertainty: 
One-way sensitivity 
analysis 
Modelling method: Cost-
benefit analysis 
- % reduction in births: Mass 
media (1.0%); evidence-based 
teen pregnancy prevention 
programme (0.6%); expanded 
access to Medicaid Family 
Planning (1.4%) 
- % reduction in number 
children born into poverty: 
Mass media (2.2%); evidence-
based teen pregnancy 
prevention programme 
(1.4%); expanded access to 
Medicaid Family Planning 
(1.8%) 
Costs: 
-Programme costs: mass 
media: £65.3 million ($100 
million); evidence-based teen 
pregnancy prevention 
programme: £94,685 million 
($145 million); expanded 
access to Medicaid Family 
Planning: £153,455 million 
($235 million) 
Public savings: 
(e.g. lower earnings of 
mother) 
Other potentially 
important societal 
costs: 
- Does not consider 
likely effect on spread 
of STIs 
- Scale-up of small 
interventions may be 
less effective than 
assumed 
- Assumption of 
effectiveness of 
national media 
campaign may be 
incorrect 
- Programme costs and 
baseline parameters 
were uncertain. 
Limitations identified 
by review team: Author 
has identified main 
limitations 
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Study details Population and 
setting 
Intervention/comparator Outcomes and methods 
of analysis 
Results Notes 
campaigns (costs); 
literature for both 
benefits and costs 
For pregnancy care alone: 
-Mass media: £24,164,437 
($37,005,263); benefit-cost 
ratio: £0.24 ($0.37) 
-Evidence-based teen 
pregnancy prevention 
programme: £241,597,209 
($369,980,412); benefit-cost 
ratio; £0.17 ($0.26) 
-Expanded access to Medicaid 
Family Planning: £79,455,150 
($121,677,106); benefit-cost 
ratio: £0.59 ($0.62) 
Pregnancy care plus infant 
medical: 
-Mass media: £58,929,344 
($90,244,018); benefit-cost 
ratio: £0.59 ($0.90) 
-Evidence-based teen 
pregnancy prevention 
programme: £51,856,523 
($79,412,746); benefit-cost 
ratio: £0.36 ($0.55) 
-Expanded access to Medicaid 
Family Planning: 
Source of funding: The 
William and Flora 
Hewlett Foundation  
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Study details Population and 
setting 
Intervention/comparator Outcomes and methods 
of analysis 
Results Notes 
£186,002,878 ($284,843,611); 
benefit-cost ratio: £0.79 
($1.21) 
Pregnancy care plus children 
benefits: 
-Mass media: £281,383,852 
($430,909,421); benefit-cost 
ratio: £2.81 ($4.31) 
-Evidence-based teen 
pregnancy prevention 
programme: £232,562,922 
($356,145,363); benefit-cost 
ratio: £1.61 ($2.46) 
-Expanded access to Medicaid 
family planning: £862,217,932 
($1,320,394,996); benefit-
cost ratio: £3.67 ($5.62) 
Secondary analysis: Findings 
were relatively insensitive to 
large changes in the 
assumptions underlying the 
analysis. For example, the 
results of the preferred 
specifications suggest that, 
even if the cost of the 
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Study details Population and 
setting 
Intervention/comparator Outcomes and methods 
of analysis 
Results Notes 
Medicaid expansion was twice 
as high as it was assumed to 
be — or if the benefits of the 
teen pregnancy prevention 
programme were twice what 
they were estimated to be — 
the benefit-cost ratios for the 
former would still be at least 
as large as for the latter. 
On the other hand, the 
results from the preferred 
specifications that account 
for spending on children 
through age 5 suggest that, 
even if these programmes 
were half as effective (or 
twice as expensive) as they 
were assumed to be, all of 
them would have benefit-cost 
ratios of greater than 1. 
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Appendix 10: Included studies table: Contraception interventions 
Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and 
methods of analysis 
Results Notes 
Bayer et al.  
(2013) 
Aim of study: To 
examine the 
cost-efficacy of 
ulipristal acetate 
(UPA) compared 
with 
levonorgestrel 
(LNG) 
Type of 
economic 
analysis: Cost-
effectiveness 
analysis 
Economic 
perspective: All 
pregnancy costs 
were obtained 
from state 
Medicaid 
payments. It is 
unclear if costs 
are measured 
from the 
Source populations: 
Women of 
reproductive age 
taking EC within 120 
hours of unprotected 
intercourse 
Setting: US 
Data sources:  
Probabilities inputs: 
- Emergency 
contraception (EC) 
and pregnancy 
following the use of 
UPA or LNG: from a 
2010 meta-analysis 
- Distribution of 
unintended 
pregnancy outcomes 
(vaginal vs caesarean 
delivery, 
spontaneous 
abortion, induced 
abortion, ectopic 
Intervention 
description: Ulipristal 
acetate (UPA) 
Comparator/control 
description: 
Levonorgestrel (LNG) 
Sample sizes: 
Simulated cohort of 
10,000 women  
Main outcome: 
Number of unattained 
pregnancy averted 
Secondary outcomes: 
Pregnancy 
complications (vaginal 
vs caesarean delivery, 
spontaneous abortion, 
induced abortion, 
ectopic pregnancy) 
Time horizon: 
Unclear, but analysis 
included a single 
menstrual cycle for 
single episode of EC 
use and expands to the 
assessment of 
pregnancy outcomes 
(so at least 10 months, 
on average) 
Costing year(s) and 
currency: 2011 USD 
Discount rates: Both 
costs and benefits 
Primary analysis:  
UPA: 
-Pregnancy rate: 54,295 
-Costs: £270,251,630 ($399.19 
million) 
-QALY: 111,813,707 
LNG: 
-Pregnancy rate: 91,884 
-Costs: £348,959,650 ($515.45 
million) 
-QALY: 111,805,654 
Overall analysis (comparing 
EC and LNG): 
-Unintended pregnancies 
averted (UPA over LNG): 
37,589 
-Costs saved: £78,735,100 
($116.3 million) 
-QALYs gained: 8,053 
-Incremental cost-
effectiveness analysis: UPA 
was a dominant intervention  
Limitations identified by 
author:  
-For the probability of EC 
failure input there is no 
distinction between different 
time frames of taking EC after 
unprotected intercourse 
- The costs of LNG and UPA 
used in the decision model 
reflect the lower end of 
published drug prices 
-The decision model did not 
include the copper-releasing 
intrauterine device (IUD) 
Limitations identified by 
review team:  
-Measure of benefit (utilities 
and QALYs) were used without 
any disaggregation (by type of 
complication or contraceptive 
method) so benefits could not 
be fully assessed 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and 
methods of analysis 
Results Notes 
societal, 
healthcare or 
personal social 
services 
perspective 
Quality score: 
Low 
Applicability: 
Partly applicable 
pregnancy): 
literature 
Costs inputs: 
- All pregnancy costs 
were obtained from 
Medicaid payments 
and costs 
- Costs of EC and 
LNG: from the 
market (price 
women pay over the 
counter (also online, 
but only for EC) 
Utilities and QALYs: 
Assumed an overall 
0.992 utility for 
unattained 
pregnancies from 
literature; not 
disaggregated by 
outcomes; authors 
said they used an 
average life 
expectancy of 55 
additional years 
after taking EC 
were discounted at 3% 
annually 
Perspective: Unclear 
(although assumed 
that it is societal) 
Measures of 
uncertainty: 
Univariate, 
multivariate and 
probabilistic sensitivity 
analyses  
Modelling method: 
Monte Carlo simulation 
for a cost-
effectiveness analysis 
Secondary analysis:  
-UPA dominates all scenarios 
-UPA is still a cost-effective 
intervention when the failure 
rate is 1.3%. There is a linear 
decrease of cost-
effectiveness when UPA 
failure increases 
-Applying a threshold of 
£67,700 ($100,000) per QALY 
gained, UPA was more cost-
effective when the UPA 
failure rate was less than 
2.17% and the price of the 
medication was less than 
£179 ($265) 
-At a willingness-to-pay (WTP) 
threshold of £67,700 
($100,000) per QALY, UPA was 
the preferred EC 96% of the 
time  
-Complications such as STIs 
were not included, so full 
benefits were not assessed 
-Perspective of analysis was 
unclear, so we could not 
assess if results could be 
extrapolated to the society or 
to Medicaid users only 
-Discount rate is not 
applicable in studies with a 
time horizon less than 1 year 
Evidence gaps and/or 
recommendations for future 
research:  
-To disaggregate benefits to 
better understand dominance 
of UPA over LNG 
-As discussed in the 
limitation, further analysis 
including other effective 
contraception methods should 
be undertaken 
Source of funding: None 
stated 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and 
methods of analysis 
Results Notes 
Foster et al. 
(2010) 
Aim of study: To 
determine the 
potential effect 
and cost-
effectiveness of 
different means 
of accessing 
emergency 
contraceptive 
pills (ECP) on 
unintended 
pregnancy rates 
in sexually active 
women 
Type of 
economic 
analysis: Cost-
benefit 
Economic 
perspective: 
Public payer of 
medical care  
Quality score: 
Medium 
Source populations: 
Sexually active 
women who are at 
risk of having 
unprotected 
intercourse 
Setting: USA 
Data sources:  
Probability of taking 
ECP: Assumptions 
Probability of 
conception: 
Available data on 
conception rates, 
mean time to use of 
ECP, and ECP 
effectiveness after 
an episode of 
unprotected 
intercourse 
Effectiveness data: 
Single-use clinical 
trials of ECP  
Costs: Medi-Cal, 
California’s Medicaid 
programme, and 
Intervention 
description:  
- Advance provision: 
women who have ECP 
on hand to use if 
needed after an episode 
of unprotected 
intercourse 
- On-demand provision: 
women who must seek 
ECP from a clinic or 
pharmacy after an 
episode of unprotected 
intercourse 
* These categories are 
evaluated as high and 
low use of emergency 
contraception:  
High use: Women with 
advance provision take 
ECP after all episodes 
of unprotected 
intercourse, women 
with on-demand access 
take ECP after half of 
episodes 
Outcomes:  
- Unintended 
pregnancy according 
to high and low use of 
ECP  
- Cost-saving ratio 
according to pharmacy 
dispensed and clinic 
dispensed 
- Sample size to test 
difference in 
pregnancies (advanced 
vs no ECP and 
advanced vs on-
demand) 
Time horizon: 1 year 
Costing year(s) and 
currency: 2005 USD 
Discount rates: Not 
applicable 
Perspective: Public 
payer of medical care 
Measures of 
uncertainty: No 
measurement of 
Primary analysis: 
Reduction in pregnancy rate 
comparing with No ECP: 
High use of emergency 
contraception: 
-Once per year 
Advance: −66 
On demand: −38 
-Once per month 
Advance: −39 
On demand: −36 
-Once per week 
Advance: −30 
On demand: −30 
Low use of emergency 
contraception: 
-Once per year 
Advance: −38 
On demand: −20 
-Once per month 
Advance: −21 
On demand: −17 
-Once per week 
Limitations identified by 
author:  
- Recent trials have shown 
failure of ECP to reduce 
pregnancy rates. However, 
the current model suggests 
that these trials have not had 
sufficient power to detect 
differences in these rates 
- The discrepancy between 
the single-use trials and the 
advance provision trial can be 
due to the overestimation of 
ECP effectiveness  
- The inflated expected 
pregnancy rate would lead to 
an overestimate of the 
effectiveness of ECP 
- The cost savings of advance 
provision will be 
underestimated to the extent 
that women keep their ECP 
supplies for longer than a year  
- the cost savings associated 
with ECP use for advance 
provision and on demand 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and 
methods of analysis 
Results Notes 
Applicability: 
Partly applicable 
Family PACT, 
California’s Medicaid 
1115 Waiver Program 
Low use: Women with 
advance provision take 
ECP after half of 
episodes of unprotected 
intercourse, women 
with on-demand access 
take ECP after one 
quarter of episodes 
Comparator/control 
description: No use of 
ECP: women who do not 
have access to ECP and 
do not use ECP 
Sample sizes: 
Simulated cohort of 
individuals derived from 
multiple estimates 
uncertainty was 
carried out 
Modelling method: 
Computer simulation 
model of pregnancies 
among sexually active 
women, Markov 
process 
Advance: −15 
On demand: −14 
Costs-savings ratio: 
pharmacy-dispensed:  
High use of emergency 
contraception: 
-Once per year 
Advance: £1.25 ($1.92) 
On demand: £1.55 ($2.39) 
-Once per month 
Advance: £1.38 ($2.12) 
On demand: £1.35 ($2.08) 
-Once per week 
Advance: £1.04 ($1.60) 
On demand: £1.04 ($1.61) 
Low use of emergency 
contraception: 
-Once per year 
Advance: £0.83 ($1.28) 
On demand: £1.62 ($2.49) 
-Once per month 
Advance: £1.41 ($2.17) 
On demand: £1.32 ($2.04) 
would be higher than 
projected because women are 
more likely to use ECP for acts 
that occur in the week before 
ovulation  
- Medical cost data may be 
lower than private health plan 
costs. Social, welfare, and 
private costs can be much 
higher 
- The study considered 
medical costs of an 
unintended pregnancy for up 
to 2 years after a birth 
- Changing behaviour was not 
considered in to the analysis 
Limitations identified by 
review team:  
- Only modelled intercourse 
where no contraception was 
used; cost effectiveness would 
be lower if emergency 
contraception used in 
situations where likelihood of 
conception is lower than with 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and 
methods of analysis 
Results Notes 
-Once/week 
Advance: £1.07 ($1.65) 
On demand: £1.06 ($1.64) 
Costs-savings ratio: Clinic-
dispensed:  
High use of emergency 
contraception: 
-Once per year 
Advance: £1.14 ($1.75) 
On demand: £0.979 ($1.50) 
-Once per month 
Advance: £0.90 ($1.39) 
On demand: £0.84 ($1.30) 
-Once per week 
Advance: £0.66 ($1.01) 
On demand: £0.65 ($1.00) 
Low use of emergency 
contraception: 
-Once per year 
Advance: £0.80 ($1.24) 
On demand: £1.01 ($1.56) 
-Once per month 
Advance: £0.97 ($1.50) 
no contraception (e.g. missed 
pill)  
- Medicaid costs may be lower 
than private health plan costs 
- Only considered medical 
costs of unintended pregnancy 
for up to 2 years after a birth 
- Social, welfare and private 
costs likely to be much higher 
- Generic emergency 
contraception may reduce 
costs and increase cost saving 
Evidence gaps and/or 
recommendations for future 
research: To model scenarios 
assessing the limitations 
discussed above for a longer 
period and include 
complications of pregnancies 
and STI risks 
Source of funding: The 
California State Department 
of Public Health, Maternal, 
Child and Adolescent Health 
Branch (MCAH), Office of 
Family Planning. 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and 
methods of analysis 
Results Notes 
On demand: £0.83 ($1.28) 
-Once per week 
Advance: £0.69 ($1.07) 
On demand: £0.67 ($1.03) 
Secondary analysis: The 
required size of a study 
designed to test differences 
in pregnancy rates between 
advance provision and no ECP 
access ranged from 133 to 
4,370 in each arm and to test 
differences in pregnancy 
rates between advance 
provision and on-demand 
provision ranged from 4,556 
to 320,926 in each arm 
Sensitivity analysis: Not 
reported 
Funder did not participate in 
the design of the study or the 
collection, management, 
analysis, and interpretation of 
the data. The funder reviewed 
and approved the final 
manuscript 
Foster et al. 
(2013) 
Aim of study: To 
examine the 
relative cost-
benefit of 
specific methods 
and evaluate the 
Source populations: 
Women aged 15 to 
44, PACT clients 
Setting: USA, 
California 
Data sources: Paid 
claims data, Family 
Intervention 
description: 
Contraceptive methods: 
Interval tubal ligation 
Tubal occlusion 
Copper intrauterine 
contraception (IUC) 
Outcomes: Costs of 
providing 
contraceptive services 
for each method; 
pregnancies averted; 
cost-savings per dollar 
expenditure 
Primary analysis: 
Pregnancies averted: 
Interval tubal ligation: 1,766 
Tubal occlusion: 355 
Copper intrauterine 
contraception (IUC): 10,264 
Limitations identified by 
author:  
- The cost savings of long-
acting methods were 
underestimated because 
women may use them for 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and 
methods of analysis 
Results Notes 
relative 
contribution of 
each method to 
the number of 
unintended 
pregnancies 
averted within 
the Family PACT 
population 
Type of 
economic 
analysis: Cost-
benefit 
Economic 
perspective: 
Public sector 
Quality score: 
Medium 
Applicability:  
Partly applicable 
PACT Medical Record 
Review, published 
estimates for 
unintended 
pregnancies in 
California, medical 
records, assumptions 
 
Hormonal IUC 
Implant 
Injectable  
Ring 
Patch 
Oral contraceptives 
Barriers (including on-
site dispensing of male 
and female condoms, 
diaphragms, and 
spermicides) 
Emergency 
contraceptives 
Comparator/control 
description:  
Comparator: Doing-
nothing scenario 
The intervention 
assumes a scenario 
where different 
contraceptive methods 
are provided to the 
simulated population 
through Family PACT (a 
reproductive health 
Time horizon: 2 years 
Costing year(s) and 
currency: 2009 USD 
Discount rates: Not 
provided  
Perspective: Public 
sector 
Measures of 
uncertainty: 
Sensitivity analyses of 
method-specific 
savings from 
preventing unintended 
pregnancies 
Modelling method: 
Model to estimate the 
number of pregnancies 
expected among 
Family PACT clients  
Hormonal IUC: 13,396 
Implant: 2,808 
Injectable: 26,053 
Ring: 12,931 
Patch: 9,005 
Oral contraceptives: 102,573 
Barriers: 17,564 
Emergency contraceptives: 
3,325 
Costs (thousands): 
Interval tubal ligation: £1,785 
($2,692) 
Tubal occlusion: £813 
($1,226) 
Copper intrauterine 
contraception (IUC): (£7,893) 
$11,905 
Hormonal IUC: £11,205 
($16,900) 
Implant: £2,532 ($3,819) 
Injectable: £29,085 ($43,869) 
Ring: £25,772 ($38,872) 
Patch: £17,976 ($27,113) 
more than two years as 
assumed in the current study 
- The duration of 
contraceptive coverage was 
underestimated for barrier 
methods  
- It is not possible to state 
whether contraceptive 
supplies that were dispensed 
were actually used 
- The study did not include 
rebates from pharmaceutical 
companies on contraceptives 
dispensed at pharmacies. As a 
consequence, the cost of 
providing some contraceptives 
was not accurately captured 
Limitations identified by 
review team: Main limitations 
already identified by authors 
Evidence gaps and/or 
recommendations for future 
research: For a public health 
perspective, implications 
regarding complications 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and 
methods of analysis 
Results Notes 
programme in USA) and 
assess the potential 
costs savings from 
pregnancies averted, 
and public sector 
expenditures on 
unintended pregnancies 
borne by federal, state 
and local governments 
Sample sizes: 
Simulated cohort of 
women aged 15 to 44; 
no size given 
Oral contraceptives: £138,352 
($208,676) 
Barrier methods: £51,412 
($77,545) 
Emergency contraceptives: 
£6,516 ($9,828) 
Cost-savings per dollar 
expenditure: 
Interval tubal ligation: £2.38 
($3.59) 
Tubal occlusion: £1.05 ($1.59) 
Copper intrauterine 
contraception (IUC): £3.36 
($5.07) 
Hormonal IUC: £3.24 ($4.89) 
Implant: £3.24 ($4.89) 
Injectable: £2.65 ($4.00) 
Ring: £1.46 ($2.20) 
Patch: £1.41 ($2.12) 
Oral contraceptives: £2.23 
($3.37) 
Barrier methods: £1.05 
($1.58) 
(including STIs) should be 
included 
Source of funding: None 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and 
methods of analysis 
Results Notes 
Emergency contraceptives: 
£1.70 ($2.56) 
Secondary analysis: None 
Sensitivity analysis:  
Scenario 1: Women use all 
methods dispensed: 
Cost-benefit of the whole 
programme: £2.33 ($3.51) 
(16% higher) 
Scenario 2: Medical costs 
through end of pregnancy 
only: 
Cost-saving/dollar 
expenditure of the whole 
programme: £0.40 ($0.61) 
Han et al. (2014) 
Aim of study: To 
determine the 
cost-
effectiveness of 
a hypothetical 
state-funded 
programme 
offering 
immediate 
Source populations: 
Adolescents aged 13-
22 years enrolled in 
a pre-natal-post-
natal programme – 
CAMP, Colorado 
Adolescent Maternity 
Program 
Intervention 
description: IPI 
insertion: subdermal 
contraception 
(etnogestrel) prior to 
hospital discharge or 
within 4 weeks after 
delivery 
Comparator/control 
description: Other 
Outcomes: Total cost 
per 1,000 women, cost 
of repeated 
pregnancy, implant 
continuation rate at 6, 
12, 24 and 36 months 
and pregnancy rates at 
6, 12, 24 and 36 
months 
Primary analysis: 
Total cost per 1,000 women 
(6, 12, 24, 36 months): 
IPI group: £475,083 
($699,680); £672,006 
($989,700); £100,492,000 
($1.48 million) and 
£157,528,000 ($2.32 million) 
Control group: £425,783 
($627,073); £10,456,600 
Limitations identified by 
author:  
- The results may be less 
generalisable because the 
analysis is based on actual 
outcomes rather than using 
hypothetical outcomes from 
the literature 
- Patients may have over- or 
under-reported both 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and 
methods of analysis 
Results Notes 
postpartum 
implant (IPI) 
insertion for 
adolescent 
mothers at 6, 12, 
24, and 36 
months 
postpartum 
Type of 
economic 
analysis: Cost-
effectiveness 
(cost-saving) 
Economic 
perspective: 
Colorado 
Medicaid 
Quality score: 
Low 
Applicability: 
Partly applicable 
Setting: USA, 
University of 
Colorado Hospital 
Data sources: 
Electronic Report on 
Adolescent 
Pregnancy, 
participants’ 
electronic medical 
records, 
questionnaires, 
Medicaid payment 
and reimbursement 
contraceptive method 
according to standard 
clinical protocols: no 
contraception, 
condoms, depot 
medroxyprogesterone 
acetate, and progestin-
only pills initiated at 
any time after delivery, 
combined hormonal 
contraception (pills, 
patch, ring) started at 
any time 4 or more 
weeks after delivery, 
implant insertion at 4 or 
more weeks after 
delivery, and 
levonorgestrel-
intrauterine system or 
copper-T 380A (IUD) 
insertion any time 6 or 
more weeks after 
delivery 
Sample sizes: 
Total: 396 
Intervention: 171 
Time horizon: 36 
months 
Costing year(s) and 
currency: 2013 USD 
Discount rates: Not 
reported 
Perspective: Colorado 
Medicaid 
Measures of 
uncertainty: 
Sensitivity analysis: 
Variation of repeat 
pregnancy rates 
Modelling method: 
N/A - not a modelling 
study 
($1.54 million); £267,526,000 
($3.94 million); and 
£465,115,000 ($6.85 million) 
Net cost per 1,000 women (6, 
12, 24, 36 months): 
-£49,299 ($72,606); £371,379 
($546,950); £167,034,000 
($2.46 million); and 
£307,587,000 ($4.53 million) 
* At 12, 24, and 36 months, 
£0.53 ($0.78), £2.40 ($3.54), 
and £4.41 ($6.50) were saved 
for every dollar spent on IPI 
insertion 
Secondary analysis:  
Implant continuation rate at 
6, 12, 24 and 36 months: 
IPI group: 97%, 86%, 
65% and 48% respectively 
Control group - by 6 months 
43.7% (implants or IDU), 34% 
(short-acting method) and 
16% (discontinued or elected 
not to use birth control)  
spontaneous miscarriages and 
induced abortions incidence. 
Thus, pregnancy data can 
introduce potential source of 
bias  
-Loss to follow-up was lower 
in the comparison group at 3 
years than the implant group 
- Pregnancy outcomes were 
cumulatively added over time 
and may result in bias from 
losing women who did not get 
pregnant, inflating overall 
pregnancy rates 
- The cost-effectiveness of IPI 
programmes may be less in 
the adult population because 
rates of unplanned repeat 
pregnancy are higher in 
adolescents than adults  
-Analysis used the Colorado 
Medicaid outpatient 
reimbursement rates for 
implant insertion and 
removal. Different inputs from 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and 
methods of analysis 
Results Notes 
Comparator: 225 
 
Pregnancy rates at 6, 12, 24 
and 36 months: 
IPI group: 0%, 2.6%, 8.1% and 
17.7% respectively 
Control group: 9.9%, 
20.1%, 46.5, and 83.7% 
respectively 
Sensitivity analysis: Cost 
savings were robust enough 
that only very large 
deviations in pregnancy rates 
would affect the overall 
result of a net savings to 
Medicaid 
different payers may change 
the results 
Limitations identified by 
review team:  
-Benefits in terms of repeat 
pregnancy rates by type of 
complications were not 
reported, thus we could not 
assess the benefits generated 
by each outcome 
-Measures of uncertainties 
were only reported to one 
parameter, repeated 
pregnancy rates for the 
comparison group; we were 
therefore unable to assess 
robustness of the model and 
to assess which parameters 
brought more uncertainty to 
the results 
-Discount rate for a 3-year 
analysis was not reported and 
we were unsure if any was 
used 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and 
methods of analysis 
Results Notes 
Evidence gaps and/or 
recommendations for future 
research:  
-Benefits should be 
disaggregated and presented, 
as well as all their 
probabilities 
-Parameters tested in the 
sensitivity analysis should be 
presented and we suggested 
that one-way sensitivity 
analysis be conducted and 
results presented first before 
a multivariate or probabilistic 
sensitivity analysis. Thus, we 
would have the chance to 
better understand which 
parameters contribute the 
most to explaining the 
estimates 
Source of funding: Authors 
report no conflict of interest 
National 
Collaborating 
Centre (NCC) for 
Women’s and 
Source populations: 
Male and females of 
reproductive age 
Setting: UK 
Intervention 
description: LARC 
methods: IDU, IUS: LNG-
Outcomes: Number of 
pregnancies averted 
by the use of one 
contraceptive method 
Primary analysis: 
Comparison across 
reversible contraceptive 
Limitations identified by 
author:  
- The relative cost-
effectiveness of LARC 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and 
methods of analysis 
Results Notes 
Children’s 
Health (2013) 
Aim of study: 
Overall aim was 
to provide 
(clinical and 
educational) 
guidance on 
LARC. The cost-
effectiveness 
analysis aimed at 
assessing LARC 
methods 
compared to 
combined oral 
contraceptive pill 
(COC) 
Type of 
economic 
analysis: Cost-
effectiveness  
Economic 
perspective: 
Public health 
(NHS) 
Data sources:  
Costs: COC use in 
England in 2002, 
2004 NHS reference 
costs, British 
National Formulary 
(49, March 2005), GP 
fee schedule, 
opinion of the 
Guideline 
Development Group 
(GDG), published 
literature 
Effectiveness: 
systematic literature 
review, agreements 
between GDG 
members, national 
statistics, published 
literature 
IUS (Mirena), injectable 
hormones, implant 
Comparator/control 
description: Combined 
oral contraceptive pill 
(COC), male condom, 
and non-reversible 
contraceptive methods 
(female and male 
sterilisation) 
Sample sizes: 
Simulated cohort of 
1,000 sexually active 
women choosing one 
method of 
contraception 
in comparison with 
another  
Time horizon: 1 to 15 
years 
Costing year(s) and 
currency: 2004-2005 
GBP 
Discount rates: 3.5% 
Perspective: NHS 
Measures of 
uncertainty: 
Sensitivity analysis, 
scenario analysis 
Modelling method: 
Decision-analytic 
model – Markov model 
methods: LARC methods, 
COC, male condom:  
1 year of use: 
Total pregnancy: 
Implant: 14 
IUS: 17 
IUD: 18 
Injectable: 33 
COC: 91 
Condom:150 
Total costs:  
Implant: £262,117 
IUS: £270,749 
IUD: £195,442 
Injectable: £190,534 
COC: £232,932 
Condom: £212,658 
Incremental cost-
effectiveness ratio: 
Implant vs IUD: 
£17,367/pregnancy averted 
IUS: dominated by implant 
methods highly sensitive to 
changes in discontinuation 
rates in several cases 
- Adverse events, side effects 
associated with contraceptive 
use and non-contraceptive 
benefits are not considered in 
the model  
Limitations identified by 
review team:  
- Key parameters were not 
assessed individually in the 
sensitivity analysis, making it 
difficult to identify which 
parameter contributes more 
uncertainty in the model 
- Authors noted that LARC and 
COC or non-reversible 
methods may not always be 
substitutes since not every 
woman will be eligible for all 
methods. This was 
acknowledged in discussion of 
model structure and 
limitations, but this scenario 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and 
methods of analysis 
Results Notes 
Quality score: 
Medium 
Applicability: 
Partly applicable 
 
IUD vs injectable: 
£339/pregnancy averted 
COC: dominated by IUD and 
injectable 
Condom: dominated by IUD 
and injectable 
2 years of use: 
Total pregnancy: 
Implant: 51 
IUD: 55 
IUS: 57 
Injectable: 99 
COC: 190 
Condom: 295 
Total costs:  
Implant: £ 322,939 
IUD: £256,572 
IUS: £337,093 
Injectable: £338,376 
COC: £406,366 
Condom: £418,125 
Incremental cost-
effectiveness ratio: 
was not incorporated in the 
sensitivity analysis 
- The model was adapted from 
a previous model but there 
was no discussion about 
validity and calibration 
Evidence gaps and/or 
recommendations for future 
research: Model can be 
validated and calibrated and 
variables should be assessed 
individually to check for 
uncertainty among 
parameters 
Source of funding: Not 
declared 
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setting 
Intervention/ 
comparator 
Outcomes and 
methods of analysis 
Results Notes 
Implant vs IDU: 
£17,866/pregnancy averted  
IUS: Dominated by implant, 
IUD  
Injectable: Dominated by 
implant, IUD, IUS 
COC: Dominated by all LARC 
methods 
Condom: Dominated by all 
LARC methods 
3 years of use: 
Total pregnancy: 
Implant: 101 
IUD:105 
IUS: 109 
Injectable: 167 
COC: 289 
Condom: 435 
Total costs:  
Implant: £400,947 
IUD: £337,207 
IUS: £418,616 
Injectable: £482,178 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and 
methods of analysis 
Results Notes 
COC: £575,320 
Condom: £616,644 
Incremental cost-
effectiveness ratio: 
Implant vs IUD: 
£14,730/pregnancy averted 
IUS: Dominated by implant, 
IUD  
Injectable: Dominated by 
implant, IUD, IUS 
COC: Dominated by all LARC 
methods 
Condom: Dominated by all 
LARC methods 
5 years of use: 
Total pregnancy: 
Implant: 215 
IUS: 228 
IUD: 232 
Injectable: 302 
COC: 482 
Condom: 707 
Total costs:  
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and 
methods of analysis 
Results Notes 
Implant: £667,275 
IUS: £603,534 
IUD: £534,555 
Injectable: £760,600 
COC: £899,697 
Condom: £993,769 
Incremental cost-
effectiveness ratio: 
Implant vs IUD: 
£7,574/pregnancy averted, 
extended dominance 
Implants vs IUS: 
£4,598/pregnancy averted 
IUS vs IUD: 
£18,845/pregnancy averted 
Injectable: Dominated by 
implant, IUD, IUS 
COC: Dominated by all LARC 
methods 
Condom: Dominated by all 
LARC methods 
10 years of use: 
Total pregnancy: 
Implant: 483 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and 
methods of analysis 
Results Notes 
IUS:522 
IUD: 551 
Injectable: 635 
COC: 932 
Condom: 1291 
Total costs:  
Implant: £1,210,419 
IUS: £1,119,079 
IUD: £1,050,425 
Injectable: £1,401,818 
COC: £1,632,762 
Condom: 1,830,496 
Incremental cost-
effectiveness ratio: 
Implant vs IUD: 
£2,342/pregnancy averted/ 
extended dominance 
Implant vs IUS: 
£2,339/pregnancy averted 
IUS vs IUD: £2,346/pregnancy 
averted  
Injectable: Dominated by 
implant, IUD, IUS  
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and 
methods of analysis 
Results Notes 
COC: Dominated by all LARC 
methods 
Condom: Dominated by all 
LARC methods 
15 years of use: 
Total pregnancy: 
Implant: 719 
IUS: 778 
IUD: 828 
Injectable: 948 
COC: 1330 
Condom: 1788 
Total costs:  
Implant: £1,622,769 
IUS: £1,563,548 
IUD: £1,469,754 
Injectable: £1,965,220 
COC: £2,260,880 
Condom: £2,534,998 
Incremental cost-
effectiveness ratio: 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and 
methods of analysis 
Results Notes 
Implant vs IUD: 
£1,403/pregnancy averted/ 
extended dominance 
Implant vs IUS: 
£999/pregnancy averted 
IUS vs IUD: £1,884/pregnancy 
averted  
Injectable: Dominated by 
implant, IUD, IUS  
COC: Dominated by all LARC 
methods 
Condom: Dominated by all 
LARC methods 
Secondary analysis: 
Comparison of LARC 
methods with non-reversible 
contraceptive methods: 
1 year of use: 
Total pregnancies: 
Male sterilisation: 7 
Female sterilisation: 19 
Implant: 719 
IUS: 778 
IUD: 828 
Appendix 10 
 
Sexual health promotion and contraceptive services in local authorities: a systematic review of economic evaluations 2010-2015  213 
 
Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and 
methods of analysis 
Results Notes 
Injectable: 948 
Total costs: 
Male sterilisation: £466,776 
Female sterilisation: £750,191 
Implant: £1,622,769 
IUS: £1,563,548 
IUD: £1,469,754 
Injectable: £1,965,220 
Incremental cost-
effectiveness ratio: 
Implant: Dominated by male 
and female sterilisation 
IUS: Dominated by male and 
female sterilisation 
IUD: Dominated by male and 
female sterilisation 
Injectable: Dominated by 
male and female sterilisation 
Sensitivity analysis: 
Comparison across reversible 
contraceptive methods: LARC 
methods, COC, male condom:  
- Varying the failure rates of 
COC and male condom by 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and 
methods of analysis 
Results Notes 
±10%: no impact in the base-
case results 
- Varying the failure rates of 
LARC methods by ±10%: no 
impact no impact in the cost-
effectiveness of the base-case 
results relative to the COC 
and male condom. No impact 
in the ranking of LARC 
methods in terms of 
effectiveness or the case 
dominance across LARC 
methods 
- Varying the failure rate of 
IUD: moderate impact on the 
ICERs of the implant versus 
IUD only for short periods of 
contraceptive use (3-4 years) 
Comparison of LARC methods 
with non-reversible 
contraceptive methods: 
- Varying the failure rates of 
female and male sterilisation 
by ±10%: no impact in the 
base-case results  
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and 
methods of analysis 
Results Notes 
- Varying the failure rates of 
LARC methods by ±10%: no 
impact in the cost-
effectiveness results 
Pilgrim et al. 
(2010) 
Aim of study: To 
assess the cost-
effectiveness of 
a range of 
interventions to 
encourage young 
people, 
especially 
socially 
disadvantaged 
young people, to 
use 
contraceptives or 
contraceptive 
services 
Type of 
economic 
analysis: Cost-
effectiveness 
Source populations:  
1. Young people 
aged 14-16 years 
who have not 
previously been a 
parent (but who may 
or may not have 
been pregnant 
without carrying to 
term) within 
secondary school 
2. Young mothers 
within a secondary 
school 
3. Young people 
aged 15–19 years 
who are sexually 
active 
Setting: UK 
Data sources:  
Probability of 
abortion and birth: 
Intervention 
description: 
1. School-based 
dispensing of hormonal 
contraceptives within 
the school (DH); school-
based dispensing of 
condoms (DC)  
2. Intensive case 
management to prevent 
repeat pregnancy 
(includes a culturally 
matched school-based 
social worker [including 
home visits], weekly 
school-based peer 
education support and 
comprehensive medical 
care including 
contraception) (ICM) 
Primary outcomes: 
Cost per pregnancy 
averted, cost per 
abortion averted 
Secondary outcomes: 
Cost of the 
intervention and 
additional 
contraception required 
as a result of the 
intervention; cost of 
maternity care; cost of 
abortion; cost of 
miscarriage/ ectopic 
pregnancy/ stillbirth; 
cost of treatment for 
low birth weight 
babies; cost of 
treatment of sexually 
transmitted infections 
(STIs); cost of 
Primary analysis:  
Model 1: Deterministic 
results (discounted) 
Total cost (billions): 
- ND: £1,527 
- DC: £1,519 
- DH: £1,417 
Cost per abortion averted: 
- DC: £815 
- DH: £1,514 (compared with 
DC) 
Cost per pregnancy averted 
(excluding benefits): 
- DC: £32 
- DH: £441 (compared with 
DC) 
Cost per pregnancy averted 
(including benefits): 
- DN: dominated by DC 
Limitations identified by 
author:  
- A lack of data on the long-
term employment and 
education impacts of teenage 
pregnancy meant that this 
could not be included in the 
analysis. If negative impacts 
on future productivity were 
included the intervention 
might appear more cost-
effective 
- Only primary transmission of 
STIs is considered in the 
model. Consideration of 
additional infections averted 
could improve the cost-
effectiveness ratio 
- The long-term implications 
of the interventions are not 
well known. For example, it is 
not clear if teenage 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and 
methods of analysis 
Results Notes 
Economic 
perspective: 
Public sector 
Quality score: 
Medium 
Applicability: 
Partly applicable 
 
National government 
statistics for England 
and Wales 
Probability of 
miscarriage and 
ectopic pregnancy: 
Hospital Episode 
Statistics (HES); a 
Denmark study was 
used to parameterise 
the miscarriage rates  
Long term of a 
teenage birth: 
Literature review 
including only UK 
papers and 
elicitation technique 
with programme 
development group 
(PDG) at NICE 
Sexually transmitted 
infection (STI) 
outcomes: NICE Sex 
and Relationship 
Education (SRE) 
3. Advance provision of 
emergency hormonal 
contraception (AP) 
Comparator/control 
description:  
1. School nurse only 
(ND) 
2. No follow-up 
following first 
pregnancy 
3. No advance provision 
of EHC (No AP) 
Sample sizes: 
Simulated cohort of 
100,00 young 
individuals 
government-funded 
benefits  
Time horizon: 
Lifetime 
Costing year(s) and 
currency: 2007-2008 
GBP 
Discount rates: 3.5% 
Perspective: Public 
sector 
Measures of 
uncertainty: One-way 
and probabilistic 
sensitivity analysis 
Modelling method: 
Cost-effectiveness 
modelling study with a 
hypothetical cohort 
over a lifetime from 
the age at which the 
intervention is 
provided; the 
following scenarios 
were modelled: 
1. School-based 
interventions for 
- DC: dominated by DH 
- DH: dominates DC and ND 
Model 2: Deterministic 
results (discounted) 
Total costs (millions): 
- No follow-up: £655,572 
- ICM: £705,730 
Cost per repeat teenage 
pregnancy averted (excluding 
benefits): ICM: £15,155 
Cost per repeat teenage 
pregnancy averted (including 
benefits): ICM: £4,031 
Model 3: Deterministic 
results (Discounted) 
Total cost (billions): 
- No AP: £1,524 
- AP: £1,447 
Cost per abortion averted: 
AP: £2,795 
Cost per age pregnancy 
averted: AP (excluding 
benefits): £310 
pregnancies are averted or 
delayed 
- Available evidence on 
contraceptive effectiveness in 
teenagers has been generated 
based on 6-12 months of 
follow-up 
- Outcomes are not reported 
in terms of QALYs gained, 
limiting the extent to which 
they can be compared with 
other interventions using this 
outcome 
- Variability in baseline health 
and risk factors is not 
captured in the model  
- The comparison within Model 
1 is highly dependent upon 
the true effectiveness of each 
of the methods of 
contraception 
- Research comparing the 
cost-effectiveness of different 
methods of contraception in 
terms of both STIs and 
contraception is sparse due to 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and 
methods of analysis 
Results Notes 
public health 
guidance  
Effectiveness: 
National statistics 
and assumptions 
Benefits: Office for 
National Statistics 
(ONS, 2009), 
previous published 
studies, assumptions 
Costs: British 
National Formulary 
(BNF 58, 2009), NICE 
assessment of Long-
Acting Reversible 
Contraception, 
health economic 
model developed for 
the NICE Sex and 
Relationship 
Education (SRE) 
public health 
guidance, NHS 
reference costs 
nulliparous young 
people 
2. School-based 
interventions to 
prevent repeat 
pregnancy 
3. Interventions to 
encourage the use of 
emergency hormonal 
contraception 
following unprotected 
sex 
Cost per age pregnancy 
averted: AP (including 
benefits) dominates 
Secondary analysis:  
Model 1: Expected results 
(discounted) 
Total cost (billions): 
- DN: £1,524 
- DC: £1,517 
- DH: £1,515 
Cost per abortion averted: 
- DC: £822 
- DH: £1,495 (compared with 
DC) 
Cost per pregnancy averted 
(excluding benefits): 
- DC: £38 
- DH: £443 (compared with 
DC) 
Cost per pregnancy averted 
(including benefits): 
- DN: dominated by DC 
- DC: dominated by DH 
the limitations around which 
outcome measure can 
reasonably capture both 
effects 
- The cost of maternity 
services may differ for 
teenage mothers compared 
with older mothers 
Limitations identified by 
review team: Authors stated 
that no preterm births were 
assessed, which may be more 
common amongst young 
people; however, this 
statement seems odd since 
multiples and low birth weight 
are included - unless low-birth 
weight is the same as 
preterm. Other adverse 
events associated with teen 
pregnancy, such as fistula, 
were not mentioned 
Evidence gaps and/or 
recommendations for future 
research: Modelling was 
based on previous model 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and 
methods of analysis 
Results Notes 
- DH: dominates DC and ND 
Model 1: Expected results 
(undiscounted) 
Total cost (billions): 
- DN: £2,307 
- DC: £2,297 
- DH: £2,295 
Cost per abortion averted: 
- DC: £848 
- DH: £1,535 (compared with 
DC) 
Cost per pregnancy averted 
(excluding benefits): 
- DC: £92 
- DH: £488 (compared with 
DC) 
Cost per pregnancy averted 
(including benefits): 
- DN: dominated by DC 
- DC: dominated by DH 
- DH: dominates DC and ND 
Model 2: Expected results 
(discounted) 
(NICE), but no discussion of 
model calibration has been 
provided 
Source of funding: Not 
declared 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and 
methods of analysis 
Results Notes 
Total cost (millions): 
- No follow-up: £654,756 
- ICM: £705,164 
Cost per repeat teenage 
pregnancy averted (excluding 
benefits): ICM: £15,175 
Cost per repeat teenage 
pregnancy averted (including 
benefits): ICM: £4,052 
Model 2: Expected results 
(undiscounted) 
Total cost (millions): 
- No follow-up: £825,978 
- ICM: £866,883 
Cost per repeat teenage 
pregnancy averted (excluding 
benefits): ICM: £15,186 
Cost per repeat teenage 
pregnancy averted (including 
benefits): ICM: £2,935 
Model 3: Expected results 
(discounted)  
Total cost (billions): 
- No AP: £1,522 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and 
methods of analysis 
Results Notes 
- AP: £1,445 
Cost per abortion averted: 
AP: £2,803 
Cost per age pregnancy 
averted: AP (excluding 
benefits): £314 
Cost per age pregnancy 
averted: AP (including 
benefits) dominates 
Model 3: Expected results 
(undiscounted)  
Total cost (billions): 
- No AP: £2,303 
- AP: £2,198 
Cost per abortion averted: 
AP: £2,948 
Cost per age pregnancy 
averted: AP (excluding 
benefits): £395 
Cost per age pregnancy 
averted: AP (including 
benefits) dominates 
Sensitivity analysis: 
Model 1: 
Appendix 10 
 
Sexual health promotion and contraceptive services in local authorities: a systematic review of economic evaluations 2010-2015  221 
 
Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and 
methods of analysis 
Results Notes 
PSA: 
The analysis shows very little 
difference in both costs and 
effectiveness between 
dispensing condoms within 
schools and dispensing 
hormonal contraceptives 
within schools. There is the 
possibility that either one 
could be more effective 
and/or more costly than the 
other  
One-way: 
-Delay in births averted (14-
16 years to 17-19 years): (1) 
DC would remain cost saving 
compared with ND for the 
cost per age 14–16 pregnancy 
averted including 
government-funded benefits; 
(2) DH would remain cost 
saving compared with DC 
within schools for this 
outcome  
- Pregnancies averted at ages 
14–16 years would have been 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and 
methods of analysis 
Results Notes 
additional: cost-effectiveness 
ratio for the cost per abortion 
averted decreases 
- Probability of condom 
failure is doubled: DC results 
in greater net costs than DH 
- Doubled risk of miscarriage: 
DC is estimated to result in 
net cost savings compared 
with ND 
- Increase in medical 
abortions: net cost savings of 
DC compared with ND 
- Increase in relative risk of 
both interventions: higher 
cost-effectiveness ratios than 
the base case analysis 
Model 2: 
PSA: 
- ICM is unlikely to result in 
net cost savings when 
excluding benefit payments 
- 20% probability that ICM will 
result in net cost savings 
(with government-funded 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and 
methods of analysis 
Results Notes 
benefits) compared with no 
follow-up after first teenage 
pregnancy 
One-way: 
- Reducing cost of 
intervention: cost per repeat 
teenage pregnancy averted 
(excluding benefits) of £6,844 
- Including benefits: ICM will 
dominate no follow-up after a 
teenage birth 
- Other variations do not have 
substantial impact upon the 
model results 
Model 3: 
PSA: 
- AP is unlikely to result in 
net cost savings using the cost 
per abortion averted outcome 
- 24% probability AP will 
result in net cost savings 
when using the cost per age 
15–19 pregnancy averted 
outcome (excluding benefit 
payments) 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and 
methods of analysis 
Results Notes 
- AP is likely to be cost saving 
using a cost per age 15–19 
pregnancy averted outcome 
(including Benefit payments) 
One-way: 
- Increasing the baseline 
usage of EHC following 
unprotected sex: AP 
dominates, including and 
excluding government-funded 
benefit payments; estimated 
cost per abortion averted 
associated with AP decreases 
to £688 
- Other variations do not have 
substantial impact upon the 
model results 
Rodriguez et al.  
(2010a) 
Aim of study: To 
estimate the 
costs of 
expanding 
Emergency 
Medicaid 
coverage to 
Source populations: 
Latina immigrant 
women in 10 states 
with a high 
proportion of 
immigrants, who 
have been in the 
United States for 
fewer than 5 years 
Intervention 
description: Expanded 
Emergency Medicaid 
coverage to include 
postpartum 
contraception: 
- IUD 
- female surgical 
sterilisation 
Main outcome:  
-Number of 
pregnancies averted 
-Net savings 
Time horizon: 5 years 
Costing year(s) and 
currency: 2002 USD 
Discount rates: 3% 
Primary analysis:  
benefits: 
-In the 4 years following 
delivery, 18.5% of EM patients 
had a subsequent admission 
at OHSU for an obstetrical 
diagnosis 
-In the absence of a 
postpartum IUD programme, 
Limitations identified by 
author:  
-Modelling limited by the 
imprecision of healthcare cost 
estimates 
- The study considered 
Medicaid payments and costs 
in only one state 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and 
methods of analysis 
Results Notes 
include 
postpartum 
contraception 
Type of 
economic 
analysis: Cost-
benefit analysis 
Economic 
perspective: 
Three 
perspectives: the 
hospital, state 
Medicaid 
programmes and 
society 
Quality score: 
Low 
Applicability: 
Partly applicable 
and have just given 
birth 
Setting: US 
Data sources: Study 
database (all women 
with EM who 
delivered at the 
Oregon Health and 
Science University – 
OHSU – in 2002); 
trial conducted by 
the World Health 
Organization, 
literature 
- DMPA 
- oral contraceptives 
- condoms 
Comparator/control 
description: Status 
quo. 
Sample sizes:  
Total: 1,037 women 
Unclear how they 
divided the groups for 
comparison  
Perspective: Hospital, 
state Medicaid 
programmes and 
society 
Measures of 
uncertainty: 
Univariate sensitivity 
analysis 
Modelling method: 
Cost-benefit analysis 
266 women per 1,000 EM 
patients will have a repeat 
pregnancy within 4 years at 
OHSU  
-For every 1,000 women who 
receive an IUD, 122 
pregnancies were expected 
due to discontinuation or 
expulsion and 18 pregnancies 
due to IUD method failure  
-It was estimated that 126 
pregnancies would be averted 
from a postpartum IUD 
programme 
Costs (4 years’ analysis): 
-IUD insertion and removal for 
1000 women estimated at 
£215,824 ($328,000)  
-For EM at hospital a cost of 
£140,812 ($214,000) (without 
IUD) and £78,302 ($119,000) 
was estimated with an IUD 
programme in place  
Cost-benefit analysis: 
-From the hospital 
perspective, the hospital 
- The additional benefits that 
family planning provides was 
not taken into account in the 
analysis 
-The study assumed normal, 
term pregnancies. However, 
some of these pregnancies 
would lead to preterm births, 
which are more expensive to 
all three payer perspectives 
-Limited ability to predict the 
effect that free postpartum 
contraception would have on 
uptake 
Limitations identified by 
review team: Authors 
identified main limitation 
related to the model in 
question 
Evidence gaps and/or 
recommendations for future 
research: Further research 
into interstate migratory 
patterns and probabilities 
should be conducted to assess 
the economic value of a 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and 
methods of analysis 
Results Notes 
would lose £0.46 per £1 (70 
cents per dollar) spent on a 
postpartum IUD programme or 
a benefit–cost ratio of 0.30 
-From the state’s 
perspective, the state would 
save £1.93 ($2.94) in costs for 
repeat obstetrical care for 
every state dollar spent on an 
IUD programme 
Secondary analysis:  
-Varying the discontinuation 
rates and expulsion rates did 
not affect the positive savings 
to the state of financing 
postpartum IUD provision 
-The programme remains 
cost-effective for the state 
unless first-year 
discontinuation rate becomes 
as high as 90%, significantly 
higher than the expected 
postpartum IUD expulsion 
rate of 12% 
-Programme costs for the 
state would break even with 
federal mandate for 
preventive coverage of new 
immigrants 
Source of funding: Funded by 
an anonymous donor. Dr 
Caughey is supported in part 
by a grant under the Robert 
Wood Johnson Foundation 
Physician Faculty Scholars 
Programme. The authors 
report no conflict of interest. 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and 
methods of analysis 
Results Notes 
costs of subsequent care if 
the IUD expulsion rate 
exceeded 70% 
-IUD costs would need to 
exceed £6,909 ($10,500) per 
woman before the programme 
would begin to cost the state 
more than future pregnancy 
costs 
Rodriguez et al. 
(2010b) 
Aim of study: To 
examine the 
hospital and 
state costs of 
offering the 
option of a 
postpartum 
intrauterine 
device (IUD) to 
an underinsured 
population of 
recent 
immigrants to 
the United States 
with Emergency 
Source populations: 
Women with EM who 
delivered at Oregon 
Health and Science 
University (OHSU) in 
July 2001 and 
December 2006 
Setting: OHSU, USA 
Data sources:  
Annual rates of 
pregnancy in the 
absence of the 
programme: Hospital 
records 
Mean pregnancy 
costs and revenue 
and probability of 
Intervention 
description: Long-
acting method of 
contraception 
postpartum to women 
with EM: hospital 
provision of IUDs 
postpartum and state 
funding of IUDs 
postpartum 
Comparator/control 
description: Hospital’s 
current policy 
of covering only the 
obstetrical delivery 
Sample sizes: 
Simulated cohort of 
Outcomes:  
Cost: Mean charges 
and mean net revenue 
for each pregnancy 
outcome type 
Benefit: Number of 
pregnancies that 
would be averted by 
offering a postpartum 
IUD to EM patients 
Time horizon: 4 years 
Costing year(s) and 
currency: 2008 USD 
Discount rates: Annual 
rate of 3% 
Primary analysis: 
State perspective 
Absence of a postpartum IUD 
programme:  
Pregnancies: 226 
Total costs: £1,371,300 ($2.1 
million) 
Postpartum IUD programme:  
Benefit: 126 pregnancies 
averted 
Total cost of the programme: 
£99,885 ($152,964) 
Costs of pregnancies 
expected: £653,000 (~$1 
million)  
Limitations identified by 
author:  
- The model underestimates 
the total costs of unintended 
pregnancy because the 
hospital does not cover 
elective, uncomplicated 
abortions 
- Data from a single hospital, 
thus the results are specific to 
this hospital and do not 
capture repeat pregnancies 
seen at other area hospitals 
- Conservative estimate of 
cost savings because repeat 
pregnancy was calculated 
from a single institution  
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and 
methods of analysis 
Results Notes 
Medicaid (EM) 
insurance 
coverage only 
Type of 
economic 
analysis: Cost–
benefit analysis 
Economic 
perspective: 
Hospital and the 
state 
Quality score: 
Low 
Applicability:  
Partly applicable 
repeat pregnancy 
and pregnancy 
outcome: 
Institution’s 
department-specific 
cost-to-charge ratio, 
hospital billing 
records  
Probability of IUD 
uptake and 
continuation: 
Hospital records and 
literature 
IDU baseline 
expulsion rates: 
Trial conducted by 
the World Health 
Organization 
Pregnancy outcomes: 
Hospital records 
individuals derived from 
multiple estimates 
Perspective: Hospital 
and the state 
Measures of 
uncertainty: 
Sensitivity analyses to 
assess how a 
decreased and 
increased expulsion 
rate would affect the 
cost outcome from 
both perspectives 
Modelling method: 
Not reported 
Net saving for the state:  
2003: £3,244 ($4,968) 
2004: £211,722 ($324,229) 
2005: £168,408 ($257,899) 
2006: £147,437 ($225,784) 
The state would save £1.92 
($2.94) in costs for repeat 
obstetrical care for every 
state dollar spent on an IUD 
programme 
Hospital perspective 
- Programme costs for an IUD, 
insertion and removal: 
£214,184 ($328,000) 
- Cost of repeat pregnancy 
without the programme: 
£139,742 ($214,000) 
- Cost of repeat pregnancy 
with the programme: £77,707 
($119,000) 
- Benefit–cost ratio of 0.30 
Secondary analysis: N/A 
Sensitivity analysis: Cost-
effectiveness of a postpartum 
- The study only considers 
women who had repeat 
pregnancies in their first 5 
years in the US and did not 
capture women who had a 
birth on EM, then became 
eligible for Standard Medicaid 
(SM) during a repeat 
obstetrical admission 
- The model includes direct 
costs associated with 
admission for an obstetrical 
diagnosis and does not 
consider that an infant born 
to a woman with EM can be 
eligible for a full array of 
public services 
- The study underestimates 
new-born costs because this 
assumes that all new-borns 
are healthy  
Limitations identified by 
review team: Details of the 
modelling method were not 
provided by the authors 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and 
methods of analysis 
Results Notes 
IUD programme is robust and 
varying the discontinuation 
and expulsion rates did not 
affect the positive savings to 
the state of financing 
postpartum IUD provision. 
The programme remains cost-
effective for the state unless 
first-year discontinuation rate 
becomes as high as 90%, 
significantly higher than the 
expected postpartum IUD 
expulsion rate of 12%. 
Programme costs for the state 
would break even with costs 
of subsequent care if the IUD 
expulsion rate exceeded 70%. 
IUD costs would need to 
exceed $10,500 per woman 
before the programme would 
begin to cost the state more 
than future pregnancy costs. 
Evidence gaps and/or 
recommendations for future 
research: The extension of 
the study to include 
complications would give a 
better scenario about IUD 
programmes  
Source of funding: Study 
funded by an anonymous 
donor 
 
Salcedo et al. 
(2010) 
Aim of study: To 
evaluate the 
Source populations: 
Low-income women 
Setting: USA, 
California 
Intervention 
description: Immediate 
post-abortion IUD 
insertion 
Outcomes: Public 
programme costs, 
rates of unintended 
pregnancy 
Including costs of only direct 
medical care of IUD 
insertion: 
1 year: £75 ($111)  
Limitations identified by 
author:  
- Future pregnancies for 
women who breastfeed may 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and 
methods of analysis 
Results Notes 
potential cost 
savings 
associated with a 
policy of 
immediate post-
abortion IUD 
insertion, 
compared to 
planned IUD 
insertion at the 
time of abortion 
follow-up  
Type of 
economic 
analysis: Cost 
saving 
Economic 
perspective: 
Public payer 
Quality score: 
Medium 
Applicability: 
Partly applicable 
Data sources:  
Model probabilities: 
Literature 
Contraception 
uptake rates: 
California Family 
Planning, Access, 
Care, and Treatment 
(PACT) female client 
population 
Cost inputs: 
California Medicaid 
and Family PACT  
 
Comparator/control 
description: Planned 
IUD insertion at the 
time of abortion follow-
up 
Sample sizes: 
Simulated cohort of 
individuals derived from 
multiple estimates 
Time horizon: 1 year 
and 5 years 
Costing year(s) and 
currency: 2011 USD 
Discount rates: 3% per 
year 
Perspective: Public 
payer 
Measures of 
uncertainty: 
Univariated (triangular 
distribution) and 
bivariated sensitivity 
analysis and Monte 
Carlo simulation with 
10,000 trials 
Modelling method: 
Decision analytic, 
Markov model  
5 years: £548 ($810) 
Including public health 
insurance and social 
programme costs:  
1 year: £1,324 ($1,956) 
5 years £2,908 ($4,296) 
Secondary analysis:  Over 5 
years, for every 1,000 low-
income women who undergo 
immediate post-abortion IUD 
placement, more than 400 
pregnancies, 180 deliveries 
and 160 abortions will be 
averted 
Sensitivity analysis: 
Sensitivity analyses 
demonstrate that results are 
robust over a wide range of 
model inputs  
Input variations for a no cost 
saving programme: 
- Over 1 year: increasing 25% 
of the IDU price and 
considering only direct costs 
be overestimated because the 
model assumes that women 
who became pregnant 
maintained the same chance 
of pregnancy in the following 
cycle  
- There is no difference 
between pregnancies that are 
avoided and those that are 
delayed as a result of public 
funding for contraception. 
Thus, when a woman delays 
pregnancy for the duration of 
the model and becomes 
pregnant later, public 
spending is only deferred. The 
study estimates that half of 
all pregnancies in the model 
are truly averted. Therefore, 
the savings would be reduced 
by less than 50% 
Limitations identified by 
review team:  
Model is heavily based on 
secondary data and authors 
should have discussed better 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and 
methods of analysis 
Results Notes 
 - Over 5 years following the 
abortion: increasing the costs 
of the IUD to £2,332 ($3,444) 
or £4,595 ($6,787), 
considering public health 
insurance and social 
programme costs respectively 
- Expulsion rates for 
immediate post-abortion IUDs 
surpassing 30% 
- Planned IUD placement at 
abortion follow-up occurring 
more than 89% of the time for 
immediate post-abortion IUD 
placement  
Monte Carlo simulations: 
Results were consistent with 
those of the univariate 
sensitivity analyses  
Considering costs of 
contraception and pregnancy-
related care:  
- Over 1 year: the programme 
was cost saving in 61% of 
scenarios  
the applicability of 
parameters and implications 
of extension of conclusions to 
the population implications 
were only partly included in 
the model (no STIs for 
example) 
Evidence gaps and/or 
recommendations for future 
research: The inclusion of 
complications would express 
the full benefits of 
interventions to society 
Source of funding: Society of 
Family Planning Research 
Fund  
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and 
methods of analysis 
Results Notes 
- Over 5 years: the 
programme was cost saving in 
84% of scenarios  
Including public health 
insurance and social 
programme costs: 
- Over 5 years: the 
programme was cost saving in 
89% and 90% of trials 
respectively 
Thomas (2012) 
Aim of study: 
Stated as ‘to 
assess the fiscal 
impact of three 
national-level 
policies designed 
to prevent 
unintended 
pregnancy’. In 
practice, the 
author wanted to 
assess the 
financial benefit 
of implementing 
interventions to 
Source populations: 
10,000 individuals 
aged 15-44 whose 
demographic 
characteristics were 
nationally 
representative (of 
USA)  
Setting: United 
States 
Data sources: The 
General Social 
Survey and the 
National Survey of 
Family Growth; the 
Guttmacher 
Intervention 
description:  
1. Mass media campaign 
2. Evidence-based teen 
pregnancy prevention 
programme  
3. Expanded access to 
Medicaid Family 
Planning 
Comparator/control 
description: N/A 
Sample sizes: Total N = 
10,000 simulation 
cohort 
Outcomes (linked to 
unattained 
pregnancies):  
Main: Benefit-cost 
ratio 
Others: % reduction in 
abortion; % reduction 
in births; % reduction 
in number of children 
born into poverty; 
programme costs, 
public savings, fiscal 
savings  
Time horizon: 5 years 
Primary analysis:  
Benefits: 
-% reduction in abortion: Mass 
media (3.9%); evidence-based 
teen pregnancy prevention 
programme (1.4%); expanded 
access to Medicaid Family 
Planning (3.5%) 
- % reduction in births: Mass 
media (1.0%); evidence-based 
teen pregnancy prevention 
programme (0.6%); expanded 
access to Medicaid Family 
Planning (1.4%) 
- % reduction in number 
children born into poverty: 
Limitations identified by 
author:  
Does not account for: 
- spending on children over 
the age of 5 
- private costs of unintended 
pregnancy (e.g. lower 
earnings of mother) 
- other potentially important 
societal costs 
Does not consider likely effect 
on spread of STIs 
Scale-up of small 
interventions may be less 
effective than assumed 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and 
methods of analysis 
Results Notes 
prevent 
unintended 
pregnancies using 
a cost-benefit 
analysis 
Type of 
economic 
analysis: Cost-
benefit 
Economic 
perspective: 
Government and 
social 
Quality score: 
Medium 
Applicability: 
Partly applicable 
Institute, the 
National Vital 
Statistics System; 
data from the 
Current Population 
Survey were used to 
parameterise the 
model that assigns 
a poverty status to 
each newborn 
child; meta-analysis 
for behaviour 
effects; Truth, 
VERB, and National 
Youth Anti-Drug 
Media (NYADMC) 
campaigns (costs); 
literature for both 
benefits and costs 
Costing year(s) and 
currency: 2008 USD 
Discount rates: 3% 
Perspective: Social 
and public sector 
(government) 
Measures of 
uncertainty: One-way 
sensitivity analysis 
Modelling method: 
Cost-benefit analysis 
Mass media (2.2%); evidence-
based teen pregnancy 
prevention programme 
(1.4%); expanded access to 
Medicaid Family Planning 
(1.8%) 
Costs: 
-Programme costs (millions): 
mass media: £65.3 ($100); 
evidence-based teen 
pregnancy prevention 
programme: £94,685 ($145); 
expanded access to Medicaid 
Family Planning: £153,455 
($235) 
Public savings: 
For pregnancy care alone: 
-Mass media: £24,164,437 
($37,005,263); benefit-cost 
ratio: £0.24 ($0.37) 
-Evidence-based teen 
pregnancy prevention 
programme: £241,597,209 
($369,980,412); benefit-cost 
ratio: £0.17 ($0.26) 
Assumption of effectiveness of 
national media campaign may 
be incorrect 
Programme costs and baseline 
parameters were uncertain 
Limitations identified by 
review team: Author has 
identified main limitations 
Evidence gaps and/or 
recommendations for future 
research: Short and long term 
complication to be taken into 
account. 
Source of funding: The 
William and Flora Hewlett 
Foundation  
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and 
methods of analysis 
Results Notes 
-Expanded access to Medicaid 
Family Planning: £79,455,150 
($121,677,106); benefit-cost 
ratio: £0.59 ($0.62) 
Pregnancy care plus infant 
medical: 
-Mass media: £58,929,344 
($90,244,018); benefit-cost 
ratio: £0.59 ($0.90) 
-Evidence-based teen 
pregnancy prevention 
programme: £51,856,523 
($79,412,746); benefit-cost 
ratio: £0.36 ($0.55) 
-Expanded access to Medicaid 
Family Planning: 
£186,002,878 ($284,843,611); 
benefit-cost ratio: £0.79 
($1.21) 
Pregnancy care plus children 
benefits: 
-Mass media: £281,383,852 
($430,909,421); benefit-cost 
ratio: £2.81 ($4.31) 
-Evidence-based teen 
pregnancy prevention 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and 
methods of analysis 
Results Notes 
programme: £232,562,922 
($356,145,363); benefit-cost 
ratio: £1.61 ($2.46) 
-Expanded access to Medicaid 
Family Planning: 
£862,217,932 
($1,320,394,996); benefit-
cost ratio: £3.67 ($5.62) 
Secondary analysis: Findings 
were relatively insensitive to 
large changes in the 
assumptions underlying the 
analysis, e.g. results of the 
preferred specifications 
suggest that, even if the cost 
of the Medicaid expansion 
were twice as high as it was 
assumed to be — or if the 
benefits of the teen 
pregnancy prevention 
programme were twice what 
they were estimated to be — 
the benefit-cost ratios for the 
former would still be at least 
as large as for the latter. 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and 
methods of analysis 
Results Notes 
Conversely, the results from 
the preferred specifications 
that account for spending on 
children through age 5 
suggest that, even if these 
programmes were half as 
effective (or twice as 
expensive) as they were 
assumed to be, all of them 
would have benefit-cost 
ratios of greater than 1 
Thomas and 
Cameron (2013) 
Aim of study: To 
calculate the 
cost of an 
unintended 
pregnancy in 
2011 and use this 
cost in a cost-
effectiveness 
model comparing 
ulipristal acetate 
(UPA) with 
levonorgestrel 
(LNG) for 
emergency 
Source populations: 
Women in England 
presenting in 
primary care for EHC 
within 24 to 72 hrs 
of unprotected 
sexual intercourse 
Setting: English 
primary care 
Data sources:  
Health outcome: 
Probabilities of 
unintended 
pregnancies from 
clinical trials of EHC, 
Intervention 
description: Ulipristal 
acetate (UPA) 30 mg 
indicated for EC within 
120 hrs of unprotected 
sexual intercourse 
(UPSI) 
Comparator/control 
description: 
Levonorgestrel (LNG) 
1.5 mg, which is 
indicated for EC if 
taken within 72 hrs of 
UPSI 
Primary outcome: 
Number of unintended 
pregnancies and direct 
and indirect costs of 
unintended pregnancy 
Secondary outcome: 
Consequence of 
unintended pregnancy 
(miscarriage, abortion, 
ectopic pregnancy, 
stillbirth or live birth) 
Time horizon: One 
year 
Costing year(s) and 
currency: 2011 GBP 
Primary analysis:  
Direct health costs of a 
pregnancy: 
-£3.9 billion (average cost: 
£3,903) 
-Cost per event: Miscarriage: 
£554; abortion: £714; ectopic 
pregnancy: £1,228; stillbirth: 
£3,765; live birth: £5,337 
Indirect health costs: 
Government expenditure on 
maternal health benefits: 
£2.3 billion plus £34 billion in 
tax credits and child benefits 
Overall analysis:  
Limitations identified by 
author:  
-Post-natal care costs for the 
mother were not included in 
the analysis 
-Cost estimates are based on 
average pregnancy costs, 
which may be different from 
the costs associated with an 
unintended pregnancy  
Limitations identified by 
review team: No additional 
limitations identified for this 
type of analysis 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and 
methods of analysis 
Results Notes 
hormonal 
contraception 
(EHC) 
Type of 
economic 
analysis: Cost-
effectiveness 
analysis 
Economic 
perspective: 
Healthcare only 
or health plus 
social care 
Quality score: 
Low 
Applicability: 
Partially 
applicable 
 
published data 
sources and studies 
conducted on 
pregnancy intention 
in women in UK. 
Measure of 
effectiveness was 
number needed to 
treat 
Costs: Records from 
the NHS hospitals; 
NHS national 
Schedule of 
Reference Costs  
Sample sizes: 
Simulated cohort of 
individuals derived from 
multiple estimates 
Discount rates: Not 
applicable as time 
horizon is one year 
Perspective: 
Healthcare and 
societal 
Measures of 
uncertainty: 
Sensitivity analysis: 
failure rates of EHC 
and costs of 
unintended 
pregnancies  
Modelling method: 
N/A - not a modelling 
study 
-Cost of treating woman with 
UPA instead of LGN: 
Healthcare cost: £1,469; 
health and societal costs: 
£1,469 (same) 
-Avoided costs (pregnancy 
averted): Healthcare costs: 
£1,663, health and societal 
costs: £2,992 
-ICER (net benefit): Costs of 
treating minus avoided costs: 
Healthcare costs: −£194; 
Health and societal costs: 
−£1,453 
Secondary analysis: None 
Sensitivity analysis: All main 
parameters were varied. The 
sensitivity analysis did not 
change the results and has 
produced negative ICERs for 
the main outcomes of 
analysis, indicating robustness 
of the cost-saving analysis 
Evidence gaps and/or 
recommendations for future 
research: Long-term 
implications for the 
interventions could be 
explored in a modelling study 
Source of funding: HRA 
Pharma UK & Ireland Ltd, 
manufacturers of ellaOne 
(UPA) 
CT has worked as a consultant 
for HRA Pharma Ltd, the 
manufacturer of UPA. SC has 
received lecture fees from 
HRA Pharma Ltd and was the 
principal investigator for the 
clinical studies of UPA, which 
were also sponsored by HRA 
Pharma Ltd 
 
Trussell et al. 
(2013) 
Source populations: 
Women aged 15–44 
years who are 
Intervention 
description: Reversible 
contraceptive methods: 
Outcomes: Cost 
impact of increased 
uptake of LARC 
Primary analysis: Impact of 
increased LARC utilisation 
(millions) 
Limitations identified by 
author:  
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and 
methods of analysis 
Results Notes 
Aim of study: To 
estimate the cost 
to third-party 
payers associated 
with unintended 
pregnancies; to 
estimate the 
proportion of this 
cost attributable 
to imperfect 
contraceptive 
adherence; and 
to estimate cost 
savings that 
might be 
generated by 
women switching 
to LARC from 
other 
contraceptive 
methods 
Type of 
economic 
analysis: Costing 
study 
Economic 
perspective: 
sexually active and 
of child-bearing age 
but who currently 
neither seek 
pregnancy nor wish 
to be permanently 
sterilised 
Setting: USA 
Data sources:  
UP related events: 
National Survey of 
Family Growth 
(NSFG), 
administrative 
claims database of 
US commercial 
health plans and 
assumptions 
Costs of UP-related 
events: Medicare 
Fee Schedule 2011 
Utilisation of 
contraceptive 
methods: NSFG 
Costs of 
contraceptives: IMS 
SARC - oral 
contraceptive pill (OC), 
male condom, patch, 
injectables and vaginal 
ring.  
LARC - implant, 
intrauterine device 
(IUD) and hormonal 
intrauterine system 
(IUS) 
Comparator/control 
description: No method 
Sample sizes: 
Simulated cohort of 
individuals derived from 
multiple estimates 
methods according to 
three scenarios: 
1. 10% of women aged 
20–29 who are 
currently using OC 
switched to LARC 
2. 10% of women aged 
20–29 who are 
currently using any 
SARC method switched 
to LARC. 
3. 10% of women aged 
20–29 who are 
currently using either 
SARC or no method 
switched to LARC 
Time horizon: 1 year 
Costing year(s) and 
currency: 2011 USD 
Discount rates: Not 
applicable; time 
horizon of one year 
Perspective: Third- 
party payers 
Current practice: 
Cost of UP: £1,639 ($2,421) 
Cost of contraception: £3,019 
($4,460) 
Total cost impact: £4,658 
($6,881) 
Scenario 1: 
-Cost of new contraceptive 
practice: 
Cost of UP: £1,604 ($2,370) 
Cost of contraception: £2,859 
($4,223) 
Total cost impact: £4,463 
($6,593) 
-Cost savings 
Cost of UP: £35 ($51) 
Cost of contraception: £160 
($237) 
Total cost impact: £195 
($288) 
Scenario 2: 
-Cost of new contraceptive 
practice: 
Cost of UP: £1,559 ($2,303) 
- The model includes first-
year failure rates for 
contraceptive methods, which 
may be higher than failure 
rates for subsequent years. 
Consequently, the estimated 
number of UPs may be 
overstated, as may cost 
savings generated from 
switching to LARC methods 
- For live births, the model 
includes only direct cost of 
delivery and omits pre-natal 
costs, long-term economic, 
social and health impacts of 
UP. Thus, the cost of UP is 
likely to be underestimated, 
as are cost savings when 
switching from SARC to LARC 
methods 
- Conservative assumption 
that 10% switch to LARC 
methods in the switching 
analysis. Potential cost 
savings arising from this 
switch may be underestimated 
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setting 
Intervention/ 
comparator 
Outcomes and 
methods of analysis 
Results Notes 
Third-party 
healthcare payer 
perspective 
Quality score: 
Medium 
Applicability: 
Partly applicable 
Multinational 
Integrated Data 
Analysis System 
(MIDAS), market 
share data used in 
conjunction with 
price data from the 
Medi-Span Master 
Drug Database, 
Medicare Fee 
Schedule, 
assumptions 
UP due to imperfect 
adherence: Research 
literature 
Cost of pregnancy 
outcomes: Medicare 
Physicians Fee 
Schedule, NSFG 
Measures of 
uncertainty: 
Sensitivity analysis 
explored the impact of 
increased use of LARC 
on potential savings 
when costs of implant, 
IUD and IUS were not 
annualised. An 
additional sensitivity 
analysis estimated the 
duration of time that 
LARC methods would 
need to be used 
following a switch to 
achieve cost 
neutrality, defined as 
a zero net cost impact 
to the payer  
Modelling method: 
Cost model  
Cost of contraception: £2,845 
($4,203) 
Total cost impact: £4,201 
($6,206) 
-Cost savings: 
Cost of UP: £79 ($117) 
Cost of contraception: £174 
($257) 
Total cost impact: £254 
($375) 
Scenario 3: 
-Cost of new contraceptive 
practice: 
Cost of UP: £1,494 ($2,207) 
Cost of contraception: £2,869 
($4,238) 
Total cost impact: £4,363 
($6,445) 
-Cost savings: 
Cost of UP: £145 ($214) 
Cost of contraception: £150 
($222) 
Total cost impact: £295 
($436) 
- The prices Medicare used to 
calculate the cost of UP 
outcomes are likely to be 
lower than costs incurred by 
private third-party payers. 
Therefore, the cost of a UP, 
and the cost savings 
generated from switching to 
LARC, may be higher in a 
private-payer setting 
- The analysis did not consider 
the cost of side-effects and 
the impact of contraceptive 
method discontinuation and 
switching beyond a 1-year 
period  
- Wholesale acquisition costs 
for contraceptives used in the 
analysis may not reflect 
actual costs faced by third-
party payers, who may obtain 
discounts or rebates 
Limitations identified by 
review team: Main limitations 
related to the model already 
identified by the authors 
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setting 
Intervention/ 
comparator 
Outcomes and 
methods of analysis 
Results Notes 
Secondary analysis:  
Estimated annual number of 
UPs: 3.11 million: 1.44 million 
live births, 1.11 million 
induced abortions, 539,000 
spontaneous abortions and 
19,000 ectopic pregnancies 
Cost for each UP in the US 
outcome: 
-Hospital inpatient: 
Live birth: £3,202 ($4,729) 
Induced abortion: £2,386 
($3,524) 
Spontaneous abortion: £1,942 
($2,869) 
Ectopic pregnancy: £3,054 
($4,511) 
-Hospital outpatient: 
Induced abortion: £1,159 
($1,712) 
Spontaneous abortion: £1,195 
($1,765) 
-Non-hospital: 
Induced abortion: £205 ($303) 
Evidence gaps and/or 
recommendations for future 
research: To include full 
range of complications (not 
only those related to delivery) 
in order to capture the full 
potential costs averted by 
society/public sector 
Source of funding: Anna 
Filonenko is a full-time 
employee of Bayer Pharma 
AG. Amy Law and Alexander 
Prezioso are full-time 
employees of Bayer 
Healthcare Pharmaceuticals 
Inc. Nathaniel Henry and 
Fareen Hassan are full-time 
employees of IMS Health and 
served as paid consultants to 
Bayer Healthcare 
Pharmaceuticals Inc. for the 
development of this study and 
manuscript. James Trussell is 
a full-time professor of 
economics and public affairs 
at Princeton University and 
received a consultancy fee 
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comparator 
Outcomes and 
methods of analysis 
Results Notes 
Spontaneous abortion: £247 
($365) 
Annual cost of UP: £3.11 
billion ($4.6 billion) 
- Annual contraceptive costs 
ranged from £15 ($22) for 
condoms to more than £677 
($1,000) for the patch 
Costs of perfect and 
imperfect adherence: 
- All SARC and LARC methods 
considered are associated 
with UP rates of 2 or less per 
100 women within the first 
year of perfect use (0.05-2) 
-Implication of imperfect 
adherence: 1.64 million UPs 
-Total cost of UP due to 
imperfect adherence: £167.22 
billion ($2.47 billion) 
Sensitivity analysis:  
- When costs are not 
annualised, in the 20–29-year 
age group, switching from 
from Bayer Pharma AG for his 
contribution to this work 
 
 
 
Appendix 10 
 
Sexual health promotion and contraceptive services in local authorities: a systematic review of economic evaluations 2010-2015  242 
 
Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and 
methods of analysis 
Results Notes 
non-LARC to LARC methods 
results in net cost increases 
- 10% of women switching to 
LARC from OCs, SARC, and no 
method results in net cost 
increases 
- Among women currently 
using OC, assuming a 10% 
switch to LARC, cost 
neutrality is achieved after 
1.33 years in women aged 20–
24 and after 1.39 years in 
women aged 25–29; among 
women currently using any 
SARC, cost neutrality is 
achieved after 1.62 years 
(aged 20–24) and 1.82 years 
(aged 25–29); among women 
currently using any SARC or 
using no method, cost 
neutrality is achieved after 
1.63 years (aged 20–24) and 
1.90 years (aged 25–29) 
Trussell et al. 
(2014) 
Source populations: 
Young women 
requiring 
Intervention 
description: LNG-IUS 
13.5 mg 
Outcomes: Cost per 
unintended pregnancy 
(UP) avoided, net 
Primary analysis: 
Effectiveness: 
- SARC: 276 UP 
Limitations identified by 
author:  
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and 
methods of analysis 
Results Notes 
Aim of study: To 
evaluate the 
cost-
effectiveness of 
LNG-IUS 13.5 mg 
in comparison 
with short-acting 
reversible 
contraceptive 
(SARC) methods 
in a cohort of 
young women in 
the United States 
from a third-
party payer’s 
perspective 
Type of 
economic 
analysis: Cost-
effectiveness 
analysis 
Economic 
perspective: 
Third-party 
payer’s 
perspective, 
side-effect costs, 
contraception in the 
United States, aged 
20–29 years 
Setting: USA 
Data sources:  
Failure and 
discontinuation 
probabilities: 
Systematic review, 
assumptions 
Contraceptive 
uptake: Recent data 
from the National 
Survey of Family 
Growth 
Costs: Medi-Span 
Master Drug 
Database, current 
Procedural 
Terminology (CPT) 
2008 Codebook 
derived from 
Healthcare Cost and 
Utilization Project 
data and the 2012 
non-facility 
Comparator/control 
description: Mixed 
market-weighted basket 
of SARC methods: 
branded and generic 
oral contraceptives 
(OC), ring, patch and 
injections; no method 
(chance) 
Sample sizes: 
Simulated cohort of 
individuals derived from 
multiple estimates 
monetary benefit 
(NMB) 
Time horizon: 3 years 
and 1 year of cycle 
length 
Costing year(s) and 
currency: 2012 USD 
Discount rates: 3% in 
all costs 
Perspective: Third-
party healthcare payer 
Measures of 
uncertainty: One-way 
and probabilistic 
sensitivity analysis and 
scenario analysis  
Modelling method: 
State transition model 
- LNG-IUS 13.5 mg: 64 UP 
Cost: 
- UDC: £ 1,257,277 
($1,862,633) 
- LNG-IUS 13.5 mg: £ 866,348 
($1,283,479) 
* LNG-IUS 13.5 mg is a 
dominant intervention 
Secondary analysis: None 
Sensitivity analysis:  
- One-way sensitivity analysis 
show that the results were 
most sensitive to the 
probability of failure of OC, 
the probability of 
discontinuation associated 
with LNG-IUS 13.5 mg and the 
cost of live births  
- The base case probability of 
failure of OC is 0.090 (typical 
use) and varying the input 
between a lower bound set to 
the perfect use probability, 
and an upper bound set to 
30% more than the base case 
- The analysis considers 
‘Typical use’ failure 
probabilities only for the first 
year of contraceptive use. 
However, failure rates are 
likely to be lower in the 
subsequent years. As a 
consequence, the cost impact 
of UP and the consequential 
incremental cost savings 
generated from UP avoided 
while on LNG-IUS 13.5 mg vs 
SARC may have been over- 
estimated in the model  
- Medicare prices are likely to 
be lower than those of private 
insurers. Therefore, the cost 
impact of UP may be 
underestimated 
- The model assumes that the 
subsequent year 
discontinuation was lower 
than discontinuation in the 
first year of use. However, 
the rate is likely to change 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and 
methods of analysis 
Results Notes 
non-medical 
direct costs and 
indirect costs not 
considered 
Quality score: 
Low 
Applicability: 
Partly applicable 
payments from the 
Medicare 
Reimbursement Fee 
Schedule; diagnosis-
related group (DRG) 
2008 Codebook, 
published data 
 
input retains a positive NMB 
and preserves the cost-
effectiveness of LNG-IUS 13.5 
mg  
- When the base case 
probability of discontinuation 
associated with LNG-IUS 13.5 
mg or the base case cost of 
live birth is varied by 30% 
NMB remains positive, 
preserving the cost-
effectiveness of LNG-IUS 13.5 
mg 
- PSA outputs demonstrated 
that 100% of model 
simulations fell in the 
southeast quadrant of the 
cost-effectiveness plane, 
indicating that the 
intervention was both 
cheaper and more effective 
than the SARC in all iterations 
- Scenario analysis assuming a 
1-year time horizon found 
LNG-IUS 13.5 mg to be more 
and it is unlikely to be the 
same across different methods  
- The absence of robust data 
on switching preferences 
necessitated a mixed market-
weighted contraceptive 
‘basket’ to act as a proxy for 
the subsequent method 
women would switch to once 
their initial method failed or 
when they chose to 
discontinue it. The mixed 
contraceptive ‘basket’ was a 
construct that approximated 
the average choices of women 
switching contraceptive 
method and was required as 
assumptions could not be 
made on the exact method to 
which women might switch 
Limitations identified by 
review team: Limited age 
group 
Evidence gaps and/or 
recommendations for future 
research: To include full 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and 
methods of analysis 
Results Notes 
effective but also more costly 
compared to the SARC 
- LNG-IUS 13.5 mg was 
therefore associated with an 
incremental cost of $2,760 
USD per UP avoided. Assuming 
a 5-year time horizon resulted 
in higher effectiveness for 
LNG-IUS 13.5 mg compared to 
the SARC and lower total 
costs meaning that LNG-IUS 
13.5 mg was considered 
dominant at 5 years  
- A scenario analysis in 
comparison to LNG-IUS 20 
mcg/24h over a 3-year time 
horizon, showed that LNG-IUS 
13.5 mg was less costly but 
also less effective 
- Over a 5-year time horizon, 
LNG-IUS 13.5 mg was more 
costly and less effective and 
dominated by LNG-IUS 20 
mcg/24h 
range of complications (not 
only those related to delivery) 
in order to capture the full 
potential costs averted by 
society/public sector 
Source of funding: Funded by 
Bayer Healthcare 
Pharmaceuticals Inc. This 
work was also supported in 
part by the Eunice Kennedy 
Shriver National Institute of 
Child Health and Human 
Development grant for 
Infrastructure for Population 
Research at Princeton 
University (Grant 
R24HD047879; to J.T.). 
Anna Filonenko is a full-time 
employee of Bayer Pharma 
AG. Jennifer Pocoski and Amy 
Law are full-time employees 
of Bayer Healthcare 
Pharmaceuticals Inc. Fareen 
Hassan and Nathaniel Henry 
are full-time employees of IMS 
Health and served as paid 
consultants to Bayer 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and 
methods of analysis 
Results Notes 
Healthcare Pharmaceuticals 
Inc. for the development of 
this study and manuscript. 
James Trussell is a full-time 
professor of economics and 
public affairs at Princeton 
University and received a 
consultancy fee from Bayer 
Pharma AG for his 
contribution to this work 
Trussell et al. 
(2015) 
Aim of study: To 
estimate the 
average annual 
cost of available 
reversible 
contraceptive 
methods in the 
United States. 
and also quantify 
minimum 
duration of use 
required for 
LARC methods to 
achieve cost-
neutrality 
Source populations: 
Women aged 20–29 
years (age group 
with the highest 
uptake of SARC 
methods) 
Setting: USA 
Data sources:  
Weights assigned to 
each SARC method 
for the mixed-SARC 
basket: Market share 
data from the most 
recent National 
Survey on Family 
Growth 
Intervention 
description: Four short-
acting reversible (SARC) 
methods – oral 
contraceptive, ring, 
patch and injection – 
and three LARC 
methods  – implant, 
copper intrauterine 
device (IUD) and 
levonorgestrel 
intrauterine system 
(LNG-IUS) 20 mcg/24h 
(total content 52 mg) 
Outcomes: Annual 
average cost per 
method and minimum 
duration of LARC 
method usage to 
achieve cost-savings 
compared to SARC 
methods 
Time horizon: 5 years 
Costing year(s) and 
currency: 2012 USD 
Discount rates: No 
discount rate applied; 
cost of each method 
was annualised for 5 
years  
Primary analysis: 
Costs: Despite high upfront 
costs associated with LARC 
methods, as duration of use 
increases, the average cost of 
LARC methods drops to 
become less expensive than 
the methods which have 
lower upfront costs. 
Minimum duration of LARC 
method to reach cost-
neutrality:  
- Average LARC vs generic OC: 
2.4 years 
- Average LARC vs ring: 0.4 
years 
Limitations identified by 
author:  
- The cost impact of UP may 
have been overestimated 
because the model take into 
account only the first year of 
‘typical-use’ failure  
- The model assumes the same 
discontinuation rate across all 
methods due to a lack of 
robust literature on 
continuation of contraceptive 
methods beyond the first year 
of use 
- The absence of robust data 
on switching preferences 
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and 
methods of analysis 
Results Notes 
relative to other 
reversible 
contraceptive 
methods while 
taking into 
consideration 
discontinuation 
Type of 
economic 
analysis: Costing 
study 
Economic 
perspective: 
Public payer 
Quality score: 
Medium 
Applicability: 
Partly applicable 
First-year 
discontinuation rate: 
Published studies 
Subsequent-year 
discontinuation rate: 
Assumption 
Alternative 
discontinuation rate: 
CHOICE study 
Transition 
probabilities: 
Systematic review 
Costs of method 
acquisition: 
Wholesale 
acquisition cost 
(WAC) price 
 
Comparator/control 
description: No method 
(chance) 
Sample sizes: 
Simulated cohort of 
individuals derived from 
multiple estimates 
Perspective: Public 
payer 
Measures of 
uncertainty: Scenario 
analysis 
Modelling method: 
State transition model  
- Average LARC vs patch: 0.3 
years 
- Average LARC vs injection: 
2.6 years 
- Average LARC vs mixed 
SARC: 2.1 years 
- Average LARC vs condom: 
3.0 years 
- Average LARC vs no method 
(chance): 1.7 years 
Secondary analysis: None 
Sensitivity analysis:  
Scenario 1: The alternative 
discontinuation rates suggest 
that results are minimally 
sensitive to discontinuation 
assumptions. 
Scenario 2: conducting the 
analysis for a different 
population has an impact on 
results, but this impact is 
minimal 
necessitated a mixed-market 
basket to act as a proxy for 
patients choosing to switch 
methods; however, this 
construct aimed to 
approximate the average 
choices of women switching 
contraceptive method  
- Medicare prices (used to 
calculate costs of unintended 
pregnancy) are expected to 
be lower than those of private 
insurers 
- This analysis was conducted 
from the public payer 
perspective, but wholesale 
acquisition costs (WACs) were 
used to estimate the 
acquisition cost of the various 
contraceptives. The results 
should support a similar 
conclusion under the private-
payer perspective because 
WACs are similar to the costs 
that private payers pay would 
face  
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Study details Population and 
setting 
Intervention/ 
comparator 
Outcomes and 
methods of analysis 
Results Notes 
Limitations identified by 
review team: Main limitations 
associated to the model 
already discussed by the 
authors 
Evidence gaps and/or 
recommendations for future 
research: To include full 
range of complications (not 
only those related to delivery) 
in order to capture the full 
potential costs averted by 
society/public sector 
Source of funding: This study 
and manuscript development 
were funded by Bayer 
Healthcare Pharmaceuticals 
Inc. and supported in part by 
the Eunice Kennedy Shriver 
National Institute of Child 
Health and Human 
development grant for 
Infrastructure for Population 
Research at Princeton 
University, grant 
R24HD047879 (J.T.) 
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Appendix 11: Structured summaries  
Bayer LL, Edelman AB Caughey AB, Rodriguez MI (2013) The price of emergency 
contraception in the United States: what is the cost-effectiveness of ulipristal acetate 
versus single-dose levonorgestrel? Contraception, 87(3): 385-390.  
This study aimed to examine the cost-efficacy of ulipristal acetate (UPA) compared to 
levonorgestrel (LNG) taken within 120 hours of unprotected intercourse, using a cost-
effectiveness analysis and decision analytic model. Within the model, US women of 
reproductive age presenting in an unspecified location were given either type of emergency 
contraception within 120 hours of unprotected intercourse, and the primary outcomes – 
pregnancies averted, costs and quality-adjusted life years (QALYs) – were derived using a 
societal perspective. Sources of evidence to inform the model included meta-analysis, 
other research literature, state Medicaid payments and costs, and a national reproductive 
health survey. QALYs were calculated to measure the impact of an unintended pregnancy 
on a woman’s quality of life, using an average life expectancy of 55 additional years after 
taking contraception. Cost-efficacy was tested using a threshold of $100,000 per QALY 
gained, calculating ICERs comparing both types of contraception. Sensitivity analyses were 
undertaken to test all inputs and also potential uncertainties around the threshold value, 
contraception failure and medication costs.  
The results indicated that using UPA would result in 37,589 fewer unintended pregnancies 
per 4,176,572 estimated US annual emergency contraception episodes (UPA 54,295 
pregnancies; LNG 91,884 pregnancies). The societal savings would be $116.3 million USD 
per year. A cost-effectiveness acceptability curve analysis indicated a 96% probability that 
UPA is more cost-effective at a willingness to pay $100,000 USD per QALY.  
This economic evaluation rated low in terms of its methodological quality. The reviewers 
noted that the analysis was limited by a number of issues, including the fact that the 
authors did not state the perspective of the analysis, making it difficult to determine 
whether the results could be extrapolated to the entire society or whether the findings 
should be interpreted only from the perspective of Medicaid users. The reviewers also 
noticed that complications such as STIs were not included. We suggest that future research 
fully assess the benefits by accounting for these issues.  
Burgos JL, Gaebler JA, Strathdee SA, Lozada R, Staines H, Patterson TL (2010) Cost-
effectiveness of an intervention to reduce HIV/STI incidence and promote condom use 
among female sex workers in the Mexico-US border region. PloS One, 5(6): e11413. 
An economic modelling study using a government healthcare payer perspective was 
undertaken in order to estimate the cost-effectiveness of a brief behavioural intervention 
of condom negotiation skills development to reduce HIV and STIs in 409 female sex workers 
in Tijuana and Ciudad Juarez, Mexico. Intervention participants were compared to 406 
female sex workers who received a presentation on HIV and STI prevention of similar 
duration, assessing self-reported high-risk sex behaviour. The effectiveness of this 
intervention was evaluated using a randomised controlled trial, which rated medium in 
terms of methodological quality, due to issues of sample representativeness, objective 
outcome measurement, non-reporting of intention to treat analysis and questionable 
generalisability to the UK context. Using a Monte Carlo Markov model design, a hypothetical 
cohort of 1,000 women were followed over the course of their lifetime. Strategies were 
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compared in terms of HIV infections, quality-adjusted life expectancy (QALE) and QALYs, 
and annual or lifetime costs. Data were drawn from the randomised controlled trial (health 
outcomes and costs), government reports and published literature.  
Analysis of the hypothetical cohort suggested that offering the intervention once only, 33 
HIV infections would be prevented (95% CI: 30-37), increasing the QALE by 151 days per 
female sex worker (FSW) (95% CI 135-171), at a cost of $183 USD per QALY gained (95% CI 
$164-$206) to prevent each HIV case. If offered annually, the intervention model suggests 
an additional 29 new HIV cases prevented (95% CI 26-33), increasing the QALE by 132 days 
(95% CI $109-$149), at a cost per additional QALY gained of $1,075 USD (95% CI $931-
$1259), at a cost of $13,413 USD (95% CI 11,697-$15,077) per HIV case averted. One-way, 
two-way and probabilistic sensitivity analyses were undertaken, including testing results 
with and without the uptake of HAART. In addition, the model was calibrated by comparing 
estimates of life expectancy, HIV incidence and median survival for women not in sex work, 
sourced from separate data sources. Major results from the sensitivity analysis showed that 
the Mujer Segura intervention would no longer be cost-effective with changes in incidence 
of HIV, syphilis, gonorrhoea and chlamydia.  
This economic evaluation rated medium in terms of its methodological quality. The 
reviewers suggest that HIV complications should be explicitly modelled into the analysis, 
rather than just implicitly through the treatment of use or non-use of HAART by CD4 levels, 
in order to better understand the implications on costs and health outcomes in the long 
term.  
Cooper K, Shepherd J, Picot J, Jones J, Kavanagh J, Harden A, Barnett-Page E, Clegg A, 
Hartwell D, Frampton G, Price A (2012) An economic model of school-based behavioral 
interventions to prevent sexually transmitted infections. International Journal of 
Technology Assessment in Health Care, 28(4), 407-414. 
In order to assess the cost-effectiveness of teacher-led and peer-led school-based sexual 
health behavioural interventions compared to standard school health education in British 
schools, a Bernoulli probability model was developed, using a UK National Health Service 
and Personal Social Services perspective. The total number of HIV, chlamydia, gonorrhoea 
and genital warts cases averted, and consequent QALY gain, cost of the intervention and 
savings in medical costs for a hypothetical cohort of 1,000 males and 1,000 females aged 15 
years were estimated for one year and cost-effectiveness was calculated. Data were 
sourced from multiple sources of evidence, including a systematic review with meta-
analysis for the effectiveness of the programme, databases from the UK health authorities, 
surveys, published and unpublished studies and assumptions.  
The results estimated that the teacher-led intervention would cost an additional €8,575, 
averting two STI cases, with a 0.35 QALY gain in comparison to standard sex education in 
British schools. This resulted in an ICER of €24,268 per QALY gained, with the largest STIs 
averted being chlamydia and the largest gains for females avoiding chlamydia infection. 
The peer-led intervention resulted in the same number of cases averted and QALYs gained. 
However, a higher ICER of €96,938 per QALY gained was incurred. The peer-led 
intervention is thus less cost-effective than the teacher-led intervention in comparison to 
standard sex education; most likely due to higher peer educator training costs. Sensitivity 
analyses were undertaken, varying the values of STIs, number of sex episodes per partner, 
the length of time the intervention effect lasted, and the difference in effectiveness if the 
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population were males aged 16 to 19 years. A series of sensitivity analysis were undertaken, 
including a probabilistic sensitivity analysis. Acceptability curves were generated to better 
understand the difference in effects for the interventions compared to the baseline 
(standard sex education in British schools). Several uncertainties were associated with the 
results, particularly regarding effectiveness. A scenario analysis was also undertaken to 
better explain the results, but some uncertainties remained due to a lack of reliable data.  
This economic evaluation rated as high in terms of its methodological quality. The 
reviewers suggest that the model be repeated using empirical data to better define 
interventions that are cost-effective.  
Crawford MJ, Sanatinia R, Barrett B, Byford S, Dean M, Green J, Jones R, Leurent B, 
Sweeting MJ, Touquet R, Greene L, Tyrer P, Ward H, Lingford-Hughes A (2015) The 
clinical and cost-effectiveness of brief advice for excessive alcohol consumption among 
people attending sexual health clinics: a randomised controlled trial. Sexually 
Transmitted Infections, 91(1): 37-43.  
This trial aimed to examine the clinical and cost-effectiveness of brief advice for excessive 
alcohol consumption amongst people aged 19 years or older attending one of three sexual 
health clinics in London, England. The study design was a cost-effectiveness analysis based 
on an integrated parallel-arm, single-blind randomised controlled trial. The effects of a 
brief alcohol advice, a health information leaflet and an offer of an appointment with an 
alcohol assessment worker were compared with provision of a health information leaflet 
alone. The researchers measured a primary outcome of 90-day alcohol consumption, and 
secondary outcomes of three months of unprotected sex, health-related quality of life and 
costs up to six months post-intervention. QALYs were calculated based on EQ-5D ratings, 
and differences in mean costs per participant determined. An NHS and personal social 
service perspective was taken. Cost-effectiveness acceptability curves were derived to 
show the likelihood that the brief intervention is more cost-effective than the control 
treatment for different values that a decision maker is willing to pay for improvements in 
outcome.  
The results suggested that no significant reductions in alcohol consumption or sexual 
behaviours occurred. While the costs were similar amongst intervention and control group 
participants (£311 and £319 respectively), and the additional cost of the intervention was 
low compared to the total cost of care provided (£12.57, standard deviation £6.59), the 
authors concluded that the intervention was not associated with clinically important 
improvements in alcohol consumption or sexual behaviour and did not provide a cost-
effective use of resources.  
The methodological quality of the integral trial was rated to be high, as the study design 
and parameters seemed to be appropriately explored and a sensitivity analysis was 
undertaken in which the authors tested the strength of the findings. In addition, 
‘bootstrap’ techniques and non-hierarchical linear models were undertaken to assess 
missing data. The time horizon was very short to capture change in individual behaviour, 
leading the reviewers to suggest that a long time horizon be used to assess potential 
complications, such as STI transmission, in the long run. 
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Foster DG, Raine TR, Brindis C, Rostovtseva DP, Darney PD (2010) Should providers give 
women advance provision of emergency contraceptive pills? A cost-effectiveness 
analysis. Women’s Health Issues, 20(4): 242-247.  
In order to examine the effects and cost-effectiveness of different means of access to 
emergency contraception (EC) on unintended pregnancy rates in sexually active women, 
the authors utilised a Markov model. This compared the effects of advance provision or on-
demand clinic or pharmacy provision against no use of EC on unintended pregnancies and 
costs in three hypothetical cohorts of one million sexually active women stratified by 
sexual behaviour risk. EC effectiveness data were derived from clinical trials and costs from 
the state Medicaid programme, utilising a societal perspective. Probabilities of taking 
contraception, conception and costs were calculated. Costs savings per dollar spent on 
each type of contraception for each risk group of women were reported.  
The results indicated that advanced provision of ECP could potentially avert the same or 
more unintended pregnancies compared to on-demand provision, with largest reductions 
for low-risk women having advance provision. The number of dollars saved on averted 
pregnancy costs for each dollar spent on advance ECP is greater than one, suggesting a cost 
saving. The authors discussed the possible implications for the results when changes in 
effectiveness were observed, but the reviewers were unsure if their statement was based 
on sensitivity analysis as the authors did not report undertaking one.  
This economic evaluation was judged to be of medium methodological quality. The 
reviewers noticed some limitations, for example that the authors only looked at savings 
from pregnancies averted for one year. If an ECP supply was kept for longer than this, the 
cost savings of advance provision would be underestimated. Further, the authors also 
assumed that unprotected acts of intercourse occurred randomly throughout the menstrual 
cycle; however, costs savings would likely be higher if women were more likely to use 
emergency contraceptive for acts that occurred in the week before ovulation. The authors 
also only modelled intercourse where no contraception was used. In this case, cost-
effectiveness would be lower if EC was used in situations where the likelihood of 
conception was lower than with no contraception (e.g. missed pill). In addition, the authors 
only considered the medical costs of unintended pregnancy for up to two years after a 
birth: in fact, social, welfare and private costs are likely to be much higher. Reviewers 
suggest that authors model scenarios assessing the identified limitations for a longer period 
and include complications such as STIs in a long-term assessment of health benefits and 
costs.  
Foster DG, Biggs MA, Malvin J, Bradsberry M, Darney P, Brindis CD (2013) Cost-savings 
from the provision of specific contraceptive methods in 2009. Women’s Health Issues, 
23(4): e265-271. 
The authors conducted a cost-benefit analysis in order to determine the relative 
contribution of new contraceptive methods to averting unintended pregnancies. Health 
insurance claims data for contraception methods provided in 2009 to US women were used 
to construct a cohort of 1,058,381 women aged 15 to 44 years. No perspective was stated. 
Eleven types of contraception methods were included and compared: tubal ligation/ 
occlusion; copper IUD; hormonal IUS; implant; injectables; ring; patch; oral contraceptives; 
barriers; and emergency contraceptives. Contraceptive coverage and costs were estimated 
for a two-year time horizon, using claims data and a review of medical records. The health 
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outcomes estimated were pregnancies expected and pregnancies averted. The cost 
outcomes were those incurred in providing contraceptive services, including clinical and 
laboratory visits.  
The authors asserted that all the contraceptive methods studied saved more in public 
expenditures for unintended pregnancy than the cost of provision. Contraceptive implants 
and copper IUD were estimated to have the highest rate of USD return at just over $5.00 
USD in averted services. Hormonal IUS was estimated to save $4.89, followed by injectable 
methods at $4.00. Short-acting contraception including oral contraceptives ($3.37), ring 
($2.20), patch ($2.12), barriers ($1.58) and emergency contraception ($2.56) ranged in cost 
savings. Tubal ligation and occlusion methods resulted in savings of $3.59 and $1.59 
respectively. Two sensitivity analyses were undertaken: (1) cost outcome calculation 
without adjustment for months of protection for short-term methods, in order to test the 
possibility of women using all the methods dispensed; and (2) calculating the return of 
contraceptive provision by examining savings through delivery or termination rather than 
two years after birth.  
This economic evaluation was judged to be of medium methodological quality. The main 
limitations associated with the study were identified by the authors, but the reviewers also 
suggest that future research should also incorporate the long-term benefits, in terms of 
costs and health outcomes, of the impact on complications such as HIV and other STIs.  
Han L, Teal SB, Sheeder J, Tocce K (2014) Preventing repeat pregnancy in adolescents: 
is immediate postpartum insertion of the contraceptive implant cost-effective? 
American Journal of Obstetrics and Gynecology, 211(1): 24.e1-24e.7.  
This study aimed to determine the cost-effectiveness of a hypothetical state-funded 
programme to provide immediate postpartum implant (IPI) insertion for teenage mothers at 
6, 12, 24 and 36 months postpartum. Data from women aged 13 to 22 years enrolled in an 
observational study of pregnancy and post-natal care were utilised. Reproductive outcomes 
for those adolescents who received IPI contraception prior to hospital discharge were 
compared to those choosing other types of contraception after delivery. Pregnancy 
outcomes were measured, including type of delivery, miscarriage and ectopic pregnancy. 
Costs were calculated using an unspecified perspective, but which appears to be health 
services, using Medicaid costs. The costs were then modelled by normalising them using a 
hypothesised cohort of 1,000 women in each group, where the costs for IPI insertion were 
estimated and total costs at 6, 12, 24 and 36 months were calculated. These included one 
year of well-baby care for delivered pregnancies.  
The results at six months suggested that the costs of the IPI group were higher than the 
comparison group by $73,000. However, at 12, 24 and 36 months, publicly funded IPIs 
would result in a savings of more than $550,000, $2.5 million and $4.5 million respectively. 
The authors estimated that for every dollar spent on IPI, $0.79, $3.54, and $6.50 would be 
saved at 12, 24, and 36 months. Expenditures between the IPI and comparison groups would 
be equal if the comparison group pregnancy rate was 13.8%, 18.6% and 30.5% at 12, 24 and 
36 months. Actual rates were 20.1%, 46.5% and 83.7%. Sensitivity analysis only varied the 
repeated pregnancy rates of the comparison group.  
This economic evaluation was judged to be of low methodological quality: by assessing only 
one parameter in the study (rather than all), the robustness of the results might be 
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compromised. The reviewers also reported that discount rates were not reported. Further, 
benefits in terms of repeat pregnancy rates were not reported by type of complications, 
thus not capturing the full benefits generated by each outcome. It was suggested that for 
future research, these issues should be overcome and that discount rates should be 
reported.  
Holtgrave DR, Maulsby C, Kharfen M, Jia Y, Wu C, Opoku J, West T, Pappas G (2012) 
Cost-utility analysis of a female condom promotion program in Washington, DC. AIDS 
and Behavior, 16(5): 1115-1120. 
This study aimed to assess the affordability, performance standards and relative cost-
effectiveness of a US-based intervention to provide female condoms and health education 
to the general population. This was done using a cost, threshold and cost-utility analysis 
modelling method. Female condom provision versus no provision was compared. Costs were 
based on service use over one year in Washington DC, using both societal and payer 
perspectives. Sources of evidence included data from the Female Health Company and MAC 
AIDS Fund for all cost elements, and Department of Health Washington DC, parameters 
from a previous model developed by the authors and literature, for health outcomes 
analysis.  
The results indicated that distributing 200,000 female condoms and health education cost 
$414,186. From a societal perspective, 1.13 HIV infections would have to be averted for the 
program to be cost-saving; from a public sector payer perspective, 1.50 would need to be 
averted and a cost-effectiveness threshold of 0.46 HIV infections averted would be 
required. Modelling analyses suggested that the intervention averted approximately 23 HIV 
infections, demonstrating net cost savings.  
The methodological quality of this study was determined to be high. When the model 
allowed for the use of male condoms by women, at a specific level, the cost-utility analysis 
was still cost-saving, as well as when allowing for the use of male condoms by females and 
female condoms were dropped as low as 7.04%; these results were shown in a sensitivity 
analysis. In addition to the limitations identified by the authors, the reviewers pointed out 
that the cost-effectiveness analysis and cost-utility analysis were not clearly stated in 
terms of the cost per outcome. The authors only presented net savings, which suggested 
that the alternative was dominant. Also, because the comparator was not clearly stated, it 
was not possible to fully understand what they were comparing. The reviewers suggest that 
future research clearly identify outcomes for a cost-effectiveness or utility analysis and 
that alternatives for dominance be fully described.  
Holtgrave DR, Wolitski RJ, Pals SL, Aidala A, Kidder DP, Vos D (2013) Cost-utility 
analysis of the housing and health intervention for homeless and unstably housed 
persons living with HIV. AIDS and Behavior, 16: 1626-1631. 
To understand the impact of providing supportive housing assistance for homeless and 
unstably housed persons living with HIV, a cost-utility analysis was conducted based on a 
trial undertaken in three major US cities. HIV viral load, emergency room use and 
perceived stress were examined in the treatment group receiving rental assistance and case 
management, compared to those who received customary housing services with case 
management. Neither a perspective of analysis or time horizon were reported. Costs 
included those for service provision, savings accrued through lowered emergency 
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department use, HIV transmissions averted and medical costs saved. QALYs saved due to 
improvements in perceived stress and HIV transmissions averted were also calculated.  
The findings suggested that cost per QALY saved through the provision of rental assistance 
was $62,493 USD. A threshold analysis was conducted to assess uncertainties around the 
parameters used in the analysis. The authors concluded that the intervention would still be 
favourable compared to any other well-accepted medical and public health services even if 
the number of HIV transmissions was at the lowest level.  
This economic evaluation rated low in terms of its methodological quality. The trial on 
which the economic evaluation was based was considered to have significant potential for 
bias, because the findings were based on ‘as-treated’ analyses rather than by intention to 
treat. Further, the model did not capture any complications associated with HIV, so none of 
the long-term benefits in terms of costs and health outcomes could be captured. In 
addition, the reviewers were unable to judge if the time horizon for the analysis was 
sufficient to capture changes in HIV transmission or behaviour, as this information was not 
reported. 
Jackson LJ, Roberts TE, Fuller SS, Sutcliffe LJ, Saunders JM, Copas AJ, Mercer CH, 
Cassell JA, Estcourt CS (2015) Exploring the costs and outcomes of sexually transmitted 
infection (STI) screening interventions targeting men in football club settings: 
preliminary cost-consequence analysis of the SPORTSMART pilot randomised controlled 
trial. Sexually Transmitted Infections, 91(2): 100-105.  
This pilot cluster randomised controlled trial aimed to compare the costs and outcomes of 
two STI screening interventions that were targeted at men aged 18 years and older in six 
English football club settings. The time horizon seemed to be one year, similar to the 
intervention, but it was not clearly stated. Cost data were collected prospectively within 
the trial. Two interventions were tested: a team captain-led and poster STI screening 
promotion or a sexual health adviser-led and poster STI screening promotion – compared to 
a poster-only STI screening promotion. Only start-up costs (i.e. the costs of the posters) 
were annuitised at a 3% rate for three years. Screening uptake for chlamydia and 
gonorrhoea testing and costs were measured and a cost-effectiveness analysis undertaken 
assessing costs per player tested, from a health systems perspective.  
The results indicated a lower uptake of screening in the captain-led arm versus the health 
adviser-led arm and the poster-only condition, which were similar (50% versus 67% and 61% 
respectively). Costs per player screened were similar in all arms (£88.89 versus £88.33 
versus £81.87 respectively), suggesting a need to further explore the acceptability of such 
interventions in non-clinical settings.  
The economic evaluation was judged to be of medium methodological quality, due to lack 
of information on the parameters used in the analysis. Clearer reporting of the 
annuitisation of costs with posters and time horizon for the analysis is required: seemingly, 
the analysis was undertaken for a time horizon of one year and the costs with posters were 
considered for three years. If this was the case, the costs may be overestimated. Several 
sensitivity analyses were undertaken, including: additional preparation costs for captains, 
reduced club costs through higher organisational level support, additional incentive costs, 
different staff arrangements, different testing kit and processing costs, and increased 
uptake. However, not all parameters included in the model were assessed in a one-way 
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sensitivity analysis. The authors clearly stated that this analysis was conducted for the pilot 
phase, justifying the conduct of a cost-consequence analysis. A full cost-effectiveness 
analysis with an exploration of all parameters in sensitivity and probabilistic analyses will 
better indicate the parameters that bring the most uncertainty around the costs and health 
outcomes. 
Kessler J, Myers JE, Nucifora KA, Mensah N, Kowalski A, Sweeney M, Toohey C, 
Khademi A, Shepard C, Cutler B, Braithwaite RS (2013) Averting HIV infections in New 
York City: a modelling approach estimating the future impact of additional behavioral 
and biomedical HIV prevention strategies. PLoS One, 8(9): e73269. 
This study aimed to determine the cost-per-HIV infection averted for multiple intervention 
strategies, in order to determine the most cost-effective combination of interventions to 
provide in New York, USA. The economic evaluation design was reported as ‘operations 
research modelling’, a method which includes techniques such as Markov modelling. 
Different combinations of 16 HIV prevention interventions were compared over varying time 
horizons up to 20 years. Costs for each intervention were obtained from The Department of 
Health and Mental Hygiene of New York City and measures of benefits were collected from 
the literature and based on assumptions made by the authors. A hypothetical cohort of all 
people in New York City in 2009 aged 0 to 75 was created and divided into subgroups based 
on gender, sexual risk behaviour, sexual identity, infection status, treatment status and 
injection drug use, and the primary outcome was cost per infection averted. The 
perspective of the analysis was from the Department of Health and Mental Hygiene and the 
City of New York.  
The results suggested that over a 20-year period, 58,632 new HIV cases would be detected. 
A total of 16,159 people were predicted to die as a result of AIDS-related conditions. A 
total of 10 unique interventions had the potential to be cost-saving: condom distribution; 
social marketing; community-based prevention; prioritised use of surveillance data (i.e., 
targeted use of HIV and STD surveillance data to prioritise risk reduction counselling and 
partner services for persons with previously diagnosed HIV infection with a new STD); 
cofactor risk reduction; screening, brief intervention and referral for treatment for 
unhealthy alcohol use (SBIRT); linkage to care; linkage to support services for HIV-positive 
persons; partner services (defined here as just partner notification and testing); and STD 
screening. Of these, implementation of evidence-based community-level interventions, STD 
screening for high-risk HIV infected persons, partner services and a linkage to support 
interventions were found to be most cost-saving and would prevent the most infections, 
resulting in a reduction of 20,211 new HIV infections per year at a cost per infection 
averted of $106,378 USD per year and cost savings over 20 years of $5 billion. Determining 
a package of interventions that were most effective (regardless of cost) resulted in 
included expanded provision of post-exposure prophylaxis for HIV-uninfected persons, 
linkage to support, social marketing for HIV-infected persons, evidence-based community-
level interventions and enhanced HIV testing in clinical settings being found to be most 
effective. The authors estimated that 33,004 new HIV infections would be averted at an 
estimated cost per infection averted of nearly $9 million USD over twenty years. A ‘test and 
treat only’ package of interventions was estimated to result in 14,048 new infections over 
20 years, with more than 80% of new infections averted and a cost per infection averted of 
over $360,000 USD. One-way and probabilistic sensitivity analysis were undertaken to test 
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for uncertainties around the parameters. Most interventions were still cost-effective or 
cost-saving even for an increase of 10% in effectiveness parameters.  
This economic evaluation rated high in terms of its methodological quality, as the authors 
calibrated their model by using empirical figures. The authors also identified the main 
limitations of the study. The reviewers suggest that in future analysis, the treatment of HIV 
should be explicitly modelled by level of CD4 and that the time horizon be extended to a 
lifetime analysis, in order to better capture the long-term benefits of intervention 
strategies.  
Lasry A, Sansom SL, Hicks KA, Uzunangelov V (2012) A model for allocating CDC’s HIV 
prevention resources in the United States. PLoS One, 7: e37545. 
This study aimed to create a model for the optimal allocation of HIV resources from the 
perspective of the Division of HIV/AIDS Prevention (DHAP) at the Centre for Disease Control 
and Prevention (CDC). The authors built two interrelated models, an epidemic dynamic 
compartmental model and an optimisation model, to assess HIV transmission and 
progression by different ethnic and HIV subgroups in the United States (men who have sex 
with men, injection drug users and heterosexuals) for a 5-year time horizon. The assessed 
interventions were those funded by the CDC: HIV testing, individual and group-level 
counselling and education. Sources of data include Cycle 6 (2002) of the National Survey of 
Family Growth (NSFG), DHAP data, other previously published studies and assumptions. The 
assessed scenarios for the projection of HIV infections over time were: 1) amounts to 
allocate each year towards interventions and population subgroups to minimise new 
infections for the general population, 2) per-person cost of testing based on the cost of 
opt-out testing in emergency department settings and the cost of a CDC-led expanded 
testing programme, also for the general population and 3) the cost of testing in STD clinic 
settings and the cost of testing in outreach settings by targeting the high-risk population.  
The results showed that for a budget of $327 million USD, no allocation of resources would 
reduce 13% of new infections, and an optimised allocation would avert 31% of new 
infections. For an HIV scenario model and a $327 million USD budget, a non-optimal 
allocation by intervention (counselling plus testing) and by risk group, would reduce the 
proportion of new infections of the general population of US adults in 29%; by risk group it 
would be: 23% for mean who have sex with men (MSM),11% to injection drug users (IDU), 
and 36% to high risk heterosexuals (HRH). An optimal budget would reduce the risk in 51%, 
11% and 38%  of cases respectively for MSM, IDU and HRH. By ethnic group, the intervention 
(counselling plus test) would reduce new infections by 32% for blacks, 17% for Hispanics and 
22% for others in a non-optimal allocation, and by 36% for blacks, 29% for Hispanics and 35% 
others in an optimal allocation. In a scenario of an intervention (counselling plus education) 
by serostatus, a non-optimal budget allocation would use 11% of the budget targeted for 
diagnosed positives and 89% for susceptibles, while in an optimised budget, 100% of the 
budget would target diagnosed positives. The authors stated that the current baseline and 
the optimal allocation of funds could be considered cost-saving when compared to the HIV 
lifetime treatment costs. In addition, the authors concluded that more funds should be 
allocated to testing and targeting MSM and IDU; that counselling and education ought to 
provide focus on HIV positive persons aware of their condition, and that interventions 
should target those with high risk of transmitting HIV. The univariate sensitivity analysis 
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showed robust results where only 9 out 100 scenarios with varying parameters changed the 
results.  
The study was rated low in its methodological quality. The reviewers noted that the time 
horizon for the analysis was too short to account for all benefits generated by reductions in 
infection and recommended that a lifetime or a longer period for analysis be considered to 
capture the long-term benefits of the intervention, including an assessment of 
complications due to HIV. 
Long EF, Mandalia R, Mandalia S, Alistar SS, Beck EJ, Brandeau ML (2014) Expanded HIV 
testing in low-prevalence, high-income countries: a cost-effectiveness analysis for the 
United Kingdom. PLOS ONE, 9(4): e95735.  
This economic evaluation aimed to estimate the effectiveness and cost-effectiveness of 
expanded HIV testing in the UK. The authors modelled different HIV epidemic scenarios 
based on different interventions in a UK adult population aged 15 to 64 years, categorised 
by country of origin and risk status for 10-year HIV prevalence and incidence, and a lifetime 
horizon for the cost per QALY analysis. These included high-risk groups, including MSM, 
people who inject drugs (PWID), and men and women from HIV-endemic countries with high 
disease prevalence. Population groups were further subdivided by HIV infection and 
diagnosis status; antiretroviral therapy (ART) status if HIV positive; HIV serostatus; and 
male circumcision status. The interventions assessed were universal HIV testing, targeted 
HIV testing and expanded ART, compared to current HIV and treatment levels (‘status 
quo’).  
The economic evaluation was a cost-utility analysis that took the perspective of society, 
healthcare and personal social services. The authors estimated HIV prevalence, incidence, 
QALYs and healthcare costs over ten years, and cost-effectiveness based on each 
intervention compared to the status quo. These were grouped according to gender, HIV 
serostatus and treatment status, injecting drug use status, including individual costs of 
voluntary counselling and testing (VCT) and ART. Costs were derived from the literature 
and health agencies in the UK and converted to 2012 GBP; all costs and QALYs were 
discounted at 3% annually.  
The findings suggested that annual HIV testing of all adults could avert 5% of new 
infections, even with no behaviour change following HIV diagnosis because of earlier ART 
initiation, or up to 18% if risky behaviour was halved. This strategy costs £67,000–£106,000 
per QALY gained. Providing annual testing only to MSM, PWID and people from HIV-endemic 
countries, and one-time testing for all other adults, would prevent 4–15% of infections, 
require one-fourth as many tests to diagnose each person with HIV, and cost £17,500 per 
QALY gained. Augmenting this programme with increased ART access could add 145,000 
QALYs to the population over 10 years, at £26,800 per QALY gained. Modelled outcomes 
were compared to available UK Health Protection Agency data on HIV prevalence, 
incidence and diagnoses and were deemed similar. All modelled parameters were tested in 
a sensitivity analysis, but only those that brought more uncertainty to the results were 
highlighted; more prominent parameters were VCT and HIV transmission probabilities. The 
authors also argued that because the effectiveness evidence of HIV risk screening and ART 
treatment was uncertain, effectiveness could be built into sensitivity analysis of the 
resulting economic model.  
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The study rated as high in terms of its methodological quality. This was a landmark cost-
effectiveness analysis of HIV screening in the UK because it was one of the first to use 
different sources of data to combine epidemiological, behaviour and CD4 bands into an 
assessment of complex HIV disease progress. The reviewers noted that in addition to the 
limitations identified by the authors, HIV treatment was not explicitly modelled; rather, it 
was assumed that upon diagnosis, individuals would have a long life expectancy. This was 
implicitly due to ART, where assumed reductions in HIV infection would be due to reduced 
viral load following initiation of ART. Future evaluations could explore the implications of 
early HIV screening on complications (costs and health outcomes). The reviewers also 
suggest that a 3.5% discount rate is applied for costs and 1.5% for health effects, rather 
than 3%. This is in line with NICE recommendations for evaluating the substantial treatment 
effects that are required to restore and maintain health over a long period of time (i.e. at 
least 30 years). 
Marseille E, Shade SB, Myers J, Morin S (2011) The cost-effectiveness of HIV prevention 
interventions for HIV-infected patients seen in clinical settings. Journal of Acquired 
Immune Deficiency Syndromes, 56(3): e87-e94. 
This is a cost-effectiveness analysis, using a computer-based epidemic HIV transmission 
model comparing three counselling-based interventions to standard care (no standard 
counselling): 1) a primary care provider-based (clinical provider) consisting of brief risk 
assessments administered by computer to patients in private while they waited for their 
medical appointments; 2) a social worker or peer educator-based (specialist), where the 
client receive a one-on-one session, group session, or a combination of both; and 3) a mix 
of primary care and specialist-based (mixed), where the intervention mixed both 
strategies, provider-delivered and specialist-delivered interventions. The outcomes of 
analysis were the unit costs for each of the intervention types, the average cost per dose-
minute of service and HIV infections averted.  
The analysis was conducted from the perspective of the health system for a three-year time 
horizon. Multiple sources of data were used and included a diverse range of providers in the 
USA – from university hospitals to health centres. In these institutions, data on all HIV-
infected patients (including new and returning patients), male patients reporting sexual 
activity with other males in the last 6 months, all MSM patients, patients diagnosed with 
HIV for at least 3 months, patients older than age 45 years reporting unprotected sex in the 
last 12 months, patients reporting sexual activity or drug use in the last 3 and 6 months, 
female patients, patients reporting risk in the last 6 months, patients with sex or drug risk 
in the last 6 months.  
The results showed that the total average costs were $146,075 USD, $337,881 and 
$268,911, for a clinical provider, specialist provider or mix of both respectively. The 
average costs per dose-minute of the service were $17.46, $7.37 and $13.78, for a clinical 
provider, specialist provider or a mix of both respectively, while the costs per HIV cases 
averted were $2.71, $1.11 and $3.02 for each outcome respectively. The cost-effectiveness 
analysis (cost per HIV case averted) compared to the baseline intervention (no standard 
intervention) estimated a ratio of $107,656 for the clinical provider and $535,782 for all 
sites combined. The clinical provider intervention dominated the specialist and the mix 
interventions. The multivariate sensitivity analysis for a threshold of $303,100 showed that 
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the clinical provider intervention would no longer be cost-effective for increases of 50% in 
the costs and if effectiveness was only 50%.  
The study was rated as high for its methodological quality. The reviewers suggested that 
future research explore complications associated with HIV infections in the long term to 
better capture health and costs benefits of the intervention. 
National Collaborating Centre for Women’s and Children’s Health (2013) Long acting 
reversible contraception: the effective and appropriate use of long acting reversible 
contraception. London: Royal College of Obstetricians and Gynaecologists Press.  
To inform national contraceptive guideline development, a decision-analytic Markov model 
was undertaken to evaluate the cost-effectiveness of LARC methods (copper IUDs, hormonal 
IUDs, injectables and implants), compared to each other and to combined oral 
contraceptives (COC), male condoms, and male and female sterilisation. This was based on 
a non-systematic review of relevant literature which did not specify its search strategy, 
inclusion criteria or methods of synthesis, resulting in an ‘unsound’ methodological quality 
rating. Using an NHS perspective, the model population was a hypothetical cohort of 1,000 
sexually active women of reproductive age who took up a contraception method at the 
beginning of the first year, then were followed forward in time allowing for expected 
population rates of discontinuation of the method. The health outcome of contraceptive 
‘failure’ was unintended pregnancy, via live birth, abortion, miscarriage and ectopic 
pregnancy. The costs estimated included: ingredient costs, healthcare resource use and 
costs resulting from any type of unintended pregnancy outcome. Sources of evidence 
included NHS reference costs, British National Formulary, Guidelines Development Group 
opinion and consensus, GP fee schedules, national statistics and literature. The results 
were analysed and presented as an annual event over a 15-year period, and economic 
outcomes were reported as the number of pregnancies averted by one contraceptive 
method compared to another. Costs and health outcomes were discount at 3.5% as 
recommended by NICE.  
The findings suggested that all LARC methods averted more pregnancies in comparison to 
COC and the male condom for up to 15 years of use. For just one year of use, the IUD and 
the injectable were more effective and less costly than COC or the male condom. Where 
contraceptive use rose to two years or more, all LARC methods dominated COC and male 
condoms.  
The methodological quality of this economic modelling study was rated as medium because 
many uncertainties were not fully described relating to the parameter and structure of the 
model. Sensitivity analyses were undertaken examining variation in: the duration of use; 
combined use with condoms; changes in ingredients and costs of health service 
comparisons; ideal use of condom and COC; and discount rates. All parameters should be 
assessed in a one-way sensitivity analysis to account for uncertainties related to them. 
Additionally, the model was adapted from previous studies, but no validation and/or 
calibration was reported. Validation and or calibration of the model outputs with empirical 
data would allow identification of the model parameter values that achieve a good fit.  
Pilgrim H, Payne N, Chilcott J, Blank L, Guillaume L, Baxter S (2010) Modelling the cost-
effectiveness of interventions to encourage young people, especially socially 
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disadvantaged young people, to use contraceptives and contraceptive services. 
Sheffield: School of Health and Related Research.  
This study aimed to establish the cost-effectiveness of interventions to encourage young 
people in the UK aged up to 19 years, including those considered disadvantaged, to use 
contraception and contraceptive services. The alternatives compared were: the dispensing 
of condoms within schools, intensive case management to prevent repeated teenage 
pregnancies, advanced provision of emergency hormonal contraception provided to those 
young people who attended a clinic for contraceptive services. These alternatives were 
assessed against the baseline alternatives of ‘current practice’, where there was no 
standardised care (preventive or curative), and this was described as a school nurse service 
where there was no follow-up following first pregnancy and no advance provision of EHC. 
These alternatives were compared using a discrete decision analytical model. Health 
outcomes were the number of pregnancies averted for the age group relevant to the 
intervention, and STI infection was estimated by adapting an existing Bernoulli model for 
HIV transmission. Costs were estimated for: the intervention and additional contraception 
required as a result; maternity care; abortion; miscarriage, ectopic pregnancy or stillbirth; 
treatment for low birth weight infants; treatment for STIs; government-funded benefits. 
Appropriate sources of evidence were used to derive the costs and probabilities for health 
outcomes. Economic outcomes were determined to be the cost for each age-specific 
pregnancy averted and the cost for each abortion avoided.  
The findings showed that the cost per abortion averted comparing school-based dispensing 
of hormonal contraceptives within the school to school-based dispensing of condoms was 
estimated at £1,514, when government-based benefits were excluded from the analysis, 
and at £441 when these benefits were included; different levels of dominance were 
observed when the different alternatives were compared. The cost per repeat teenage 
pregnancy averted for intensive case management compared to the current practice 
(baseline) was estimated at £15,155, excluding government-based benefits, and £4,031 
when these benefits were included. Analyses for the advanced provision of EHC compared 
to the baseline showed that the cost per abortion averted was £2,975 and the cost per age 
pregnancy averted was £310, when government-based benefits were assessed; the 
advanced provision of EHC was dominated by the baseline regarding the cost per age 
pregnancy averted when government-based benefits were included.  
The methodological quality of this economic modelling study was rated as medium because 
the parameters used in the model were not validated and calibrated using empirical data. A 
wide variety of sensitivity analyses were undertaken examining variations in both health 
outcomes and costs. The authors stated that no preterm births were assessed, which may 
be more common amongst young people. However, the reviewers noted a discrepancy in 
that multiples and low birth weight were included, suggesting that the authors incorrectly 
equated low-birth weight with preterm birth. Other adverse events associated with teen 
pregnancy, such as fistula, were not mentioned, and these should be taken into account in 
future cost-effectiveness analyses.  
Roberts TE, Tsourapas A, Sutcliffe L, Cassell J, Estcourt C (2012) Is Accelerated Partner 
Therapy (APT) a cost-effective alternative to routine patient referral partner 
notification in the UK? Preliminary cost-consequence analysis of an exploratory trial. 
Sexually Transmitted Infections, 88:16-20. 
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This economic evaluation focused on adult clients aged 18 to 64 years old at two GUM 
clinics and six community pharmacies that were participating in an exploratory clinical trial 
in the UK. It aimed to assess two new models of partner notification, known as Accelerated 
Partner Therapy (APT) delivered via telephone or community pharmacy, as compared with 
routine patient referral partner notification, for sex partners of people with chlamydia, 
gonorrhoea and non-gonococcal urethritis. The time horizon for this analysis was not clearly 
stated, but appears to be for one year. Data on health, patient uptake and costs came from 
a trial, previous studies databases and government agencies. The primary health outcome 
was the proportion of sex partners for each partner notification intervention assumed 
treated within 4 to 6 weeks after index patient diagnosis. The effectiveness study on which 
the economic evaluation was based was considered to have a potential risk of bias because 
not all eligible clients were invited to participate in the study and analyses were based on 
patients who received treatment outside of their randomised groups; its methodological 
rating was thus low. The economic evaluation employed a cost consequence analysis, using 
an NHS perspective.  
The findings suggested that the APT strategies were similar in cost per partner treated 
(hotline £54; pharmacy £53) and slightly more than routine partner notification (£46); in 
addition, the intervention strategies achieved the highest proportion of partners treated 
(35% and 34% respectively), compared to 11% of partners treated in the comparison 
condition.  
This study rated medium on methods for its economic evaluation. The main limitations of 
the study are that, as an exploratory analysis, emphasis should be given to the assessment 
of key parameters used in the model to better understand sources of uncertainties. 
However, the authors stated that, because this was a preliminary economic analysis 
alongside a clinical trial, they did not undertake sensitivity analyses. The reviewers 
disagree with this statement and note that efforts should be made to better understand the 
impact of specific parameters on economic evaluations that informs policy makers, 
especially when effectiveness was considered to be affected by serious risk of bias.  
Rodriguez MI, Caughey AB, Edelman A, Darney PD, Foster DG (2010a) Cost-benefit 
analysis of state- and hospital-funded postpartum intrauterine contraception at a 
university hospital for recent immigrants to the United States. Contraception, 81(4): 
304-308. 
A cost-benefit analysis was undertaken using a hospital and state perspective. Using a 
retrospective cohort study design, this study compared the hospital and state costs of post-
natal IUD insertion for recent US immigrants with Emergency Medicaid insurance coverage 
for the delivery only. The population under study comprised all women who delivered at a 
university hospital in Portland, Oregon during 2002 and were followed for four years. 
Although further details of their socio-demographic characteristics are not clear, it is 
implied that they are recent immigrants to the US. The interventions being tested were the 
provision of usual care (delivery only) versus usual care plus post-natal IUD insertion. 
Drawing on hospital records, a previous trial and literature, the following were calculated: 
pregnancy costs and revenue, probabilities of repeat pregnancy and pregnancy outcome 
(vaginal delivery, caesarean section, vaginal delivery with sterilisation, ectopic pregnancy, 
spontaneous/threatened abortion, and probability of IUD uptake and continuation.  
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The results suggested that the post-natal IUD programme would not be cost beneficial from 
the hospital perspective, because it was estimated that for each dollar spent, 70 cents 
would be lost. In contrast, from the state perspective, a cost savings of $2.94 for each 
dollar spent would be expected from a state-financed programme. Sensitivity analyses were 
undertaken by varying the IUD discontinuation and expulsion rates and examining univariate 
costs from both perspectives. Model inputs were varied between one half and two times the 
baseline estimates. The main results for the sensitivity analysis showed that varying the 
discontinuation rates and expulsion rates did not affect the positive savings to the state of 
financing postpartum IUD provision and that the programme remained cost-effective for 
the state unless first-year discontinuation rate rose to 90%: this is significantly higher than 
the expected postpartum IUD expulsion rate of 12%. The results also suggested that the 
programme costs for the state would break even with costs of subsequent care if the IUD 
expulsion rate exceeded 70%, and that IUD costs would need to exceed $10,500 per woman 
before the programme would begin to cost the state more than future pregnancy costs.  
This study rated low in terms of its methodological quality, as the reviewers noted that 
further research is necessary into interstate migratory patterns and their probabilities in 
order to better interpret the results. Complete details of the modelling methods were not 
provided, making it difficult to assess the model’s structure and validity. The model would 
need to be extended to include complications for a better understanding of the benefits of 
IUD use.  
Rodriguez MI, Jensen JT, Darney PD, Little SE, Caughey AB (2010b) The financial 
effects of expanding postpartum contraception for new immigrants. Obstetrics and 
Gynecology, 115(3): 552-558.  
A Markov decision-analytic model was used to determine the cost benefits of expanding 
health insurance coverage to include post-natal contraception for Latina immigrant women 
in US states with a high proportion of new immigrants. Provision of family planning services 
versus no such service provision were compared, examining the probability of pregnancy 
and pregnancy outcomes of miscarriage, elective termination, ectopic and viable 
pregnancies. Data on health benefits and costs originated from the study database and a 
trial from the World Health Organization. The perspectives of the hospital, state funding 
programmes and society were examined.  
The results suggested that over a five-year period, from a societal perspective $17,793 per 
woman could be saved, incurring a loss of $367 for hospitals and saving Medicaid $108 per 
woman. The authors reported the use of a Monte Carlo simulation to test uncertainty; 
further one-way and multi-way sensitivity analyses were undertaken around all inputs. 
From the hospital perspective, postpartum contraception was not cost-saving compared to 
the baseline policy, but it was from the state’s perspective; from a society perspective, the 
intervention was cost-saving regardless the immigration status of the intervention 
population.  
The study was rated low in terms of its methodological quality, and the reviewers 
suggested that further research into interstate migratory patterns and probabilities should 
be conducted to assess the economic value of a federal mandate for preventive coverage of 
new immigrants. 
Appendix 11 
 
Sexual health promotion and contraceptive services in local authorities: a systematic 
review of economic evaluations 2010-2015  264 
 
Ruger JP, Abdallah AB, Ng NY, Luekens C, Cottler L (2014) Cost-effectiveness of 
interventions to prevent HIV and STDs among women: a randomized controlled trial. 
AIDS and Behavior, 18: 1913-1923. 
This study aimed to assess the cost-effectiveness of interventions to reduce risk-taking 
behaviours and HIV incidence in US intravenous drug-using women aged 18 or older who 
were identified as in need of treatment by outreach workers. Data were derived from a 
randomised controlled trial testing two interventions. In addition to standard HIV testing 
with pre- and post-test counselling, participants in one arm were offered a well-woman 
examination of history taking, and routine breast and pelvic examination with Pap smear; a 
second intervention evaluated both the standard HIV testing and well-woman examination 
with a four-session education intervention focused on health promotion, stress coping, 
health and nutrition, substance abuse and HIV/AIDS. Outcome measures included baseline 
and 12-month assessment for HIV, hepatitis C, syphilis, chlamydia and gonorrhoea. The RCT 
rated low in terms of methodological quality, as randomisation, allocation concealment and 
loss to follow-up were not well described. To conduct the economic evaluation, a combined 
cost-effectiveness and cost-utility analysis design was used, and societal and provider 
perspectives were adopted.  
The findings from the trial suggested that the well-woman examination was more costly 
and less effective than the standard intervention for HIV; and that for the modelled 
outcomes (relative to the standard intervention), the well-woman examination cost 
£137,280 ($208,316, 2003 USD) per primary HIV infection averted. Results from modelling 
suggested that for hepatitis C infection rates, the well-woman examination was less costly 
and more effective compared to the four-education session at £72,034 (£109,308, 2007-
2008 USD) per additional infection averted. Similarly, the well-woman examination was less 
costly and more effective than the four-session education intervention in reducing 
gonorrhoea rates (£706,949, $1,072,760, per additional QALY). However, for chlamydia 
rates, the four-education session was less costly and more effective than the well-woman 
examination at £2,273,217, $3,449,495) per additional QALY. One-way sensitivity analyses 
were undertaken for both the trial and the model, and bi- and multivariate analyses were 
conducted and acceptability curves calculated; the results were robust for most scenarios, 
the main exception being for hepatitis C, where the four education sessions were not cost-
effective when the parameters changed.  
This economic evaluation rated high in terms of its methodological quality. Assessing HIV 
complications by differences in CD4 level should be undertaken to foster understanding of 
the intervention’s long term benefits.  
Salcedo J, Sorenson A, Rodriguez MI (2013) Cost analysis of immediate postabortal IUD 
insertion compared to planned IUD insertion at the time of abortion follow up. 
Contraception, 87(4): 404-408.  
In order to evaluate the potential cost savings possible in providing immediate post-
abortion IUD insertion versus planned IUD insertion at abortion follow-up, a decision-
analytic Markov model was conducted from a California state public payer perspective. A 
hypothetical cohort of low-income women who were seeking abortion was derived from the 
California Family Planning, Access, Care, and Treatment (PACT) programme, serving a low-
income female client population. Public programme costs and unintended pregnancy rates 
were the primary and secondary outcomes respectively; costs were modelled with one- and 
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five-year time horizons. Costs included: medical care for contraception and pregnancy-
related care, public health insurance and social programmes for which a woman and her 
dependent children would be eligible. Health outcomes included: pregnancy, delivery, 
abortion, miscarriage or an ectopic pregnancy. Sources of evidence included the PACT 
female client population, Medicaid and literature. Outcomes and costs were calculated 
over five years.  
The results suggested that for each woman who had an immediate post-abortion IUD 
placement, public programmes would save $111 USD over one year compared to planned 
IUD insertion at abortion follow-up. This cost savings increased to $810 over five years. 
When public health insurance and programme costs were added in, savings increased to 
$1,956 and $4,296 over one and five years respectively. The authors asserted that for every 
1,000 low-income women who underwent post-abortion IUD insertion, more than 400 
pregnancies, 180 deliveries and 160 abortions would be avoided. Univariate and 
multivariate sensitivity analyses showed that the results were robust for a range of 
variation of parameters.  
The methodological quality of this study was determined to be medium. The reviewers 
noted that the model was heavily based on secondary data and the authors should have 
discussed better the applicability of the parameters to the population. Further, the 
implications of extending these conclusions to the population should be considered, as the 
implications were only partly included in the model (for example, no STIs were included). 
For future research where secondary data is used, validation of the data should be 
undertaken by comparing the results to official figures and testing these figures within the 
model.  
Schackman BR, Metsch LR, Colfax GN, Leff JA, Wong A, Scott CA, Feaster DJ, Gooden L, 
Matheson T, Haynes LF, Paltiel AD, Walensky RP (2013) The cost-effectiveness of rapid 
HIV testing in substance abuse treatment: results of a randomized trial. Drug and 
Alcohol Dependence, 28(1-2): 90-97. 
In order to estimate the cost-effectiveness of HIV testing strategies to provide guidance to 
policy makers and substance abuse treatment programmes, the authors undertook a cost-
effectiveness and cost-utility analysis by modelling findings from an intervention study 
targeting high-risk groups presenting at a substance use treatment clinic using a societal 
perspective. Here, on-site rapid HIV testing with information only or on-site rapid HIV 
testing with risk-reduction counselling were compared with off-site HIV testing and referral 
in terms of costs and sexual risk behaviour. Risk of bias assessment suggested that this trial 
was of medium quality, due to the lack of reporting of allocation concealment and 
questions about the sample’s representativeness to the intended population. Data sources 
were varied: utilities for QALYs were derived from a SF-6D data from a national survey of 
HIV infected individuals; the National Drug Abuse Treatment Clinical Trials Network (CTN) 
HIV Rapid Testing and Counselling Study (CTN 0032), the Multicentre AIDS Cohort Study 
(MACS) and published literature for the population in substance abuse treatment, and the 
costs were estimated by using the medical service utilisation data from a national cohort 
and national costs. 
The results from the modelling study indicated that on-site rapid testing and information 
only was found to dominate the other conditions, resulting in a cost-effectiveness ratio of 
£39,979 ($60,300, 2009 USD) per QALY. This exceeds the NICE cost-effectiveness threshold. 
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The on-site rapid testing with counselling cost £7 ($11) more per person but did not provide 
additional benefit. Varying prevalence of undiagnosed HIV and varying probability of testing 
were modelled and reported. The sensitivity analysis showed varied results: changing the 
prevalence of undiagnosed HIV, a higher cost-effectiveness ratio was observed for on-site 
testing plus information compared to no intervention; the cost-effectiveness ratio was 
$82,800/QALY, when varying the probability of testing. Other variations had little impact 
on cost-effectiveness ratios.  
This economic evaluation rated high in terms of its methodological quality. The authors 
acknowledged the main limitations for their model and analysis and the reviewers did not 
have further suggestions.  
Thomas A (2012) Three strategies to prevent unintended pregnancy. Journal of Policy 
Analysis and Management, 31(2): 280-311.  
This multi-intervention modelling study used cost-benefit analysis methods to examine the 
fiscal impact of three national strategies to prevent unintended pregnancy in low-income 
US populations. These included a national media campaign encouraging condom use in 
unmarried men aged 15 to 44; a national school-based pregnancy prevention programme for 
high-risk low-income young women and men; and an expansion in Medicaid funding for 
family planning services for low-income women. A governmental perspective was employed 
(i.e. costs to the taxpayer for programme implementation and benefits of costs savings 
from reduced benefits payment) over a one-year and five-year time horizon. To 
parameterise the model (e.g. to assign a poverty status to each newborn child), data were 
used from a wide range of sources, including: the General Social Survey and the National 
Survey of Family Growth, the Guttmacher Institute, the National Vital Statistics 
System, and the Population Survey. Other data used to estimate benefits and costs 
included: a meta-analysis for behaviour effects and data from the Truth, VERB and 
National Youth Anti-Drug Media (NYADMC) campaigns. For ease of reading, each 
intervention and its resulting costs and benefits are presented separately below. 
Model 1: Mass media campaign for condom use  
In terms of benefits, the mass media intervention would potentially reduce abortion by 
3.9%, births by 1% and number of children born into poverty by 2.2%; the programme would 
cost $100 million USD. The benefit-cost ratios would be $0.37 USD for pregnancy care 
alone, $0.90 USD for pregnancy care plus infant medical assistance and $4.31 USD for 
pregnancy care and children’s benefits. 
Model 2: Pregnancy prevention programme for unintended teenage pregnancy  
For this intervention, reductions in abortion, births, and number of children born into 
poverty were estimated to be 1.4%, 0.6% and 1.4% respectively. The programme would cost 
$145 million USD. The benefit-cost ratios would be $0.26 USD for pregnancy care alone, 
$0.55 USD for pregnancy care plus infant medical assistance, and $2.46 USD for pregnancy 
care and children’s benefits. 
Model 3: Expansion in Medicaid funding for family planning services  
The expansion in Medicaid would reduce abortion by 3.5%, births by 1.4% and number of 
children born into poverty by 1.8% in this analysis; The programme would cost $235 million 
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USD. The benefit-cost ratios would be $0.62 USD for pregnancy care alone, $1.21 USD for 
pregnancy care plus infant medical assistance, and $5.62 USD for pregnancy care and 
children’s benefits. 
Sensitivity analysis showed that that the results were robust and insensitive to a range of 
variations into the parameters. The study was rated as medium by the reviewers. The main 
limitations were discussed by the authors. Short- and long-term complications associated 
with unintended pregnancies (and unprotected sex) should be taken into account to further 
understand the interventions’ benefits (in terms of health outcomes) and costs. 
Thomas CM, Cameron S (2013) Can we reduce costs and prevent more unintended 
pregnancies? A cost of illness and cost-effectiveness study comparing two methods of 
EHC. BMJ Open, 3(12): e003815.  
This study aimed to calculate the cost of an unintended pregnancy and use this cost to 
assess the comparative cost-effectiveness of ulipristal acetate (UPA) and levonorgestrel 
(LNG) for emergency hormonal contraception (EHC) within a one-year time horizon. Women 
in England in 2011 presenting in primary care for EHC within 24 to 72 hours of unprotected 
sexual intercourse were the population of interest. The primary outcome was the number 
of unintended pregnancies and the associated direct and indirect costs. Secondary 
outcomes included miscarriage, abortion, ectopic pregnancy, stillbirth or live birth. A 
health and health plus social care perspective was employed. Data were sourced from 
published studies of costs and outcomes, including a previous trial of these contraceptives 
on unintended pregnancy. The incremental cost-effectiveness ratio of UPA compared to 
LNG was calculated.  
The findings suggested that one unintended pregnancy cost £1,663 in direct healthcare 
costs, rising to £2,922 when social costs were factored in; and costs were £194 less in direct 
health costs to prevent one more pregnancy with UPA than with LNG. When the social costs 
of pregnancy were added, this cost-saving potential was increased to £1,453 for each extra 
pregnancy avoided with UPA compared to with LNG.  
The methodological quality of this economic modelling study was rated as low due to 
limitations in outcome measurement, model cycle, baseline estimates of health effect and 
resource use, and sensitivity analyses and model calibration, and unclear reporting of the 
time horizon and adverse events. Sensitivity analyses were undertaken examining the 
impact of changes in the cost of pregnancy and failure rate of either contraception 
method. The authors have identified major limitations associated with their analysis and 
the reviewers only recommended that for future analysis, complications associated with 
STIs are taken into account using a wider time horizon.  
Trussell J, Henry N, Hassan F, Prezioso A, Law A, Filonenko A (2013) Burden of 
unintended pregnancy in the United States: potential savings with increased use of 
long-acting reversible contraception. Contraception, 87(2): 154-161. 
This economic evaluation of cost savings aimed to evaluate the total costs of unintended 
pregnancy in the US and the impact of LARCs versus usual care on healthcare costs, using a 
third-party healthcare payer perspective. The population under study comprised all US 
childbearing women aged 15 to 44 years who were sexually active but also neither sought 
pregnancy nor wished sterilisation, i.e. in need of reversible contraceptive use. Ten 
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different types of short-acting and long-active reversible contraceptives were assessed, 
including no contraception. Individuals were separated into 5-year age groups and 
contraceptive use over one year was analysed. The health outcomes under study included 
live birth, induced abortion, spontaneous abortion and ectopic pregnancy. The health 
outcomes were obtained from a nationally representative survey of pregnancy, birth, 
parenting and health undertaken by the Centres for Disease Control and Prevention. The 
costs associated with contraceptive use and unintended pregnancy healthcare were 
calculated using the Medicaid Fee Schedule.  
The estimated results suggested that unintended pregnancy costs $4.6 billion USD annually. 
Of this, 53% was estimated to be attributed to poor contraceptive adherence, with the 
highest number occurring in women aged 20 to 29 years. The authors suggested that $288 
million yearly in unintended pregnancy healthcare costs could be saved if even 10% of all 
women aged 20 to 29 years took up LARC rather than oral contraceptives. Sensitivity 
analysis showed an increase in costs for changes in parameters, but cost neutrality was 
achieved when number of years was varied.  
The study was determined to be of medium methodological quality. The authors have 
discussed the main limitations of their study, but the reviewers suggest that future 
research assume a longer-term assessment of complications associated with unintended 
pregnancies, in order to better inform policy makers about the benefits of interventions. 
Trussell J, Hassan F, Henry N, Pocoski J, Law A, Filonenko A (2014) Cost-effectiveness 
analysis of levonorgestrel-releasing intrauterine system (LNG-IUS) 13.5 mg in 
contraception. Contraception, 89(5): 451-459.  
A state transmission economic model was developed to evaluate the cost-effectiveness (i.e. 
cost per pregnancy avoided) of an initial method, unintended pregnancy and subsequent 
method of contraception over a three-year period of use, from a third-party payer 
perspective. The levonorgestrel-releasing intrauterine system 13.5 mg (LNG-IUS) was tested 
against short-acting reversible contraceptive methods (SARCs) in a cohort of 1,000 US 
women aged 20 to 29 years. Contraceptive rates, method failure and discontinuation rates 
were calculated from the National Survey of Family Growth, a systematic review and 
assumptions. Health outcomes included live birth, induced or spontaneous abortion or 
ectopic pregnancy. The costs of contraceptive method, administration of method and cost 
of method failure were calculated using the Medi-Span Master Drug Database, the 
Procedural Terminology (CPT) 2008 Codebook, Medicare, project and published data and 
the Diagnosis-Related Group (DRG) 2008 Codebook.  
The results indicated that LNG-IUS resulted in 69 unintended pregnancies compared to 276 
in those using SARCs. It was also less costly at initiation ($1.28 million USD versus $1.86 
million). Lower drug acquisition ($650,320 vs $943,956) and method failure costs ($14,026 
vs $299,784) were considered to be offset by the higher medical resources needed for 
insertion and removal ($415,810 vs $215,481). The costs associated with subsequent 
method use were lower in those choosing LNG-IUS over SARCs ($203,322 vs $403,412).  
A one-way sensitivity analysis showed that many parameters were sensitive to changes. A 
probabilistic sensitivity analysis showed that the intervention was both cheaper and more 
effective than the SARC method for all iterations: analysis of LNG-IUS 20 mcg/24h over a 
three-year time horizon showed that LNG-IUS 13.5 mg was less costly but also less 
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effective. Similarly, in a five-year time horizon, LNG-IUS 13.5 mg was more costly and less 
effective and was therefore dominated by LNG-IUS 20 mcg/24h. The quality rating of this 
economic evaluation on assessment was low. The reviewers noted that a limited age group 
was explored in the analysis and that future results should assess the extent to which this 
influenced the study’s outcomes. In addition, the modelling of complications associated 
with unintended pregnancies (including HIV and STIs) should be assessed in order to better 
capture the intervention’s long-term benefits.  
Trussell J, Hassan F, Lowin J, Law A, Filonenko A (2015) Achieving cost-neutrality with 
long-acting reversible contraceptive methods. Contraception, 91(1): 49-56.  
In order to estimate the average annual costs of reversible contraceptives and to quantify 
the minimum duration of use required for LARC methods to achieve cost-neutrality, a 
three-state economic model was developed. Based on a third-party public payer model (i.e. 
considering direct medical costs only), this estimated and compared the relative costs of 
four SARC methods (oral contraception, ring, patch and injection), three LARC methods 
(implant, copper IUD, LNG-IUS) and no contraception, over a five-year time horizon. LARC 
was also compared with a weighted average of available SARCs only. The population cohort 
consisted of 1,000 US women aged 20 to 29 years. Health outcomes of interest included live 
birth, spontaneous or induced abortion and ectopic pregnancy. Cost data included 
contraceptive acquisition, administration and failure. Data on method-specific failure and 
discontinuation rates were obtained from the National Survey on Family Growth, the 
CHOICE study, a systematic literature review, published literature and assumptions. The 
authors stated that cost data were obtained from the wholesale acquisition cost (WAC) 
price; however, it was unclear which organisation provided this information. 
For each woman per year, the findings suggested that copper IUD ($304) and LNG-IUS 20 
mcg/24 hours ($308) were the least expensive methods in terms of direct medical costs. 
SARC methods were higher, ranging from injection to patch ($732) per woman, per year. No 
contraception cost an average of $509.60 per woman yearly. The authors estimated that 
any LARC would need to be used for a minimum of 2.1 years for the method to be cost-
saving compared to SARC methods. Minimum impact was observed in the results when 
assumptions about discontinuation rate were changed.  
This study rated medium in terms of methodological quality. The reviewers suggested the 
inclusion of long-term complications in the analysis to better understand the benefits of the 
interventions. It is possible that the costs of interventions may have been underestimated 
because only the price of wholesale acquisition were used, suggesting that a full-cost 
approach is needed for future cost-analysis. 
Turner KM, Round J, Horner P, Macleod J, Goldenberg S, Deol A, Adams EJ (2014) An 
early evaluation of clinical and economic costs and benefits of implementing point of 
care NAAT tests for chlamydia trachomatis and neisseria gonorrhoea in genitourinary 
medicine clinics in England. Sexually Transmitted Infections, 90(2): 104-111. 
The aim of this study was to estimate the costs and benefits of clinical pathways using a 
point of care nucleic acid amplification test (POC NAAT) for chlamydia and gonorrhoea in 
genitourinary medicine (GUM) clinics, compared with standard off-site laboratory testing. A 
one- to 28-day cycle length decision analytic model of cost-effectiveness and cost-utility 
analysis was used, based on a modelled cohort of 1.2 million index patients to simulate the 
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number of STI screening tests undertaken at GUM clinics in England. Data were derived 
from health agencies official figures, literature and assumptions. A societal, healthcare and 
personal social services perspective was used. The primary outcome was the incremental 
cost-effectiveness ratio of standard off-site laboratory testing compared to NAATs (total 
cost per QALY gained), with secondary outcomes comprising the number of inappropriate 
treatments, complications and transmissions averted.  
The findings suggested that the POC NAAT was more effective and cheaper, costing £103.9 
million compared with £115.6 million for standard care, and was associated with an 
increase of 46 QALYs. Further, it was suggested that same-day testing, diagnosis and 
treatment might prevent 189 cases of pelvic inflammatory disease and 17,561 onward 
transmissions per year.  
This study was determined to be of high methodological quality by the reviewers, and the 
limitations were more associated with the availability of quality data to model the 
implications of POC NAAT testing on STIs. Sensitivity analyses were undertaken to examine 
differences in results by shorter time to treatment, no progression to pelvic inflammatory 
disease, lower baseline prevalence, higher POC test acquisition cost, and patient disutility 
whilst awaiting results. The authors have identified most of the studies’ limitations, 
including that their assessment of complications was based only on pelvic inflammatory 
disease in women. This was justified by the absence of national data on early screening for 
other complications. The reviewers suggested that further analyses should be conducted to 
better understand changes in uptake over time, possibly by combining qualitative research 
on patient experiences of the impact of POC NAAT testing with quantitative research on the 
prevalence of complications. The resulting information could be generated as independent 
arms of a future model for evaluating the cost-benefit of POC NAAT.  
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Appendix 12: Costs and outcomes table: UK studies 
Table A12.1: UK studies: STI screening/treatment  
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Long et al. 
(2014)  
[CUA]  
 
 
 
Current HIV testing and treatment 
(Baseline) 
3,500 new infections per year 
6,100 new diagnoses per year 
      
   
Universal HIV testing every 1, 2 and 
3 years versus current HIV testing 
and treatment  
1-18% new infections averted over 1-3 years       
  
 
£67,000-106,000 per QALY gained (2012 GBP) over 10 years, 
depending on sexual partner reduction behaviour 
 
Universal annual HIV testing versus 
current HIV testing and treatment 
(Baseline) 
5-18% new infections averted        
  £4.61 per test    
57,400 QALYs gained   
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Targeted annual HIV testing versus 
universal one-time HIV testing  
4-15% of new infections averted 
¼ as many tests to diagnose people living with HIV 
£0.75 per test; 42,900 QALYs gained 
      
 
  
£17,500 per QALY gained  
Targeted annual HIV testing and 
anti-retroviral treatment (ART) 
versus one-time universal HIV 
testing and current treatment  
 
QALY: 145,300       
 
 
 
 £3.49 per test 
145,000 QALYs added to population over 10 years 
 
 
£26,800 per QALY gained   
Turner et al. 
(2014) 
[CEA, CUA] 
Standard care, off-site testing [C] Cost £11.7 million (2012 GBP) 
QALY: 184,012 
         
189 cases of pelvic inflammatory disease prevented per year          
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Point of care chlamydia/ gonorrhoea 
testing in GUM clinics versus 
standard off-site testing 
17,561 onward transmissions prevented per year 
£11.7 million per 46 QALYs gained 
 
Roberts et al. 
(2012) 
[CCA] 
Accelerated Partner Therapy via 
telephone versus routine patient 
referral partner notification 
35% of partners treated [I] versus 11% of partners [C] 
£54 per partner treated [I] versus £46 per partner [C]  
(2008 GBP) 
   
 
 
 
   
Accelerated Partner Therapy via 
community pharmacy versus routine 
patient referral partner notification 
34% of partners treated [I] versus 11% of partners [C] 
£53 per partner treated [I] versus £46 per partner [C] 
   
 
 
 
   
Jackson et al. 
(2015) 
[CEA] 
Team captain-led STI screening 
promotion versus poster-only STI 
screening promotion 
50% screening uptake [I] versus 61% screening uptake [C] 
£88.89 per participant screened [I] versus £81.87 per 
participants screened [C] (2012-2013 GBP) 
 
 
  
 
 
 
   
Sexual health adviser-led STI 
screening promotion versus poster-
only STI screening promotion 
67% screening uptake [I] versus 61% screening uptake [C] 
£88.33 per participant screened [I] versus £81.87 per 
participant screened [C] 
     
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[CBA]=cost-benefit analysis; [CCA]=cost-consequence analysis; [CEA]=cost-effectiveness analysis; [CSA]=cost saving analysis; [CUA]=cost utility analysis; 
[I]=intervention condition; [C]= comparison condition
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Table A12.2: UK studies: Contraception 
Study Intervention Outcomes Cost-effectiveness NICE rating 
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Thomas and 
Cameron 
(2013)  
[CEA] 
Cost-effectiveness comparison 
of ulipristal acetate (UPA) 
versus levonorgestrel (LNG) 
within 72 hours of 
unprotected sex 
Primary: Number of unintended pregnancies estimated at ‘almost 
25%’ 
Secondary: Miscarriage, abortion, ectopic, stillbirth, live birth 
Associated costs of unintended pregnancy £1,663 - £2,922 
(depending on perspective)  
   
 
 
 
   
UPA cost £194 - £1,453 less per avoided pregnancy than LNG (2011 
GBP) 
 
National 
Collaborating 
Centre (NCC) 
(2013) 
[CEA] 
LARC methods (IUD, IUS, 
implant, injectable) versus 
UDCs (combined oral 
contraceptive (COC), male 
condom) 
Over 15 years: All LARCs dominated COCs and condoms (see 
Evidence Tables for more detail) 
   
   
   
First three years: Implant dominated all other LARCs costing 
between £14,730 - £17,866 per pregnancy averted (2004-2005 
GBP) 
 
Appendix 12 
 
Sexual health promotion and contraceptive services in local authorities: a systematic review of economic evaluations 2010-2015  276 
 
Study Intervention Outcomes Cost-effectiveness NICE rating 
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Pilgrim et al. 
(2010)  
 [CEA] 
 
 
 
School nurse services only; no 
dispensing of condoms or 
contraceptives [C] 
11,392 abortions / 2,186 pregnancies 
Total costs £1,527,318,794 (2007-2008 GBP) 
   
 
 
 
   
School-based condom 
provision versus school nurse 
services only 
11,153 estimated abortions 
1,778 estimated pregnancies 
Total estimated costs £1,517,225,105 
   
 
 
 
   
Estimated cost outcomes: 
£38 for each pregnancy averted 
£822 for each abortion avoided 
 
School-based hormonal 
contraceptive provision to 
sexually active nulliparous 14-
11,103 estimated abortions 
1,693 estimated pregnancies 
Total estimated costs £1,515,641,998 
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Study Intervention Outcomes Cost-effectiveness NICE rating 
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16 year olds versus condom 
provision and school nurse  
Estimated cost outcomes: 
£443 for each averted pregnancy (2007-2008 GBP) 
£1,453 for each abortion avoided 
 
School-based peer education 
and social work case 
management to prevent 
repeat pregnancy in teen 
mothers attending school 
versus no follow-up after first 
pregnancy 
No follow-up [C]:  
31,464 repeat pregnancies  
Total cost £655,572,463  
Case management follow-up [I]: 
19,022 repeat pregnancies  
Total cost £705,730,087 
   
  
 
 
 
   
Estimated cost outcomes: £4,031 - £15,155 per repeat pregnancy 
averted (2007-2008 GBP) 
 
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Study Intervention Outcomes Cost-effectiveness NICE rating 
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Advance provision of EHC to 
sexually active high risk teens 
aged 15-19 years versus no 
advance provision of EHC 
No advance provision [C]: 
11,241 abortions / 11,363 pregnancies 
Total costs: £1,524,674,862  
Advance provision [I]: 
11,241 abortions / 11,363 pregnancies 
Total costs: £1,447,599,721  
 
   
  
 
 
 
   
Estimated cost outcomes: 
£310 per pregnancy averted 
£2,795 per abortion avoided (2007-2008 GBP) 
 
[CBA]=cost-benefit analysis; [CCA]=cost-consequence analysis; [CEA]=cost-effectiveness analysis; [CSA]=cost saving analysis; [CUA]=cost utility analysis; 
[I]=intervention condition; [C]= comparison condition 
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Table A12.3: UK studies: Health promotion 
Study Intervention Outcomes Cost-effectiveness NICE 
Rating 
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Cooper et al. 
(2012)  
[CEA] 
 
 
 
1. Teacher-led 20 session STI 
prevention intervention or  
2. Peer-led three session STI 
prevention intervention versus 
standard sexual health education [C] 
Compared to standard sex education [C], teacher-led 
intervention would have net additional cost £6,375 (€8,575) 
and avoid two extra STI cases for 0.35 increase in QALY 
       
 
  
Incremental cost-effectiveness ratio: £18,041 (€24,268) per 
QALY gained (2011-2012 Euro) 
Peer-led intervention cost £12,050 (€16,210) per case avoided 
 
 
 
Incremental cost-effectiveness ratio: £72,062 (€96,938) per 
QALY gained  
  
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Study Intervention Outcomes Cost-effectiveness NICE 
Rating 
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Crawford et 
al. (2015) 
[CEA] 
Cost year(s) 
and currency: 
2010-2011 GBP 
 
Brief alcohol advice, health 
information leaflet and referral 
offer versus health information 
leaflet only 
No significant reductions in:  
90-day alcohol consumption or  
Rates of unprotected sex in past 3 months 
£311 per person intervention  
£319 per person control 
   
 
 
     
 
 
Additional cost of intervention £12.57, SD £6.59 
QALYs 0.007 lower in brief intervention group and costs £8.41 
higher 
  
ICER: −£1,200 per QALY (2010-2011 GBP)   
Jackson et al. 
(2015) 
[CCA] 
Team captain-led STI screening 
promotion versus poster-only STI 
screening promotion 
50% screening uptake [I] versus 61% screening uptake [C] 
£88.89 per player screened [I] versus £81.87 per player 
screened [C] (2012-2013 GBP) 
   
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Study Intervention Outcomes Cost-effectiveness NICE 
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 Sexual health adviser-led STI 
screening promotion v. poster-only 
STI screening promotion 
67% screening uptake versus 61% screening uptake [C] 
£88.33 per player screened [I] versus £81.87 per player 
screened [C] 
     
 
   
Pilgrim et al. 
(2010)  
 [CEA] 
 
 
 
 
 
 
 
School nurse services only; no 
dispensing of condoms or 
contraceptives [C] 
11,392 abortions 
2,186 pregnancies 
Total costs £1,527,318,794 (2007-2008 GBP) 
   
 
 
 
   
School-based condom provision 
versus school nurse services only 
11,153 estimated abortions 
1,778 estimated pregnancies 
   
 
 
 
   
Total estimated costs £1,517,225,105 
Estimated cost £38 for each pregnancy averted 
Estimated cost £822 for each abortion avoided 
 
School-based hormonal 
contraceptive provision to sexually 
active nulliparous 14-16 year olds 
11,103 estimated abortions 
1,693 estimated pregnancies 
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Study Intervention Outcomes Cost-effectiveness NICE 
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versus condom provision and school 
nurse  
Total estimated costs £1,515,641,998 (2007-2008 GBP) 
Estimated cost outcome £443 for each averted pregnancy  
Estimated cost outcome £1453 for each abortion avoided 
 
School-based peer education and 
social work case management to 
prevent repeat pregnancy in teen 
mothers attending school versus no 
follow-up after first pregnancy 
No follow-up [C]:  
31,464 repeat pregnancies  
Total cost £655,572,463  
   
 
 
 
   Case management follow-up [I]: 
19,022 repeat pregnancies 
Total cost £705,730,087 
Estimated cost £4,031 - £15,155 per repeat pregnancy 
averted 
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Study Intervention Outcomes Cost-effectiveness NICE 
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Advance provision of EHC to sexually 
active high risk teens aged 15-19 
years versus no advance provision of 
EHC 
No advance provision [C]: 
11,241 abortions / 11,363 pregnancies 
Total costs: £1,524,674,862  
Advance provision [I]: 
11,241 abortions / 11,363 pregnancies 
Total costs: £1,447,599,721  
   
 
 
 
 
 
   
Cost £310 per pregnancy averted 
Cost £2,795 per abortion avoided (2007-2008 GBP) 
 
[CBA]=cost-benefit analysis; [CCA]=cost-consequence analysis; [CEA]=cost-effectiveness analysis; [CSA]=cost saving analysis; [CUA]=cost utility analysis; 
[I]=intervention condition; [C]= comparison condition 
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Appendix 13: Costs and Outcomes table: Contraception interventions 
Table A13.1: Emergency hormonal contraception 
Study Intervention Outcomes Cost-effectiveness NICE rating 
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Foster et al. 
(2010) 
[CBA] 
 
 
 
Advance EC provision versus no 
access/use of EC  
On-demand clinic and pharmacy 
provision of EC versus no 
access/use of EC 
For high- and low-frequency use, advance and on-demand 
provision both result in a lower pregnancy rate than no access  
For high- and low-frequency use, cost-savings ratio higher in 
advance provision than on-demand provision but both still greater 
than 1.00 (i.e. no. of $ saved on averting pregnancy is greater 
than no. of $ spent on EC) (2005 USD)    
 
 
 
   
 
Pharmacy-dispensed advance provision: £0.83 ($1.28) - £1.41 
($2.17) saved for each $ spent (2005 USD) 
 
 
Clinic-dispensed advance provision: £0.66 ($1.01) - £1.14 ($1.75) 
saved for each $ spent 
 
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Clinic-dispensed on-demand provision: £0.65 ($1.00) - £1.01 
($1.56) saved for each $ spent 
 
Pharmacy-dispensed on-demand provision: £1.04 ($1.61) - £1.62 
($2.49) saved for each $ spent 
 
Bayer et al. 
(2013) 
[CEA] 
Oral ulipristal acetate at 120 
hours versus oral levonorgestrel 
at 120 hours 
UPA:  
54,295 unintended pregnancies 
£270,251,630 ($399.19 million) (2011 USD) 
LNG: 
91,884 unintended pregnancies 
£348,959,650 ($515.45 million) 
UPA v. LNG: 
37,589 pregnancies averted 
      
 
 
 
 
 
   
£78,735,100 ($116 million) saved for 8,053 QALYs gained 
UPA was dominant intervention 
 
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Study Intervention Outcomes Cost-effectiveness NICE rating 
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Thomas and 
Cameron 
(2013) 
[CEA] 
Cost-effectiveness comparison of 
ulipristal acetate (UPA) versus 
levonorgestrel (LNG) within 72 
hours of unprotected sex 
Primary: Number of unintended pregnancies estimated at ‘almost 
25%’ 
Secondary: Miscarriage, abortion, ectopic, stillbirth, live birth 
Associated costs of unintended pregnancy £1,663-2,922 
(depending on perspective)  
   
 
 
 
   
UPA cost £194-1,453 less per avoided pregnancy than LNG (2011 
GBP) 
 
[CBA]=cost-benefit analysis; [CCA]=cost-consequence analysis; [CEA]=cost-effectiveness analysis; [CSA]=cost saving analysis; [CUA]=cost utility analysis 
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Table A13.2: Long-acting reversible contraception 
Study Intervention Outcomes Cost-effectiveness NICE rating 
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Foster et al. 
(2013) 
[CBA] 
 
 
 
 
All contraceptive methods 
provided versus no care 
provision  
Averted pregnancies:  
Oral contraceptives: 102,000 
Injectables: 26,000 
IUC: 24,000 
Barrier: 18,000 
Patch: 9,000 
Implants: 3,000 
Operative: 2,100 
Copper intrauterine contraception (IUC): £3.36 ($5.07) (2009 
USD) saved for each $ spent 
Hormonal IUC: £3.24 ($4.89) saved for each $ spent 
Implant: £3.24 ($4.89) saved for each $ spent 
Injectable: £2.65 ($4.00) saved for each $ spent 
   
 
 
 
 
 
 
 
 
   
Appendix 13 
 
Sexual health promotion and contraceptive services in local authorities: a systematic review of economic evaluations 2010-2015  288 
 
Study Intervention Outcomes Cost-effectiveness NICE rating 
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Interval tubal ligation: £2.38 ($3.59) saved for each $ spent 
Oral contraceptives: £2.23 ($3.37) saved for each $ spent 
Emergency contraceptives: £1.70 ($2.56) saved for each $ spent 
Ring: £1.46 ($2.20) saved for each $ spent 
Patch: £1.41 ($2.12) saved for each $ spent 
Tubal occlusion: £1.05 ($1.59) saved for each $ spent 
Barrier methods: £1.05 ($1.58) saved for each $ spent 
 
 
 
 
 
 
 
Trussell et al. 
(2015) 
[Cost study] 
LARCs (implant, copper IUD, 
LNG-IUS) versus no method 
LARCs versus UDCs (OC, ring, 
patch, injectables) 
 
Minimum duration of LARC method to reach cost-neutrality:  
Average LARC vs generic OC: 2.4 years 
Average LARC vs ring: 0.4 years 
Average LARC vs patch: 0.3 years 
Average LARC vs injection: 2.6 years 
Average LARC vs mixed SARC: 2.1 years 
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Average LARC vs condom: 3.0 years 
Average LARC vs no method (chance): 1.7 years 
2.1 years of LARCs would result in cost savings compared to UDCs  
NCC (2013) 
[CEA] 
LARC methods (IUD, IUS, 
implant, injectable) 
versus UDCs (combined oral 
contraceptive (COC), male 
condom)  
Number of pregnancies averted 
Costs for intervention and additional care 
(See Evidence Tables for more details) 
First three years: Implant dominated all other LARCs costing 
between £14,730 - £17,866 per pregnancy averted (2004-2005 
GBP) 
   
 
 
 
 
    
Over 15 years: All LARCs dominated COCs and condoms  
Trussell et al. 
(2014) 
[CEA] 
Levonorgestrel (LNG) IUS versus 
UDCs (OC, ring, patch, 
injectables, implant, condom) 
UDC:  
276 unintended pregnancies 
Costs £ 1,257,277 ($1,862,633) (2012 USD) 
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LNG-IUS: 
64 unintended pregnancies 
Costs £ 866,348 ($1,283,479)  
 
LNG-IUS cost-effective (‘dominates’) in comparison to SARCs   
Trussell et al. 
(2013) 
[CSA] 
 
 
 
 
Three scenarios of switching to 
LARCs (implant, IUD, IUS) 
1. 10% of women aged 20–29 
who are currently using OC 
switched to LARC 
2. 10% of women aged 20–29 
who are currently using any 
UDC method (OCs, condoms, 
patch, injectables, vaginal ring) 
switched to LARC 
Current practice 
Cost of UP: £1,639 ($2,421) (2011 USD) 
Cost of contraception: £3,019 ($4,460) 
Total cost impact: £4,658 ($6,881) 
Scenario 1 cost savings: 
Cost of unplanned pregnancy (UP): £35 ($51) 
Cost of contraception: £160 ($237) 
Total cost impact: £195 ($288) 
Scenario 2 cost savings: 
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3. 10% of women aged 20–29 
who are currently using either 
UDC or no method switched to 
LARC  
Cost of UP: £79 ($117) 
Cost of contraception: £174 ($257) 
Total cost impact: £254 ($375) 
Scenario 3 cost savings: 
Cost of UP: £145 ($214) 
Cost of contraception: £150 ($222) 
Total cost impact: £295 ($436) 
Higher LARC uptake generates cost savings in: 
Women switching from OCs to LARCs 
Women switching from no method to LARCs 
Cost neutrality achieved (all age groups): used at least two years 
 
 
Han et al. 
(2014) 
[CEA,CSA] 
Post-natal implant insertion to 
adolescent mothers versus 
Intervention: 
£475,083 ($699,680) (6 months) (2013 USD) 
£672,006 ($989,700) (12 months) 
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standard contraceptive 
initiation  
£1,004,920 ($1.48 million) (24 months) 
£1,575,280 ($2.32 million) (36 months) 
Comparison: 
£425,783 ($627,073) (6 months) 
£1,045,660 ($1.54 million) (12 months) 
£2,675,260 ($3.94 million) (24 months) 
£4,651,150 ($6.85 million) (36 months) 
£0.53 ($0.79) saved for each $1 spent on programme (12m) 
 
 
£2.40 ($3.54) saved for each $1 spent on programme (24m) 
£4.41 ($6.50) saved for each $1 spent on programme (36 m) 
 
 
Rodriguez et 
al. (2010a) 
[CBA] 
Expanded Medicaid (EM) 
coverage for post-natal 
contraception versus regular 
coverage for recent immigrants 
Estimated 126 pregnancies avoided through EM coverage 
£140,812 ($214,000) without EM programme (2002 USD) 
£78,302 ($119,000) with EM IUD programme 
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Hospital perspective: Hospital would lose £0.46 per £1 (70 cents 
per dollar) spent on a postpartum IUD programme 
State perspective: state would save £1.92 ($2.94) in costs for 
repeat obstetrical care for every state dollar spent on an IUD 
programme 
Rodriguez et 
al. (2010b) 
[CBA] 
 
 
Post-natal IUD insertion versus 
routine post-natal care (no IUD) 
Routine post-natal care [C]: 
Pregnancies: 226 
Total costs: £1,371,300 ($2.1 million) (2008 USD) 
Cost of repeat pregnancy without the programme: £139,742 
($214,000) 
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Cost of repeat pregnancy with the programme: £77,707 
($119,000) 
Hospital perspective: 
Programme costs for an IUD, insertion and removal: £214,184 
($328,000) 
State perspective:  
£1.92 ($2.94) saved per $1.00 spent on IUD insertion  
Benefit–cost ratio of 0.30  
  
 
Salcedo et al. 
(2013) 
[CSA] 
Immediate post-abortion IUD 
placement versus IUD 
placement at post-abortion 
follow-up visit 
At 5 years: 
400 pregnancies avoided 
180 deliveries avoided 
160 abortions avoided  
Immediate post-abortion insertion saves £75-548 ($111-810) (at 1 
and 5 years) per woman in direct costs compared to insertion at 
follow-up visit (2011 USD) 
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With societal costs included, this increases to savings of £1,324-
2,908 ($1,956-4,296) per woman compared to insertion at 
follow-up visit 
 
 
[CBA]=cost-benefit analysis; [CCA]=cost-consequence analysis; [CEA]=cost-effectiveness analysis; [CSA]=cost saving analysis; [CUA]=cost utility analysis; 
[C]= comparison condition 
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Table A13.3: General contraceptive services 
Study Intervention Outcomes Cost-effectiveness NICE rating 
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Thomas (2012) 
[CBA]  
 
 
 
Mass media campaign to 
promote condom use to 
unmarried males aged 15 to 44 
years old v. no programme 
Benefits:  
Pregnancy: 1.7% reduction 
Abortions: 3.9% reduction 
Births: 1.0% reduction 
Births into poverty: 2.2% reduction 
Costs: £65.3 million ($100 million) (2008 USD) 
£2.81 ($4.31) saved for each $1 spent 
   
 
 
 
 
 
 
 
   
Teen pregnancy prevention 
programmes to unmarried low 
SES youth v. no programme 
Benefits:  
Pregnancy: 0.8% reduction 
Abortions: 1.4% reduction  
Births: 0.6% reduction 
Births into poverty: 1.4% reduction 
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Costs: £94,685 million ($145 million) 
£1.61 ($2.46) saved for each $1 spent 
 
Expanded Medicaid for 
contraception to unmarried low 
SES youth v. no programme 
Benefits:  
Pregnancy: 1.9% reduction 
Abortions: 3.5% reduction 
Births: 1.4% reduction 
Births into poverty: 1.8% reduction 
Costs: £153,455 million ($235 million) 
£3.67 ($5.62) saved for each $1 spent 
   
 
 
 
 
 
 
 
   
Pilgrim et al. 
(2010) 
School nurse services only; no 
dispensing of condoms or 
contraceptives [C] 
11,392 abortions / 2,186 pregnancies 
Total costs £1,527,318,794 (2007-2008 GBP) 
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[CEA] 
 
 
 
 
 
 
School-based condom provision 
versus school nurse services 
only 
11,153 estimated abortions 
1,778 estimated pregnancies 
Total estimated costs £1,517,225,105 
Estimated cost £38 for each pregnancy averted 
Estimated cost £822 for each abortion avoided (2007-2008 GBP) 
   
 
 
    
School-based hormonal 
contraceptive provision to 
sexually active nulliparous 14-
16 year olds versus condom 
provision and school nurse  
11,103 estimated abortions 
1,693 estimated pregnancies 
Total estimated costs £1,515,641,998 
Estimated cost outcome £443 for each averted pregnancy 
(2007-2008 GBP) 
Estimated cost outcome £1,453 for each abortion avoided  
   
 
 
 
 
    
School-based intensive peer 
education and social work case 
management to prevent repeat 
pregnancy in teen mothers 
No follow-up [C]:  
31,464 repeat pregnancies  
Total cost £655,572,463  
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M
o
re
 c
o
stly
, le
ss e
ffe
c
tiv
e
 
L
e
ss c
o
stly
, le
ss e
ffe
c
tiv
e
 
M
o
re
 c
o
stly
, m
o
re
 e
ffe
c
tiv
e
 
S
im
ila
r c
o
st, sim
ila
r e
ffe
c
t 
L
e
ss c
o
stly
, m
o
re
 e
ffe
c
tiv
e
 
C
o
st sa
v
in
g
 
<
£
2
0
,0
0
0
 p
e
r Q
A
L
Y
 
£
2
0
-3
0
,0
0
0
 p
e
r Q
A
L
Y
 
>
£
3
0
,0
0
0
 p
e
r Q
A
L
Y
 
attending school versus no 
follow-up after first pregnancy 
Case management follow-up [I]: 
19,022 repeat pregnancies  
Total cost £705,730,087 
Estimated cost £4,031-15,155 per repeat pregnancy averted 
(2007-2008 GBP) 
 
Advance provision of EHC to 
sexually active high risk teens 
aged 15-19 years versus no 
advance provision of EHC 
No advance provision [C]: 
11,241 abortions / 11,363 pregnancies 
Total costs: £1,524,674,862  
Advance provision [I]: 
11,241 abortions / 11,363 pregnancies 
Total costs: £1,447,599,721  
   
 
 
 
     
Cost £310 per pregnancy averted 
Cost £2,795 per abortion avoided 
(2007-2008 GBP) 
 
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[CBA]=cost-benefit analysis; [CCA]=cost-consequence analysis; [CEA]=cost-effectiveness analysis; [CSA]=cost saving analysis; [CUA]=cost utility analysis; 
[I]=intervention condition; [C]= comparison condition 
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Appendix 14: Costs and outcomes table: Health promotion interventions  
Table A14.1: Health promotion: HIV prevention 
Study Intervention Outcomes Cost-effectiveness NICE rating 
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Burgos et al. 
(2010) 
[CEA 
 
 
 
Brief behavioural condom 
negotiation skills intervention to 
reduce STI and HIV among female 
sex workers versus time-equivalent 
didactic STI and HIV prevention 
session [C] 
No intervention: 
- Cost: £12,730 ($19,200) 
- QALYs gained: 21,863 
Without universal HAART access: 
Comparing one session of intervention to [C]: 
33 HIV infections averted for 151 days of QALE, costing £121 
($183) per QALY and £1,571 ($2,370) to prevent each HIV 
case (2009 USD) 
      
 
 
 
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Considering universal HAART access: 
Comparing annual sessions of intervention to once-only 
session and comparative condition [C]: 
An additional 29 new HIV cases would be prevented, at a cost 
per QALY gained of £713 ($1,075) and £8,893 ($13,413) per 
HIV case averted 
 
Holtgrave et al. 
(2012) 
[CEA, CUA]  
Female condom distribution and HIV 
prevention education programme 
targeting general population (men 
and women) versus no intervention 
[C] 
200,000 condoms distributed and education services provided 
at a cost of £279,575 ($414,186) (2012 USD) 
Cost £2.15 ($3.19) per product used (incl. education services) 
Cost saving:  
1.13 infections averted (societal perspective) 
1.50 infections averted (public payer perspective) 
   
 
 
 
 
   
Cost-effectiveness threshold of HIV infections averted = 0.46; 
intervention averted estimated 23 HIV infections per 
intervention provided 
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Holtgrave et al. 
(2013) 
[CUA] 
Rental assistance for homeless and 
unstably housed HIV-infected 
persons versus no intervention [C] 
0.01567 HIV transmissions averted 
£63 ($97) per client emergency room use savings (2005 USD)  
0.0324 QALYs gained in improved perceived stress  
Cost per QALY saved by intervention £40,558 ($62,493) 
   
 
    
 
 
Marseille et al. 
(2011) 
[CEA] 
 
 
Three interventions targeting HIV-
infected individuals: 
1. Primary care clinical provider-
based brief computer-based risk 
assessment and individual 
counselling for HIV transmission 
Estimated HIV cases prevented and costs over 3 years: 
Clinical provider 2.71 cases costing £98,601 ($146,075) (2010 
USD) 
Peer educator 1.11 cases costing £228,070 ($337,881) 
Mixed services 3.02 cases costing £181,515 ($268,911) 
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 prevention; 2. Peer educator-based 
individual or group counselling; 3. 
Mixed primary care provide and 
peer-educator based counselling for 
HIV prevention versus standard care 
(risk assessment without specific 
counselling) [C] 
Compared to no intervention, clinical provider intervention 
was most cost-effective at £72,668 ($107,656) per HIV case 
averted (this dominated peer educator and mixed services 
interventions) 
 
Ruger et al. 
(2014) 
[CEA, CUA] 
 
1. Well-woman examination (WWE) 
plus standard care or  
2. Four HIV prevention educational 
sessions (4ES) plus well-woman 
examination plus standard care  
versus standard care alone [C] 
targeted to women who inject drugs 
HIV outcomes: Four-session education (4ES) intervention was 
cost saving in relation to well-woman examination (WWE) 
intervention 
 
 
 
     
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Sanders et al. 
(2010) 
[CEA] 
 
 
1. Nurse-initiated routine screening 
with traditional HIV testing and 
counselling or  
2. Nurse-initiated routine screening 
with rapid HIV testing and 
streamlined counselling  
versus traditional HIV testing and 
counselling [C] 
Traditional HIV testing and counselling: per patient lifetime 
discounted costs of: £31,379 ($48,650) and benefits of 16.271 
QALYs (2007 USD) 
Nurse-initiated routine screening with traditional HIV testing 
and counselling: increased lifetime costs by £34 ($53) and 
benefits by 0.0013 QALYs (corresponding to 0.48 quality-
adjusted life days) 
  
 
 
 
 
 
  
  
 Nurse-initiated routine screening with rapid HIV testing and 
streamlined counselling: cost £42 ($66) more than traditional 
screening with an increase of 0.0018 QALYs (0.66 quality-
adjusted life days). Incremental cost-effectiveness of £6,876 
($10,660) per QALY relative to traditional testing and 
counselling  
   
Nurse-initiated routine screening with rapid HIV testing and 
streamlined counselling, without benefits to partners from 
reduced HIV transmission: Incremental cost-effectiveness of 
   
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£23,472 ($36,390) per QALY compared to traditional testing 
and counselling  
Schackman et 
al. (2013) 
[CEA] 
 
During community-based substance 
abuse treatment: 
1. On-site rapid HIV testing with 
information only or 
2. On-site rapid HIV testing with risk 
reduction counselling  
versus off-site HIV testing and 
referral [C] 
 
Offer of off-site test: 
Cost-effectiveness ratio (cost per QALY): dominated  
        
On-site test + information: 
Cost-effectiveness ratio (cost per QALY): £39,979 ($60,300) 
(2009 USD) 
 
 
On-site test + counselling: 
Cost-effectiveness ratio (cost per QALY): dominated 
On-site rapid testing with counselling costs $36 more per 
person but without added benefit 
 
 
Kessler et al. 
(2013) 
Individual and optimal combinations 
of multiple HIV prevention 
programmes: clinical and non-
Model predicted: 58,632 new cases of HIV infection over a 20-
year period, during which 16,159 persons were predicted to 
have died of AIDS-related conditions  
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[CSA] 
 
 
 
clinical testing; condom distribution; 
post-exposure prophylaxis; linkage 
to care, care coordination; STI 
screening; partner services; risk-
reduction education; linkage to 
support; social marketing; 
community-based interventions; 
prioritised surveillance data; social 
services; brief screening and 
intervention; and screening for co-
morbidity factors versus no 
intervention 
2,932 new HIV infections per year 
808 HIV-related deaths per year 
All cost saving: 
Cost per infection averted: 
Condom distribution (all risk groups): £126,368 ($187,212) 
(2010 USD) 
Social marketing (all): £55,709 ($82,532) 
Community-based prevention (all): £4,482 ($7,173)  
Prioritised use of surveillance data (HIV-infected): £18,673 
($27,663)  
Cofactor risk reduction (HIV-infected, high risk): £21,130 
($31,304)  
Brief intervention and referral for alcohol use (HIV-infected, 
high risk): £24,821 ($36,772)  
Linkage to care (HIV-infected): £257,112 ($380,906)  
  
Appendix 14 
 
Sexual health promotion and contraceptive services in local authorities: a systematic review of economic evaluations 2010-2015  308 
 
Study Intervention Outcomes Cost-effectiveness NICE rating 
M
o
re
 c
o
stly
, le
ss e
ffe
c
tiv
e
 
L
e
ss c
o
stly
, le
ss e
ffe
c
tiv
e
 
M
o
re
 c
o
stly
, m
o
re
 e
ffe
c
tiv
e
 
S
im
ila
r c
o
st, sim
ila
r e
ffe
c
t 
L
e
ss c
o
stly
, m
o
re
 e
ffe
c
tiv
e
 
C
o
st sa
v
in
g
 
<
£
2
0
,0
0
0
 p
e
r Q
A
L
Y
 
£
2
0
-3
0
,0
0
0
 p
e
r Q
A
L
Y
 
>
£
3
0
,0
0
0
 p
e
r Q
A
L
Y
 
Linkage to support services (HIV-infected) £83,896 ($124,291)  
Partner services (HIV infected and partners): £133,821 
($198,253)  
STI screening (HIV infected high risk): £228,843 ($339,026) 
All not cost-saving: 
STI screening (HIV uninfected only): £322,639 ($477,984) 
Risk reduction (HIV infected only): £518,016 ($767,431) 
Social services (HIV uninfected high risk): £706,311 
($1,046,387) 
Care coordination (HIV infected on ART): £781,784 
($1,158,199) 
Testing – clinical (HIV uninfected) £1,190,066 ($1,763,061) 
Testing – non-clinical (HIV uninfected): £2,099,507 
($3,110,381) 
Cofactors (HIV uninfected high risk): £2,451,098 ($3,631,257) 
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Brief screening and alcohol intervention (HIV uninfected, high 
risk): £2,629,434 ($3,895,458) 
Pre-exposure prophylaxis (HIV uninfected high risk): £6.075 
million ($9,803,449) 
STI screening (HIV uninfected high risk): £7,698,044 
($11,404,509) 
Pre-exposure prophylaxis (HIV uninfected only: £9,812,825 
($14,537,519) 
STD screening (all): £11,907,321 ($17,640,475) 
Lasry et al. 
(2012) 
[CSA] 
1. Current national provision of HIV 
testing and individual and group-
level counselling and education 
interventions or  
2. An optimised scenario in which 
funding is reallocated to provide: 
Model predicts (over 5 years): 252,000 new HIV infections 
(versus no funding)  
Current £216.8 million ($327 million) budget (2009 USD): 
223,000 new HIV infections (baseline scenario) 
13% of new infections averted and £37,334 ($56,311) per 
infection averted (current versus no funding) 
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targeted testing for MSM and IVDU, 
targeted counselling and education 
for HIV-infected individuals, and 
targeted interventions to high-risk 
rather than general population, 
versus no funding 
Optimised £216.8 million ($327) million budget: 192,000 new 
HIV infections  
31% of new infections averted and £17,985 ($27,128) per 
infection averted (optimised versus no funding) 
 
[CBA]=cost-benefit analysis; [CCA]=cost-consequence analysis; [CEA]=cost-effectiveness analysis; [CSA]=cost saving analysis; [CUA]=cost utility analysis; 
[I]=intervention condition; [C]= comparison condition
Appendix 14 
 
Sexual health promotion and contraceptive services in local authorities: a systematic review of economic evaluations 2010-2015  311 
 
Table A14.2: Health promotion: STI prevention 
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Cooper et al. 
(2012) 
[CEA] 
Universally targeted:  
1. Teacher-led 20 session STI 
prevention intervention or  
2. Peer-led three session STI 
prevention intervention  
versus standard sexual health 
education [C] 
Compared to standard sex education [C], teacher-led 
intervention would have net additional cost £6,375 (€8,575) 
and avoid two extra STI cases for 0.35 increase in QALY 
(2011-2012 Euro) 
Incremental cost-effectiveness ratio: £18,041 (€24,268) per 
QALY gained  
      
 
  
 
 
 
Compared to the teacher-led intervention, peer-led 
intervention cost £12,050 (€16,210) per case avoided 
Incremental cost-effectiveness ratio: £72,062 (€96,938) per 
QALY gained 
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Crawford et al. 
(2015) 
[CUA] 
 
 
Brief alcohol advice, health 
information leaflet and referral offer 
versus health information leaflet only 
No significant reductions in:  
90-day alcohol consumption or  
Rates of unprotected sex in past 3 months 
£311 per person intervention 
£319 per person control 
Additional cost of intervention £12.57, SD £6.59 
   
 
 
  
 
 
 
 
 
 
 
 
QALYs 0.007 lower in brief intervention group and costs 
£8.41 higher 
ICER: −£1,200 per QALY 
 
 
Jackson et al. 
(2015) 
[CCA] 
Team captain-led STI screening 
promotion versus poster-only STI 
screening promotion 
50% screening uptake [I] versus 61% screening uptake [C] 
£88.89 per participant screened [I] versus £81.87 per 
participants screened [C] 
   
 
     
Sexual health adviser-led STI 
screening promotion versus poster-
only STI screening promotion 
67% screening uptake [I] versus 61% screening uptake [C] 
         
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£88.33 per participant screened [I] versus £81.87 per 
participant screened [C] 
Pilgrim et al. 
(2010) 
[CEA] 
 
 
 
 
 
School nurse services only; no 
dispensing of condoms or 
contraceptives [C] 
11,392 abortions 
2,186 pregnancies 
Total costs £1,527,318,794 (2007-2008 GBP) 
   
 
     
School-based condom provision versus 
school nurse services only 
11,153 estimated abortions 
1,778 estimated pregnancies 
Total estimated costs £1,517,225,105 
Estimated cost £38 for each pregnancy averted 
   
  
 
 
    
School-based hormonal contraceptive 
provision to sexually active 
nulliparous 14-16 year olds versus 
condom provision and school nurse 
11,103 estimated abortions 
1,693 estimated pregnancies 
Total estimated costs £1,515,641,998 
Estimated cost outcome £443 for each averted pregnancy  
Estimated cost outcome £1453 for each abortion avoided 
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School-based peer education and 
social work case management to 
prevent repeat pregnancy in teen 
mothers attending school versus no 
follow-up after first pregnancy 
No follow-up [C]:  
31,464 repeat pregnancies  
Total cost £655,572,463  
         
Case management follow-up [I]: 
19,022 repeat pregnancies 
Total cost £705,730,087 
Estimated cost £4,031-15,155 per repeat pregnancy averted 
 
Advance provision of EHC to sexually 
active high risk teens aged 15-19 
years versus no advance provision of 
EHC 
No advance provision [C]: 
11,241 abortions / 11,363 pregnancies 
Total costs: £1,524,674,862 (2007-2008 GBP) 
   
  
    Advance provision [I]: 
11,241 abortions / 11,363 pregnancies 
Total costs: £1,447,599,721  
Estimated cost £310 per pregnancy averted 
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Estimated cost £2,795 per abortion avoided 
Ruger et al. 
(2014) 
[CEA, CUA] 
 
 
 
1. Well-woman examination (WWE) 
plus standard care or  
2. Four HIV prevention educational 
sessions (4ES) plus well-woman 
examination plus standard care  
versus standard care alone [C] 
targeted to women who inject drugs 
Modelling results: 
Hepatitis C: WWE was less costly and more effective 
compared to 4ES: £72,034 ($109,308) per additional 
infection averted (£27,996 ($42,482) QALYs gained) 
   
 
 
  
 
 
 
  
 
 
 
 
 
 
Chlamydia: 4ES was less costly than WWE: £2,273,217 
($3,449,495) per additional QALY  
 
Gonorrhoea: WWE was less costly than 4ES: £706,949 
($1,072,760) per additional QALY  
 
Thomas (2012) 
[CBA] 
Mass media campaign to promote 
condom use to unmarried males 15-44 
years old versus no programme 
Benefits:  
Pregnancy: 1.7% reduction 
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Thomas (2012) 
cont’d. 
Abortions: 3.9% reduction 
Births: 1.0% reduction 
Births into poverty: 2.2% reduction 
Costs: £65.3 million ($100 million) (2008 USD) 
£2.81 ($4.31) saved for each $1 spent 
 
 
 
 
Teen pregnancy prevention 
programmes to unmarried low SES 
youth versus no programme 
Benefits:  
Pregnancy: 0.8% reduction 
Abortions: 1.4% reduction  
Births: 0.6% reduction 
Births into poverty: 1.4% reduction 
Costs: £94,685 million ($145 million) 
£1.61 ($2.46) saved for each $1 spent 
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Expanded Medicaid for contraception 
to unmarried low SES youth versus no 
programme 
Benefits:  
Pregnancy: 1.9% reduction 
Abortions: 3.5% reduction 
Births: 1.4% reduction 
Births into poverty: 1.8% reduction 
Costs: £153,455 million ($235 million) 
£3.67 ($5.62) saved for each $1 spent 
      
 
 
 
 
   
[CBA]=cost-benefit analysis; [CCA]=cost-consequence analysis; [CEA]=cost-effectiveness analysis; [CSA]=cost saving analysis; [CUA]=cost utility analysis; 
[I]=intervention condition; [C]= comparison condition 
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